<!DOCTYPE html>
<html prefix="dc: http://purl.org/dc/terms/ mw: http://mediawiki.org/rdf/" about="http://en.wikipedia.org/wiki/Special:Redirect/revision/884807353"><head prefix="mwr: http://en.wikipedia.org/wiki/Special:Redirect/"><meta property="mw:TimeUuid" content="b0db6ec0-37e5-11e9-b4ca-eade620ba8f4"/><meta charset="utf-8"/><meta property="mw:pageNamespace" content="0"/><meta property="mw:pageId" content="27158894"/><link rel="dc:replaces" resource="mwr:revision/884774431"/><meta property="dc:modified" content="2019-02-24T03:38:33.000Z"/><meta property="mw:revisionSHA1" content="e7dc0fa357734660d46e4735aabdc8bd94321113"/><meta property="mw:html:version" content="2.1.0"/><link rel="dc:isVersionOf" href="//en.wikipedia.org/wiki/Addiction"/><title>Addiction</title><base href="//en.wikipedia.org/wiki/"/><link rel="stylesheet" href="//en.wikipedia.org/w/load.php?modules=mediawiki.legacy.commonPrint%2Cshared%7Cmediawiki.skinning.content.parsoid%7Cmediawiki.skinning.interface%7Cskins.vector.styles%7Csite.styles%7Cext.cite.style%7Cext.cite.styles%7Cmediawiki.page.gallery.styles&amp;only=styles&amp;skin=vector"/><!--[if lt IE 9]><script src="//en.wikipedia.org/w/load.php?modules=html5shiv&amp;only=scripts&amp;skin=vector&amp;sync=1"></script><script>html5.addElements('figure-inline');</script><![endif]--><meta http-equiv="content-language" content="en"/><meta http-equiv="vary" content="Accept"/></head><body id="mwAA" lang="en" class="mw-content-ltr sitedir-ltr ltr mw-body-content parsoid-body mediawiki mw-parser-output" dir="ltr"><section data-mw-section-id="0" id="mwAQ"><div role="note" class="hatnote navigation-not-searchable" about="#mwt1" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"redirect","href":"./Template:Redirect"},"params":{"1":{"wt":"Addictive"},"2":{"wt":"other uses"},"3":{"wt":"Addiction (disambiguation)"},"4":{"wt":"and"},"5":{"wt":"Addictive (disambiguation)"}},"i":0}}]}' id="mwAg">"Addictive" redirects here. For other uses, see <a rel="mw:WikiLink" href="./Addiction_(disambiguation)" title="Addiction (disambiguation)">Addiction (disambiguation)</a> and <a rel="mw:WikiLink" href="./Addictive_(disambiguation)" title="Addictive (disambiguation)">Addictive (disambiguation)</a>.</div>
<p id="mwAw"><span typeof="mw:Nowiki mw:Transclusion" about="#mwt2" data-mw='{"parts":[{"template":{"target":{"wt":"Use dmy dates","href":"./Template:Use_dmy_dates"},"params":{"date":{"wt":"November 2018"}},"i":0}}]}' id="mwBA"></span><link rel="mw:PageProp/Category" href="./Category:Use_dmy_dates_from_November_2018" about="#mwt2" id="mwBQ"/></p>
<table class="infobox" style="width:22em" about="#mwt5" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"Infobox medical condition (new)\n","href":"./Template:Infobox_medical_condition_(new)"},"params":{"name":{"wt":"Addiction"},"synonym":{"wt":"&apos;&apos;Severe substance use disorder&apos;&apos;&lt;ref name=\"Surgeon General severe SUD\">{{cite web | title=Facing Addiction in America: The Surgeon General’s Report on Alcohol, Drugs, and Health | url=https://addiction.surgeongeneral.gov/sites/default/files/surgeon-generals-report.pdf | website = Office of the Surgeon General | publisher=US Department of Health and Human Services | date=November 2016 | accessdate=28 January 2017 | pages = 35–37, 45, 63, 155, 317, 338 | quote = }}&lt;/ref>&lt;ref name=\"Brain disease\" />"},"image":{"wt":"Brain metabolism and drug addiction.jpg"},"caption":{"wt":"[[Brain positron emission tomography]] images that compare [[Human brain#Metabolism|brain metabolism]] in a healthy individual and a cocaine addict"},"alt":{"wt":"PET images showing brain metabolism in drug addicts vs controls"},"field":{"wt":"[[Psychiatry]]"},"width":{"wt":"390"},"pronounce":{"wt":""},"specialty":{"wt":""},"symptoms":{"wt":""},"complications":{"wt":""},"onset":{"wt":""},"duration":{"wt":""},"types":{"wt":""},"causes":{"wt":""},"risks":{"wt":""},"diagnosis":{"wt":""},"differential":{"wt":""},"prevention":{"wt":""},"treatment":{"wt":""},"medication":{"wt":""},"prognosis":{"wt":""},"frequency":{"wt":""},"deaths":{"wt":""}},"i":0}}]}' id="mwBg"><tbody><tr><th colspan="2" style="text-align:center;font-size:125%;font-weight:bold;background:#ccc">Addiction</th></tr><tr><th scope="row">Synonym</th><td><i>Severe substance use disorder</i><sup about="#mwt1355" class="mw-ref" id="cite_ref-Surgeon_General_severe_SUD_1-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Surgeon General severe SUD"},"body":{"id":"mw-reference-text-cite_note-Surgeon_General_severe_SUD-1"}}'><a href="./Addiction#cite_note-Surgeon_General_severe_SUD-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></sup><sup about="#mwt439" class="mw-ref" id="cite_ref-Brain_disease_2-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Brain disease"}}'><a href="./Addiction#cite_note-Brain_disease-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></sup></td></tr><tr><td colspan="2" style="text-align:center"><figure-inline typeof="mw:Image" data-mw='{"caption":"PET images showing brain metabolism in drug addicts vs controls"}'><a href="./File:Brain_metabolism_and_drug_addiction.jpg"><img alt="PET images showing brain metabolism in drug addicts vs controls" resource="./File:Brain_metabolism_and_drug_addiction.jpg" src="//upload.wikimedia.org/wikipedia/commons/thumb/9/91/Brain_metabolism_and_drug_addiction.jpg/390px-Brain_metabolism_and_drug_addiction.jpg" data-file-width="678" data-file-height="377" data-file-type="bitmap" height="217" width="390" srcset="//upload.wikimedia.org/wikipedia/commons/9/91/Brain_metabolism_and_drug_addiction.jpg 2x, //upload.wikimedia.org/wikipedia/commons/thumb/9/91/Brain_metabolism_and_drug_addiction.jpg/585px-Brain_metabolism_and_drug_addiction.jpg 1.5x"/></a></figure-inline></td></tr><tr><td colspan="2" style="text-align:center"><a rel="mw:WikiLink" href="./Brain_positron_emission_tomography" title="Brain positron emission tomography">Brain positron emission tomography</a> images that compare <a rel="mw:WikiLink" href="./Human_brain#Metabolism" title="Human brain">brain metabolism</a> in a healthy individual and a cocaine addict</td></tr><tr><th scope="row"><a rel="mw:WikiLink" href="./Specialty_(medicine)" title="Specialty (medicine)">Specialty</a></th><td><a rel="mw:WikiLink" href="./Psychiatry" title="Psychiatry">Psychiatry</a></td></tr></tbody></table>

<table class="infobox" style="width:22em;width:404px; ; border-collapse:collapse;" about="#mwt6" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"addiction glossary","href":"./Template:Addiction_glossary"},"params":{"reverse citation order":{"wt":"yes"},"width":{"wt":"404px"}},"i":0}}]}' id="mwBw"><tbody><tr><th colspan="2" style="text-align:center;font-size:125%;font-weight:bold;font-size:100%; background:#FFCC66; -moz-box-shadow: inset 3px 3px 0 #fafafa, inset -3px -3px 0 #fafafa; -webkit-box-shadow: inset 3px 3px 0 #fafafa, inset -3px -3px 0 #fafafa; box-shadow: inset 3px 3px 0 #fafafa, inset -3px -3px 0 #fafafa;; padding:5px;">Addiction and dependence glossary<sup about="#mwt1377" class="mw-ref" id="cite_ref-Cellular_basis_3-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Cellular basis"},"body":{"id":"mw-reference-text-cite_note-Cellular_basis-3"}}'><a href="./Addiction#cite_note-Cellular_basis-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></sup><sup about="#mwt1379" class="mw-ref" id="cite_ref-Addiction_glossary_4-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Addiction glossary"},"body":{"id":"mw-reference-text-cite_note-Addiction_glossary-4"}}'><a href="./Addiction#cite_note-Addiction_glossary-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></sup><sup about="#mwt1381" class="mw-ref" id="cite_ref-Nestler_Labs_Glossary_5-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Nestler Labs Glossary"},"body":{"id":"mw-reference-text-cite_note-Nestler_Labs_Glossary-5"}}'><a href="./Addiction#cite_note-Nestler_Labs_Glossary-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></sup><sup about="#mwt1383" class="mw-ref" id="cite_ref-Brain_disease_2-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Brain disease"},"body":{"id":"mw-reference-text-cite_note-Brain_disease-2"}}'><a href="./Addiction#cite_note-Brain_disease-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></sup></th></tr><tr><td colspan="2" style="text-align:center;text-align:left; padding-left:0;">
<ul><li><b><a rel="mw:WikiLink" href="./Addiction" title="Addiction">addiction</a></b> – a <a rel="mw:WikiLink" href="./Brain_disorder" title="Brain disorder" class="mw-redirect">brain disorder</a> characterized by <a rel="mw:WikiLink/Interwiki" href="https://en.wiktionary.org/wiki/compulsive" title="wikt:compulsive">compulsive</a> engagement in rewarding <a rel="mw:WikiLink" href="./Stimulus_(psychology)" title="Stimulus (psychology)">stimuli</a> despite adverse consequences</li>
<li><b><a rel="mw:WikiLink" href="./Addictive_behavior" title="Addictive behavior">addictive behavior</a></b> – a behavior that is both rewarding and reinforcing</li>
<li><b><a rel="mw:WikiLink" href="./Addiction" title="Addiction">addictive drug</a></b> – a drug that is both rewarding and reinforcing</li>
<li><b><a rel="mw:WikiLink" href="./Substance_dependence" title="Substance dependence">dependence</a></b> – an adaptive state associated with a withdrawal syndrome upon cessation of repeated exposure to a stimulus (e.g., drug intake)</li>
<li><b><a rel="mw:WikiLink" href="./Reverse_tolerance" title="Reverse tolerance">drug sensitization</a></b> or <b>reverse tolerance</b> – the escalating effect of a drug resulting from repeated administration at a given dose</li>
<li><b><a rel="mw:WikiLink" href="./Drug_withdrawal" title="Drug withdrawal">drug withdrawal</a></b> – symptoms that occur upon cessation of repeated drug use</li>
<li><b><a rel="mw:WikiLink" href="./Physical_dependence" title="Physical dependence">physical dependence</a></b> – dependence that involves persistent physical–<a rel="mw:WikiLink/Interwiki" href="https://en.wiktionary.org/wiki/somatic" title="wikt:somatic">somatic</a> withdrawal symptoms (e.g., fatigue and <a rel="mw:WikiLink" href="./Delirium_tremens" title="Delirium tremens">delirium tremens</a>)</li>
<li><b><a rel="mw:WikiLink" href="./Psychological_dependence" title="Psychological dependence">psychological dependence</a></b> – dependence that involves emotional–motivational withdrawal symptoms (e.g., <a rel="mw:WikiLink" href="./Dysphoria" title="Dysphoria">dysphoria</a> and <a rel="mw:WikiLink" href="./Anhedonia" title="Anhedonia">anhedonia</a>)</li>
<li><b><a rel="mw:WikiLink" href="./Reinforcement" title="Reinforcement">reinforcing</a> stimuli</b> – stimuli that increase the probability of repeating behaviors paired with them</li>
<li><b><a rel="mw:WikiLink" href="./Reward_system" title="Reward system">rewarding</a> stimuli</b> – stimuli that the brain interprets as intrinsically positive and desirable or as something to approach</li>
<li><b><a rel="mw:WikiLink" href="./Sensitization" title="Sensitization">sensitization</a></b> – an amplified response to a stimulus resulting from repeated exposure to it</li>
<li><b><a rel="mw:WikiLink" href="./Substance_use_disorder" title="Substance use disorder">substance use disorder</a></b> – a condition in which the use of substances leads to clinically and functionally significant impairment or distress</li>
<li><b><a rel="mw:WikiLink" href="./Drug_tolerance" title="Drug tolerance">tolerance</a></b> – the diminishing effect of a drug resulting from repeated administration at a given dose</li></ul>
</td></tr><tr><td colspan="2" style="text-align:center;text-align:right; padding-top:0; padding-right:5px;"><div class="plainlinks hlist navbar mini"><ul><li class="nv-view"><a rel="mw:WikiLink" href="./Template:Addiction_glossary" title="Template:Addiction glossary"><abbr title="View this template">v</abbr></a></li><li class="nv-talk"><a rel="mw:WikiLink" href="./Template_talk:Addiction_glossary" title="Template talk:Addiction glossary"><abbr title="Discuss this template">t</abbr></a></li><li class="nv-edit"><a rel="mw:ExtLink" class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Addiction_glossary&amp;action=edit"><abbr title="Edit this template">e</abbr></a></li></ul></div></td></tr></tbody></table>
<p id="mwCA"><span typeof="mw:Nowiki mw:Transclusion" about="#mwt7" data-mw='{"parts":[{"template":{"target":{"wt":"EngvarA","href":"./Template:EngvarA"},"params":{"date":{"wt":"September 2016"}},"i":0}}]}' id="mwCQ"></span><link rel="mw:PageProp/Category" href="./Category:Use_American_English_from_September_2016" about="#mwt7"/><link rel="mw:PageProp/Category" href="./Category:All_Wikipedia_articles_written_in_American_English" about="#mwt7" id="mwCg"/>
<b id="mwCw">Addiction</b> is a <a rel="mw:WikiLink" href="./Brain_disorder" title="Brain disorder" id="mwDA" class="mw-redirect">brain disorder</a> characterized by compulsive engagement in <a rel="mw:WikiLink" href="./Reward_system" title="Reward system" id="mwDQ">rewarding</a> stimuli despite adverse consequences.<sup about="#mwt19" class="mw-ref" id="cite_ref-9" rel="dc:references" typeof="mw:Transclusion  mw:Extension/ref" data-mw='{"parts":[{"template":{"target":{"wt":"refn","href":"./Template:Refn"},"params":{"1":{"wt":"&lt;ref name=\"Cellular basis\" />&lt;ref name=\"Nestler Labs Glossary\" />&lt;ref name=\"Brain disease\" />&lt;ref name=\"pmid18790142\">{{cite journal |vauthors=Angres DH, Bettinardi-Angres K | title = The disease of addiction: origins, treatment, and recovery | journal = Disease-a-Month | volume = 54 | issue = 10 | pages = 696–721 |date=October 2008| pmid = 18790142 | doi = 10.1016/j.disamonth.2008.07.002 | url = }}&lt;/ref>&lt;ref name=\"NHM addiction-reward-reinforcement\" />&lt;ref name=\"Reward system and psychostimulants\" />"}},"i":0}}]}'><a href="./Addiction#cite_note-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></sup> Despite the involvement of a number of psychosocial factors, a biological process<span typeof="mw:Entity" id="mwDg"> </span>– one which is induced by repeated exposure to an addictive stimulus<span typeof="mw:Entity" id="mwDw"> </span>– is the core <a rel="mw:WikiLink" href="./Pathology" title="Pathology" id="mwEA">pathology</a> that drives the development and maintenance of an addiction.<sup about="#mwt22" class="mw-ref" id="cite_ref-Cellular_basis_3-2" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Cellular basis"}}'><a href="./Addiction#cite_note-Cellular_basis-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></sup><sup about="#mwt1281" class="mw-ref" id="cite_ref-10" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{},"body":{"id":"mw-reference-text-cite_note-10"}}'><a href="./Addiction#cite_note-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></sup> The two properties that characterize all addictive stimuli are that they are <a rel="mw:WikiLink" href="./Positive_reinforcement" title="Positive reinforcement" id="mwEQ" class="mw-redirect">reinforcing</a> (i.e., they increase the likelihood that a person will seek repeated exposure to them) and <a rel="mw:WikiLink" href="./Intrinsic_reward" title="Intrinsic reward" id="mwEg" class="mw-redirect">intrinsically rewarding</a> (i.e., they are perceived as being inherently positive, desirable, and pleasurable).<sup about="#mwt24" class="mw-ref" id="cite_ref-Cellular_basis_3-3" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Cellular basis"}}'><a href="./Addiction#cite_note-Cellular_basis-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></sup><sup about="#mwt26" class="mw-ref" id="cite_ref-Nestler_Labs_Glossary_5-2" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Nestler Labs Glossary"}}'><a href="./Addiction#cite_note-Nestler_Labs_Glossary-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></sup><sup about="#mwt28" class="mw-ref" id="cite_ref-Reward_system_and_psychostimulants_8-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Reward system and psychostimulants"}}'><a href="./Addiction#cite_note-Reward_system_and_psychostimulants-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></sup></p>

<p id="mwEw">Addiction is a disorder of the brain's <a rel="mw:WikiLink" href="./Reward_system" title="Reward system" id="mwFA">reward system</a> which arises through <a rel="mw:WikiLink" href="./Transcriptional" title="Transcriptional" id="mwFQ" class="mw-redirect">transcriptional</a> and <a rel="mw:WikiLink" href="./Epigenetic" title="Epigenetic" id="mwFg" class="mw-redirect">epigenetic</a> mechanisms and develops over time from chronically high levels of exposure to an addictive stimulus (e.g., eating food, the use of cocaine, engagement in sexual activity, participation in high-thrill cultural activities such as gambling, etc.).<sup about="#mwt49" class="mw-ref" id="cite_ref-Cellular_basis_3-4" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Cellular basis"}}'><a href="./Addiction#cite_note-Cellular_basis-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></sup><sup about="#mwt51" class="mw-ref" id="cite_ref-What_the_ΔFosB?_11-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"What the ΔFosB?"}}'><a href="./Addiction#cite_note-What_the_ΔFosB?-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></sup><sup about="#mwt53" class="mw-ref" id="cite_ref-Natural_and_drug_addictions_12-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Natural and drug addictions"}}'><a href="./Addiction#cite_note-Natural_and_drug_addictions-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></sup> <a rel="mw:WikiLink" href="./ΔFosB" title="ΔFosB" id="mwFw" class="mw-redirect">ΔFosB</a>, a gene <a rel="mw:WikiLink" href="./Transcription_factor" title="Transcription factor" id="mwGA">transcription factor</a>, is a critical component and common factor in the development of virtually all forms of behavioral and drug addictions.<sup about="#mwt55" class="mw-ref" id="cite_ref-What_the_ΔFosB?_11-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"What the ΔFosB?"}}'><a href="./Addiction#cite_note-What_the_ΔFosB?-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></sup><sup about="#mwt57" class="mw-ref" id="cite_ref-Natural_and_drug_addictions_12-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Natural and drug addictions"}}'><a href="./Addiction#cite_note-Natural_and_drug_addictions-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></sup><sup about="#mwt59" class="mw-ref" id="cite_ref-G9a_reverses_ΔFosB_plasticity_13-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"G9a reverses ΔFosB plasticity"}}'><a href="./Addiction#cite_note-G9a_reverses_ΔFosB_plasticity-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></sup><sup about="#mwt61" class="mw-ref" id="cite_ref-Nestler_14-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Nestler"}}'><a href="./Addiction#cite_note-Nestler-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></sup> Two decades of research into ΔFosB's role in addiction have demonstrated that addiction arises, and the associated compulsive behavior intensifies or attenuates, along with the <a rel="mw:WikiLink" href="./Overexpression" title="Overexpression" id="mwGQ" class="mw-redirect">overexpression</a> of ΔFosB in the <a rel="mw:WikiLink" href="./D1-type" title="D1-type" id="mwGg" class="mw-redirect">D1-type</a> <a rel="mw:WikiLink" href="./Medium_spiny_neuron" title="Medium spiny neuron" id="mwGw">medium spiny neurons</a> of the <a rel="mw:WikiLink" href="./Nucleus_accumbens" title="Nucleus accumbens" id="mwHA">nucleus accumbens</a>.<sup about="#mwt63" class="mw-ref" id="cite_ref-Cellular_basis_3-5" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Cellular basis"}}'><a href="./Addiction#cite_note-Cellular_basis-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></sup><sup about="#mwt65" class="mw-ref" id="cite_ref-What_the_ΔFosB?_11-2" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"What the ΔFosB?"}}'><a href="./Addiction#cite_note-What_the_ΔFosB?-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></sup><sup about="#mwt67" class="mw-ref" id="cite_ref-Natural_and_drug_addictions_12-2" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Natural and drug addictions"}}'><a href="./Addiction#cite_note-Natural_and_drug_addictions-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></sup><sup about="#mwt69" class="mw-ref" id="cite_ref-G9a_reverses_ΔFosB_plasticity_13-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"G9a reverses ΔFosB plasticity"}}'><a href="./Addiction#cite_note-G9a_reverses_ΔFosB_plasticity-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></sup> Due to the causal relationship between ΔFosB expression and addictions, it is used <a rel="mw:WikiLink" href="./Preclinical_research" title="Preclinical research" id="mwHQ" class="mw-redirect">preclinically</a> as an addiction <a rel="mw:WikiLink" href="./Biomarker_(medicine)" title="Biomarker (medicine)" id="mwHg">biomarker</a>.<sup about="#mwt71" class="mw-ref" id="cite_ref-Cellular_basis_3-6" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Cellular basis"}}'><a href="./Addiction#cite_note-Cellular_basis-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></sup><sup about="#mwt1283" class="mw-ref" id="cite_ref-What_the_ΔFosB?_11-3" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"What the ΔFosB?"},"body":{"id":"mw-reference-text-cite_note-What_the_ΔFosB?-11"}}'><a href="./Addiction#cite_note-What_the_ΔFosB?-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></sup><sup about="#mwt1285" class="mw-ref" id="cite_ref-G9a_reverses_ΔFosB_plasticity_13-2" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"G9a reverses ΔFosB plasticity"},"body":{"id":"mw-reference-text-cite_note-G9a_reverses_ΔFosB_plasticity-13"}}'><a href="./Addiction#cite_note-G9a_reverses_ΔFosB_plasticity-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></sup>  ΔFosB expression in these neurons directly and positively regulates drug <a rel="mw:WikiLink" href="./Self-administration" title="Self-administration" id="mwHw">self-administration</a> and <a rel="mw:WikiLink" href="./Addiction#Sensitization" id="mwIA">reward sensitization</a> through <a rel="mw:WikiLink" href="./Positive_reinforcement" title="Positive reinforcement" id="mwIQ" class="mw-redirect">positive reinforcement</a>, while decreasing sensitivity to <a rel="mw:WikiLink/Interwiki" href="https://en.wiktionary.org/wiki/aversion" title="wikt:aversion" id="mwIg">aversion</a>.<sup about="#mwt47" class="mw-ref" id="cite_ref-ΔFosB_behaviors_15-0" rel="dc:references" typeof="mw:Transclusion  mw:Extension/ref" data-mw='{"parts":[{"template":{"target":{"wt":"#tag:ref","function":"tag"},"params":{"1":{"wt":"A decrease in aversion sensitivity, in simpler terms, means that an individual&apos;s behavior is less likely to be influenced by undesirable outcomes."},"group":{"wt":"\"note\""},"name":{"wt":"\"ΔFosB behaviors\""}},"i":0}}]}'><a href="./Addiction#cite_note-ΔFosB_behaviors-15" style="counter-reset: mw-Ref 1;" data-mw-group="note"><span class="mw-reflink-text">[note 1]</span></a></sup><sup about="#mwt73" class="mw-ref" id="cite_ref-Cellular_basis_3-7" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Cellular basis"}}'><a href="./Addiction#cite_note-Cellular_basis-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></sup><sup about="#mwt75" class="mw-ref" id="cite_ref-What_the_ΔFosB?_11-4" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"What the ΔFosB?"}}'><a href="./Addiction#cite_note-What_the_ΔFosB?-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></sup></p>

<p id="mwIw">Addiction exacts an "astoundingly high financial and human toll" on individuals and society as a whole.<sup about="#mwt1287" class="mw-ref" id="cite_ref-Societal_toll_16-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Societal toll"},"body":{"id":"mw-reference-text-cite_note-Societal_toll-16"}}'><a href="./Addiction#cite_note-Societal_toll-16" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></sup><sup about="#mwt1289" class="mw-ref" id="cite_ref-Epidem_17-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Epidem"},"body":{"id":"mw-reference-text-cite_note-Epidem-17"}}'><a href="./Addiction#cite_note-Epidem-17" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></sup><sup about="#mwt92" class="mw-ref" id="cite_ref-ABAM_18-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"ABAM"}}'><a href="./Addiction#cite_note-ABAM-18" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></sup> In the United States, the total economic cost to society is greater than that of all types of <a rel="mw:WikiLink" href="./Diabetes" title="Diabetes" id="mwJA" class="mw-redirect">diabetes</a> and all <a rel="mw:WikiLink" href="./Cancer" title="Cancer" id="mwJQ">cancers</a> combined.<sup about="#mwt94" class="mw-ref" id="cite_ref-ABAM_18-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"ABAM"}}'><a href="./Addiction#cite_note-ABAM-18" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></sup> These costs arise from the direct adverse effects of drugs and associated healthcare costs (e.g., <a rel="mw:WikiLink" href="./Emergency_medical_services" title="Emergency medical services" id="mwJg">emergency medical services</a> and <a rel="mw:WikiLink" href="./Patient#Outpatients_and_inpatients" title="Patient" id="mwJw">outpatient and inpatient care</a>), <a rel="mw:WikiLink" href="./Sequela" title="Sequela" id="mwKA">long-term complications</a> (e.g., <a rel="mw:WikiLink" href="./Lung_cancer" title="Lung cancer" id="mwKQ">lung cancer</a> from smoking <a rel="mw:WikiLink" href="./Tobacco_products" title="Tobacco products" id="mwKg">tobacco products</a>, <a rel="mw:WikiLink" href="./Liver_cirrhosis" title="Liver cirrhosis" id="mwKw" class="mw-redirect">liver cirrhosis</a> and <a rel="mw:WikiLink" href="./Alcohol-related_dementia" title="Alcohol-related dementia" id="mwLA">dementia</a> from chronic <a rel="mw:WikiLink" href="./Alcohol_(drug)" title="Alcohol (drug)" id="mwLQ">alcohol</a> consumption, and <a rel="mw:WikiLink" href="./Meth_mouth" title="Meth mouth" id="mwLg">meth mouth</a> from <a rel="mw:WikiLink" href="./Methamphetamine" title="Methamphetamine" id="mwLw">methamphetamine</a> use), the loss of productivity and associated <a rel="mw:WikiLink" href="./Welfare" title="Welfare" id="mwMA">welfare</a> costs, fatal and non-fatal <a rel="mw:WikiLink" href="./Accident" title="Accident" id="mwMQ">accidents</a> (e.g., <a rel="mw:WikiLink" href="./Traffic_collision" title="Traffic collision" id="mwMg">traffic collisions</a>), suicides, homicides, and incarceration, among others.<sup about="#mwt96" class="mw-ref" id="cite_ref-Societal_toll_16-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Societal toll"}}'><a href="./Addiction#cite_note-Societal_toll-16" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></sup><sup about="#mwt98" class="mw-ref" id="cite_ref-Epidem_17-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Epidem"}}'><a href="./Addiction#cite_note-Epidem-17" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></sup><sup about="#mwt100" class="mw-ref" id="cite_ref-ABAM_18-2" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"ABAM"}}'><a href="./Addiction#cite_note-ABAM-18" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></sup><sup about="#mwt1291" class="mw-ref" id="cite_ref-INCB_2013_19-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"INCB 2013"},"body":{"id":"mw-reference-text-cite_note-INCB_2013-19"}}'><a href="./Addiction#cite_note-INCB_2013-19" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></sup> Classic hallmarks of addiction include impaired control over substances or behavior, preoccupation with substance or behavior, and continued use despite consequences.<sup about="#mwt1293" class="mw-ref" id="cite_ref-pmid1501306_20-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"pmid1501306"},"body":{"id":"mw-reference-text-cite_note-pmid1501306-20"}}'><a href="./Addiction#cite_note-pmid1501306-20" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></sup> Habits and patterns associated with addiction are typically characterized by immediate gratification (short-term reward), coupled with delayed deleterious effects (long-term costs).<sup about="#mwt1295" class="mw-ref" id="cite_ref-pmid3278676_21-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"pmid3278676"},"body":{"id":"mw-reference-text-cite_note-pmid3278676-21"}}'><a href="./Addiction#cite_note-pmid3278676-21" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></sup></p>

<p id="mwMw">Examples of drug and behavioral addictions include <a rel="mw:WikiLink" href="./Alcoholism" title="Alcoholism" id="mwNA">alcoholism</a>, <a rel="mw:WikiLink" href="./Cannabis_use_disorder" title="Cannabis use disorder" id="mwNQ">marijuana addiction</a>, <a rel="mw:WikiLink" href="./Amphetamine_addiction" title="Amphetamine addiction" id="mwNg" class="mw-redirect">amphetamine addiction</a>, <a rel="mw:WikiLink" href="./Cocaine_addiction" title="Cocaine addiction" id="mwNw" class="mw-redirect">cocaine addiction</a>, <a rel="mw:WikiLink" href="./Nicotine#Reinforcement_disorders" title="Nicotine" id="mwOA">nicotine addiction</a>, <a rel="mw:WikiLink" href="./Opioid_use_disorder" title="Opioid use disorder" id="mwOQ">opioid addiction</a>, <a rel="mw:WikiLink" href="./Food_addiction" title="Food addiction" id="mwOg">food addiction</a>, <a rel="mw:WikiLink" href="./Gambling_addiction" title="Gambling addiction" id="mwOw" class="mw-redirect">gambling addiction</a>, and <a rel="mw:WikiLink" href="./Sexual_addiction" title="Sexual addiction" id="mwPA">sexual addiction</a>. The only behavioral addiction recognized by the <a rel="mw:WikiLink" href="./DSM-5" title="DSM-5" id="mwPQ">DSM-5</a> and the <a rel="mw:WikiLink" href="./ICD-10" title="ICD-10" id="mwPg">ICD-10</a> is gambling addiction.  The term <i id="mwPw">addiction</i> is misused frequently to refer to other compulsive behaviors or disorders, particularly <i id="mwQA"><a rel="mw:WikiLink" href="./Substance_dependence" title="Substance dependence" id="mwQQ">dependence</a></i>, in news media.<sup about="#mwt1297" class="mw-ref" id="cite_ref-Addiction-dependence_distinction_22-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Addiction-dependence distinction"},"body":{"id":"mw-reference-text-cite_note-Addiction-dependence_distinction-22"}}'><a href="./Addiction#cite_note-Addiction-dependence_distinction-22" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></sup> An important distinction between drug addiction and dependence is that drug dependence is a disorder in which cessation of drug use results in an unpleasant state of <a rel="mw:WikiLink" href="./Drug_withdrawal" title="Drug withdrawal" id="mwQg">withdrawal</a>, which can lead to further drug use.<sup about="#mwt105" class="mw-ref" id="cite_ref-NHMH_3e_terms-DSM_flaw_23-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"NHMH_3e terms-DSM flaw"}}'><a href="./Addiction#cite_note-NHMH_3e_terms-DSM_flaw-23" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></sup>  Addiction is the compulsive use of a substance or performance of a behavior that is independent of withdrawal. Addiction can occur in the absence of dependence, and dependence can occur in the absence of addiction, although the two often occur together.</p>
<style data-mw-deduplicate="TemplateStyles:r872693506" typeof="mw:Extension/templatestyles mw:Transclusion" about="#mwt106" data-mw='{"parts":[{"template":{"target":{"wt":"TOC limit","href":"./Template:TOC_limit"},"params":{"1":{"wt":"3"}},"i":0}}]}' id="mwQw">.mw-parser-output .toclimit-2 .toclevel-1 ul,.mw-parser-output .toclimit-3 .toclevel-2 ul,.mw-parser-output .toclimit-4 .toclevel-3 ul,.mw-parser-output .toclimit-5 .toclevel-4 ul,.mw-parser-output .toclimit-6 .toclevel-5 ul,.mw-parser-output .toclimit-7 .toclevel-6 ul{display:none}</style><div class="toclimit-3" about="#mwt106" id="mwRA"><meta property="mw:PageProp/toc"/></div>

</section><section data-mw-section-id="1" id="mwRQ"><h2 id="Neuropsychology">Neuropsychology</h2>
<table class="box-Expand_section plainlinks metadata ambox mbox-small-left ambox-content" role="presentation" about="#mwt107" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"expand section","href":"./Template:Expand_section"},"params":{"date":{"wt":"February 2016"}},"i":0}}]}' id="mwRg"><tbody><tr><td class="mbox-image"><figure-inline typeof="mw:Image mw:ExpandedAttrs" about="#mwt757" data-mw='{"attribs":[["alt",{"html":"alt=&lt;span typeof=\"mw:Entity\" data-parsoid=&apos;{\"src\":\"&amp;amp;#91;\",\"srcContent\":\"[\"}&apos;>[&lt;/span>icon&lt;span typeof=\"mw:Entity\" data-parsoid=&apos;{\"src\":\"&amp;amp;#93;\",\"srcContent\":\"]\"}&apos;>]&lt;/span>","txt":"[icon]"}]]}'><a href="./File:Wiki_letter_w_cropped.svg"><img alt="[icon]" resource="./File:Wiki_letter_w_cropped.svg" src="//upload.wikimedia.org/wikipedia/commons/thumb/1/1c/Wiki_letter_w_cropped.svg/20px-Wiki_letter_w_cropped.svg.png" data-file-width="44" data-file-height="31" data-file-type="drawing" height="14" width="20" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/1/1c/Wiki_letter_w_cropped.svg/40px-Wiki_letter_w_cropped.svg.png 2x, //upload.wikimedia.org/wikipedia/commons/thumb/1/1c/Wiki_letter_w_cropped.svg/30px-Wiki_letter_w_cropped.svg.png 1.5x"/></a></figure-inline></td><td class="mbox-text"><div class="mbox-text-span">This section <b>needs expansion</b>. <small>You can help by <a rel="mw:ExtLink" class="external text" href="//en.wikipedia.org/w/index.php?title=Addiction&amp;action=edit&amp;section=">adding to it</a>.</small>  <small class="date-container"><i>(<span class="date">February 2016</span>)</i></small></div></td></tr></tbody></table><link rel="mw:PageProp/Category" href="./Category:Articles_to_be_expanded_from_February_2016" about="#mwt107"/><link rel="mw:PageProp/Category" href="./Category:All_articles_to_be_expanded" about="#mwt107"/><link rel="mw:PageProp/Category" href="./Category:Articles_using_small_message_boxes" about="#mwt107" id="mwRw"/>
<p id="mwSA"><a rel="mw:WikiLink" href="./Cognitive_control" title="Cognitive control" id="mwSQ" class="mw-redirect">Cognitive control</a> and <a rel="mw:WikiLink" href="./Stimulus_control" title="Stimulus control" id="mwSg">stimulus control</a>, which is associated with <a rel="mw:WikiLink" href="./Operant_conditioning" title="Operant conditioning" id="mwSw">operant</a> and <a rel="mw:WikiLink" href="./Classical_conditioning" title="Classical conditioning" id="mwTA">classical conditioning</a>, represent opposite processes (i.e., internal vs external or environmental, respectively) that compete over the control of an individual's elicited behaviors.<sup about="#mwt1299" class="mw-ref" id="cite_ref-Cognitive_-_stimulus_24-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Cognitive - stimulus"},"body":{"id":"mw-reference-text-cite_note-Cognitive_-_stimulus-24"}}'><a href="./Addiction#cite_note-Cognitive_-_stimulus-24" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></sup> Cognitive control, and particularly <a rel="mw:WikiLink" href="./Inhibitory_control" title="Inhibitory control" id="mwTQ">inhibitory control over behavior</a>, is impaired in both addiction and <a rel="mw:WikiLink" href="./Attention_deficit_hyperactivity_disorder" title="Attention deficit hyperactivity disorder" id="mwTg">attention deficit hyperactivity disorder</a>.<sup about="#mwt1301" class="mw-ref" id="cite_ref-Executive_functions_25-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Executive functions"},"body":{"id":"mw-reference-text-cite_note-Executive_functions-25"}}'><a href="./Addiction#cite_note-Executive_functions-25" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></sup><sup about="#mwt1303" class="mw-ref" id="cite_ref-NHM-Cognitive_Control_26-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"NHM-Cognitive Control"},"body":{"id":"mw-reference-text-cite_note-NHM-Cognitive_Control-26"}}'><a href="./Addiction#cite_note-NHM-Cognitive_Control-26" style="counter-reset: mw-Ref 25;"><span class="mw-reflink-text">[25]</span></a></sup> Stimulus-driven behavioral responses (i.e., stimulus control) that are associated with a particular <a rel="mw:WikiLink" href="./Rewarding_stimulus" title="Rewarding stimulus" id="mwTw" class="mw-redirect">rewarding stimulus</a> tend to dominate one's behavior in an addiction.<sup about="#mwt116" class="mw-ref" id="cite_ref-NHM-Cognitive_Control_26-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"NHM-Cognitive Control"}}'><a href="./Addiction#cite_note-NHM-Cognitive_Control-26" style="counter-reset: mw-Ref 25;"><span class="mw-reflink-text">[25]</span></a></sup></p>

<section data-mw-section-id="2" id="mwUA"><h3 id="Stimulus_control_of_behavior">Stimulus control of behavior</h3>
<div role="note" class="hatnote navigation-not-searchable" about="#mwt117" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"see also","href":"./Template:See_also"},"params":{"1":{"wt":"Stimulus control"}},"i":0}}]}' id="mwUQ">See also: <a rel="mw:WikiLink" href="./Stimulus_control" title="Stimulus control">Stimulus control</a></div>

</section><section data-mw-section-id="3" id="mwUg"><h3 id="Cognitive_control_of_behavior">Cognitive control of behavior</h3>
<div role="note" class="hatnote navigation-not-searchable" about="#mwt118" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"see also","href":"./Template:See_also"},"params":{"1":{"wt":"Cognitive control"}},"i":0}}]}' id="mwUw">See also: <a rel="mw:WikiLink" href="./Cognitive_control" title="Cognitive control" class="mw-redirect">Cognitive control</a></div>

</section></section><section data-mw-section-id="4" id="mwVA"><h2 id="Behavioral_addiction">Behavioral addiction</h2>
<div role="note" class="hatnote navigation-not-searchable" about="#mwt119" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"Main","href":"./Template:Main"},"params":{"1":{"wt":"Behavioral addiction"}},"i":0}}]}' id="mwVQ">Main article: <a rel="mw:WikiLink" href="./Behavioral_addiction" title="Behavioral addiction">Behavioral addiction</a></div>
<p id="mwVg">The term <i id="mwVw">behavioral addiction</i> refers to a <a rel="mw:WikiLink" href="./Compulsive_behavior" title="Compulsive behavior" id="mwWA">compulsion</a> to engage in a <a rel="mw:WikiLink" href="./Natural_reward" title="Natural reward" id="mwWQ" class="mw-redirect">natural reward</a> – which is a behavior that is inherently rewarding (i.e., desirable or appealing) – despite adverse consequences.<sup about="#mwt1305" class="mw-ref" id="cite_ref-NHM_addiction-reward-reinforcement_7-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"NHM addiction-reward-reinforcement"},"body":{"id":"mw-reference-text-cite_note-NHM_addiction-reward-reinforcement-7"}}'><a href="./Addiction#cite_note-NHM_addiction-reward-reinforcement-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></sup><sup about="#mwt129" class="mw-ref" id="cite_ref-Natural_and_drug_addictions_12-3" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Natural and drug addictions"}}'><a href="./Addiction#cite_note-Natural_and_drug_addictions-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></sup><sup about="#mwt131" class="mw-ref" id="cite_ref-Nestler_14-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Nestler"}}'><a href="./Addiction#cite_note-Nestler-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></sup> Preclinical evidence has demonstrated that marked increases in the expression of ΔFosB through repetitive and excessive exposure to a natural reward induces the same behavioral effects and <a rel="mw:WikiLink" href="./Neuroplasticity" title="Neuroplasticity" id="mwWg">neuroplasticity</a> as occurs in a drug addiction.<sup about="#mwt133" class="mw-ref" id="cite_ref-Natural_and_drug_addictions_12-4" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Natural and drug addictions"}}'><a href="./Addiction#cite_note-Natural_and_drug_addictions-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></sup><sup about="#mwt135" class="mw-ref" id="cite_ref-Systematic_review_-_yet_another_DSM_fail_27-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Systematic review - yet another DSM fail"}}'><a href="./Addiction#cite_note-Systematic_review_-_yet_another_DSM_fail-27" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></sup><sup about="#mwt137" class="mw-ref" id="cite_ref-Amph-Sex_X-sensitization_through_D1_signaling_28-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Amph-Sex X-sensitization through D1 signaling"}}'><a href="./Addiction#cite_note-Amph-Sex_X-sensitization_through_D1_signaling-28" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></sup><sup about="#mwt139" class="mw-ref" id="cite_ref-Amph-Sex_X-sensitization_through_NMDA_signaling_29-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Amph-Sex X-sensitization through NMDA signaling"}}'><a href="./Addiction#cite_note-Amph-Sex_X-sensitization_through_NMDA_signaling-29" style="counter-reset: mw-Ref 28;"><span class="mw-reflink-text">[28]</span></a></sup></p>

<p id="mwWw">Reviews of both clinical research in humans and preclinical studies involving ΔFosB have identified compulsive sexual activity – specifically, any form of <a rel="mw:WikiLink" href="./Sexual_intercourse" title="Sexual intercourse" id="mwXA">sexual intercourse</a> – as an addiction (i.e., <a rel="mw:WikiLink" href="./Sexual_addiction" title="Sexual addiction" id="mwXQ">sexual addiction</a>).<sup about="#mwt150" class="mw-ref" id="cite_ref-Natural_and_drug_addictions_12-5" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Natural and drug addictions"}}'><a href="./Addiction#cite_note-Natural_and_drug_addictions-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></sup><sup about="#mwt152" class="mw-ref" id="cite_ref-Systematic_review_-_yet_another_DSM_fail_27-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Systematic review - yet another DSM fail"}}'><a href="./Addiction#cite_note-Systematic_review_-_yet_another_DSM_fail-27" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></sup> Moreover, <a rel="mw:WikiLink" href="./Addiction#Reward_sensitization" id="mwXg">reward cross-sensitization</a> between <a rel="mw:WikiLink" href="./Amphetamine" title="Amphetamine" id="mwXw">amphetamine</a> and sexual activity, meaning that exposure to one increases the desire for both, has been shown to occur preclinically and clinically as a <a rel="mw:WikiLink" href="./Dopamine_dysregulation_syndrome" title="Dopamine dysregulation syndrome" id="mwYA">dopamine dysregulation syndrome</a>;<sup about="#mwt154" class="mw-ref" id="cite_ref-Natural_and_drug_addictions_12-6" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Natural and drug addictions"}}'><a href="./Addiction#cite_note-Natural_and_drug_addictions-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></sup><sup about="#mwt156" class="mw-ref" id="cite_ref-Systematic_review_-_yet_another_DSM_fail_27-2" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Systematic review - yet another DSM fail"}}'><a href="./Addiction#cite_note-Systematic_review_-_yet_another_DSM_fail-27" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></sup><sup about="#mwt158" class="mw-ref" id="cite_ref-Amph-Sex_X-sensitization_through_D1_signaling_28-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Amph-Sex X-sensitization through D1 signaling"}}'><a href="./Addiction#cite_note-Amph-Sex_X-sensitization_through_D1_signaling-28" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></sup><sup about="#mwt160" class="mw-ref" id="cite_ref-Amph-Sex_X-sensitization_through_NMDA_signaling_29-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Amph-Sex X-sensitization through NMDA signaling"}}'><a href="./Addiction#cite_note-Amph-Sex_X-sensitization_through_NMDA_signaling-29" style="counter-reset: mw-Ref 28;"><span class="mw-reflink-text">[28]</span></a></sup> ΔFosB <a rel="mw:WikiLink" href="./Gene_expression" title="Gene expression" id="mwYQ">expression</a> is required for this cross-sensitization effect, which intensifies with the level of ΔFosB expression.<sup about="#mwt162" class="mw-ref" id="cite_ref-Natural_and_drug_addictions_12-7" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Natural and drug addictions"}}'><a href="./Addiction#cite_note-Natural_and_drug_addictions-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></sup><sup about="#mwt164" class="mw-ref" id="cite_ref-Amph-Sex_X-sensitization_through_D1_signaling_28-2" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Amph-Sex X-sensitization through D1 signaling"}}'><a href="./Addiction#cite_note-Amph-Sex_X-sensitization_through_D1_signaling-28" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></sup><sup about="#mwt166" class="mw-ref" id="cite_ref-Amph-Sex_X-sensitization_through_NMDA_signaling_29-2" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Amph-Sex X-sensitization through NMDA signaling"}}'><a href="./Addiction#cite_note-Amph-Sex_X-sensitization_through_NMDA_signaling-29" style="counter-reset: mw-Ref 28;"><span class="mw-reflink-text">[28]</span></a></sup></p>

<p id="mwYg">Reviews of preclinical studies indicate that long-term frequent and excessive consumption of high fat or sugar foods can produce an addiction (<a rel="mw:WikiLink" href="./Food_addiction" title="Food addiction" id="mwYw">food addiction</a>).<sup about="#mwt170" class="mw-ref" id="cite_ref-Natural_and_drug_addictions_12-8" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Natural and drug addictions"}}'><a href="./Addiction#cite_note-Natural_and_drug_addictions-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></sup><sup about="#mwt172" class="mw-ref" id="cite_ref-Nestler_14-2" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Nestler"}}'><a href="./Addiction#cite_note-Nestler-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></sup></p>

<p id="mwZA">Gambling is a natural reward which is associated with compulsive behavior and for which clinical diagnostic manuals, namely the <a rel="mw:WikiLink" href="./DSM-5" title="DSM-5" id="mwZQ">DSM-5</a>, have identified diagnostic criteria for an "addiction".<sup about="#mwt180" class="mw-ref" id="cite_ref-Natural_and_drug_addictions_12-9" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Natural and drug addictions"}}'><a href="./Addiction#cite_note-Natural_and_drug_addictions-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></sup> In order for a person's gambling behavior to meet criteria of an addiction, it shows certain characteristics, such as mood modification, compulsivity, and withdrawal. There is evidence from functional neuroimaging that gambling activates the reward system and the <a rel="mw:WikiLink" href="./Mesolimbic_pathway" title="Mesolimbic pathway" id="mwZg">mesolimbic pathway</a> in particular.<sup about="#mwt182" class="mw-ref" id="cite_ref-Natural_and_drug_addictions_12-10" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Natural and drug addictions"}}'><a href="./Addiction#cite_note-Natural_and_drug_addictions-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></sup><sup about="#mwt184" class="mw-ref" id="cite_ref-Behavioral_addictions_30-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Behavioral addictions"}}'><a href="./Addiction#cite_note-Behavioral_addictions-30" style="counter-reset: mw-Ref 29;"><span class="mw-reflink-text">[29]</span></a></sup>  Similarly, shopping and playing video games are associated with compulsive behaviors in humans and have also been shown to activate the mesolimbic pathway and other parts of the reward system.<sup about="#mwt186" class="mw-ref" id="cite_ref-Natural_and_drug_addictions_12-11" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Natural and drug addictions"}}'><a href="./Addiction#cite_note-Natural_and_drug_addictions-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></sup> Based upon this evidence, <a rel="mw:WikiLink" href="./Gambling_addiction" title="Gambling addiction" id="mwZw" class="mw-redirect">gambling addiction</a>, <a rel="mw:WikiLink" href="./Video_game_addiction" title="Video game addiction" id="mwaA">video game addiction</a>, and <a rel="mw:WikiLink" href="./Shopping_addiction" title="Shopping addiction" id="mwaQ">shopping addiction</a> are classified accordingly.<sup about="#mwt188" class="mw-ref" id="cite_ref-Natural_and_drug_addictions_12-12" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Natural and drug addictions"}}'><a href="./Addiction#cite_note-Natural_and_drug_addictions-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></sup><sup about="#mwt190" class="mw-ref" id="cite_ref-Behavioral_addictions_30-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Behavioral addictions"}}'><a href="./Addiction#cite_note-Behavioral_addictions-30" style="counter-reset: mw-Ref 29;"><span class="mw-reflink-text">[29]</span></a></sup></p>

</section><section data-mw-section-id="5" id="mwag"><h2 id="Risk_factors">Risk factors</h2>
<div role="note" class="hatnote navigation-not-searchable" about="#mwt191" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"See","href":"./Template:See"},"params":{"1":{"wt":"Addiction vulnerability"}},"i":0}}]}' id="mwaw">Further information: <a rel="mw:WikiLink" href="./Addiction_vulnerability" title="Addiction vulnerability">Addiction vulnerability</a></div>

<p id="mwbA">There are a number of genetic and environmental risk factors for developing an addiction, that vary across the population.<sup about="#mwt198" class="mw-ref" id="cite_ref-Cellular_basis_3-8" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Cellular basis"}}'><a href="./Addiction#cite_note-Cellular_basis-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></sup><sup about="#mwt200" class="mw-ref" id="cite_ref-Transgenerational_epigenetic_inheritance_in_addiction_31-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Transgenerational epigenetic inheritance in addiction"}}'><a href="./Addiction#cite_note-Transgenerational_epigenetic_inheritance_in_addiction-31" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></sup> Genetic and environmental risk factors each account for roughly half of an individual's risk for developing an addiction;<sup about="#mwt202" class="mw-ref" id="cite_ref-Cellular_basis_3-9" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Cellular basis"}}'><a href="./Addiction#cite_note-Cellular_basis-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></sup> the contribution from epigenetic risk factors to the total risk is unknown.<sup about="#mwt204" class="mw-ref" id="cite_ref-Transgenerational_epigenetic_inheritance_in_addiction_31-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Transgenerational epigenetic inheritance in addiction"}}'><a href="./Addiction#cite_note-Transgenerational_epigenetic_inheritance_in_addiction-31" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></sup> Even in individuals with a relatively low genetic risk, exposure to sufficiently high doses of an addictive drug for a long period of time (e.g., weeks–months) can result in an addiction.<sup about="#mwt206" class="mw-ref" id="cite_ref-Cellular_basis_3-10" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Cellular basis"}}'><a href="./Addiction#cite_note-Cellular_basis-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></sup></p>

<section data-mw-section-id="6" id="mwbQ"><h3 id="Genetic_factors">Genetic factors</h3>
<div role="note" class="hatnote navigation-not-searchable" about="#mwt207" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"See also","href":"./Template:See_also"},"params":{"1":{"wt":"Alcoholism#Genetic variation"}},"i":0}}]}' id="mwbg">See also: <a rel="mw:WikiLink" href="./Alcoholism#Genetic_variation" title="Alcoholism">Alcoholism §<span typeof="mw:Entity"> </span>Genetic variation</a></div>

<p id="mwbw">It has long been established that genetic factors along with environmental (e.g., psychosocial) factors are significant contributors to addiction vulnerability.<sup about="#mwt215" class="mw-ref" id="cite_ref-Cellular_basis_3-11" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Cellular basis"}}'><a href="./Addiction#cite_note-Cellular_basis-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></sup><sup about="#mwt217" class="mw-ref" id="cite_ref-Transgenerational_epigenetic_inheritance_in_addiction_31-2" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Transgenerational epigenetic inheritance in addiction"}}'><a href="./Addiction#cite_note-Transgenerational_epigenetic_inheritance_in_addiction-31" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></sup> <a rel="mw:WikiLink" href="./Epidemiological_method" title="Epidemiological method" id="mwcA">Epidemiological</a> studies estimate that genetic factors account for 40–60% of the risk factors for <a rel="mw:WikiLink" href="./Alcoholism" title="Alcoholism" id="mwcQ">alcoholism</a>.<link rel="mw:PageProp/Category" href="./Category:All_articles_with_unsourced_statements" about="#mwt212" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"Citation needed","href":"./Template:Citation_needed"},"params":{"date":{"wt":"June 2018"}},"i":0}}]}' id="mwcg"/><link rel="mw:PageProp/Category" href="./Category:Articles_with_unsourced_statements_from_June_2018" about="#mwt212"/><sup class="noprint Inline-Template Template-Fact" style="white-space:nowrap;" about="#mwt212" id="mwcw"><span typeof="mw:Entity">[</span><i><a rel="mw:WikiLink" href="./Wikipedia:Citation_needed" title="Wikipedia:Citation needed"><span title="This claim needs references to reliable sources. (June 2018)">citation needed</span></a></i><span typeof="mw:Entity">]</span></sup> Similar rates of heritability for other types of drug addiction have been indicated by other studies.<sup about="#mwt219" class="mw-ref" id="cite_ref-Kendler94_32-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Kendler94"}}'><a href="./Addiction#cite_note-Kendler94-32" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></sup> Knestler hypothesized in 1964 that a gene or group of genes might contribute to predisposition to addiction in several ways. For example, altered levels of a normal protein due to environmental factors could then change the structure or functioning of specific brain neurons during development. These altered brain neurons could change the susceptibility of an individual to an initial drug use experience. In support of this hypothesis, animal studies have shown that environmental factors such as stress can affect an animal's genotype.<sup about="#mwt1261" class="mw-ref" id="cite_ref-Kendler94_32-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Kendler94"},"body":{"id":"mw-reference-text-cite_note-Kendler94-32"}}'><a href="./Addiction#cite_note-Kendler94-32" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></sup></p>

<p id="mwdA">Overall, the data implicating specific genes in the development of drug addiction is mixed for most genes. One reason for this may be that the case is due to a focus of current research on common variants. Many addiction studies focus on common variants with an allele frequency of greater than 5% in the general population; however, when associated with disease, these only confer a small amount of additional risk with an odds ratio of 1.1–1.3 percent. On the other hand, the rare variant hypothesis states that genes with low frequencies in the population (&lt;1%) confer much greater additional risk in the development of the disease.<sup about="#mwt1263" class="mw-ref" id="cite_ref-pmid23454283_33-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"pmid23454283"},"body":{"id":"mw-reference-text-cite_note-pmid23454283-33"}}'><a href="./Addiction#cite_note-pmid23454283-33" style="counter-reset: mw-Ref 32;"><span class="mw-reflink-text">[32]</span></a></sup></p>

<p id="mwdQ"><a rel="mw:WikiLink" href="./Genome-wide_association_study" title="Genome-wide association study" id="mwdg">Genome-wide association studies</a> (GWAS) are used to examine genetic associations with dependence, addiction, and drug use. These studies employ an unbiased approach to finding genetic associations with specific phenotypes and give equal weight to all regions of DNA, including those with no ostensible relationship to drug metabolism or response. These studies rarely identify genes from proteins previously described via animal knockout models and candidate gene analysis. Instead, large percentages of genes involved in processes such as cell adhesion are commonly identified. This is not to say that previous findings, or the GWAS findings, are erroneous. The important effects of <a rel="mw:WikiLink" href="./Endophenotype" title="Endophenotype" id="mwdw">endophenotypes</a> are typically not capable of being captured by these methods. Furthermore, genes identified in GWAS for drug addiction may be involved either in adjusting brain behavior prior to drug experiences, subsequent to them, or both.
<sup about="#mwt1265" class="mw-ref" id="cite_ref-34" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{},"body":{"id":"mw-reference-text-cite_note-34"}}'><a href="./Addiction#cite_note-34" style="counter-reset: mw-Ref 33;"><span class="mw-reflink-text">[33]</span></a></sup></p>

<p id="mweA">A study that highlights the significant role genetics play in addiction is the twin studies. Twins have similar and sometimes identical genetics. Analyzing these genes in relation to genetics has helped geneticists understand how much of a role genes play in addiction. Studies performed on twins found that rarely did only one twin have an addiction. In most cases where at least one twin suffered from an addiction, both did, and often to the same substance.<sup about="#mwt1267" class="mw-ref" id="cite_ref-Crowe1991_35-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Crowe1991"},"body":{"id":"mw-reference-text-cite_note-Crowe1991-35"}}'><a href="./Addiction#cite_note-Crowe1991-35" style="counter-reset: mw-Ref 34;"><span class="mw-reflink-text">[34]</span></a></sup> Cross addiction is when already has a predisposed addiction and then starts to become addicted to something different. If one family member has a history of addiction, the chances of a relative or close family developing those same habits are much higher than one who has not been introduced to addiction at a young age.<sup about="#mwt1269" class="mw-ref" id="cite_ref-36" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{},"body":{"id":"mw-reference-text-cite_note-36"}}'><a href="./Addiction#cite_note-36" style="counter-reset: mw-Ref 35;"><span class="mw-reflink-text">[35]</span></a></sup> In a recent study done by the National Institute on Drug Abuse, from 2002 to 2017, overdose deaths have almost tripled amongst male and females. In 2017, 72,306 overdose deaths happened in the U.S. that were reported.<sup about="#mwt1271" class="mw-ref" id="cite_ref-37" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{},"body":{"id":"mw-reference-text-cite_note-37"}}'><a href="./Addiction#cite_note-37" style="counter-reset: mw-Ref 36;"><span class="mw-reflink-text">[36]</span></a></sup></p>

</section><section data-mw-section-id="7" id="mweQ"><h3 id="Environmental_factors">Environmental factors</h3>

<p id="mweg">Environmental risk factors for addiction are the experiences of an individual during their lifetime that interact with the individual's genetic composition to increase or decrease his or her vulnerability to addiction.<sup about="#mwt236" class="mw-ref" id="cite_ref-Cellular_basis_3-12" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Cellular basis"}}'><a href="./Addiction#cite_note-Cellular_basis-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></sup>  A number of different environmental factors have been implicated as risk factors for addiction, including various psychosocial stressors;<sup about="#mwt238" class="mw-ref" id="cite_ref-Cellular_basis_3-13" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Cellular basis"}}'><a href="./Addiction#cite_note-Cellular_basis-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></sup> however, an individual's exposure to an addictive drug is by far the most significant environmental risk factor for addiction.<sup about="#mwt240" class="mw-ref" id="cite_ref-Cellular_basis_3-14" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Cellular basis"}}'><a href="./Addiction#cite_note-Cellular_basis-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></sup> The <a rel="mw:WikiLink" href="./National_Institute_on_Drug_Abuse" title="National Institute on Drug Abuse" id="mwew">National Institute on Drug Abuse</a> (NIDA) cites lack of parental supervision, the prevalence of peer substance use, drug availability, and poverty as risk factors for substance use among children and adolescents.<sup about="#mwt1273" class="mw-ref" id="cite_ref-Abuse_38-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Abuse"},"body":{"id":"mw-reference-text-cite_note-Abuse-38"}}'><a href="./Addiction#cite_note-Abuse-38" style="counter-reset: mw-Ref 37;"><span class="mw-reflink-text">[37]</span></a></sup></p>

<p id="mwfA">Adverse childhood experiences (ACEs) are various forms of <a rel="mw:WikiLink" href="./Child_maltreatment" title="Child maltreatment" id="mwfQ" class="mw-redirect">maltreatment</a> and household dysfunction experienced in childhood. The <a rel="mw:WikiLink" href="./Adverse_Childhood_Experiences_Study" title="Adverse Childhood Experiences Study" id="mwfg">Adverse Childhood Experiences Study</a> by the <a rel="mw:WikiLink" href="./Centers_for_Disease_Control_and_Prevention" title="Centers for Disease Control and Prevention" id="mwfw">Centers for Disease Control and Prevention</a> has shown a strong <a rel="mw:WikiLink" href="./Dose–response_relationship" title="Dose–response relationship" id="mwgA">dose–response relationship</a> between ACEs and numerous health, social, and behavioral problems throughout a person's lifespan, including those associated with <a rel="mw:WikiLink" href="./Substance_abuse" title="Substance abuse" id="mwgQ">substance abuse</a>.<sup about="#mwt250" class="mw-ref" id="cite_ref-SAMHSA_ACE_39-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"SAMHSA_ACE"}}'><a href="./Addiction#cite_note-SAMHSA_ACE-39" style="counter-reset: mw-Ref 38;"><span class="mw-reflink-text">[38]</span></a></sup> Children's neurological development can be permanently disrupted when they are chronically exposed to stressful events such as physical, emotional, or sexual abuse, physical or emotional neglect, witnessing violence in the household, or  a parent being incarcerated or suffering from a mental illness. As a result, the child's cognitive functioning or ability to cope with negative or disruptive emotions may be impaired. Over time, the child may adopt substance use as a coping mechanism, particularly during <a rel="mw:WikiLink" href="./Adolescence" title="Adolescence" id="mwgg">adolescence</a>.<sup about="#mwt1275" class="mw-ref" id="cite_ref-SAMHSA_ACE_39-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"SAMHSA_ACE"},"body":{"id":"mw-reference-text-cite_note-SAMHSA_ACE-39"}}'><a href="./Addiction#cite_note-SAMHSA_ACE-39" style="counter-reset: mw-Ref 38;"><span class="mw-reflink-text">[38]</span></a></sup> A study of 900 court cases involving children who experienced abuse found that a vast amount of them went on to suffer from some form of addiction in their adolescence or adult life.<sup about="#mwt252" class="mw-ref" id="cite_ref-Enoch2011_40-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Enoch2011"}}'><a href="./Addiction#cite_note-Enoch2011-40" style="counter-reset: mw-Ref 39;"><span class="mw-reflink-text">[39]</span></a></sup> This pathway towards addiction that is opened through stressful experiences during childhood can be avoided by a change in environmental factors throughout an individual's life and opportunities of professional help.<sup about="#mwt1277" class="mw-ref" id="cite_ref-Enoch2011_40-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Enoch2011"},"body":{"id":"mw-reference-text-cite_note-Enoch2011-40"}}'><a href="./Addiction#cite_note-Enoch2011-40" style="counter-reset: mw-Ref 39;"><span class="mw-reflink-text">[39]</span></a></sup> If one has friends or peers who engage in drug use favorably, the chances of them developing an addiction increases. Family conflict and home management is also a cause for one to become engaged in drug or alcohol use.<sup about="#mwt1279" class="mw-ref" id="cite_ref-41" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{},"body":{"id":"mw-reference-text-cite_note-41"}}'><a href="./Addiction#cite_note-41" style="counter-reset: mw-Ref 40;"><span class="mw-reflink-text">[40]</span></a></sup></p>
<!--[[Psychological trauma|Traumatic experiences]] have been linked to the development of [[Substance&#x2D;related disorder|addictive and substance&#x2D;related problems]].<ref name="pmid8711018"&#x3E;{{cite journal | vauthors = Stewart SH | title = Alcohol abuse in individuals exposed to trauma: a critical review | journal = Psychological Bulletin | volume = 120 | issue = 1 | pages = 83–112 | date = July 1996 | pmid = 8711018 | doi = | url = }}</ref&#x3E;<ref&#x3E;{{cite book | vauthors = Bailey KM, Stewart SH | chapter = Relations among trauma, PTSD, and substance misuse: The scope of the problem. | title = Trauma and Substance Abuse: Causes, Consequences, and Treatment of Comorbid Disorders | edition = 2nd | veditors = Ouimette P, Read JP | publisher =  American Psychological Association | location = Washington, DC| date = 2014 | pages = 11–34 }}</ref&#x3E; Interpersonal traumas, such as [[child abuse]] and [[Assault|violent assaults]], are particularly predictive of substance&#x2D;related problems.<ref&#x3E;{{cite journal | vauthors = Guina J, Nahhas RW, Goldberg AJ, Farnsworth S | title = PTSD Symptom Severities, Interpersonal Traumas, and Benzodiazepines Are Associated with Substance&#x2D;Related Problems in Trauma Patients | journal = Journal of Clinical Medicine | volume = 5 | issue = 8 | pages = 70 | date = August 2016 | pmid = 27517964 | pmc = 4999790 | doi = 10.3390/jcm5080070 }}</ref&#x3E;<ref&#x3E;Ford, J.D.; Elhai, J.D.; Connor, D.F.; Frueh, B.C. Poly&#x2D;victimization and risk of posttraumatic, depressive, and substance use disorders and involvement in delinquency in a national sample of adolescents. J. Adolesc. Health 2010, 46, 545–52.</ref&#x3E;<ref&#x3E;{{cite journal = Sullivan TP, Cavanaugh CE, Buckner JD, Edmondson D | title = Intimate partner violence (IPV) and drug and alcohol use problems among community women: The roles of physical, sexual, and psychological IPV and PTSD. | journal = J. Trauma Stress | date = 2009 | volume = 22 | pages = 575–84 }}</ref&#x3E;
-->

<section data-mw-section-id="8" id="mwgw"><h4 id="Age">Age</h4>

<p id="mwhA">Adolescence represents a period of unique vulnerability for developing an addiction.<sup about="#mwt1253" class="mw-ref" id="cite_ref-42" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{},"body":{"id":"mw-reference-text-cite_note-42"}}'><a href="./Addiction#cite_note-42" style="counter-reset: mw-Ref 41;"><span class="mw-reflink-text">[41]</span></a></sup> In adolescence, the incentive-rewards systems in the brain mature well before the cognitive control center. This consequentially grants the incentive-rewards systems a disproportionate amount of power in the behavioral decision-making process. Therefore, adolescents are increasingly likely to act on their impulses and engage in risky, potentially addicting behavior before considering the consequences.<sup about="#mwt1255" class="mw-ref" id="cite_ref-43" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{},"body":{"id":"mw-reference-text-cite_note-43"}}'><a href="./Addiction#cite_note-43" style="counter-reset: mw-Ref 42;"><span class="mw-reflink-text">[42]</span></a></sup> Not only are adolescents more likely to initiate and maintain drug use, but once addicted they are more resistant to treatment and more liable to relapse.<sup about="#mwt1257" class="mw-ref" id="cite_ref-44" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{},"body":{"id":"mw-reference-text-cite_note-44"}}'><a href="./Addiction#cite_note-44" style="counter-reset: mw-Ref 43;"><span class="mw-reflink-text">[43]</span></a></sup><sup about="#mwt1259" class="mw-ref" id="cite_ref-45" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{},"body":{"id":"mw-reference-text-cite_note-45"}}'><a href="./Addiction#cite_note-45" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></sup></p>

<p id="mwhQ">Statistics have shown that those who start to drink alcohol at a younger age are more likely to become dependent later on. About 33% of the population tasted their first alcohol between the ages of 15 and 17, while 18% experienced it prior to this. As for alcohol abuse or dependence, the numbers start off high with those who first drank before they were 12 and then drop off after that. For example, 16% of alcoholics began drinking prior to turning 12 years old, while only 9% first touched alcohol between 15 and 17. This percentage is even lower, at 2.6%, for those who first started the habit after they were 21.<sup about="#mwt1309" class="mw-ref" id="cite_ref-46" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{},"body":{"id":"mw-reference-text-cite_note-46"}}'><a href="./Addiction#cite_note-46" style="counter-reset: mw-Ref 45;"><span class="mw-reflink-text">[45]</span></a></sup></p>

<p id="mwhg">Most individuals are exposed to and use addictive drugs for the first time during their teenage years.<sup about="#mwt275" class="mw-ref" id="cite_ref-Drug_use_trends_47-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Drug use trends"}}'><a href="./Addiction#cite_note-Drug_use_trends-47" style="counter-reset: mw-Ref 46;"><span class="mw-reflink-text">[46]</span></a></sup> In the United States, there were just over 2.8<span typeof="mw:Entity" id="mwhw"> </span>million new users of illicit drugs in 2013 (~7,800 new users per day);<sup about="#mwt277" class="mw-ref" id="cite_ref-Drug_use_trends_47-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Drug use trends"}}'><a href="./Addiction#cite_note-Drug_use_trends-47" style="counter-reset: mw-Ref 46;"><span class="mw-reflink-text">[46]</span></a></sup> among them, 54.1% were under 18<span typeof="mw:Entity" id="mwiA"> </span>years of age.<sup about="#mwt1311" class="mw-ref" id="cite_ref-Drug_use_trends_47-2" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Drug use trends"},"body":{"id":"mw-reference-text-cite_note-Drug_use_trends-47"}}'><a href="./Addiction#cite_note-Drug_use_trends-47" style="counter-reset: mw-Ref 46;"><span class="mw-reflink-text">[46]</span></a></sup> In 2011, there were approximately 20.6<span typeof="mw:Entity" id="mwiQ"> </span>million people in the United States over the age of 12 with an addiction.<sup about="#mwt1313" class="mw-ref" id="cite_ref-:0_48-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":":0"},"body":{"id":"mw-reference-text-cite_note-:0-48"}}'><a href="./Addiction#cite_note-:0-48" style="counter-reset: mw-Ref 47;"><span class="mw-reflink-text">[47]</span></a></sup> Over 90% of those with an addiction began drinking, smoking or using illicit drugs before the age of 18.<sup about="#mwt279" class="mw-ref" id="cite_ref-:0_48-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":":0"}}'><a href="./Addiction#cite_note-:0-48" style="counter-reset: mw-Ref 47;"><span class="mw-reflink-text">[47]</span></a></sup></p>

</section><section data-mw-section-id="9" id="mwig"><h4 id="Comorbid_disorders">Comorbid disorders</h4>
<p id="mwiw">Individuals with <a rel="mw:WikiLink" href="./Comorbid" title="Comorbid" id="mwjA" class="mw-redirect">comorbid</a> (i.e., co-occurring) mental health disorders such as depression, anxiety, attention-deficit/hyperactivity disorder (ADHD) or post-traumatic stress disorder are more likely to develop substance use disorders.<sup about="#mwt1315" class="mw-ref" id="cite_ref-49" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{},"body":{"id":"mw-reference-text-cite_note-49"}}'><a href="./Addiction#cite_note-49" style="counter-reset: mw-Ref 48;"><span class="mw-reflink-text">[48]</span></a></sup><sup about="#mwt1317" class="mw-ref" id="cite_ref-50" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{},"body":{"id":"mw-reference-text-cite_note-50"}}'><a href="./Addiction#cite_note-50" style="counter-reset: mw-Ref 49;"><span class="mw-reflink-text">[49]</span></a></sup><sup about="#mwt1319" class="mw-ref" id="cite_ref-51" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{},"body":{"id":"mw-reference-text-cite_note-51"}}'><a href="./Addiction#cite_note-51" style="counter-reset: mw-Ref 50;"><span class="mw-reflink-text">[50]</span></a></sup> The <a rel="mw:WikiLink" href="./National_Institute_on_Drug_Abuse" title="National Institute on Drug Abuse" about="#mwt288" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"Abbrlink","href":"./Template:Abbrlink"},"params":{"1":{"wt":"NIDA"},"2":{"wt":"National Institute on Drug Abuse"}},"i":0}}]}' id="mwjQ"><abbr title="National Institute on Drug Abuse" about="#mwt954" typeof="mw:ExpandedAttrs" data-mw='{"attribs":[[{"txt":"title"},{"html":"&lt;span typeof=\"mw:Nowiki\" data-parsoid=\"{}\">National Institute on Drug Abuse&lt;/span>"}]]}'>NIDA</abbr></a> cites early aggressive behavior as a risk factor for substance use.<sup about="#mwt291" class="mw-ref" id="cite_ref-Abuse_38-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Abuse"}}'><a href="./Addiction#cite_note-Abuse-38" style="counter-reset: mw-Ref 37;"><span class="mw-reflink-text">[37]</span></a></sup> A study by the <a rel="mw:WikiLink" href="./National_Bureau_of_Economic_Research" title="National Bureau of Economic Research" id="mwjg">National Bureau of Economic Research</a> found that there is a "definite connection between mental illness and the use of addictive substances" and a majority of mental health patients participate in the use of these substances: 38% alcohol, 44% cocaine, and 40% cigarettes.<sup about="#mwt1321" class="mw-ref" id="cite_ref-52" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{},"body":{"id":"mw-reference-text-cite_note-52"}}'><a href="./Addiction#cite_note-52" style="counter-reset: mw-Ref 51;"><span class="mw-reflink-text">[51]</span></a></sup></p>

</section></section><section data-mw-section-id="10" id="mwjw"><h3 id="Epigenetic_factors">Epigenetic factors</h3>

<section data-mw-section-id="11" id="mwkA"><h4 id="Transgenerational_epigenetic_inheritance">Transgenerational epigenetic inheritance</h4>
<div role="note" class="hatnote navigation-not-searchable" about="#mwt292" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"See also","href":"./Template:See_also"},"params":{"1":{"wt":"Transgenerational epigenetic inheritance"}},"i":0}}]}' id="mwkQ">See also: <a rel="mw:WikiLink" href="./Transgenerational_epigenetic_inheritance" title="Transgenerational epigenetic inheritance">Transgenerational epigenetic inheritance</a></div>
<p id="mwkg"><a rel="mw:WikiLink" href="./Epigenetic" title="Epigenetic" id="mwkw" class="mw-redirect">Epigenetic</a> genes and their products (e.g., proteins) are the key components through which environmental influences can affect the genes of an individual;<sup about="#mwt301" class="mw-ref" id="cite_ref-Transgenerational_epigenetic_inheritance_in_addiction_31-3" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Transgenerational epigenetic inheritance in addiction"}}'><a href="./Addiction#cite_note-Transgenerational_epigenetic_inheritance_in_addiction-31" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></sup> they also serve as the mechanism responsible for <a rel="mw:WikiLink" href="./Transgenerational_epigenetic_inheritance" title="Transgenerational epigenetic inheritance" id="mwlA">transgenerational epigenetic inheritance</a>, a phenomenon in which environmental influences on the genes of a parent can affect the associated traits and <a rel="mw:WikiLink" href="./Behavioral_phenotype" title="Behavioral phenotype" id="mwlQ" class="mw-redirect">behavioral phenotypes</a> of their offspring (e.g., behavioral responses to environmental stimuli).<sup about="#mwt303" class="mw-ref" id="cite_ref-Transgenerational_epigenetic_inheritance_in_addiction_31-4" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Transgenerational epigenetic inheritance in addiction"}}'><a href="./Addiction#cite_note-Transgenerational_epigenetic_inheritance_in_addiction-31" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></sup> In addiction, epigenetic mechanisms play a central role in the <a rel="mw:WikiLink" href="./Pathophysiology" title="Pathophysiology" id="mwlg">pathophysiology</a> of the disease;<sup about="#mwt305" class="mw-ref" id="cite_ref-Cellular_basis_3-15" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Cellular basis"}}'><a href="./Addiction#cite_note-Cellular_basis-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></sup> it has been noted that some of the alterations to the <a rel="mw:WikiLink" href="./Epigenome" title="Epigenome" id="mwlw">epigenome</a> which arise through chronic exposure to addictive stimuli during an addiction can be transmitted across generations, in turn affecting the behavior of one's children (e.g., the child's behavioral responses to addictive drugs and <a rel="mw:WikiLink" href="./Natural_reward" title="Natural reward" id="mwmA" class="mw-redirect">natural rewards</a>).<sup about="#mwt1323" class="mw-ref" id="cite_ref-Transgenerational_epigenetic_inheritance_in_addiction_31-5" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Transgenerational epigenetic inheritance in addiction"},"body":{"id":"mw-reference-text-cite_note-Transgenerational_epigenetic_inheritance_in_addiction-31"}}'><a href="./Addiction#cite_note-Transgenerational_epigenetic_inheritance_in_addiction-31" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></sup><sup about="#mwt1325" class="mw-ref" id="cite_ref-pmid26572641_53-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"pmid26572641"},"body":{"id":"mw-reference-text-cite_note-pmid26572641-53"}}'><a href="./Addiction#cite_note-pmid26572641-53" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></sup></p>

<p id="mwmQ">The general classes of epigenetic alterations that have been implicated in transgenerational epigenetic inheritance include <a rel="mw:WikiLink" href="./DNA_methylation" title="DNA methylation" id="mwmg">DNA methylation</a>, <a rel="mw:WikiLink" href="./Histone_modification" title="Histone modification" id="mwmw" class="mw-redirect">histone modifications</a>, and <a rel="mw:WikiLink" href="./Downregulation_and_upregulation" title="Downregulation and upregulation" id="mwnA">downregulation or upregulation</a> of <a rel="mw:WikiLink" href="./MicroRNA" title="MicroRNA" id="mwnQ">microRNAs</a>.<sup about="#mwt319" class="mw-ref" id="cite_ref-Transgenerational_epigenetic_inheritance_in_addiction_31-6" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Transgenerational epigenetic inheritance in addiction"}}'><a href="./Addiction#cite_note-Transgenerational_epigenetic_inheritance_in_addiction-31" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></sup> With respect to addiction, more research is needed to determine the specific <a rel="mw:WikiLink" href="./Heredity" title="Heredity" id="mwng">heritable</a> epigenetic alterations that arise from various forms of addiction in humans and the corresponding behavioral phenotypes from these epigenetic alterations that occur in human offspring.<sup about="#mwt321" class="mw-ref" id="cite_ref-Transgenerational_epigenetic_inheritance_in_addiction_31-7" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Transgenerational epigenetic inheritance in addiction"}}'><a href="./Addiction#cite_note-Transgenerational_epigenetic_inheritance_in_addiction-31" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></sup><sup about="#mwt323" class="mw-ref" id="cite_ref-pmid26572641_53-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"pmid26572641"}}'><a href="./Addiction#cite_note-pmid26572641-53" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></sup> Based upon preclinical evidence from <a rel="mw:WikiLink" href="./Animal_research" title="Animal research" id="mwnw" class="mw-redirect">animal research</a>, certain addiction-induced epigenetic alterations in rats can be transmitted from parent to offspring and produce behavioral phenotypes that decrease the offspring's risk of developing an addiction.<sup about="#mwt317" class="mw-ref" id="cite_ref-54" rel="dc:references" typeof="mw:Transclusion  mw:Extension/ref" data-mw='{"parts":[{"template":{"target":{"wt":"#tag:ref","function":"tag"},"params":{"1":{"wt":"According to a review of experimental animal models that examined the transgenerational epigenetic inheritance of [[epigenetic mark]]s that occur in addiction, alterations in [[histone acetylation]] – specifically, di-acetylation of [[lysine]] [[residue (amino acid)|residues]] 9 and 14 on [[histone 3]] (i.e., [[H3K9ac2]] and [[H3K14ac2]]) in association with [[BDNF]] [[gene promoter]]s – have been shown to occur within the [[medial prefrontal cortex]] (mPFC), [[testes]], and [[sperm]] of cocaine-addicted male rats.&lt;ref name=\"Transgenerational epigenetic inheritance in addiction\" /> These epigenetic alterations in the rat mPFC result in increased BDNF [[gene expression]] within the mPFC, which in turn blunts the [[reward system|rewarding properties]] of cocaine and reduces cocaine [[self-administration]].&lt;ref name=\"Transgenerational epigenetic inheritance in addiction\" /> The male but not female offspring of these cocaine-exposed rats inherited both epigenetic marks (i.e., di-acetylation of lysine residues 9 and 14 on histone 3) within mPFC neurons, the corresponding increase in BDNF expression within mPFC neurons, and the behavioral phenotype associated with these effects (i.e., a reduction in cocaine reward, resulting in reduced cocaine-seeking by these male offspring).&lt;ref name=\"Transgenerational epigenetic inheritance in addiction\" /> Consequently, the transmission of these two cocaine-induced epigenetic alterations (i.e., H3K9ac2 and H3K14ac2) in rats from male fathers to male offspring served to reduce the offspring&apos;s risk of developing an addiction to cocaine.&lt;ref name=\"Transgenerational epigenetic inheritance in addiction\" /> {{As of|2018|post=,}} neither the heritability of these epigenetic marks in humans nor the behavioral effects of the marks within human mPFC neurons has been established.&lt;ref name=\"Transgenerational epigenetic inheritance in addiction\" />"},"group":{"wt":"\"note\""}},"i":0}}]}'><a href="./Addiction#cite_note-54" style="counter-reset: mw-Ref 2;" data-mw-group="note"><span class="mw-reflink-text">[note 2]</span></a></sup><sup about="#mwt325" class="mw-ref" id="cite_ref-Transgenerational_epigenetic_inheritance_in_addiction_31-13" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Transgenerational epigenetic inheritance in addiction"}}'><a href="./Addiction#cite_note-Transgenerational_epigenetic_inheritance_in_addiction-31" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></sup> More generally, the heritable behavioral phenotypes that are derived from addiction-induced epigenetic alterations and transmitted from parent to offspring may serve to either increase or decrease the offspring's risk of developing an addiction.<sup about="#mwt327" class="mw-ref" id="cite_ref-Transgenerational_epigenetic_inheritance_in_addiction_31-14" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Transgenerational epigenetic inheritance in addiction"}}'><a href="./Addiction#cite_note-Transgenerational_epigenetic_inheritance_in_addiction-31" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></sup><sup about="#mwt329" class="mw-ref" id="cite_ref-pmid26572641_53-2" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"pmid26572641"}}'><a href="./Addiction#cite_note-pmid26572641-53" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></sup></p>

</section></section></section><section data-mw-section-id="12" id="mwoA"><h2 id="Mechanisms">Mechanisms<span id="Biomolecular_mechanisms" about="#mwt330" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"anchor","href":"./Template:Anchor"},"params":{"1":{"wt":"Biomolecular mechanisms"}},"i":0}}]}'></span></h2>
<table class="infobox" style="width:22em;width:610px; ; border-collapse:collapse;" about="#mwt331" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"Transcription factor glossary","href":"./Template:Transcription_factor_glossary"},"params":{"width":{"wt":"610px"}},"i":0}}]}' id="mwoQ"><tbody><tr><th colspan="2" style="text-align:center;font-size:125%;font-weight:bold;font-size:100%; background:#FFCC66; -moz-box-shadow: inset 3px 3px 0 #fafafa, inset -3px -3px 0 #fafafa; -webkit-box-shadow: inset 3px 3px 0 #fafafa, inset -3px -3px 0 #fafafa; box-shadow: inset 3px 3px 0 #fafafa, inset -3px -3px 0 #fafafa;; padding:5px;">Transcription factor glossary</th></tr><tr><td colspan="2" style="text-align:center;text-align:left; padding-left:0;">
<ul><li><b><a rel="mw:WikiLink" href="./Gene_expression" title="Gene expression">gene expression</a></b> – the process by which information from a <a rel="mw:WikiLink" href="./Gene" title="Gene">gene</a> is used in the synthesis of a functional gene product such as a <a rel="mw:WikiLink" href="./Protein" title="Protein">protein</a></li>
<li><b><a rel="mw:WikiLink" href="./Transcription_(genetics)" title="Transcription (genetics)" class="mw-redirect">transcription</a></b> – the process of making <a rel="mw:WikiLink" href="./Messenger_RNA" title="Messenger RNA">messenger RNA</a> (mRNA) from a <a rel="mw:WikiLink" href="./DNA" title="DNA">DNA</a> template by <a rel="mw:WikiLink" href="./RNA_polymerase" title="RNA polymerase">RNA polymerase</a></li>
<li><b><a rel="mw:WikiLink" href="./Transcription_factor" title="Transcription factor">transcription factor</a></b> – a protein that binds to DNA and regulates gene expression by promoting or suppressing transcription</li>
<li><b><a rel="mw:WikiLink" href="./Transcriptional_regulation" title="Transcriptional regulation">transcriptional regulation</a></b> – <i>controlling</i> the rate of gene transcription for example by helping or hindering RNA polymerase binding to DNA</li>
<li><b><a rel="mw:WikiLink" href="./Upregulation" title="Upregulation" class="mw-redirect">upregulation</a></b>, <b>activation</b>, or <b>promotion</b> – <i>increase</i> the rate of gene transcription</li>
<li><b><a rel="mw:WikiLink" href="./Downregulation" title="Downregulation" class="mw-redirect">downregulation</a></b>, <b>repression</b>, or <b>suppression</b> – <i>decrease</i> the rate of gene transcription</li>
<li><b><a rel="mw:WikiLink" href="./Coactivator_(genetics)" title="Coactivator (genetics)">coactivator</a></b> – a protein that works with transcription factors to <i>increase</i> the rate of gene transcription</li>
<li><b><a rel="mw:WikiLink" href="./Corepressor_(genetics)" title="Corepressor (genetics)" class="mw-redirect">corepressor</a></b> – a protein that works with transcription factors to <i>decrease</i> the rate of gene transcription</li>
<li><b><a rel="mw:WikiLink" href="./Response_element" title="Response element">response element</a></b> – a specific sequence of DNA that a transcription factor binds to</li></ul>
</td></tr><tr><td colspan="2" style="text-align:center;text-align:right; padding-top:0; padding-right:5px;"><div class="plainlinks hlist navbar mini"><ul><li class="nv-view"><a rel="mw:WikiLink" href="./Template:Transcription_factor_glossary" title="Template:Transcription factor glossary"><abbr title="View this template">v</abbr></a></li><li class="nv-talk"><a rel="mw:WikiLink" href="./Template_talk:Transcription_factor_glossary" title="Template talk:Transcription factor glossary"><abbr title="Discuss this template">t</abbr></a></li><li class="nv-edit"><a rel="mw:ExtLink" class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Transcription_factor_glossary&amp;action=edit"><abbr title="Edit this template">e</abbr></a></li></ul></div></td></tr></tbody></table>
<span about="#mwt332" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"Psychostimulant addiction","href":"./Template:Psychostimulant_addiction"},"params":{"Colorcode":{"wt":"yes"},"align":{"wt":"right"}},"i":0}}]}' id="mwog">
</span><table role="presentation" cellpadding="0" style="border-spacing:0; clear:right; float:right;" about="#mwt332">
<tbody><tr>
<td><div class="thumb tright">
<div class="thumbinner" style="width:602px; ">
<div style="clear: both; font-weight: bold; font-size: 106.4%; text-align: center; background-color: #F0F8FF;margin-bottom:3px;"><a rel="mw:WikiLink" href="./Signaling_cascade" title="Signaling cascade" class="mw-redirect">Signaling cascade</a> in the <a rel="mw:WikiLink" href="./Nucleus_accumbens" title="Nucleus accumbens">nucleus accumbens</a> that results in psychostimulant addiction<br/><div class="plainlinks hlist navbar mini"><ul><li class="nv-view"><a rel="mw:WikiLink" href="./Template:Psychostimulant_addiction" title="Template:Psychostimulant addiction"><abbr title="View this template">v</abbr></a></li><li class="nv-talk"><a rel="mw:WikiLink" href="./Template_talk:Psychostimulant_addiction" title="Template talk:Psychostimulant addiction"><abbr title="Discuss this template">t</abbr></a></li><li class="nv-edit"><a rel="mw:ExtLink" class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Psychostimulant_addiction&amp;action=edit"><abbr title="Edit this template">e</abbr></a></li></ul></div></div>
<div style="position:relative; width:600px; height:620px; overflow:hidden; border:solid #ccc 1px; background-color:white;">
<div style="left:0px; top:0px; width:600px; position:absolute"> <figure-inline typeof="mw:Image"><a href="./COMMONS:File:ΔFosB.svg"><img alt="The signaling cascade involved in psychostimulant addiction" resource="./File:ΔFosB.svg" src="//upload.wikimedia.org/wikipedia/commons/thumb/4/47/%CE%94FosB.svg/600px-%CE%94FosB.svg.png" data-file-width="935" data-file-height="965" data-file-type="drawing" height="619" width="600" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/4/47/%CE%94FosB.svg/1200px-%CE%94FosB.svg.png 2x, //upload.wikimedia.org/wikipedia/commons/thumb/4/47/%CE%94FosB.svg/900px-%CE%94FosB.svg.png 1.5x"/></a></figure-inline>
</div> 
<div style="text-align:center; font-size:14px; line-height:110%;">
<div style="background-color:transparent; color:black"><div id="annotation_475x5" style="position:absolute; left:475px; top:5px;   font-size:12px;   line-height:14px; "><span style="background-color:transparent; "><b>Note: colored text contains article links.</b></span></div>

<div id="annotation_320x325" style="position:absolute; left:320px; top:325px;      line-height:110% "><span style="background-color:transparent; "><a rel="mw:WikiLink" href="./Nuclear_pore" title="Nuclear pore">Nuclear pore</a></span></div>
<div id="annotation_350x362" style="position:absolute; left:350px; top:362px;      line-height:110% "><span style="background-color:transparent; "><a rel="mw:WikiLink" href="./Nuclear_membrane" title="Nuclear membrane" class="mw-redirect">Nuclear membrane</a></span></div>
<div id="annotation_475x425" style="position:absolute; left:475px; top:425px;      line-height:110% "><span style="background-color:transparent; "><a rel="mw:WikiLink" href="./Plasma_membrane" title="Plasma membrane" class="mw-redirect">Plasma membrane</a></span></div>

<div id="annotation_65x48" style="position:absolute; left:65px; top:48px;      line-height:110% "><span style="background-color:transparent; "><a rel="mw:WikiLink" href="./Calcium_channel,_voltage-dependent,_L_type,_alpha_1C_subunit" title="Calcium channel, voltage-dependent, L type, alpha 1C subunit" class="mw-redirect">Ca<sub>v</sub>1.2</a></span></div>
<div id="annotation_43x98" style="position:absolute; left:43px; top:98px;      line-height:110% "><span style="background-color:transparent; "><a rel="mw:WikiLink" href="./NMDA_receptor" title="NMDA receptor">NMDAR</a></span></div>
<div id="annotation_33x185" style="position:absolute; left:33px; top:185px;      line-height:110% "><span style="background-color:transparent; "><a rel="mw:WikiLink" href="./AMPA_receptor" title="AMPA receptor">AMPAR</a></span></div>
<div id="annotation_41x238" style="position:absolute; left:41px; top:238px;      line-height:110% "><span style="background-color:transparent; "><a rel="mw:WikiLink" href="./Dopamine_receptor_D1" title="Dopamine receptor D1">DRD1</a></span></div>
<div id="annotation_42x285" style="position:absolute; left:42px; top:285px;      line-height:110% "><span style="background-color:transparent; "><a rel="mw:WikiLink" href="./Dopamine_receptor_D5" title="Dopamine receptor D5">DRD5</a></span></div>
<div id="annotation_47x331" style="position:absolute; left:47px; top:331px;      line-height:110% "><span style="background-color:transparent; "><a rel="mw:WikiLink" href="./Dopamine_receptor_D2" title="Dopamine receptor D2">DRD2</a></span></div>
<div id="annotation_56x366" style="position:absolute; left:56px; top:366px;      line-height:110% "><span style="background-color:transparent; "><a rel="mw:WikiLink" href="./Dopamine_receptor_D3" title="Dopamine receptor D3">DRD3</a></span></div>
<div id="annotation_84x385" style="position:absolute; left:84px; top:385px;      line-height:110% "><span style="background-color:transparent; "><a rel="mw:WikiLink" href="./Dopamine_receptor_D4" title="Dopamine receptor D4">DRD4</a></span></div>

<div id="annotation_172x256" style="position:absolute; left:172px; top:256px;      line-height:110% "><span style="background-color:transparent; "><a rel="mw:WikiLink" href="./Gs_alpha_subunit" title="Gs alpha subunit">G<sub>s</sub></a></span></div>
<div id="annotation_173x325" style="position:absolute; left:173px; top:325px;      line-height:110% "><span style="background-color:transparent; "><a rel="mw:WikiLink" href="./Gi_alpha_subunit" title="Gi alpha subunit">G<sub>i/o</sub></a></span></div>
<div id="annotation_234x288" style="position:absolute; left:234px; top:288px;      line-height:110% "><span style="background-color:transparent; "><a rel="mw:WikiLink" href="./Adenylyl_cyclase" title="Adenylyl cyclase">AC</a></span></div>
<div id="annotation_18x595" style="position:absolute; left:18px; top:595px;   font-size:9.5px;   line-height:11.5px; "><span style="background-color:transparent; "><a rel="mw:WikiLink" href="./Cyclic_adenosine_monophosphate" title="Cyclic adenosine monophosphate"><b>cAMP</b></a></span></div>
<div id="annotation_269x340" style="position:absolute; left:269px; top:340px;   font-size:10px;   line-height:12px; "><span style="background-color:transparent; "><a rel="mw:WikiLink" href="./Cyclic_adenosine_monophosphate" title="Cyclic adenosine monophosphate"><b>cAMP</b></a></span></div>
<div id="annotation_312x288" style="position:absolute; left:312px; top:288px;      line-height:110% "><span style="background-color:transparent; "><a rel="mw:WikiLink" href="./Protein_kinase_A" title="Protein kinase A">PKA</a></span></div>

<div id="annotation_228x110.5" style="position:absolute; left:228px; top:110.5px;      line-height:110% "><span style="background-color:transparent; "><a rel="mw:WikiLink" href="./Calmodulin" title="Calmodulin">CaM</a></span></div>
<div id="annotation_329x99" style="position:absolute; left:329px; top:99px;      line-height:110% "><span style="background-color:transparent; "><a rel="mw:WikiLink" href="./Ca2+/calmodulin-dependent_protein_kinase_II" title="Ca2+/calmodulin-dependent protein kinase II">CaMKII</a></span></div>
<div id="annotation_301x215" style="position:absolute; left:301px; top:215px;      line-height:110% "><span style="background-color:transparent; "><a rel="mw:WikiLink" href="./Dopamine-_and_cAMP-regulated_neuronal_phosphoprotein" title="Dopamine- and cAMP-regulated neuronal phosphoprotein" class="mw-redirect">DARPP-32</a></span></div>
<div id="annotation_328x161.5" style="position:absolute; left:328px; top:161.5px;      line-height:110% "><span style="background-color:transparent; "><a rel="mw:WikiLink" href="./Protein_phosphatase_1" title="Protein phosphatase 1">PP1</a></span></div>
<div id="annotation_247.5x159" style="position:absolute; left:247.5px; top:159px;      line-height:110% "><span style="background-color:transparent; "><a rel="mw:WikiLink" href="./Protein_phosphatase_2B" title="Protein phosphatase 2B" class="mw-redirect">PP2B</a></span></div>

<div id="annotation_458x163" style="position:absolute; left:458px; top:163px;      line-height:110% "><span style="background-color:transparent; "><a rel="mw:WikiLink" href="./Cyclic_AMP_response_element-binding_protein" title="Cyclic AMP response element-binding protein" class="mw-redirect"><span style="color:MediumVioletRed">CREB</span></a></span></div>
<div id="annotation_440x222" style="position:absolute; left:440px; top:222px;      line-height:110% "><span style="background-color:transparent; "><b><a rel="mw:WikiLink" href="./ΔFosB" title="ΔFosB" class="mw-redirect"><span style="color:MediumVioletRed">ΔFosB</span></a></b></span></div>
<div id="annotation_447x241" style="position:absolute; left:447px; top:241px;      line-height:110% "><span style="background-color:transparent; "><b><a rel="mw:WikiLink" href="./JunD" title="JunD"><span style="color:MediumVioletRed">JunD</span></a></b></span></div>
<div id="annotation_542x233.5" style="position:absolute; left:542px; top:233.5px;      line-height:110% "><span style="background-color:transparent; "><a rel="mw:WikiLink" href="./C-Fos" title="C-Fos"><span style="color:MediumVioletRed"><span class="nowrap">c-Fos</span></span></a></span></div>
<div id="annotation_442x274.5" style="position:absolute; left:442px; top:274.5px;      line-height:110% "><span style="background-color:transparent; "><a rel="mw:WikiLink" href="./Sirtuin_1" title="Sirtuin 1">SIRT1</a></span></div>
<div id="annotation_468.5x299" style="position:absolute; left:468.5px; top:299px;      line-height:110% "><span style="background-color:transparent; "><a rel="mw:WikiLink" href="./Histone_deacetylase_1" title="Histone deacetylase 1" class="mw-redirect">HDAC1</a></span></div>

<div id="annotation_495x35" style="position:absolute; left:495px; top:35px;      line-height:110% "><span style="background-color:transparent; "><sup about="#mwt997" class="mw-ref" id="cite_ref-55" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"group":"Color legend"},"body":{"id":"mw-reference-text-cite_note-55"}}'><a href="./Addiction#cite_note-55" style="counter-reset: mw-Ref 1;" data-mw-group="Color legend"><span class="mw-reflink-text">[Color legend 1]</span></a></sup></span></div></div>
</div>
</div>
<div class="thumbcaption" style="clear:left"><div style="float:left;margin-right:0.5em"><figure-inline typeof="mw:Image" data-mw='{"caption":"The image above contains clickable links"}'><span><img alt="The image above contains clickable links" resource="./File:Interactive_icon.svg" src="//upload.wikimedia.org/wikipedia/commons/thumb/e/e6/Interactive_icon.svg/18px-Interactive_icon.svg.png" data-file-width="133" data-file-height="200" data-file-type="drawing" height="27" width="18" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/e/e6/Interactive_icon.svg/36px-Interactive_icon.svg.png 2x, //upload.wikimedia.org/wikipedia/commons/thumb/e/e6/Interactive_icon.svg/27px-Interactive_icon.svg.png 1.5x"/></span></figure-inline></div>This diagram depicts the signaling events in the <a rel="mw:WikiLink" href="./Mesolimbic_pathway" title="Mesolimbic pathway">brain's reward center</a> that are induced by chronic high-dose exposure to psychostimulants that increase the concentration of synaptic dopamine, like <a rel="mw:WikiLink" href="./Amphetamine" title="Amphetamine">amphetamine</a>, <a rel="mw:WikiLink" href="./Methamphetamine" title="Methamphetamine">methamphetamine</a>, and <a rel="mw:WikiLink" href="./Phenethylamine" title="Phenethylamine">phenethylamine</a>. Following presynaptic <a rel="mw:WikiLink" href="./Dopamine" title="Dopamine">dopamine</a> and <a rel="mw:WikiLink" href="./Glutamate" title="Glutamate" class="mw-redirect">glutamate</a> <a rel="mw:WikiLink" href="./Cotransmission" title="Cotransmission" class="mw-redirect">co-release</a> by such psychostimulants,<sup about="#mwt982" class="mw-ref" id="cite_ref-Nestler-Renthal_Figure_2_56-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Nestler-Renthal Figure 2"}}'><a href="./Addiction#cite_note-Nestler-Renthal_Figure_2-56" style="counter-reset: mw-Ref 53;"><span class="mw-reflink-text">[53]</span></a></sup><sup about="#mwt1522" class="mw-ref" id="cite_ref-Glutamate-dopamine_cotransmission_review_57-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Glutamate-dopamine cotransmission review"},"body":{"id":"mw-reference-text-cite_note-Glutamate-dopamine_cotransmission_review-57"}}'><a href="./Addiction#cite_note-Glutamate-dopamine_cotransmission_review-57" style="counter-reset: mw-Ref 54;"><span class="mw-reflink-text">[54]</span></a></sup> <a rel="mw:WikiLink" href="./Neurotransmitter_receptor" title="Neurotransmitter receptor">postsynaptic receptors</a> for these <a rel="mw:WikiLink" href="./Neurotransmitter" title="Neurotransmitter">neurotransmitters</a> trigger internal signaling events through a <a rel="mw:WikiLink" href="./CAMP-dependent_pathway" title="CAMP-dependent pathway">cAMP-dependent pathway</a> and a <a rel="mw:WikiLink" href="./Calcium_signaling" title="Calcium signaling">calcium-dependent pathway</a> that ultimately result in increased <abbr title="cAMP response element-binding protein" about="#mwt994" typeof="mw:ExpandedAttrs" data-mw='{"attribs":[[{"txt":"title"},{"html":"&lt;span typeof=\"mw:Nowiki\" data-parsoid=\"{}\">cAMP response element-binding protein&lt;/span>"}]]}'>CREB</abbr> phosphorylation.<sup about="#mwt984" class="mw-ref" id="cite_ref-Nestler-Renthal_Figure_2_56-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Nestler-Renthal Figure 2"}}'><a href="./Addiction#cite_note-Nestler-Renthal_Figure_2-56" style="counter-reset: mw-Ref 53;"><span class="mw-reflink-text">[53]</span></a></sup><sup about="#mwt1524" class="mw-ref" id="cite_ref-Amphetamine_KEGG_ΔFosB_58-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Amphetamine KEGG ΔFosB"},"body":{"id":"mw-reference-text-cite_note-Amphetamine_KEGG_ΔFosB-58"}}'><a href="./Addiction#cite_note-Amphetamine_KEGG_ΔFosB-58" style="counter-reset: mw-Ref 55;"><span class="mw-reflink-text">[55]</span></a></sup><sup about="#mwt1526" class="mw-ref" id="cite_ref-Meth_cAMP/calcium-dependent_cascade_59-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Meth cAMP/calcium-dependent cascade"},"body":{"id":"mw-reference-text-cite_note-Meth_cAMP/calcium-dependent_cascade-59"}}'><a href="./Addiction#cite_note-Meth_cAMP/calcium-dependent_cascade-59" style="counter-reset: mw-Ref 56;"><span class="mw-reflink-text">[56]</span></a></sup>  Phosphorylated CREB increases levels of ΔFosB, which in turn represses the <span class="nowrap">c-Fos</span> gene with the help of <a rel="mw:WikiLink" href="./Corepressor" title="Corepressor">corepressors</a>;<sup about="#mwt1528" class="mw-ref" id="cite_ref-Nestler-Renthal_Figure_2_56-2" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Nestler-Renthal Figure 2"},"body":{"id":"mw-reference-text-cite_note-Nestler-Renthal_Figure_2-56"}}'><a href="./Addiction#cite_note-Nestler-Renthal_Figure_2-56" style="counter-reset: mw-Ref 53;"><span class="mw-reflink-text">[53]</span></a></sup><sup about="#mwt986" class="mw-ref" id="cite_ref-Nestler1_60-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Nestler1"}}'><a href="./Addiction#cite_note-Nestler1-60" style="counter-reset: mw-Ref 57;"><span class="mw-reflink-text">[57]</span></a></sup><sup about="#mwt988" class="mw-ref" id="cite_ref-Nestler2_61-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Nestler2"}}'><a href="./Addiction#cite_note-Nestler2-61" style="counter-reset: mw-Ref 58;"><span class="mw-reflink-text">[58]</span></a></sup> <span class="nowrap">c-Fos</span> <a rel="mw:WikiLink" href="./Gene_repression" title="Gene repression" class="mw-redirect">repression</a> acts as a molecular switch that enables the accumulation of ΔFosB in the neuron.<sup about="#mwt1530" class="mw-ref" id="cite_ref-{{nowrap|c-Fos}}_repression_62-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"{{nowrap|c-Fos}} repression"},"body":{"id":"mw-reference-text-cite_note-{{nowrap|c-Fos}}_repression-62"}}'><a href="./Addiction#cite_note-{{nowrap|c-Fos}}_repression-62" style="counter-reset: mw-Ref 59;"><span class="mw-reflink-text">[59]</span></a></sup> A highly stable (phosphorylated) form of ΔFosB, one that persists in neurons for <span class="nowrap">1–2</span><span typeof="mw:Entity"> </span>months, slowly accumulates following repeated high-dose exposure to stimulants through this process.<sup about="#mwt990" class="mw-ref" id="cite_ref-Nestler1_60-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Nestler1"}}'><a href="./Addiction#cite_note-Nestler1-60" style="counter-reset: mw-Ref 57;"><span class="mw-reflink-text">[57]</span></a></sup><sup about="#mwt992" class="mw-ref" id="cite_ref-Nestler2_61-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Nestler2"}}'><a href="./Addiction#cite_note-Nestler2-61" style="counter-reset: mw-Ref 58;"><span class="mw-reflink-text">[58]</span></a></sup> ΔFosB functions as "one of the master control proteins" that produces addiction-related <a rel="mw:WikiLink" href="./Neuroplasticity" title="Neuroplasticity">structural changes in the brain</a>, and upon sufficient accumulation, with the help of its downstream targets (e.g., <a rel="mw:WikiLink" href="./Nuclear_factor_kappa_B" title="Nuclear factor kappa B" class="mw-redirect">nuclear factor kappa B</a>), it induces an addictive state.<sup about="#mwt1532" class="mw-ref" id="cite_ref-Nestler1_60-2" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Nestler1"},"body":{"id":"mw-reference-text-cite_note-Nestler1-60"}}'><a href="./Addiction#cite_note-Nestler1-60" style="counter-reset: mw-Ref 57;"><span class="mw-reflink-text">[57]</span></a></sup><sup about="#mwt1534" class="mw-ref" id="cite_ref-Nestler2_61-2" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Nestler2"},"body":{"id":"mw-reference-text-cite_note-Nestler2-61"}}'><a href="./Addiction#cite_note-Nestler2-61" style="counter-reset: mw-Ref 58;"><span class="mw-reflink-text">[58]</span></a></sup></div>
</div>
</div></td></tr>
</tbody></table>
<p id="mwow">Chronic addictive drug use causes alterations in <a rel="mw:WikiLink" href="./Gene_expression" title="Gene expression" id="mwpA">gene expression</a> in the <a rel="mw:WikiLink" href="./Mesocorticolimbic_projection" title="Mesocorticolimbic projection" id="mwpQ" class="mw-redirect">mesocorticolimbic projection</a>.<sup about="#mwt356" class="mw-ref" id="cite_ref-Nestler_14-3" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Nestler"}}'><a href="./Addiction#cite_note-Nestler-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></sup><sup about="#mwt1327" class="mw-ref" id="cite_ref-Nestler,_Hyman,_and_Malenka_2_63-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Nestler, Hyman, and Malenka 2"},"body":{"id":"mw-reference-text-cite_note-Nestler,_Hyman,_and_Malenka_2-63"}}'><a href="./Addiction#cite_note-Nestler,_Hyman,_and_Malenka_2-63" style="counter-reset: mw-Ref 60;"><span class="mw-reflink-text">[60]</span></a></sup><sup about="#mwt1329" class="mw-ref" id="cite_ref-Addiction_genetics_64-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Addiction genetics"},"body":{"id":"mw-reference-text-cite_note-Addiction_genetics-64"}}'><a href="./Addiction#cite_note-Addiction_genetics-64" style="counter-reset: mw-Ref 61;"><span class="mw-reflink-text">[61]</span></a></sup>  The most important <a rel="mw:WikiLink" href="./Transcription_factor" title="Transcription factor" id="mwpg">transcription factors</a> that produce these alterations are <a rel="mw:WikiLink" href="./ΔFosB" title="ΔFosB" id="mwpw" class="mw-redirect">ΔFosB</a>, <a rel="mw:WikiLink" href="./Cyclic_adenosine_monophosphate" title="Cyclic adenosine monophosphate" id="mwqA">cAMP</a> response element binding protein (<a rel="mw:WikiLink" href="./CAMP_response_element_binding_protein" title="CAMP response element binding protein" id="mwqQ" class="mw-redirect">CREB</a>), and nuclear factor kappa B (<a rel="mw:WikiLink" href="./Nuclear_factor_kappa_B" title="Nuclear factor kappa B" id="mwqg" class="mw-redirect">NF-κB</a>).<sup about="#mwt358" class="mw-ref" id="cite_ref-Nestler_14-4" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Nestler"}}'><a href="./Addiction#cite_note-Nestler-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></sup> ΔFosB is the most significant biomolecular mechanism in addiction because the <a rel="mw:WikiLink" href="./Overexpression" title="Overexpression" id="mwqw" class="mw-redirect">overexpression</a> of ΔFosB in the <a rel="mw:WikiLink" href="./D1-type" title="D1-type" id="mwrA" class="mw-redirect">D1-type</a> <a rel="mw:WikiLink" href="./Medium_spiny_neuron" title="Medium spiny neuron" id="mwrQ">medium spiny neurons</a> in the <a rel="mw:WikiLink" href="./Nucleus_accumbens" title="Nucleus accumbens" id="mwrg">nucleus accumbens</a> is <a rel="mw:WikiLink" href="./Necessary_and_sufficient" title="Necessary and sufficient" id="mwrw" class="mw-redirect">necessary and sufficient</a> for many of the neural adaptations and behavioral effects (e.g., expression-dependent increases in drug <a rel="mw:WikiLink" href="./Self-administration" title="Self-administration" id="mwsA">self-administration</a> and <a rel="mw:WikiLink" href="./Addiction#Sensitization" id="mwsQ">reward sensitization</a>) seen in drug addiction.<sup about="#mwt360" class="mw-ref" id="cite_ref-Nestler_14-5" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Nestler"}}'><a href="./Addiction#cite_note-Nestler-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></sup> ΔFosB expression in <a rel="mw:WikiLink" href="./Nucleus_accumbens" title="Nucleus accumbens" id="mwsg">nucleus accumbens</a> <a rel="mw:WikiLink" href="./D1-type" title="D1-type" id="mwsw" class="mw-redirect">D1-type</a> <a rel="mw:WikiLink" href="./Medium_spiny_neuron" title="Medium spiny neuron" id="mwtA">medium spiny neurons</a> directly and positively regulates drug <a rel="mw:WikiLink" href="./Self-administration" title="Self-administration" id="mwtQ">self-administration</a> and <a rel="mw:WikiLink" href="./Addiction#Sensitization" id="mwtg">reward sensitization</a> through <a rel="mw:WikiLink" href="./Positive_reinforcement" title="Positive reinforcement" id="mwtw" class="mw-redirect">positive reinforcement</a> while decreasing sensitivity to <a rel="mw:WikiLink/Interwiki" href="https://en.wiktionary.org/wiki/aversion" title="wikt:aversion" id="mwuA">aversion</a>.<sup about="#mwt362" class="mw-ref" id="cite_ref-ΔFosB_behaviors_15-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"ΔFosB behaviors","group":"note"}}'><a href="./Addiction#cite_note-ΔFosB_behaviors-15" style="counter-reset: mw-Ref 1;" data-mw-group="note"><span class="mw-reflink-text">[note 1]</span></a></sup><sup about="#mwt364" class="mw-ref" id="cite_ref-Cellular_basis_3-16" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Cellular basis"}}'><a href="./Addiction#cite_note-Cellular_basis-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></sup><sup about="#mwt366" class="mw-ref" id="cite_ref-What_the_ΔFosB?_11-5" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"What the ΔFosB?"}}'><a href="./Addiction#cite_note-What_the_ΔFosB?-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></sup> ΔFosB has been implicated in mediating addictions to many different drugs and drug classes, including <a rel="mw:WikiLink" href="./Alcoholism" title="Alcoholism" id="mwuQ">alcohol</a>, <a rel="mw:WikiLink" href="./Amphetamine" title="Amphetamine" id="mwug">amphetamine</a> and other <a rel="mw:WikiLink" href="./Substituted_amphetamines" title="Substituted amphetamines" id="mwuw" class="mw-redirect">substituted amphetamines</a>, <a rel="mw:WikiLink" href="./Cannabinoid" title="Cannabinoid" id="mwvA">cannabinoids</a>, <a rel="mw:WikiLink" href="./Cocaine" title="Cocaine" id="mwvQ">cocaine</a>, <a rel="mw:WikiLink" href="./Methylphenidate" title="Methylphenidate" id="mwvg">methylphenidate</a>, <a rel="mw:WikiLink" href="./Nicotine" title="Nicotine" id="mwvw">nicotine</a>, <a rel="mw:WikiLink" href="./Opiates" title="Opiates" id="mwwA" class="mw-redirect">opiates</a>, <a rel="mw:WikiLink" href="./Phenylcyclidine" title="Phenylcyclidine" id="mwwQ" class="mw-redirect">phenylcyclidine</a>, and <a rel="mw:WikiLink" href="./Propofol" title="Propofol" id="mwwg">propofol</a>, among others.<sup about="#mwt368" class="mw-ref" id="cite_ref-What_the_ΔFosB?_11-6" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"What the ΔFosB?"}}'><a href="./Addiction#cite_note-What_the_ΔFosB?-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></sup><!--Preceding review covers ΔFosB in propofol addiction--><sup about="#mwt370" class="mw-ref" id="cite_ref-Nestler_14-6" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Nestler"}}'><a href="./Addiction#cite_note-Nestler-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></sup><sup about="#mwt372" class="mw-ref" id="cite_ref-Nestler,_Hyman,_and_Malenka_2_63-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Nestler, Hyman, and Malenka 2"}}'><a href="./Addiction#cite_note-Nestler,_Hyman,_and_Malenka_2-63" style="counter-reset: mw-Ref 60;"><span class="mw-reflink-text">[60]</span></a></sup><sup about="#mwt1331" class="mw-ref" id="cite_ref-Alcoholism_ΔFosB_65-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Alcoholism ΔFosB"},"body":{"id":"mw-reference-text-cite_note-Alcoholism_ΔFosB-65"}}'><a href="./Addiction#cite_note-Alcoholism_ΔFosB-65" style="counter-reset: mw-Ref 62;"><span class="mw-reflink-text">[62]</span></a></sup><sup about="#mwt1333" class="mw-ref" id="cite_ref-MPH_ΔFosB_66-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"MPH ΔFosB"},"body":{"id":"mw-reference-text-cite_note-MPH_ΔFosB-66"}}'><a href="./Addiction#cite_note-MPH_ΔFosB-66" style="counter-reset: mw-Ref 63;"><span class="mw-reflink-text">[63]</span></a></sup>  <a rel="mw:WikiLink" href="./ΔJunD" title="ΔJunD" id="mwww" class="mw-redirect">ΔJunD</a>, a transcription factor, and <a rel="mw:WikiLink" href="./EHMT2" title="EHMT2" id="mwxA">G9a</a>, a <a rel="mw:WikiLink" href="./Histone_methyltransferase" title="Histone methyltransferase" id="mwxQ">histone methyltransferase</a>, both oppose the function of ΔFosB and inhibit increases in its expression.<sup about="#mwt374" class="mw-ref" id="cite_ref-Cellular_basis_3-17" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Cellular basis"}}'><a href="./Addiction#cite_note-Cellular_basis-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></sup><sup about="#mwt376" class="mw-ref" id="cite_ref-Nestler_14-7" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Nestler"}}'><a href="./Addiction#cite_note-Nestler-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></sup><sup about="#mwt378" class="mw-ref" id="cite_ref-Nestler_2014_epigenetics_67-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Nestler 2014 epigenetics"}}'><a href="./Addiction#cite_note-Nestler_2014_epigenetics-67" style="counter-reset: mw-Ref 64;"><span class="mw-reflink-text">[64]</span></a></sup> Increases in nucleus accumbens ΔJunD expression (via <a rel="mw:WikiLink" href="./Viral_vector" title="Viral vector" id="mwxg">viral vector</a>-mediated gene transfer) or G9a expression (via pharmacological means) reduces, or with a large increase can even block, many of the neural and behavioral alterations that result from chronic high-dose use of addictive drugs (i.e., the alterations mediated by ΔFosB).<sup about="#mwt380" class="mw-ref" id="cite_ref-G9a_reverses_ΔFosB_plasticity_13-3" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"G9a reverses ΔFosB plasticity"}}'><a href="./Addiction#cite_note-G9a_reverses_ΔFosB_plasticity-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></sup><sup about="#mwt382" class="mw-ref" id="cite_ref-Nestler_14-8" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Nestler"}}'><a href="./Addiction#cite_note-Nestler-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></sup></p>

<p id="mwxw">ΔFosB also plays an important role in regulating behavioral responses to <a rel="mw:WikiLink" href="./Natural_reward" title="Natural reward" id="mwyA" class="mw-redirect">natural rewards</a>, such as palatable food, sex, and exercise.<sup about="#mwt402" class="mw-ref" id="cite_ref-Nestler_14-9" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Nestler"}}'><a href="./Addiction#cite_note-Nestler-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></sup><sup about="#mwt1337" class="mw-ref" id="cite_ref-ΔFosB_reward_68-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"ΔFosB reward"},"body":{"id":"mw-reference-text-cite_note-ΔFosB_reward-68"}}'><a href="./Addiction#cite_note-ΔFosB_reward-68" style="counter-reset: mw-Ref 65;"><span class="mw-reflink-text">[65]</span></a></sup> Natural rewards, like drugs of abuse, <a rel="mw:WikiLink" href="./Inducible_gene" title="Inducible gene" id="mwyQ" class="mw-redirect">induce gene expression</a> of ΔFosB in the nucleus accumbens, and chronic acquisition of these rewards can result in a similar pathological addictive state through ΔFosB overexpression.<sup about="#mwt1339" class="mw-ref" id="cite_ref-Natural_and_drug_addictions_12-13" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Natural and drug addictions"},"body":{"id":"mw-reference-text-cite_note-Natural_and_drug_addictions-12"}}'><a href="./Addiction#cite_note-Natural_and_drug_addictions-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></sup><sup about="#mwt404" class="mw-ref" id="cite_ref-Nestler_14-10" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Nestler"}}'><a href="./Addiction#cite_note-Nestler-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></sup><sup about="#mwt406" class="mw-ref" id="cite_ref-ΔFosB_reward_68-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"ΔFosB reward"}}'><a href="./Addiction#cite_note-ΔFosB_reward-68" style="counter-reset: mw-Ref 65;"><span class="mw-reflink-text">[65]</span></a></sup> Consequently, ΔFosB is the key transcription factor involved in addictions to natural rewards (i.e., behavioral addictions) as well;<sup about="#mwt1341" class="mw-ref" id="cite_ref-Nestler_14-11" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Nestler"},"body":{"id":"mw-reference-text-cite_note-Nestler-14"}}'><a href="./Addiction#cite_note-Nestler-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></sup><sup about="#mwt408" class="mw-ref" id="cite_ref-Natural_and_drug_addictions_12-14" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Natural and drug addictions"}}'><a href="./Addiction#cite_note-Natural_and_drug_addictions-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></sup><sup about="#mwt410" class="mw-ref" id="cite_ref-ΔFosB_reward_68-2" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"ΔFosB reward"}}'><a href="./Addiction#cite_note-ΔFosB_reward-68" style="counter-reset: mw-Ref 65;"><span class="mw-reflink-text">[65]</span></a></sup> in particular, ΔFosB in the nucleus accumbens is critical for the <a rel="mw:WikiLink" href="./Reinforcing" title="Reinforcing" id="mwyg" class="mw-redirect">reinforcing</a> effects of sexual reward.<sup about="#mwt412" class="mw-ref" id="cite_ref-ΔFosB_reward_68-3" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"ΔFosB reward"}}'><a href="./Addiction#cite_note-ΔFosB_reward-68" style="counter-reset: mw-Ref 65;"><span class="mw-reflink-text">[65]</span></a></sup> Research on the interaction between natural and drug rewards suggests that dopaminergic psychostimulants (e.g., <a rel="mw:WikiLink" href="./Amphetamine" title="Amphetamine" id="mwyw">amphetamine</a>) and sexual behavior act on similar biomolecular mechanisms to induce ΔFosB in the nucleus accumbens and possess bidirectional cross-<a rel="mw:WikiLink" href="./Sensitization" title="Sensitization" id="mwzA">sensitization</a> effects that are mediated through ΔFosB.<sup about="#mwt414" class="mw-ref" id="cite_ref-Natural_and_drug_addictions_12-15" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Natural and drug addictions"}}'><a href="./Addiction#cite_note-Natural_and_drug_addictions-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></sup><sup about="#mwt1343" class="mw-ref" id="cite_ref-Amph-Sex_X-sensitization_through_D1_signaling_28-3" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Amph-Sex X-sensitization through D1 signaling"},"body":{"id":"mw-reference-text-cite_note-Amph-Sex_X-sensitization_through_D1_signaling-28"}}'><a href="./Addiction#cite_note-Amph-Sex_X-sensitization_through_D1_signaling-28" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></sup><sup about="#mwt1345" class="mw-ref" id="cite_ref-Amph-Sex_X-sensitization_through_NMDA_signaling_29-3" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Amph-Sex X-sensitization through NMDA signaling"},"body":{"id":"mw-reference-text-cite_note-Amph-Sex_X-sensitization_through_NMDA_signaling-29"}}'><a href="./Addiction#cite_note-Amph-Sex_X-sensitization_through_NMDA_signaling-29" style="counter-reset: mw-Ref 28;"><span class="mw-reflink-text">[28]</span></a></sup>  This phenomenon is notable since, in humans, a <a rel="mw:WikiLink" href="./Dopamine_dysregulation_syndrome" title="Dopamine dysregulation syndrome" id="mwzQ">dopamine dysregulation syndrome</a>, characterized by drug-induced compulsive engagement in natural rewards (specifically, sexual activity, shopping, and gambling), has also been observed in some individuals taking <a rel="mw:WikiLink" href="./Dopaminergic" title="Dopaminergic" id="mwzg">dopaminergic</a> medications.<sup about="#mwt416" class="mw-ref" id="cite_ref-Natural_and_drug_addictions_12-16" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Natural and drug addictions"}}'><a href="./Addiction#cite_note-Natural_and_drug_addictions-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></sup></p>

<p id="mwzw"><a rel="mw:WikiLink" href="./ΔFosB" title="ΔFosB" id="mw0A" class="mw-redirect">ΔFosB</a> inhibitors (drugs or treatments that oppose its action) may be an effective treatment for addiction and addictive disorders.<sup about="#mwt1347" class="mw-ref" id="cite_ref-Malenka_2009_04_69-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Malenka_2009_04"},"body":{"id":"mw-reference-text-cite_note-Malenka_2009_04-69"}}'><a href="./Addiction#cite_note-Malenka_2009_04-69" style="counter-reset: mw-Ref 66;"><span class="mw-reflink-text">[66]</span></a></sup></p>

<p id="mw0Q">The release of <a rel="mw:WikiLink" href="./Dopamine" title="Dopamine" id="mw0g">dopamine</a> in the <a rel="mw:WikiLink" href="./Nucleus_accumbens" title="Nucleus accumbens" id="mw0w">nucleus accumbens</a> plays a role in the reinforcing qualities of many forms of stimuli, including naturally reinforcing stimuli like palatable food and sex.<sup about="#mwt1349" class="mw-ref" id="cite_ref-Salamone_70-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Salamone"},"body":{"id":"mw-reference-text-cite_note-Salamone-70"}}'><a href="./Addiction#cite_note-Salamone-70" style="counter-reset: mw-Ref 67;"><span class="mw-reflink-text">[67]</span></a></sup><sup about="#mwt1351" class="mw-ref" id="cite_ref-Kauer_71-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Kauer"},"body":{"id":"mw-reference-text-cite_note-Kauer-71"}}'><a href="./Addiction#cite_note-Kauer-71" style="counter-reset: mw-Ref 68;"><span class="mw-reflink-text">[68]</span></a></sup> Altered dopamine <a rel="mw:WikiLink" href="./Neurotransmission" title="Neurotransmission" id="mw1A">neurotransmission</a> is frequently observed following the development of an addictive state.<sup about="#mwt434" class="mw-ref" id="cite_ref-Natural_and_drug_addictions_12-17" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Natural and drug addictions"}}'><a href="./Addiction#cite_note-Natural_and_drug_addictions-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></sup> In humans and lab animals that have developed an addiction, alterations in dopamine or <a rel="mw:WikiLink" href="./Opioid" title="Opioid" id="mw1Q">opioid</a> neurotransmission in the nucleus accumbens and other parts of the <a rel="mw:WikiLink" href="./Striatum" title="Striatum" id="mw1g">striatum</a> are evident.<sup about="#mwt436" class="mw-ref" id="cite_ref-Natural_and_drug_addictions_12-18" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Natural and drug addictions"}}'><a href="./Addiction#cite_note-Natural_and_drug_addictions-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></sup> Studies have found that use of certain drugs (e.g., <a rel="mw:WikiLink" href="./Cocaine" title="Cocaine" id="mw1w">cocaine</a>) affect <a rel="mw:WikiLink" href="./Cholinergic_neuron" title="Cholinergic neuron" id="mw2A">cholinergic neurons</a> that innervate the <a rel="mw:WikiLink" href="./Reward_system" title="Reward system" id="mw2Q">reward system</a>, in turn affecting dopamine signaling in this region.<sup about="#mwt1353" class="mw-ref" id="cite_ref-Witten_72-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Witten"},"body":{"id":"mw-reference-text-cite_note-Witten-72"}}'><a href="./Addiction#cite_note-Witten-72" style="counter-reset: mw-Ref 69;"><span class="mw-reflink-text">[69]</span></a></sup></p>

<section data-mw-section-id="13" id="mw2g"><h3 id="Reward_system">Reward system</h3>
<div role="note" class="hatnote navigation-not-searchable" about="#mwt440" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"main","href":"./Template:Main"},"params":{"1":{"wt":"Reward system"}},"i":0}}]}' id="mw2w">Main article: <a rel="mw:WikiLink" href="./Reward_system" title="Reward system">Reward system</a></div>
<table class="box-Expand_section plainlinks metadata ambox mbox-small-left ambox-content" role="presentation" about="#mwt441" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"expand section","href":"./Template:Expand_section"},"params":{"date":{"wt":"August 2015"}},"i":0}}]}' id="mw3A"><tbody><tr><td class="mbox-image"><figure-inline typeof="mw:Image mw:ExpandedAttrs" about="#mwt1089" data-mw='{"attribs":[["alt",{"html":"alt=&lt;span typeof=\"mw:Entity\" data-parsoid=&apos;{\"src\":\"&amp;amp;#91;\",\"srcContent\":\"[\"}&apos;>[&lt;/span>icon&lt;span typeof=\"mw:Entity\" data-parsoid=&apos;{\"src\":\"&amp;amp;#93;\",\"srcContent\":\"]\"}&apos;>]&lt;/span>","txt":"[icon]"}]]}'><a href="./File:Wiki_letter_w_cropped.svg"><img alt="[icon]" resource="./File:Wiki_letter_w_cropped.svg" src="//upload.wikimedia.org/wikipedia/commons/thumb/1/1c/Wiki_letter_w_cropped.svg/20px-Wiki_letter_w_cropped.svg.png" data-file-width="44" data-file-height="31" data-file-type="drawing" height="14" width="20" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/1/1c/Wiki_letter_w_cropped.svg/40px-Wiki_letter_w_cropped.svg.png 2x, //upload.wikimedia.org/wikipedia/commons/thumb/1/1c/Wiki_letter_w_cropped.svg/30px-Wiki_letter_w_cropped.svg.png 1.5x"/></a></figure-inline></td><td class="mbox-text"><div class="mbox-text-span">This section <b>needs expansion</b>. <small>You can help by <a rel="mw:ExtLink" class="external text" href="//en.wikipedia.org/w/index.php?title=Addiction&amp;action=edit&amp;section=">adding to it</a>.</small>  <small class="date-container"><i>(<span class="date">August 2015</span>)</i></small></div></td></tr></tbody></table><link rel="mw:PageProp/Category" href="./Category:Articles_to_be_expanded_from_August_2015" about="#mwt441"/><link rel="mw:PageProp/Category" href="./Category:All_articles_to_be_expanded" about="#mwt441"/><link rel="mw:PageProp/Category" href="./Category:Articles_using_small_message_boxes" about="#mwt441" id="mw3Q"/>

<section data-mw-section-id="14" id="mw3g"><h4 id="Mesocorticolimbic_pathway">Mesocorticolimbic pathway</h4>
<span about="#mwt444" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"Annotated image 4\n","href":"./Template:Annotated_image_4"},"params":{"caption":{"wt":"Top: this depicts the initial effects of high dose exposure to an addictive drug on [[gene expression]] in the [[nucleus accumbens]] for various Fos family proteins (i.e., [[c-Fos]], [[FosB]], [[ΔFosB]], [[Fra1]], and [[Fra2]]).&lt;br />Bottom: this illustrates the progressive increase in ΔFosB expression in the nucleus accumbens following repeated twice daily drug binges, where these [[phosphorylated]] (35–37&amp;nbsp;[[kilodalton]]) ΔFosB [[isoform]]s persist in the [[D1-type]] [[medium spiny neurons]] of the nucleus accumbens for up to 2&amp;nbsp;months.&lt;!--The following named ref is transcluded in from \"Template:Psychostimulant addiction\"-->&lt;ref name=\"Nestler2\" />&lt;ref name=\"pmid11572966\">{{cite journal |vauthors=Nestler EJ, Barrot M, Self DW | title = DeltaFosB: a sustained molecular switch for addiction | journal = Proc. Natl. Acad. Sci. U.S.A. | volume = 98 | issue = 20 | pages = 11042–46 |date=September 2001 | pmid = 11572966 | pmc = 58680 | doi = 10.1073/pnas.191352698 | quote = Although the ΔFosB signal is relatively long-lived, it is not permanent. ΔFosB degrades gradually and can no longer be detected in brain after 1–2 months of drug withdrawal&amp;nbsp;... Indeed, ΔFosB is the longest-lived adaptation known to occur in adult brain, not only in response to drugs of abuse, but to any other perturbation (that doesn&apos;t involve lesions) as well. }}&lt;/ref>"},"header":{"wt":"ΔFosB accumulation from excessive drug use"},"header_background":{"wt":"aliceblue"},"alt":{"wt":"ΔFosB accumulation graph"},"image":{"wt":"ΔFosB accumulation.svg"},"align":{"wt":"right"},"icon":{"wt":"none"},"image-width":{"wt":"400"},"image-left":{"wt":"0"},"image-top":{"wt":"0"},"width":{"wt":"400"},"height":{"wt":"440"},"annotations":{"wt":""}},"i":0}}]}' id="mw3w">
</span><table role="presentation" cellpadding="0" style="border-spacing:0; clear:right; float:right;" about="#mwt444">
<tbody><tr>
<td><div class="thumb tright">
<div class="thumbinner" style="width:402px; ">
<div style="clear: both; font-weight: bold; font-size: 106.4%; text-align: center; background-color: aliceblue;margin-bottom:3px;">ΔFosB accumulation from excessive drug use</div>
<div style="position:relative; width:400px; height:440px; overflow:hidden; border:solid #ccc 1px; background-color:white;">
<div style="left:0px; top:0px; width:400px; position:absolute"> <figure-inline typeof="mw:Image"><a href="./COMMONS:File:ΔFosB_accumulation.svg"><img alt="ΔFosB accumulation graph" resource="./File:ΔFosB_accumulation.svg" src="//upload.wikimedia.org/wikipedia/commons/thumb/4/4b/%CE%94FosB_accumulation.svg/400px-%CE%94FosB_accumulation.svg.png" data-file-width="400" data-file-height="440" data-file-type="drawing" height="440" width="400" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/4/4b/%CE%94FosB_accumulation.svg/800px-%CE%94FosB_accumulation.svg.png 2x, //upload.wikimedia.org/wikipedia/commons/thumb/4/4b/%CE%94FosB_accumulation.svg/600px-%CE%94FosB_accumulation.svg.png 1.5x"/></a></figure-inline>
</div> 
<div style="text-align:center; line-height:110%;">
<div style="background-color:transparent; color:black"></div>
</div>
</div>
<div class="thumbcaption" style="clear:left">Top: this depicts the initial effects of high dose exposure to an addictive drug on <a rel="mw:WikiLink" href="./Gene_expression" title="Gene expression">gene expression</a> in the <a rel="mw:WikiLink" href="./Nucleus_accumbens" title="Nucleus accumbens">nucleus accumbens</a> for various Fos family proteins (i.e., <a rel="mw:WikiLink" href="./C-Fos" title="C-Fos">c-Fos</a>, <a rel="mw:WikiLink" href="./FosB" title="FosB" class="mw-redirect">FosB</a>, <a rel="mw:WikiLink" href="./ΔFosB" title="ΔFosB" class="mw-redirect">ΔFosB</a>, <a rel="mw:WikiLink" href="./Fra1" title="Fra1" class="mw-redirect">Fra1</a>, and <a rel="mw:WikiLink" href="./Fra2" title="Fra2" class="mw-redirect">Fra2</a>).<br/>Bottom: this illustrates the progressive increase in ΔFosB expression in the nucleus accumbens following repeated twice daily drug binges, where these <a rel="mw:WikiLink" href="./Phosphorylated" title="Phosphorylated" class="mw-redirect">phosphorylated</a> (35–37<span typeof="mw:Entity"> </span><a rel="mw:WikiLink" href="./Kilodalton" title="Kilodalton" class="mw-redirect">kilodalton</a>) ΔFosB <a rel="mw:WikiLink" href="./Isoform" title="Isoform" class="mw-redirect">isoforms</a> persist in the <a rel="mw:WikiLink" href="./D1-type" title="D1-type" class="mw-redirect">D1-type</a> <a rel="mw:WikiLink" href="./Medium_spiny_neurons" title="Medium spiny neurons" class="mw-redirect">medium spiny neurons</a> of the nucleus accumbens for up to 2<span typeof="mw:Entity"> </span>months.<sup about="#mwt1088" class="mw-ref" id="cite_ref-Nestler2_61-3" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Nestler2"}}'><a href="./Addiction#cite_note-Nestler2-61" style="counter-reset: mw-Ref 58;"><span class="mw-reflink-text">[58]</span></a></sup><sup about="#mwt1798" class="mw-ref" id="cite_ref-pmid11572966_73-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"pmid11572966"},"body":{"id":"mw-reference-text-cite_note-pmid11572966-73"}}'><a href="./Addiction#cite_note-pmid11572966-73" style="counter-reset: mw-Ref 70;"><span class="mw-reflink-text">[70]</span></a></sup></div>
</div>
</div></td></tr>
</tbody></table>
<p id="mw4A">Understanding the pathways in which drugs act and how drugs can alter those pathways is key when examining the biological basis of drug addiction. The reward pathway, known as the <a rel="mw:WikiLink" href="./Mesolimbic_system" title="Mesolimbic system" id="mw4Q" class="mw-redirect">mesolimbic pathway</a>, or its extension, the <a rel="mw:WikiLink" href="./Mesocorticolimbic_pathway" title="Mesocorticolimbic pathway" id="mw4g" class="mw-redirect">mesocorticolimbic pathway</a>, is characterized by the interaction of several areas of the brain.</p>
<ul id="mw4w"><li id="mw5A">The projections from the <a rel="mw:WikiLink" href="./Ventral_tegmentum" title="Ventral tegmentum" id="mw5Q" class="mw-redirect">ventral tegmental area</a> (VTA) are a network of <a rel="mw:WikiLink" href="./Dopaminergic" title="Dopaminergic" id="mw5g">dopaminergic</a> <a rel="mw:WikiLink" href="./Neurons" title="Neurons" id="mw5w" class="mw-redirect">neurons</a> with <a rel="mw:WikiLink/Interwiki" href="https://en.wiktionary.org/wiki/colocalize" title="wikt:colocalize" id="mw6A">co-localized</a> postsynaptic <a rel="mw:WikiLink" href="./Glutamate" title="Glutamate" id="mw6Q" class="mw-redirect">glutamate</a> receptors (<a rel="mw:WikiLink" href="./AMPAR" title="AMPAR" id="mw6g" class="mw-redirect">AMPAR</a> and <a rel="mw:WikiLink" href="./NMDAR" title="NMDAR" id="mw6w" class="mw-redirect">NMDAR</a>). These cells respond when stimuli indicative of a reward are present. The VTA supports learning and sensitization development and releases DA into the <a rel="mw:WikiLink" href="./Forebrain" title="Forebrain" id="mw7A">forebrain</a>.<sup about="#mwt1357" class="mw-ref" id="cite_ref-Jones_and_Bonci_74-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Jones and Bonci"},"body":{"id":"mw-reference-text-cite_note-Jones_and_Bonci-74"}}'><a href="./Addiction#cite_note-Jones_and_Bonci-74" style="counter-reset: mw-Ref 71;"><span class="mw-reflink-text">[71]</span></a></sup> These neurons also project and release DA into the nucleus accumbens,<sup about="#mwt1359" class="mw-ref" id="cite_ref-Eisch_and_Harburg_75-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Eisch and Harburg"},"body":{"id":"mw-reference-text-cite_note-Eisch_and_Harburg-75"}}'><a href="./Addiction#cite_note-Eisch_and_Harburg-75" style="counter-reset: mw-Ref 72;"><span class="mw-reflink-text">[72]</span></a></sup> through the <a rel="mw:WikiLink" href="./Mesolimbic_pathway" title="Mesolimbic pathway" id="mw7Q">mesolimbic pathway</a>. Virtually all drugs causing drug addiction increase the dopamine release in the mesolimbic pathway,<sup about="#mwt1361" class="mw-ref" id="cite_ref-Rang_76-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Rang"},"body":{"id":"mw-reference-text-cite_note-Rang-76"}}'><a href="./Addiction#cite_note-Rang-76" style="counter-reset: mw-Ref 73;"><span class="mw-reflink-text">[73]</span></a></sup> in addition to their specific effects.</li>
<li id="mw7g">The <a rel="mw:WikiLink" href="./Nucleus_accumbens" title="Nucleus accumbens" id="mw7w">nucleus accumbens</a> (NAcc) is one output of the VTA projections.  The nucleus accumbens itself consists mainly of <a rel="mw:WikiLink" href="./GABA" title="GABA" id="mw8A" class="mw-redirect">GABAergic</a> <a rel="mw:WikiLink" href="./Medium_spiny_neuron" title="Medium spiny neuron" id="mw8Q">medium spiny neurons</a> (MSNs).<sup about="#mwt1363" class="mw-ref" id="cite_ref-Kourrich_77-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Kourrich"},"body":{"id":"mw-reference-text-cite_note-Kourrich-77"}}'><a href="./Addiction#cite_note-Kourrich-77" style="counter-reset: mw-Ref 74;"><span class="mw-reflink-text">[74]</span></a></sup> The NAcc is associated with acquiring and eliciting conditioned behaviors, and is involved in the increased sensitivity to drugs as addiction progresses.<sup about="#mwt457" class="mw-ref" id="cite_ref-Jones_and_Bonci_74-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Jones and Bonci"}}'><a href="./Addiction#cite_note-Jones_and_Bonci-74" style="counter-reset: mw-Ref 71;"><span class="mw-reflink-text">[71]</span></a></sup> Overexpression of <a rel="mw:WikiLink" href="./ΔFosB" title="ΔFosB" id="mw8g" class="mw-redirect">ΔFosB</a> in the nucleus accumbens is a necessary common factor in essentially all known forms of addiction;<sup about="#mwt459" class="mw-ref" id="cite_ref-Cellular_basis_3-18" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Cellular basis"}}'><a href="./Addiction#cite_note-Cellular_basis-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></sup> ΔFosB is a strong positive modulator of <a rel="mw:WikiLink" href="./Positively_reinforced" title="Positively reinforced" id="mw8w" class="mw-redirect">positively reinforced</a> behaviors.<sup about="#mwt461" class="mw-ref" id="cite_ref-Cellular_basis_3-19" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Cellular basis"}}'><a href="./Addiction#cite_note-Cellular_basis-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></sup></li>
<li id="mw9A">The <a rel="mw:WikiLink" href="./Prefrontal_cortex" title="Prefrontal cortex" id="mw9Q">prefrontal cortex</a>, including the <a rel="mw:WikiLink" href="./Anterior_cingulate" title="Anterior cingulate" id="mw9g" class="mw-redirect">anterior cingulate</a> and <a rel="mw:WikiLink" href="./Orbitofrontal_cortex" title="Orbitofrontal cortex" id="mw9w">orbitofrontal</a> cortices,<sup about="#mwt1365" class="mw-ref" id="cite_ref-Kalivas_and_Volkow_78-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Kalivas and Volkow"},"body":{"id":"mw-reference-text-cite_note-Kalivas_and_Volkow-78"}}'><a href="./Addiction#cite_note-Kalivas_and_Volkow-78" style="counter-reset: mw-Ref 75;"><span class="mw-reflink-text">[75]</span></a></sup> is another VTA output in the mesocorticolimbic pathway; it is important for the integration of information which helps determine whether a behavior will be elicited.<sup about="#mwt1367" class="mw-ref" id="cite_ref-Floresco_79-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Floresco"},"body":{"id":"mw-reference-text-cite_note-Floresco-79"}}'><a href="./Addiction#cite_note-Floresco-79" style="counter-reset: mw-Ref 76;"><span class="mw-reflink-text">[76]</span></a></sup> It is also critical for forming associations between the rewarding experience of drug use and cues in the environment. Importantly, these cues are strong mediators of drug-seeking behavior and can trigger relapse even after months or years of abstinence.<sup about="#mwt1369" class="mw-ref" id="cite_ref-80" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{},"body":{"id":"mw-reference-text-cite_note-80"}}'><a href="./Addiction#cite_note-80" style="counter-reset: mw-Ref 77;"><span class="mw-reflink-text">[77]</span></a></sup></li></ul>
<p id="mw-A">Other brain structures that are involved in addiction include:</p>
<ul id="mw-Q"><li id="mw-g">The <a rel="mw:WikiLink" href="./Basolateral_amygdala" title="Basolateral amygdala" id="mw-w">basolateral amygdala</a> projects into the NAcc and is thought to also be important for motivation.<sup about="#mwt470" class="mw-ref" id="cite_ref-Floresco_79-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Floresco"}}'><a href="./Addiction#cite_note-Floresco-79" style="counter-reset: mw-Ref 76;"><span class="mw-reflink-text">[76]</span></a></sup></li>
<li id="mw_A">The <a rel="mw:WikiLink" href="./Hippocampus" title="Hippocampus" id="mw_Q">hippocampus</a> is involved in drug addiction, because of its role in learning and memory. Much of this evidence stems from investigations showing that manipulating cells in the hippocampus alters dopamine levels in NAcc and firing rates of VTA dopaminergic cells.<sup about="#mwt473" class="mw-ref" id="cite_ref-Eisch_and_Harburg_75-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Eisch and Harburg"}}'><a href="./Addiction#cite_note-Eisch_and_Harburg-75" style="counter-reset: mw-Ref 72;"><span class="mw-reflink-text">[72]</span></a></sup></li></ul>

</section><section data-mw-section-id="15" id="mw_g"><h4 id="Role_of_dopamine_and_glutamate">Role of dopamine and glutamate</h4>

<p id="mw_w">Dopamine is the primary neurotransmitter of the reward system in the brain. It plays a role in regulating movement, emotion, cognition, motivation, and feelings of pleasure.<sup about="#mwt1371" class="mw-ref" id="cite_ref-arch_81-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"arch"},"body":{"id":"mw-reference-text-cite_note-arch-81"}}'><a href="./Addiction#cite_note-arch-81" style="counter-reset: mw-Ref 78;"><span class="mw-reflink-text">[78]</span></a></sup> Natural rewards, like eating, as well as recreational drug use cause a release of dopamine, and are associated with the reinforcing nature of these stimuli.<sup about="#mwt482" class="mw-ref" id="cite_ref-arch_81-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"arch"}}'><a href="./Addiction#cite_note-arch-81" style="counter-reset: mw-Ref 78;"><span class="mw-reflink-text">[78]</span></a></sup><sup about="#mwt1373" class="mw-ref" id="cite_ref-drugs-brain_82-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"drugs-brain"},"body":{"id":"mw-reference-text-cite_note-drugs-brain-82"}}'><a href="./Addiction#cite_note-drugs-brain-82" style="counter-reset: mw-Ref 79;"><span class="mw-reflink-text">[79]</span></a></sup> Nearly all addictive drugs, directly or indirectly, act upon the brain's reward system by heightening dopaminergic activity.<sup about="#mwt1375" class="mw-ref" id="cite_ref-addict_83-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"addict"},"body":{"id":"mw-reference-text-cite_note-addict-83"}}'><a href="./Addiction#cite_note-addict-83" style="counter-reset: mw-Ref 80;"><span class="mw-reflink-text">[80]</span></a></sup></p>

<p id="mwAQA">Excessive intake of many types of addictive drugs results in repeated release of high amounts of dopamine, which in turn affects the reward pathway directly through heightened <a rel="mw:WikiLink" href="./Dopamine_receptor" title="Dopamine receptor" id="mwAQE">dopamine receptor</a> activation. Prolonged and abnormally high levels of dopamine in the <a rel="mw:WikiLink" href="./Synaptic_cleft" title="Synaptic cleft" id="mwAQI" class="mw-redirect">synaptic cleft</a> can induce receptor <a rel="mw:WikiLink" href="./Downregulation_and_upregulation" title="Downregulation and upregulation" id="mwAQM">downregulation</a> in the neural pathway. Downregulation of <a rel="mw:WikiLink" href="./Mesolimbic" title="Mesolimbic" id="mwAQQ" class="mw-redirect">mesolimbic</a> dopamine receptors can result in a decrease in the sensitivity to natural reinforcers.<sup about="#mwt485" class="mw-ref" id="cite_ref-arch_81-2" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"arch"}}'><a href="./Addiction#cite_note-arch-81" style="counter-reset: mw-Ref 78;"><span class="mw-reflink-text">[78]</span></a></sup></p>

<p id="mwAQU">Drug seeking behavior is induced by glutamatergic projections from the prefrontal cortex to the nucleus accumbens. This idea is supported with data from experiments showing that drug seeking behavior can be prevented following the inhibition of <a rel="mw:WikiLink" href="./AMPA" title="AMPA" id="mwAQY">AMPA</a> glutamate receptors and glutamate release in the nucleus accumbens.<sup about="#mwt488" class="mw-ref" id="cite_ref-Kalivas_and_Volkow_78-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Kalivas and Volkow"}}'><a href="./Addiction#cite_note-Kalivas_and_Volkow-78" style="counter-reset: mw-Ref 75;"><span class="mw-reflink-text">[75]</span></a></sup></p>

</section></section><section data-mw-section-id="16" id="mwAQc"><h3 id="Reward_sensitization">Reward sensitization<span id="Sensitization" about="#mwt489" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"anchor","href":"./Template:Anchor"},"params":{"1":{"wt":"Sensitization"},"2":{"wt":"Drug sensitization"}},"i":0}}]}'></span><span id="Drug_sensitization" about="#mwt489"></span></h3><!--"Drug sensitization" redirects here, do not change without correcting the redirect-->
<table class="wikitable" style="text-align:center; float:right; margin-left:1em;" id="mwAQg">
<caption id="mwAQk">Neural and behavioral effects of validated ΔFosB transcriptional targets in the <a rel="mw:WikiLink" href="./Striatum" title="Striatum" id="mwAQo">striatum</a><sup about="#mwt498" class="mw-ref" id="cite_ref-What_the_ΔFosB?_11-7" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"What the ΔFosB?"}}'><a href="./Addiction#cite_note-What_the_ΔFosB?-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></sup><sup about="#mwt1385" class="mw-ref" id="cite_ref-pmid18640924_84-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"pmid18640924"},"body":{"id":"mw-reference-text-cite_note-pmid18640924-84"}}'><a href="./Addiction#cite_note-pmid18640924-84" style="counter-reset: mw-Ref 81;"><span class="mw-reflink-text">[81]</span></a></sup></caption>
<tbody id="mwAQs"><tr id="mwAQw"><th scope="col" id="mwAQ0">Target<br id="mwAQ4"/>gene</th>
<th scope="col" id="mwAQ8">Target<br id="mwARA"/><a rel="mw:WikiLink" href="./Gene_expression" title="Gene expression" id="mwARE">expression</a></th>
<th scope="col" id="mwARI">Neural effects</th>
<th scope="col" id="mwARM">Behavioral effects</th></tr>
<tr id="mwARQ">
<td scope="row" style="height: 40px" id="mwARU"><a rel="mw:WikiLink" href="./C-Fos" title="C-Fos" id="mwARY">c-Fos</a></td><td id="mwARc">↓</td><td id="mwARg">Molecular switch enabling the chronic<br id="mwARk"/>induction of ΔFosB<sup about="#mwt503" class="mw-ref" id="cite_ref-85" rel="dc:references" typeof="mw:Transclusion  mw:Extension/ref" data-mw='{"parts":[{"template":{"target":{"wt":"#tag:ref","function":"tag"},"params":{"1":{"wt":"In other words, c-Fos [[gene repression|repression]] allows ΔFosB to more rapidly accumulate within the D1-type medium spiny neurons of the nucleus accumbens because it is selectively induced in this state.&lt;ref name=\"Cellular basis\" /> Prior to c-Fos repression, all Fos family proteins (e.g., c-Fos, [[Fra1]], [[Fra2]], [[FosB]], and ΔFosB) are induced together, with ΔFosB expression increasing to a lesser extent.&lt;ref name=\"Cellular basis\" />"},"group":{"wt":"\"note\""}},"i":0}}]}'><a href="./Addiction#cite_note-85" style="counter-reset: mw-Ref 3;" data-mw-group="note"><span class="mw-reflink-text">[note 3]</span></a></sup></td><td id="mwARo">–</td></tr>
<tr id="mwARs">
<td scope="row" style="height: 40px" id="mwARw"><a rel="mw:WikiLink" href="./Dynorphin" title="Dynorphin" id="mwAR0">dynorphin</a></td><td id="mwAR4">↓<br id="mwAR8"/><sup about="#mwt508" class="mw-ref" id="cite_ref-86" rel="dc:references" typeof="mw:Transclusion  mw:Extension/ref" data-mw='{"parts":[{"template":{"target":{"wt":"#tag:ref","function":"tag"},"params":{"1":{"wt":"According to two medical reviews, ΔFosB has been implicated in causing both increases and decreases in dynorphin expression in different studies;&lt;ref name=\"What the ΔFosB?\" />&lt;ref name=\"pmid18640924\" /> this table entry reflects only a decrease. "},"group":{"wt":"\"note\""}},"i":0}}]}'><a href="./Addiction#cite_note-86" style="counter-reset: mw-Ref 4;" data-mw-group="note"><span class="mw-reflink-text">[note 4]</span></a></sup></td><td style="text-align:left" id="mwASA"><span typeof="mw:Transclusion mw:Entity" about="#mwt509" data-mw='{"parts":[{"template":{"target":{"wt":"bull","href":"./Template:Bull"},"params":{},"i":0}}]}' id="mwASE"> </span><span typeof="mw:Entity" about="#mwt509">•</span><span typeof="mw:Entity" about="#mwt509"> </span>Downregulation of <a rel="mw:WikiLink" href="./Κ-opioid_receptor" title="Κ-opioid receptor" id="mwASI">κ-opioid</a> feedback loop</td><td style="text-align:left" id="mwASM"><span typeof="mw:Transclusion mw:Entity" about="#mwt510" data-mw='{"parts":[{"template":{"target":{"wt":"bull","href":"./Template:Bull"},"params":{},"i":0}}]}' id="mwASQ"> </span><span typeof="mw:Entity" about="#mwt510">•</span><span typeof="mw:Entity" about="#mwt510"> </span>Increased drug reward</td></tr>
<tr id="mwASU">
<td scope="row" style="height: 40px" id="mwASY"><a rel="mw:WikiLink" href="./NF-κB" title="NF-κB" id="mwASc">NF-κB</a></td><td id="mwASg">↑</td><td style="text-align:left" id="mwASk"><span typeof="mw:Transclusion mw:Entity" about="#mwt511" data-mw='{"parts":[{"template":{"target":{"wt":"bull","href":"./Template:Bull"},"params":{},"i":0}}]}' id="mwASo"> </span><span typeof="mw:Entity" about="#mwt511">•</span><span typeof="mw:Entity" about="#mwt511"> </span>Expansion of <a rel="mw:WikiLink" href="./Nucleus_accumbens" title="Nucleus accumbens" id="mwASs">NAcc</a> dendritic processes<br id="mwASw"/><span typeof="mw:Transclusion mw:Entity" about="#mwt512" data-mw='{"parts":[{"template":{"target":{"wt":"bull","href":"./Template:Bull"},"params":{},"i":0}}]}' id="mwAS0"> </span><span typeof="mw:Entity" about="#mwt512">•</span><span typeof="mw:Entity" about="#mwt512"> </span>NF-κB inflammatory response in the <abbr title="nucleus accumbens" about="#mwt513" typeof="mw:Transclusion mw:ExpandedAttrs" data-mw='{"parts":[{"template":{"target":{"wt":"abbr","href":"./Template:Abbr"},"params":{"1":{"wt":"NAcc"},"2":{"wt":"nucleus accumbens"}},"i":0}}]}' id="mwAS4">NAcc</abbr><br id="mwAS8"/><span typeof="mw:Transclusion mw:Entity" about="#mwt514" data-mw='{"parts":[{"template":{"target":{"wt":"bull","href":"./Template:Bull"},"params":{},"i":0}}]}' id="mwATA"> </span><span typeof="mw:Entity" about="#mwt514">•</span><span typeof="mw:Entity" about="#mwt514"> </span>NF-κB inflammatory response in the <a rel="mw:WikiLink" href="./Caudate_putamen" title="Caudate putamen" about="#mwt515" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"abbrlink","href":"./Template:Abbrlink"},"params":{"1":{"wt":"CP"},"2":{"wt":"caudate putamen"}},"i":0}}]}' id="mwATE" class="mw-redirect"><abbr title="caudate putamen" about="#mwt1079" typeof="mw:ExpandedAttrs" data-mw='{"attribs":[[{"txt":"title"},{"html":"&lt;span typeof=\"mw:Nowiki\" data-parsoid=\"{}\">caudate putamen&lt;/span>"}]]}'>CP</abbr></a></td><td style="text-align:left" id="mwATI"><span typeof="mw:Transclusion mw:Entity" about="#mwt516" data-mw='{"parts":[{"template":{"target":{"wt":"bull","href":"./Template:Bull"},"params":{},"i":0}}]}' id="mwATM"> </span><span typeof="mw:Entity" about="#mwt516">•</span><span typeof="mw:Entity" about="#mwt516"> </span>Increased drug reward<br id="mwATQ"/><span typeof="mw:Transclusion mw:Entity" about="#mwt517" data-mw='{"parts":[{"template":{"target":{"wt":"bull","href":"./Template:Bull"},"params":{},"i":0}}]}' id="mwATU"> </span><span typeof="mw:Entity" about="#mwt517">•</span><span typeof="mw:Entity" about="#mwt517"> </span>Increased drug reward<br id="mwATY"/><span typeof="mw:Transclusion mw:Entity" about="#mwt518" data-mw='{"parts":[{"template":{"target":{"wt":"bull","href":"./Template:Bull"},"params":{},"i":0}}]}' id="mwATc"> </span><span typeof="mw:Entity" about="#mwt518">•</span><span typeof="mw:Entity" about="#mwt518"> </span><a rel="mw:WikiLink" href="./Stereotypy" title="Stereotypy" id="mwATg">Locomotor sensitization</a></td></tr>
<tr id="mwATk">
<td scope="row" style="height: 40px" id="mwATo"><a rel="mw:WikiLink" href="./GluR2" title="GluR2" id="mwATs" class="mw-redirect">GluR2</a></td><td id="mwATw">↑</td><td style="text-align:left" id="mwAT0"><span typeof="mw:Transclusion mw:Entity" about="#mwt519" data-mw='{"parts":[{"template":{"target":{"wt":"bull","href":"./Template:Bull"},"params":{},"i":0}}]}' id="mwAT4"> </span><span typeof="mw:Entity" about="#mwt519">•</span><span typeof="mw:Entity" about="#mwt519"> </span>Decreased <a rel="mw:WikiLink" href="./Sensitization" title="Sensitization" id="mwAT8">sensitivity</a> to <a rel="mw:WikiLink" href="./Glutamate" title="Glutamate" id="mwAUA" class="mw-redirect">glutamate</a></td><td style="text-align:left" id="mwAUE"><span typeof="mw:Transclusion mw:Entity" about="#mwt520" data-mw='{"parts":[{"template":{"target":{"wt":"bull","href":"./Template:Bull"},"params":{},"i":0}}]}' id="mwAUI"> </span><span typeof="mw:Entity" about="#mwt520">•</span><span typeof="mw:Entity" about="#mwt520"> </span>Increased drug reward</td></tr>
<tr id="mwAUM">
<td scope="row" style="height: 40px" id="mwAUQ"><a rel="mw:WikiLink" href="./Cdk5" title="Cdk5" id="mwAUU" class="mw-redirect">Cdk5</a></td><td id="mwAUY">↑</td><td style="text-align:left" id="mwAUc"><span typeof="mw:Transclusion mw:Entity" about="#mwt521" data-mw='{"parts":[{"template":{"target":{"wt":"bull","href":"./Template:Bull"},"params":{},"i":0}}]}' id="mwAUg"> </span><span typeof="mw:Entity" about="#mwt521">•</span><span typeof="mw:Entity" about="#mwt521"> </span><a rel="mw:WikiLink" href="./GluR1" title="GluR1" id="mwAUk" class="mw-redirect">GluR1</a> synaptic protein phosphorylation<br id="mwAUo"/><span typeof="mw:Transclusion mw:Entity" about="#mwt522" data-mw='{"parts":[{"template":{"target":{"wt":"bull","href":"./Template:Bull"},"params":{},"i":0}}]}' id="mwAUs"> </span><span typeof="mw:Entity" about="#mwt522">•</span><span typeof="mw:Entity" about="#mwt522"> </span>Expansion of <abbr title="nucleus accumbens" about="#mwt523" typeof="mw:Transclusion mw:ExpandedAttrs" data-mw='{"parts":[{"template":{"target":{"wt":"abbr","href":"./Template:Abbr"},"params":{"1":{"wt":"NAcc"},"2":{"wt":"nucleus accumbens"}},"i":0}}]}' id="mwAUw">NAcc</abbr> dendritic processes</td><td id="mwAU0">Decreased drug reward<br id="mwAU4"/><small id="mwAU8">(net effect)</small></td></tr>
</tbody></table>
<p id="mwAVA"><b id="mwAVE">Reward sensitization</b> is a process that causes an increase in the amount of reward (specifically, <a rel="mw:WikiLink" href="./Incentive_salience" title="Incentive salience" id="mwAVI" class="mw-redirect">incentive salience</a><sup about="#mwt533" class="mw-ref" id="cite_ref-89" rel="dc:references" typeof="mw:Transclusion  mw:Extension/ref" data-mw='{"parts":[{"template":{"target":{"wt":"#tag:ref","function":"tag"},"params":{"1":{"wt":"Incentive salience, the \"[[motivational salience]]\" for a reward, is a \"desire\" or \"want\" attribute, which includes a motivational component, that the brain assigns to a rewarding stimulus.&lt;ref name=\"Incentive salience and motivation review\" />&lt;ref name=\"NAcc function\" /> As a consequence, incentive salience acts as a motivational \"magnet\" for a rewarding stimulus that commands attention, induces approach, and causes the rewarding stimulus to be sought out.&lt;ref name=\"Incentive salience and motivation review\">{{cite journal | vauthors = Berridge KC | title = From prediction error to incentive salience: mesolimbic computation of reward motivation | journal = Eur. J. Neurosci. | volume = 35 | issue = 7 | pages = 1124–43 | date = April 2012 | pmid = 22487042 | pmc = 3325516 | doi = 10.1111/j.1460-9568.2012.07990.x | quote = Here I discuss how mesocorticolimbic mechanisms generate the motivation component of incentive salience. Incentive salience takes Pavlovian learning and memory as one input and as an equally important input takes neurobiological state factors (e.g. drug states, appetite states, satiety states) that can vary independently of learning. Neurobiological state changes can produce unlearned fluctuations or even reversals in the ability of a previously learned reward cue to trigger motivation. Such fluctuations in cue-triggered motivation can dramatically depart from all previously learned values about the associated reward outcome.&amp;nbsp;... Associative learning and prediction are important contributors to motivation for rewards. Learning gives incentive value to arbitrary cues such as a Pavlovian conditioned stimulus (CS) that is associated with a reward (unconditioned stimulus or UCS). Learned cues for reward are often potent triggers of desires. For example, learned cues can trigger normal appetites in everyone, and can sometimes trigger compulsive urges and relapse in addicts.&lt;br />Cue-triggered ‘wanting’ for the UCS&lt;br />A brief CS encounter (or brief UCS encounter) often primes a pulse of elevated motivation to obtain and consume more reward UCS. This is a signature feature of incentive salience.&lt;br />Cue as attractive motivational magnets&lt;br />When a Pavlovian CS+ is attributed with incentive salience it not only triggers ‘wanting’ for its UCS, but often the cue itself becomes highly attractive – even to an irrational degree. This cue attraction is another signature feature of incentive salience&amp;nbsp;... Two recognizable features of incentive salience are often visible that can be used in neuroscience experiments: (i) UCS-directed ‘wanting’ – CS-triggered pulses of intensified ‘wanting’ for the UCS reward; and (ii) CS-directed ‘wanting’ – motivated attraction to the Pavlovian cue, which makes the arbitrary CS stimulus into a motivational magnet.}}&lt;/ref>"},"group":{"wt":"\"note\""}},"i":0}}]}'><a href="./Addiction#cite_note-89" style="counter-reset: mw-Ref 5;" data-mw-group="note"><span class="mw-reflink-text">[note 5]</span></a></sup>) that is assigned by the brain to a rewarding stimulus (e.g., a drug). In simple terms, when reward sensitization to a specific stimulus (e.g., a drug) occurs, an individual's "wanting" or desire for the stimulus itself and its associated <a rel="mw:WikiLink" href="./Cue_reactivity" title="Cue reactivity" id="mwAVM">cues</a> increases.<sup about="#mwt1387" class="mw-ref" id="cite_ref-NAcc_function_88-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"NAcc function"},"body":{"id":"mw-reference-text-cite_note-NAcc_function-88"}}'><a href="./Addiction#cite_note-NAcc_function-88" style="counter-reset: mw-Ref 83;"><span class="mw-reflink-text">[83]</span></a></sup><sup about="#mwt536" class="mw-ref" id="cite_ref-Incentive_salience_and_motivation_review_87-2" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Incentive salience and motivation review"}}'><a href="./Addiction#cite_note-Incentive_salience_and_motivation_review-87" style="counter-reset: mw-Ref 82;"><span class="mw-reflink-text">[82]</span></a></sup><sup about="#mwt538" class="mw-ref" id="cite_ref-Reinforcement_in_addiction_90-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Reinforcement in addiction"}}'><a href="./Addiction#cite_note-Reinforcement_in_addiction-90" style="counter-reset: mw-Ref 84;"><span class="mw-reflink-text">[84]</span></a></sup> Reward sensitization normally occurs following chronically high levels of exposure to the stimulus. <a rel="mw:WikiLink" href="./ΔFosB" title="ΔFosB" id="mwAVQ" class="mw-redirect">ΔFosB</a> (DeltaFosB) expression in <a rel="mw:WikiLink" href="./D1-type" title="D1-type" id="mwAVU" class="mw-redirect">D1-type</a> <a rel="mw:WikiLink" href="./Medium_spiny_neuron" title="Medium spiny neuron" id="mwAVY">medium spiny neurons</a> in the <a rel="mw:WikiLink" href="./Nucleus_accumbens" title="Nucleus accumbens" id="mwAVc">nucleus accumbens</a> has been shown to directly and positively regulate reward sensitization involving drugs and natural rewards.<sup about="#mwt540" class="mw-ref" id="cite_ref-Cellular_basis_3-22" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Cellular basis"}}'><a href="./Addiction#cite_note-Cellular_basis-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></sup><sup about="#mwt542" class="mw-ref" id="cite_ref-What_the_ΔFosB?_11-9" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"What the ΔFosB?"}}'><a href="./Addiction#cite_note-What_the_ΔFosB?-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></sup><sup about="#mwt544" class="mw-ref" id="cite_ref-G9a_reverses_ΔFosB_plasticity_13-4" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"G9a reverses ΔFosB plasticity"}}'><a href="./Addiction#cite_note-G9a_reverses_ΔFosB_plasticity-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></sup></p>

<p id="mwAVg">"Cue-induced wanting" or "cue-triggered wanting", a form of craving that occurs in addiction, is responsible for the majority of compulsive behavior that addicts exhibit.<sup about="#mwt556" class="mw-ref" id="cite_ref-Incentive_salience_and_motivation_review_87-3" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Incentive salience and motivation review"}}'><a href="./Addiction#cite_note-Incentive_salience_and_motivation_review-87" style="counter-reset: mw-Ref 82;"><span class="mw-reflink-text">[82]</span></a></sup><sup about="#mwt1389" class="mw-ref" id="cite_ref-Reinforcement_in_addiction_90-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Reinforcement in addiction"},"body":{"id":"mw-reference-text-cite_note-Reinforcement_in_addiction-90"}}'><a href="./Addiction#cite_note-Reinforcement_in_addiction-90" style="counter-reset: mw-Ref 84;"><span class="mw-reflink-text">[84]</span></a></sup> During the development of an addiction, the repeated association of otherwise neutral and even non-rewarding <a rel="mw:WikiLink" href="./Stimulation" title="Stimulation" id="mwAVk">stimuli</a> with drug consumption triggers an <a rel="mw:WikiLink" href="./Associative_learning" title="Associative learning" id="mwAVo" class="mw-redirect">associative learning</a> process that causes these previously neutral stimuli to act as <a rel="mw:WikiLink" href="./Reinforcement#Secondary_reinforcers" title="Reinforcement" id="mwAVs">conditioned positive reinforcers</a> of addictive drug use (i.e., these stimuli start to function as <a rel="mw:WikiLink" href="./Drug_cues" title="Drug cues" id="mwAVw" class="mw-redirect">drug cues</a>).<sup about="#mwt558" class="mw-ref" id="cite_ref-Incentive_salience_and_motivation_review_87-4" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Incentive salience and motivation review"}}'><a href="./Addiction#cite_note-Incentive_salience_and_motivation_review-87" style="counter-reset: mw-Ref 82;"><span class="mw-reflink-text">[82]</span></a></sup><sup about="#mwt1391" class="mw-ref" id="cite_ref-Pleasure_system_-_incentive_sensitization_91-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Pleasure system - incentive sensitization"},"body":{"id":"mw-reference-text-cite_note-Pleasure_system_-_incentive_sensitization-91"}}'><a href="./Addiction#cite_note-Pleasure_system_-_incentive_sensitization-91" style="counter-reset: mw-Ref 85;"><span class="mw-reflink-text">[85]</span></a></sup><sup about="#mwt560" class="mw-ref" id="cite_ref-Reinforcement_in_addiction_90-2" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Reinforcement in addiction"}}'><a href="./Addiction#cite_note-Reinforcement_in_addiction-90" style="counter-reset: mw-Ref 84;"><span class="mw-reflink-text">[84]</span></a></sup> As conditioned positive reinforcers of drug use, these previously neutral stimuli are assigned incentive salience (which manifests as a craving)<span typeof="mw:Entity" id="mwAV0"> </span>– sometimes at pathologically high levels due to reward sensitization<span typeof="mw:Entity" id="mwAV4"> </span>– which can <a rel="mw:WikiLink" href="./Pavlovian-instrumental_transfer" title="Pavlovian-instrumental transfer" id="mwAV8">transfer to the primary reinforcer</a> (e.g., the use of an addictive drug) with which it was originally paired.<sup about="#mwt562" class="mw-ref" id="cite_ref-Incentive_salience_and_motivation_review_87-5" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Incentive salience and motivation review"}}'><a href="./Addiction#cite_note-Incentive_salience_and_motivation_review-87" style="counter-reset: mw-Ref 82;"><span class="mw-reflink-text">[82]</span></a></sup><sup about="#mwt564" class="mw-ref" id="cite_ref-Pleasure_system_-_incentive_sensitization_91-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Pleasure system - incentive sensitization"}}'><a href="./Addiction#cite_note-Pleasure_system_-_incentive_sensitization-91" style="counter-reset: mw-Ref 85;"><span class="mw-reflink-text">[85]</span></a></sup><sup about="#mwt566" class="mw-ref" id="cite_ref-Reinforcement_in_addiction_90-3" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Reinforcement in addiction"}}'><a href="./Addiction#cite_note-Reinforcement_in_addiction-90" style="counter-reset: mw-Ref 84;"><span class="mw-reflink-text">[84]</span></a></sup></p>

<p id="mwAWA">Research on the interaction between natural and drug rewards suggests that dopaminergic psychostimulants (e.g., <a rel="mw:WikiLink" href="./Amphetamine" title="Amphetamine" id="mwAWE">amphetamine</a>) and sexual behavior act on similar biomolecular mechanisms to induce ΔFosB in the nucleus accumbens and possess a bidirectional <b id="mwAWI">reward cross-sensitization</b> effect<sup about="#mwt577" class="mw-ref" id="cite_ref-92" rel="dc:references" typeof="mw:Transclusion  mw:Extension/ref" data-mw='{"parts":[{"template":{"target":{"wt":"#tag:ref","function":"tag"},"params":{"1":{"wt":"In simplest terms, this means that when either amphetamine or sex is perceived as more alluring or desirable through reward sensitization, this effect occurs with the other as well."},"group":{"wt":"\"note\""}},"i":0}}]}'><a href="./Addiction#cite_note-92" style="counter-reset: mw-Ref 6;" data-mw-group="note"><span class="mw-reflink-text">[note 6]</span></a></sup> that is mediated through ΔFosB.<sup about="#mwt579" class="mw-ref" id="cite_ref-Natural_and_drug_addictions_12-19" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Natural and drug addictions"}}'><a href="./Addiction#cite_note-Natural_and_drug_addictions-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></sup><sup about="#mwt581" class="mw-ref" id="cite_ref-Amph-Sex_X-sensitization_through_D1_signaling_28-4" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Amph-Sex X-sensitization through D1 signaling"}}'><a href="./Addiction#cite_note-Amph-Sex_X-sensitization_through_D1_signaling-28" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></sup><sup about="#mwt583" class="mw-ref" id="cite_ref-Amph-Sex_X-sensitization_through_NMDA_signaling_29-4" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Amph-Sex X-sensitization through NMDA signaling"}}'><a href="./Addiction#cite_note-Amph-Sex_X-sensitization_through_NMDA_signaling-29" style="counter-reset: mw-Ref 28;"><span class="mw-reflink-text">[28]</span></a></sup> In contrast to ΔFosB's reward-sensitizing effect, <a rel="mw:WikiLink" href="./CREB" title="CREB" id="mwAWM">CREB</a> transcriptional activity decreases user's sensitivity to the rewarding effects of the substance. CREB transcription in the nucleus accumbens is implicated in <a rel="mw:WikiLink" href="./Psychological_dependence" title="Psychological dependence" id="mwAWQ">psychological dependence</a> and symptoms involving a <a rel="mw:WikiLink" href="./Anhedonia" title="Anhedonia" id="mwAWU">lack of pleasure or motivation</a> during <a rel="mw:WikiLink" href="./Drug_withdrawal" title="Drug withdrawal" id="mwAWY">drug withdrawal</a>.<sup about="#mwt585" class="mw-ref" id="cite_ref-Cellular_basis_3-23" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Cellular basis"}}'><a href="./Addiction#cite_note-Cellular_basis-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></sup><sup about="#mwt587" class="mw-ref" id="cite_ref-pmid11572966_73-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"pmid11572966"}}'><a href="./Addiction#cite_note-pmid11572966-73" style="counter-reset: mw-Ref 70;"><span class="mw-reflink-text">[70]</span></a></sup><sup about="#mwt589" class="mw-ref" id="cite_ref-pmid18640924_84-2" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"pmid18640924"}}'><a href="./Addiction#cite_note-pmid18640924-84" style="counter-reset: mw-Ref 81;"><span class="mw-reflink-text">[81]</span></a></sup></p>

<p id="mwAWc">The set of proteins known as "<a rel="mw:WikiLink" href="./Regulators_of_G_protein_signaling" title="Regulators of G protein signaling" id="mwAWg" class="mw-redirect">regulators of G protein signaling</a>" (RGS), particularly <a rel="mw:WikiLink" href="./RGS4" title="RGS4" id="mwAWk">RGS4</a> and <a rel="mw:WikiLink" href="./RGS9-2" title="RGS9-2" id="mwAWo" class="mw-redirect">RGS9-2</a>, have been implicated in modulating some forms of opioid sensitization, including reward sensitization.<sup about="#mwt1435" class="mw-ref" id="cite_ref-RGS_opioid_93-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"RGS opioid"},"body":{"id":"mw-reference-text-cite_note-RGS_opioid-93"}}'><a href="./Addiction#cite_note-RGS_opioid-93" style="counter-reset: mw-Ref 86;"><span class="mw-reflink-text">[86]</span></a></sup></p>
<div style="clear:both;" about="#mwt592" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"clear","href":"./Template:Clear"},"params":{},"i":0}}]}' id="mwAWs"></div>
<center about="#mwt593" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"Addiction-related plasticity","href":"./Template:Addiction-related_plasticity"},"params":{"title":{"wt":"Summary of addiction-related plasticity"}},"i":0}}]}' id="mwAWw"> 
<table class="wikitable unsortable" style="width: 100%; text-align:center">
<caption>Summary of addiction-related plasticity</caption>
<tbody><tr><th scope="col" style="width: 25%;" rowspan="2">Form of <a rel="mw:WikiLink" href="./Neuroplasticity" title="Neuroplasticity">neuroplasticity</a><br/> or <a rel="mw:WikiLink" href="./Behavioral_plasticity" title="Behavioral plasticity">behavioral plasticity</a></th>
<th scope="col" style="width: 25%;" colspan="6">Type of <a rel="mw:WikiLink" href="./Reinforcement#Primary_reinforcers" title="Reinforcement">reinforcer</a></th>
<th scope="col" style="width: 15%;" rowspan="2"><small>Sources</small></th></tr>
<tr>
<th scope="col" style="width: 15%;">Opiates</th>
<th scope="col" style="width: 15%;">Psychostimulants</th>
<th scope="col" style="width: 15%;">High fat or sugar food</th>
<th scope="col" style="width: 15%;"><a rel="mw:WikiLink" href="./Sexual_intercourse" title="Sexual intercourse">Sexual intercourse</a></th>
<th scope="col" style="width: 15%;"><a rel="mw:WikiLink" href="./Neurobiological_effects_of_physical_exercise" title="Neurobiological effects of physical exercise">Physical exercise<br/>(aerobic)</a></th>
<th scope="col" style="width: 15%;"><a rel="mw:WikiLink" href="./Environmental_enrichment_(neural)" title="Environmental enrichment (neural)" class="mw-redirect">Environmental<br/>enrichment</a></th></tr>
<tr>
<td scope="row" style="height: 40px"><a rel="mw:WikiLink" href="./ΔFosB" title="ΔFosB" class="mw-redirect">ΔFosB</a> expression in<br/><a rel="mw:WikiLink" href="./Nucleus_accumbens" title="Nucleus accumbens">nucleus accumbens</a> <a rel="mw:WikiLink" href="./D1-type" title="D1-type" class="mw-redirect">D1-type</a> <a rel="mw:WikiLink" href="./Medium_spiny_neurons" title="Medium spiny neurons" class="mw-redirect"><abbr title="medium spiny neurons" about="#mwt1853" typeof="mw:ExpandedAttrs" data-mw='{"attribs":[[{"txt":"title"},{"html":"&lt;span typeof=\"mw:Nowiki\" data-parsoid=\"{}\">medium spiny neurons&lt;/span>"}]]}'>MSNs</abbr></a></td>
<td>↑</td><td>↑</td><td>↑</td><td>↑</td><td>↑</td><td>↑</td><td><sup about="#mwt1826" class="mw-ref" id="cite_ref-Natural_and_drug_addictions_12-20" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Natural and drug addictions"}}'><a href="./Addiction#cite_note-Natural_and_drug_addictions-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></sup></td></tr>
<tr>
<th scope="col" colspan="8">Behavioral plasticity</th></tr>
<tr>
<td scope="row" style="height: 40px">Escalation of intake</td>
<td>Yes</td><td>Yes</td><td>Yes</td><td></td><td></td><td></td><td><sup about="#mwt1828" class="mw-ref" id="cite_ref-Natural_and_drug_addictions_12-21" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Natural and drug addictions"}}'><a href="./Addiction#cite_note-Natural_and_drug_addictions-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></sup></td></tr>
<tr>
<td scope="row" style="height: 40px">Psychostimulant<br/><a rel="mw:WikiLink" href="./Addiction#Reward_sensitization" title="Addiction">cross-sensitization</a></td>
<td>Yes</td><td>Not applicable</td><td>Yes</td><td>Yes</td><td>Attenuated</td><td>Attenuated</td><td><sup about="#mwt1830" class="mw-ref" id="cite_ref-Natural_and_drug_addictions_12-22" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Natural and drug addictions"}}'><a href="./Addiction#cite_note-Natural_and_drug_addictions-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></sup></td></tr>
<tr>
<td scope="row" style="height: 40px">Psychostimulant<br/><a rel="mw:WikiLink" href="./Self-administration" title="Self-administration">self-administration</a></td>
<td>↑</td><td>↑</td><td>↓</td><td></td><td>↓</td><td>↓</td><td><sup about="#mwt1832" class="mw-ref" id="cite_ref-Natural_and_drug_addictions_12-23" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Natural and drug addictions"}}'><a href="./Addiction#cite_note-Natural_and_drug_addictions-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></sup></td></tr>
<tr>
<td scope="row" style="height: 40px">Psychostimulant<br/><a rel="mw:WikiLink" href="./Conditioned_place_preference" title="Conditioned place preference">conditioned place preference</a></td>
<td>↑</td><td>↑</td><td>↓</td><td>↑</td><td>↓</td><td>↑</td><td><sup about="#mwt1834" class="mw-ref" id="cite_ref-Natural_and_drug_addictions_12-24" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Natural and drug addictions"}}'><a href="./Addiction#cite_note-Natural_and_drug_addictions-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></sup></td></tr>
<tr>
<td scope="row" style="height: 40px"><a rel="mw:WikiLink" href="./Reinstatement_of_drug-seeking_behavior" title="Reinstatement of drug-seeking behavior" class="mw-redirect">Reinstatement of drug-seeking behavior</a></td>
<td>↑</td><td>↑</td><td></td><td></td><td>↓</td><td>↓</td><td><sup about="#mwt1836" class="mw-ref" id="cite_ref-Natural_and_drug_addictions_12-25" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Natural and drug addictions"}}'><a href="./Addiction#cite_note-Natural_and_drug_addictions-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></sup></td></tr>
<tr>
<th scope="col" colspan="8">Neurochemical plasticity</th></tr>
<tr>
<td scope="row" style="height: 40px"><a rel="mw:WikiLink" href="./CAMP_response_element-binding_protein" title="CAMP response element-binding protein" class="mw-redirect"><abbr title="cAMP response element-binding protein" about="#mwt1854" typeof="mw:ExpandedAttrs" data-mw='{"attribs":[[{"txt":"title"},{"html":"&lt;span typeof=\"mw:Nowiki\" data-parsoid=\"{}\">cAMP response element-binding protein&lt;/span>"}]]}'>CREB</abbr></a> <a rel="mw:WikiLink" href="./Phosphorylation" title="Phosphorylation">phosphorylation</a><br/>in the <span class="nowrap">nucleus accumbens</span></td>
<td>↓</td><td>↓</td><td>↓</td><td></td><td>↓</td><td>↓</td><td><sup about="#mwt1838" class="mw-ref" id="cite_ref-Natural_and_drug_addictions_12-26" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Natural and drug addictions"}}'><a href="./Addiction#cite_note-Natural_and_drug_addictions-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></sup></td></tr>
<tr>
<td scope="row" style="height: 40px">Sensitized <a rel="mw:WikiLink" href="./Dopamine" title="Dopamine">dopamine</a> response<br/>in the <span class="nowrap">nucleus accumbens</span></td>
<td>No</td><td>Yes</td><td>No</td><td>Yes</td><td></td><td></td><td><sup about="#mwt1840" class="mw-ref" id="cite_ref-Natural_and_drug_addictions_12-27" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Natural and drug addictions"}}'><a href="./Addiction#cite_note-Natural_and_drug_addictions-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></sup></td></tr>
<tr>
<td scope="row" style="height: 40px">Altered <a rel="mw:WikiLink" href="./Striatum" title="Striatum">striatal</a> <a rel="mw:WikiLink" href="./Dopamine_receptor" title="Dopamine receptor">dopamine signaling</a></td>
<td>↓<a rel="mw:WikiLink" href="./DRD2" title="DRD2" class="mw-redirect">DRD2</a>, ↑<a rel="mw:WikiLink" href="./DRD3" title="DRD3" class="mw-redirect">DRD3</a></td><td>↑<a rel="mw:WikiLink" href="./DRD1" title="DRD1" class="mw-redirect">DRD1</a>, ↓<a rel="mw:WikiLink" href="./DRD2" title="DRD2" class="mw-redirect">DRD2</a>, ↑<a rel="mw:WikiLink" href="./DRD3" title="DRD3" class="mw-redirect">DRD3</a></td><td>↑<a rel="mw:WikiLink" href="./DRD1" title="DRD1" class="mw-redirect">DRD1</a>, ↓<a rel="mw:WikiLink" href="./DRD2" title="DRD2" class="mw-redirect">DRD2</a>, ↑<a rel="mw:WikiLink" href="./DRD3" title="DRD3" class="mw-redirect">DRD3</a></td><td></td><td>↑<a rel="mw:WikiLink" href="./DRD2" title="DRD2" class="mw-redirect">DRD2</a></td><td>↑<a rel="mw:WikiLink" href="./DRD2" title="DRD2" class="mw-redirect">DRD2</a></td><td><sup about="#mwt1842" class="mw-ref" id="cite_ref-Natural_and_drug_addictions_12-28" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Natural and drug addictions"}}'><a href="./Addiction#cite_note-Natural_and_drug_addictions-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></sup></td></tr>
<tr>
<td scope="row" style="height: 40px">Altered striatal <a rel="mw:WikiLink" href="./Opioid_receptor" title="Opioid receptor">opioid signaling</a></td>
<td>No change or<br/>↑<a rel="mw:WikiLink" href="./Μ-opioid_receptor" title="Μ-opioid receptor">μ-opioid receptors</a></td><td>↑<a rel="mw:WikiLink" href="./Μ-opioid_receptor" title="Μ-opioid receptor">μ-opioid receptors</a><br/>↑<a rel="mw:WikiLink" href="./Κ-opioid_receptor" title="Κ-opioid receptor">κ-opioid receptors</a></td><td>↑<a rel="mw:WikiLink" href="./Μ-opioid_receptor" title="Μ-opioid receptor">μ-opioid receptors</a></td><td>↑<a rel="mw:WikiLink" href="./Μ-opioid_receptor" title="Μ-opioid receptor">μ-opioid receptors</a></td><td>No change</td><td>No change</td><td><sup about="#mwt1844" class="mw-ref" id="cite_ref-Natural_and_drug_addictions_12-29" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Natural and drug addictions"}}'><a href="./Addiction#cite_note-Natural_and_drug_addictions-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></sup></td></tr>
<tr>
<td scope="row" style="height: 40px">Changes in striatal <a rel="mw:WikiLink" href="./Opioid_peptide" title="Opioid peptide">opioid peptides</a></td>
<td>↑<a rel="mw:WikiLink" href="./Dynorphin" title="Dynorphin">dynorphin</a><br/>No change: <a rel="mw:WikiLink" href="./Enkephalin" title="Enkephalin">enkephalin</a></td><td>↑<a rel="mw:WikiLink" href="./Dynorphin" title="Dynorphin">dynorphin</a></td><td>↓<a rel="mw:WikiLink" href="./Enkephalin" title="Enkephalin">enkephalin</a></td><td></td><td>↑<a rel="mw:WikiLink" href="./Dynorphin" title="Dynorphin">dynorphin</a></td><td>↑<a rel="mw:WikiLink" href="./Dynorphin" title="Dynorphin">dynorphin</a></td><td><sup about="#mwt1846" class="mw-ref" id="cite_ref-Natural_and_drug_addictions_12-30" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Natural and drug addictions"}}'><a href="./Addiction#cite_note-Natural_and_drug_addictions-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></sup></td></tr>
<tr>
<th scope="col" colspan="8"><a rel="mw:WikiLink" href="./Dopaminergic_pathways#Pathways" title="Dopaminergic pathways">Mesocorticolimbic</a> <a rel="mw:WikiLink" href="./Synaptic_plasticity" title="Synaptic plasticity">synaptic plasticity</a></th></tr>
<tr>
<td scope="row" style="height: 40px">Number of <a rel="mw:WikiLink" href="./Dendrite" title="Dendrite">dendrites</a> in the <span class="nowrap">nucleus accumbens</span></td>
<td>↓</td><td>↑</td><td></td><td>↑</td><td></td><td></td><td><sup about="#mwt1848" class="mw-ref" id="cite_ref-Natural_and_drug_addictions_12-31" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Natural and drug addictions"}}'><a href="./Addiction#cite_note-Natural_and_drug_addictions-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></sup></td></tr>
<tr>
<td scope="row" style="height: 40px"><a rel="mw:WikiLink" href="./Dendritic_spine" title="Dendritic spine">Dendritic spine</a> density in<br/>the <span class="nowrap">nucleus accumbens</span></td>
<td>↓</td><td>↑</td><td></td><td>↑</td><td></td><td></td><td><sup about="#mwt1850" class="mw-ref" id="cite_ref-Natural_and_drug_addictions_12-32" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Natural and drug addictions"}}'><a href="./Addiction#cite_note-Natural_and_drug_addictions-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></sup></td></tr>

</tbody></table></center>
<div style="clear:both;" about="#mwt594" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"clear","href":"./Template:Clear"},"params":{},"i":0}}]}' id="mwAW0"></div>

</section><section data-mw-section-id="17" id="mwAW4"><h3 id="Neuroepigenetic_mechanisms">Neuroepigenetic mechanisms</h3>
<div role="note" class="hatnote navigation-not-searchable" about="#mwt595" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"See also","href":"./Template:See_also"},"params":{"1":{"wt":"Neuroepigenetics"},"2":{"wt":"Chromatin remodeling"}},"i":0}}]}' id="mwAW8">See also: <a rel="mw:WikiLink" href="./Neuroepigenetics" title="Neuroepigenetics">Neuroepigenetics</a> and <a rel="mw:WikiLink" href="./Chromatin_remodeling" title="Chromatin remodeling">Chromatin remodeling</a></div>
<table class="box-Expand_section plainlinks metadata ambox ambox-content" role="presentation" about="#mwt597" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"Expand section","href":"./Template:Expand_section"},"params":{"1":{"wt":"the table of drug-induced chromatin modifications from figure 2 of this&lt;ref name=\"Chromatin states\" /> review; an explanation of the relationship between class I [[HDAC]]s—[[H3K9ac]]/[[H3K9ac2]], [[G9a]]—[[H3K9me2]], and transcriptional mechanisms (i.e., phospho-CREB and FosB–ΔFosB)"},"date":{"wt":"June 2018"},"small":{"wt":"no"}},"i":0}}]}' id="mwAXA"><tbody><tr><td class="mbox-image"><div style="width:52px"><figure-inline typeof="mw:Image mw:ExpandedAttrs" about="#mwt1554" data-mw='{"attribs":[["alt",{"html":"alt=&lt;span typeof=\"mw:Entity\" data-parsoid=&apos;{\"src\":\"&amp;amp;#91;\",\"srcContent\":\"[\"}&apos;>[&lt;/span>icon&lt;span typeof=\"mw:Entity\" data-parsoid=&apos;{\"src\":\"&amp;amp;#93;\",\"srcContent\":\"]\"}&apos;>]&lt;/span>","txt":"[icon]"}]]}'><a href="./File:Wiki_letter_w_cropped.svg"><img alt="[icon]" resource="./File:Wiki_letter_w_cropped.svg" src="//upload.wikimedia.org/wikipedia/commons/thumb/1/1c/Wiki_letter_w_cropped.svg/44px-Wiki_letter_w_cropped.svg.png" data-file-width="44" data-file-height="31" data-file-type="drawing" height="31" width="44" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/1/1c/Wiki_letter_w_cropped.svg/88px-Wiki_letter_w_cropped.svg.png 2x, //upload.wikimedia.org/wikipedia/commons/thumb/1/1c/Wiki_letter_w_cropped.svg/66px-Wiki_letter_w_cropped.svg.png 1.5x"/></a></figure-inline></div></td><td class="mbox-text"><div class="mbox-text-span">This section <b>needs expansion</b><span typeof="mw:Entity"> </span>with: the table of drug-induced chromatin modifications from figure 2 of this<sup about="#mwt1553" class="mw-ref" id="cite_ref-Chromatin_states_94-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Chromatin states"}}'><a href="./Addiction#cite_note-Chromatin_states-94" style="counter-reset: mw-Ref 87;"><span class="mw-reflink-text">[87]</span></a></sup> review; an explanation of the relationship between class I <a rel="mw:WikiLink" href="./HDAC" title="HDAC" class="mw-redirect">HDACs</a>—<a rel="mw:WikiLink" href="./H3K9ac" title="H3K9ac" class="new">H3K9ac</a>/<a rel="mw:WikiLink" href="./H3K9ac2" title="H3K9ac2" class="new">H3K9ac2</a>, <a rel="mw:WikiLink" href="./G9a" title="G9a" class="mw-redirect">G9a</a>—<a rel="mw:WikiLink" href="./H3K9me2" title="H3K9me2">H3K9me2</a>, and transcriptional mechanisms (i.e., phospho-CREB and FosB–ΔFosB). <small>You can help by <a rel="mw:ExtLink" class="external text" href="//en.wikipedia.org/w/index.php?title=Addiction&amp;action=edit&amp;section=">adding to it</a>.</small>  <small class="date-container"><i>(<span class="date">June 2018</span>)</i></small></div></td></tr></tbody></table><link rel="mw:PageProp/Category" href="./Category:Articles_to_be_expanded_from_June_2018" about="#mwt597"/><link rel="mw:PageProp/Category" href="./Category:All_articles_to_be_expanded" about="#mwt597" id="mwAXE"/><!--
&#x2D;Should probably mention the following since it's related to both the mechanisms and research sections:
1) Prolonged inhibition of class I HDACs results in histone hyper&#x2D;acetylation, which in turn increases G9a expression and H3K9me2 synthesis
2) G9a catalyzes H3K9 dimethylation (H3K9me2 synthesis)
3) H3K9me2 is a repressive epigenetic mark that inhibits the induction of DeltaFosB in the NAcc by preventing transcription of the FosB gene
i.e., +HDACi → ↑ H3 acetylation &#x26; ↑H4 acetylation → ↑G9a → ↑H3K9me2 synthesis
4) The feedback loop involving: +drug → ↑ΔFosB → ↓G9a → ↓H3K9me2 → ↑ΔFosB
-->
<p id="mwAXI">Altered <a rel="mw:WikiLink" href="./Epigenetic" title="Epigenetic" id="mwAXM" class="mw-redirect">epigenetic</a> regulation of <a rel="mw:WikiLink" href="./Gene_expression" title="Gene expression" id="mwAXQ">gene expression</a> within the brain's reward system plays a significant and complex role in the development of drug addiction.<sup about="#mwt607" class="mw-ref" id="cite_ref-Nestler_2014_epigenetics_67-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Nestler 2014 epigenetics"}}'><a href="./Addiction#cite_note-Nestler_2014_epigenetics-67" style="counter-reset: mw-Ref 64;"><span class="mw-reflink-text">[64]</span></a></sup><sup about="#mwt609" class="mw-ref" id="cite_ref-Chromatin_states_94-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Chromatin states"}}'><a href="./Addiction#cite_note-Chromatin_states-94" style="counter-reset: mw-Ref 87;"><span class="mw-reflink-text">[87]</span></a></sup> Addictive drugs are associated with three types of epigenetic modifications within neurons.<sup about="#mwt611" class="mw-ref" id="cite_ref-Nestler_2014_epigenetics_67-2" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Nestler 2014 epigenetics"}}'><a href="./Addiction#cite_note-Nestler_2014_epigenetics-67" style="counter-reset: mw-Ref 64;"><span class="mw-reflink-text">[64]</span></a></sup> These are (1) <a rel="mw:WikiLink" href="./Histone_modification" title="Histone modification" id="mwAXU" class="mw-redirect">histone modifications</a>, (2) <a rel="mw:WikiLink" href="./Epigenetic_methylation" title="Epigenetic methylation" id="mwAXY" class="mw-redirect">epigenetic methylation</a> of DNA at <a rel="mw:WikiLink" href="./CpG_site" title="CpG site" id="mwAXc">CpG sites</a> at (or adjacent to) particular genes, and (3) epigenetic <a rel="mw:WikiLink" href="./Downregulation_and_upregulation" title="Downregulation and upregulation" id="mwAXg">downregulation or upregulation</a> of <a rel="mw:WikiLink" href="./MicroRNA" title="MicroRNA" id="mwAXk">microRNAs</a> which have particular target genes.<sup about="#mwt613" class="mw-ref" id="cite_ref-Nestler_2014_epigenetics_67-3" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Nestler 2014 epigenetics"}}'><a href="./Addiction#cite_note-Nestler_2014_epigenetics-67" style="counter-reset: mw-Ref 64;"><span class="mw-reflink-text">[64]</span></a></sup><sup about="#mwt615" class="mw-ref" id="cite_ref-Nestler_14-12" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Nestler"}}'><a href="./Addiction#cite_note-Nestler-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></sup><sup about="#mwt617" class="mw-ref" id="cite_ref-Chromatin_states_94-2" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Chromatin states"}}'><a href="./Addiction#cite_note-Chromatin_states-94" style="counter-reset: mw-Ref 87;"><span class="mw-reflink-text">[87]</span></a></sup>  As an example, while hundreds of genes in the cells of the nucleus accumbens (NAc) exhibit histone modifications following drug exposure – particularly, altered acetylation and methylation states of <a rel="mw:WikiLink" href="./Histone" title="Histone" id="mwAXo">histone</a> <a rel="mw:WikiLink" href="./Residue_(chemistry)#Biochemistry" title="Residue (chemistry)" id="mwAXs">residues</a><sup about="#mwt619" class="mw-ref" id="cite_ref-Chromatin_states_94-3" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Chromatin states"}}'><a href="./Addiction#cite_note-Chromatin_states-94" style="counter-reset: mw-Ref 87;"><span class="mw-reflink-text">[87]</span></a></sup> – most other genes in the NAc cells do not show such changes.<sup about="#mwt621" class="mw-ref" id="cite_ref-Nestler_2014_epigenetics_67-4" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Nestler 2014 epigenetics"}}'><a href="./Addiction#cite_note-Nestler_2014_epigenetics-67" style="counter-reset: mw-Ref 64;"><span class="mw-reflink-text">[64]</span></a></sup></p>

</section></section><section data-mw-section-id="18" id="mwAXw"><h2 id="Diagnosis">Diagnosis</h2>
<div role="note" class="hatnote navigation-not-searchable" about="#mwt622" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"Further","href":"./Template:Further"},"params":{"1":{"wt":"Substance use disorder#Diagnosis"},"2":{"wt":"Problem gambling#Diagnosis"}},"i":0}}]}' id="mwAX0">Further information: <a rel="mw:WikiLink" href="./Substance_use_disorder#Diagnosis" title="Substance use disorder">Substance use disorder §<span typeof="mw:Entity"> </span>Diagnosis</a>, and <a rel="mw:WikiLink" href="./Problem_gambling#Diagnosis" title="Problem gambling">Problem gambling §<span typeof="mw:Entity"> </span>Diagnosis</a></div>
<p id="mwAX4">The 5th edition of the <a rel="mw:WikiLink" href="./Diagnostic_and_Statistical_Manual_of_Mental_Disorders" title="Diagnostic and Statistical Manual of Mental Disorders" id="mwAX8">Diagnostic and Statistical Manual of Mental Disorders</a> (DSM-5) uses the term "<a rel="mw:WikiLink" href="./Substance_use_disorder" title="Substance use disorder" id="mwAYA">substance use disorder</a>" to refer to a spectrum of drug use-related disorders.  The DSM-5 eliminates the terms "<a rel="mw:WikiLink" href="./Drug_abuse" title="Drug abuse" id="mwAYE" class="mw-redirect">abuse</a>" and "dependence" from diagnostic categories, instead using the specifiers of <i id="mwAYI">mild</i>, <i id="mwAYM">moderate</i> and <i id="mwAYQ">severe</i> to indicate the extent of disordered use.  These specifiers are determined by the number of diagnostic criteria present in a given case.  In the DSM-5, the term <i id="mwAYU">drug addiction</i> is synonymous with <i id="mwAYY">severe substance use disorder</i>.<sup about="#mwt626" class="mw-ref" id="cite_ref-Surgeon_General_severe_SUD_1-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Surgeon General severe SUD"}}'><a href="./Addiction#cite_note-Surgeon_General_severe_SUD-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></sup><sup about="#mwt628" class="mw-ref" id="cite_ref-Brain_disease_2-3" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Brain disease"}}'><a href="./Addiction#cite_note-Brain_disease-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></sup></p>

<p id="mwAYc">The DSM-5 introduced a new diagnostic category for behavioral addictions; however, <a rel="mw:WikiLink" href="./Problem_gambling" title="Problem gambling" id="mwAYg">problem gambling</a> is the only condition included in that category in the 5th edition.<sup about="#mwt633" class="mw-ref" id="cite_ref-Addiction-dependence_distinction_22-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Addiction-dependence distinction"}}'><a href="./Addiction#cite_note-Addiction-dependence_distinction-22" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></sup> <a rel="mw:WikiLink" href="./Internet_gaming_disorder" title="Internet gaming disorder" id="mwAYk" class="new">Internet gaming disorder</a> is listed as a "condition requiring further study" in the DSM-5.<sup about="#mwt1437" class="mw-ref" id="cite_ref-95" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{},"body":{"id":"mw-reference-text-cite_note-95"}}'><a href="./Addiction#cite_note-95" style="counter-reset: mw-Ref 88;"><span class="mw-reflink-text">[88]</span></a></sup></p>

<p id="mwAYo">Past editions have used <a rel="mw:WikiLink" href="./Physical_dependence" title="Physical dependence" id="mwAYs">physical dependence</a> and the associated withdrawal syndrome to identify an addictive state. <a rel="mw:WikiLink" href="./Physical_dependence" title="Physical dependence" id="mwAYw">Physical dependence</a> occurs when the body has adjusted by incorporating the substance into its "normal" functioning – i.e., attains <a rel="mw:WikiLink" href="./Homeostasis" title="Homeostasis" id="mwAY0">homeostasis</a> – and therefore physical withdrawal symptoms occur upon cessation of use.<sup about="#mwt1439" class="mw-ref" id="cite_ref-pmid10511013_96-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"pmid10511013"},"body":{"id":"mw-reference-text-cite_note-pmid10511013-96"}}'><a href="./Addiction#cite_note-pmid10511013-96" style="counter-reset: mw-Ref 89;"><span class="mw-reflink-text">[89]</span></a></sup> Tolerance is the process by which the body continually adapts to the substance and requires increasingly larger amounts to achieve the original effects. Withdrawal refers to physical and psychological symptoms experienced when  reducing or discontinuing a substance that the body has become dependent on. Symptoms of withdrawal generally include but are not limited to <a rel="mw:WikiLink" href="./Anxiety" title="Anxiety" id="mwAY4">anxiety</a>, <a rel="mw:WikiLink" href="./Irritability" title="Irritability" id="mwAY8">irritability</a>, intense <a rel="mw:WikiLink" href="./Craving_(withdrawal)" title="Craving (withdrawal)" id="mwAZA">cravings</a> for the substance, <a rel="mw:WikiLink" href="./Nausea" title="Nausea" id="mwAZE">nausea</a>, <a rel="mw:WikiLink" href="./Hallucinations" title="Hallucinations" id="mwAZI" class="mw-redirect">hallucinations</a>, <a rel="mw:WikiLink" href="./Headaches" title="Headaches" id="mwAZM" class="mw-redirect">headaches</a>, cold sweats, and <a rel="mw:WikiLink" href="./Tremor" title="Tremor" id="mwAZQ">tremors</a>.</p>

<p id="mwAZU">Medical researchers who actively study addiction have criticized the DSM classification of addiction for being flawed and involving arbitrary diagnostic criteria.<sup about="#mwt1441" class="mw-ref" id="cite_ref-NHMH_3e_terms-DSM_flaw_23-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"NHMH_3e terms-DSM flaw"},"body":{"id":"mw-reference-text-cite_note-NHMH_3e_terms-DSM_flaw-23"}}'><a href="./Addiction#cite_note-NHMH_3e_terms-DSM_flaw-23" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></sup> Writing in 2013, the director of the United States <a rel="mw:WikiLink" href="./National_Institute_of_Mental_Health" title="National Institute of Mental Health" id="mwAZY">National Institute of Mental Health</a> discussed the invalidity of the DSM-5's classification of mental disorders:<sup about="#mwt1443" class="mw-ref" id="cite_ref-DSM-V_Insel_97-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"DSM-V Insel"},"body":{"id":"mw-reference-text-cite_note-DSM-V_Insel-97"}}'><a href="./Addiction#cite_note-DSM-V_Insel-97" style="counter-reset: mw-Ref 90;"><span class="mw-reflink-text">[90]</span></a></sup></p>
<blockquote id="mwAZc"><p id="mwAZg"> While DSM has been described as a "Bible" for the field, it is, at best, a dictionary, creating a set of labels and defining each. The strength of each of the editions of DSM has been "reliability" – each edition has ensured that clinicians use the same terms in the same ways. The weakness is its lack of validity. Unlike our definitions of ischemic heart disease, lymphoma, or AIDS, the DSM diagnoses are based on a consensus about clusters of clinical symptoms, not any objective laboratory measure. In the rest of medicine, this would be equivalent to creating diagnostic systems based on the nature of chest pain or the quality of fever.</p></blockquote>

<p id="mwAZk">As a diagnostic <a rel="mw:WikiLink" href="./Biomarker_(medicine)" title="Biomarker (medicine)" id="mwAZo">biomarker</a>, <a rel="mw:WikiLink" href="./ΔFosB" title="ΔFosB" id="mwAZs" class="mw-redirect">ΔFosB</a> expression could be used to diagnose an addiction in humans, but this would require a <a rel="mw:WikiLink" href="./Brain_biopsy" title="Brain biopsy" id="mwAZw">brain biopsy</a> and therefore is not used in clinical practice.</p>

</section><section data-mw-section-id="19" id="mwAZ0"><h2 id="Treatment">Treatment</h2>
<div role="note" class="hatnote navigation-not-searchable" about="#mwt640" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"see also","href":"./Template:See_also"},"params":{"1":{"wt":"Addiction recovery groups"},"2":{"wt":"Cognitive behavioral therapy"},"3":{"wt":"Drug rehabilitation"}},"i":0}}]}' id="mwAZ4">See also: <a rel="mw:WikiLink" href="./Addiction_recovery_groups" title="Addiction recovery groups">Addiction recovery groups</a>, <a rel="mw:WikiLink" href="./Cognitive_behavioral_therapy" title="Cognitive behavioral therapy">Cognitive behavioral therapy</a>, and <a rel="mw:WikiLink" href="./Drug_rehabilitation" title="Drug rehabilitation">Drug rehabilitation</a></div>
<p id="mwAZ8">According to a review, "in order to be effective, all pharmacological or biologically based treatments for addiction need to be integrated into other established forms of addiction rehabilitation, such as cognitive behavioral therapy, individual and group psychotherapy, behavior-modification strategies, twelve-step programs, and residential treatment facilities."<sup about="#mwt643" class="mw-ref" id="cite_ref-Reward_system_and_psychostimulants_8-2" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Reward system and psychostimulants"}}'><a href="./Addiction#cite_note-Reward_system_and_psychostimulants-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></sup></p>

<section data-mw-section-id="20" id="mwAaA"><h3 id="Behavioral_therapy">Behavioral therapy</h3>
<p id="mwAaE">A meta-analytic review on the efficacy of various <a rel="mw:WikiLink" href="./Behavioral_therapy" title="Behavioral therapy" id="mwAaI" class="mw-redirect">behavioral therapies</a> for treating drug and behavioral addictions found that <a rel="mw:WikiLink" href="./Cognitive_behavioral_therapy" title="Cognitive behavioral therapy" id="mwAaM">cognitive behavioral therapy</a> (e.g., <a rel="mw:WikiLink" href="./Relapse_prevention" title="Relapse prevention" id="mwAaQ">relapse prevention</a> and <a rel="mw:WikiLink" href="./Contingency_management" title="Contingency management" id="mwAaU">contingency management</a>), <a rel="mw:WikiLink" href="./Motivational_interviewing" title="Motivational interviewing" id="mwAaY">motivational interviewing</a>, and a <a rel="mw:WikiLink" href="./Community_reinforcement_approach_and_family_training" title="Community reinforcement approach and family training" id="mwAac">community reinforcement approach</a> were effective interventions with moderate effect sizes.<sup about="#mwt1445" class="mw-ref" id="cite_ref-German_meta-analysis_98-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"German meta-analysis"},"body":{"id":"mw-reference-text-cite_note-German_meta-analysis-98"}}'><a href="./Addiction#cite_note-German_meta-analysis-98" style="counter-reset: mw-Ref 91;"><span class="mw-reflink-text">[91]</span></a></sup></p>

<p id="mwAag">Clinical and preclinical evidence indicate that consistent aerobic exercise, especially endurance exercise (e.g., <a rel="mw:WikiLink" href="./Marathon_running" title="Marathon running" id="mwAak" class="mw-redirect">marathon running</a>), actually prevents the development of certain drug addictions and is an effective adjunct treatment for drug addiction, and for psychostimulant addiction in particular.<sup about="#mwt665" class="mw-ref" id="cite_ref-Natural_and_drug_addictions_12-33" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Natural and drug addictions"}}'><a href="./Addiction#cite_note-Natural_and_drug_addictions-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></sup><sup about="#mwt1447" class="mw-ref" id="cite_ref-Addiction_review_2016_99-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Addiction review 2016"},"body":{"id":"mw-reference-text-cite_note-Addiction_review_2016-99"}}'><a href="./Addiction#cite_note-Addiction_review_2016-99" style="counter-reset: mw-Ref 92;"><span class="mw-reflink-text">[92]</span></a></sup><sup about="#mwt1449" class="mw-ref" id="cite_ref-Running_vs_addiction_100-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Running vs addiction"},"body":{"id":"mw-reference-text-cite_note-Running_vs_addiction-100"}}'><a href="./Addiction#cite_note-Running_vs_addiction-100" style="counter-reset: mw-Ref 93;"><span class="mw-reflink-text">[93]</span></a></sup><sup about="#mwt667" class="mw-ref" id="cite_ref-Exercise_Rev_3_101-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Exercise Rev 3"}}'><a href="./Addiction#cite_note-Exercise_Rev_3-101" style="counter-reset: mw-Ref 94;"><span class="mw-reflink-text">[94]</span></a></sup><sup about="#mwt1451" class="mw-ref" id="cite_ref-Exercise,_addiction_prevention,_and_ΔFosB_102-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Exercise, addiction prevention, and ΔFosB"},"body":{"id":"mw-reference-text-cite_note-Exercise,_addiction_prevention,_and_ΔFosB-102"}}'><a href="./Addiction#cite_note-Exercise,_addiction_prevention,_and_ΔFosB-102" style="counter-reset: mw-Ref 95;"><span class="mw-reflink-text">[95]</span></a></sup>  Consistent aerobic exercise magnitude-dependently (i.e., by duration and intensity) reduces drug addiction risk, which appears to occur through the reversal of drug induced addiction-related neuroplasticity.<sup about="#mwt669" class="mw-ref" id="cite_ref-Natural_and_drug_addictions_12-34" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Natural and drug addictions"}}'><a href="./Addiction#cite_note-Natural_and_drug_addictions-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></sup><sup about="#mwt671" class="mw-ref" id="cite_ref-Running_vs_addiction_100-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Running vs addiction"}}'><a href="./Addiction#cite_note-Running_vs_addiction-100" style="counter-reset: mw-Ref 93;"><span class="mw-reflink-text">[93]</span></a></sup> One review noted that exercise may prevent the development of drug addiction by altering <a rel="mw:WikiLink" href="./ΔFosB" title="ΔFosB" id="mwAao" class="mw-redirect">ΔFosB</a> or <span class="nowrap" about="#mwt662" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"nowrap","href":"./Template:Nowrap"},"params":{"1":{"wt":"[[c-Fos]]"}},"i":0}}]}' id="mwAas"><a rel="mw:WikiLink" href="./C-Fos" title="C-Fos">c-Fos</a></span> <a rel="mw:WikiLink" href="./Immunoreactivity" title="Immunoreactivity" id="mwAaw" class="mw-redirect">immunoreactivity</a> in the <a rel="mw:WikiLink" href="./Striatum" title="Striatum" id="mwAa0">striatum</a> or other parts of the <a rel="mw:WikiLink" href="./Reward_system" title="Reward system" id="mwAa4">reward system</a>.<sup about="#mwt673" class="mw-ref" id="cite_ref-Exercise,_addiction_prevention,_and_ΔFosB_102-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Exercise, addiction prevention, and ΔFosB"}}'><a href="./Addiction#cite_note-Exercise,_addiction_prevention,_and_ΔFosB-102" style="counter-reset: mw-Ref 95;"><span class="mw-reflink-text">[95]</span></a></sup> Aerobic exercise decreases drug self-administration, reduces the likelihood of relapse, and induces opposite effects on <a rel="mw:WikiLink" href="./Striatum" title="Striatum" id="mwAa8">striatal</a> <a rel="mw:WikiLink" href="./Dopamine_receptor_D2" title="Dopamine receptor D2" id="mwAbA">dopamine receptor D<sub id="mwAbE">2</sub></a> (DRD2) signaling (increased DRD2 density) to those induced by addictions to several drug classes (decreased DRD2 density).<sup about="#mwt675" class="mw-ref" id="cite_ref-Natural_and_drug_addictions_12-35" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Natural and drug addictions"}}'><a href="./Addiction#cite_note-Natural_and_drug_addictions-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></sup><sup about="#mwt677" class="mw-ref" id="cite_ref-Running_vs_addiction_100-2" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Running vs addiction"}}'><a href="./Addiction#cite_note-Running_vs_addiction-100" style="counter-reset: mw-Ref 93;"><span class="mw-reflink-text">[93]</span></a></sup> Consequently, consistent aerobic exercise may lead to better treatment outcomes when used as an adjunct treatment for drug addiction.<sup about="#mwt679" class="mw-ref" id="cite_ref-Natural_and_drug_addictions_12-36" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Natural and drug addictions"}}'><a href="./Addiction#cite_note-Natural_and_drug_addictions-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></sup><sup about="#mwt681" class="mw-ref" id="cite_ref-Running_vs_addiction_100-3" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Running vs addiction"}}'><a href="./Addiction#cite_note-Running_vs_addiction-100" style="counter-reset: mw-Ref 93;"><span class="mw-reflink-text">[93]</span></a></sup><sup about="#mwt1453" class="mw-ref" id="cite_ref-Exercise_Rev_3_101-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Exercise Rev 3"},"body":{"id":"mw-reference-text-cite_note-Exercise_Rev_3-101"}}'><a href="./Addiction#cite_note-Exercise_Rev_3-101" style="counter-reset: mw-Ref 94;"><span class="mw-reflink-text">[94]</span></a></sup></p>

</section><section data-mw-section-id="21" id="mwAbI"><h3 id="Medication">Medication</h3>

<section data-mw-section-id="22" id="mwAbM"><h4 id="Alcohol_addiction">Alcohol addiction</h4>
<div role="note" class="hatnote navigation-not-searchable" about="#mwt682" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"further","href":"./Template:Further"},"params":{"1":{"wt":"Alcoholism"}},"i":0}}]}' id="mwAbQ">Further information: <a rel="mw:WikiLink" href="./Alcoholism" title="Alcoholism">Alcoholism</a></div>
<p id="mwAbU">Alcohol, like opioids, can induce a severe state of <a rel="mw:WikiLink" href="./Physical_dependence" title="Physical dependence" id="mwAbY">physical dependence</a> and produce withdrawal symptoms such as <a rel="mw:WikiLink" href="./Delirium_tremens" title="Delirium tremens" id="mwAbc">delirium tremens</a>. Because of this, treatment for alcohol addiction usually involves a combined approach dealing with dependence and addiction simultaneously.</p>

<p id="mwAbg">Pharmacological treatments for alcohol addiction include drugs like <a rel="mw:WikiLink" href="./Naltrexone" title="Naltrexone" id="mwAbk">naltrexone</a> (opioid antagonist), <a rel="mw:WikiLink" href="./Disulfiram" title="Disulfiram" id="mwAbo">disulfiram</a>, <a rel="mw:WikiLink" href="./Acamprosate" title="Acamprosate" id="mwAbs">acamprosate</a>, and <a rel="mw:WikiLink" href="./Topiramate" title="Topiramate" id="mwAbw">topiramate</a>.<sup about="#mwt1455" class="mw-ref" id="cite_ref-103" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{},"body":{"id":"mw-reference-text-cite_note-103"}}'><a href="./Addiction#cite_note-103" style="counter-reset: mw-Ref 96;"><span class="mw-reflink-text">[96]</span></a></sup><sup about="#mwt1457" class="mw-ref" id="cite_ref-104" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{},"body":{"id":"mw-reference-text-cite_note-104"}}'><a href="./Addiction#cite_note-104" style="counter-reset: mw-Ref 97;"><span class="mw-reflink-text">[97]</span></a></sup> Rather than substituting for alcohol, these drugs are intended to affect the desire to drink, either by directly reducing cravings as with acamprosate and topiramate, or by producing unpleasant effects when alcohol is consumed, as with disulfiram. These drugs can be effective if treatment is maintained, but compliance can be an issue as alcoholic patients often forget to take their medication, or discontinue use because of excessive side effects.<sup about="#mwt1459" class="mw-ref" id="cite_ref-105" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{},"body":{"id":"mw-reference-text-cite_note-105"}}'><a href="./Addiction#cite_note-105" style="counter-reset: mw-Ref 98;"><span class="mw-reflink-text">[98]</span></a></sup><sup about="#mwt1461" class="mw-ref" id="cite_ref-106" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{},"body":{"id":"mw-reference-text-cite_note-106"}}'><a href="./Addiction#cite_note-106" style="counter-reset: mw-Ref 99;"><span class="mw-reflink-text">[99]</span></a></sup> According to a <a rel="mw:WikiLink" href="./Cochrane_Collaboration" title="Cochrane Collaboration" id="mwAb0" class="mw-redirect">Cochrane Collaboration</a> review, the opioid antagonist <a rel="mw:WikiLink" href="./Naltrexone" title="Naltrexone" id="mwAb4">naltrexone</a> has been shown to be an effective treatment for alcoholism, with the effects lasting three to twelve months after the end of treatment.<sup about="#mwt1463" class="mw-ref" id="cite_ref-107" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{},"body":{"id":"mw-reference-text-cite_note-107"}}'><a href="./Addiction#cite_note-107" style="counter-reset: mw-Ref 100;"><span class="mw-reflink-text">[100]</span></a></sup></p>

</section><section data-mw-section-id="23" id="mwAb8"><h4 id="Behavioral_addictions">Behavioral addictions</h4>
<div role="note" class="hatnote navigation-not-searchable relarticle mainarticle selfreference noprint" about="#mwt693" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"transcluded section","href":"./Template:Transcluded_section"},"params":{"source":{"wt":"Behavioral addiction"}},"i":0}}]}' id="mwAcA">This section is <a rel="mw:WikiLink" href="./Wikipedia:Transclusion" title="Wikipedia:Transclusion">transcluded</a> from <a rel="mw:WikiLink" href="./Behavioral_addiction" title="Behavioral addiction">Behavioral addiction</a>. <span class="plainlinks" style="font-style: normal"><span style="font-size:85%;">(<a rel="mw:ExtLink" class="external text" href="//en.wikipedia.org/w/index.php?title=Behavioral_addiction&amp;action=edit">edit</a> <span typeof="mw:Entity">|</span> <a rel="mw:ExtLink" class="external text" href="//en.wikipedia.org/w/index.php?title=Behavioral_addiction&amp;action=history">history</a>)</span></span></div>
<p about="#mwt694" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"trim","href":"./Template:Trim"},"params":{"1":{"wt":"{{#section-h:Behavioral addiction|Treatment}}"}},"i":0}}]}' id="mwAcE">Behavioral addiction is a treatable condition. Treatment options include <a rel="mw:WikiLink" href="./Psychotherapy" title="Psychotherapy">psychotherapy</a> and <a rel="mw:WikiLink" href="./Psychopharmacology" title="Psychopharmacology">psychopharmacotherapy</a> (i.e., medications) or a combination of both. <a rel="mw:WikiLink" href="./Cognitive_behavioral_therapy" title="Cognitive behavioral therapy">Cognitive behavioral therapy</a> (CBT) is the most common form of psychotherapy used in treating behavioral addictions; it focuses on identifying patterns that trigger <a rel="mw:WikiLink" href="./Compulsive_behavior" title="Compulsive behavior">compulsive behavior</a> and making lifestyle changes to promote healthier behaviors. Currently, there are no medications approved for treatment of behavioral addictions in general, but some medications used for treatment of drug addiction may also be beneficial with specific behavioral addictions.<sup about="#mwt1859" class="mw-ref" id="cite_ref-Behavioral_addictions_30-2" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Behavioral addictions"},"body":{"id":"mw-reference-text-cite_note-Behavioral_addictions-30"}}'><a href="./Addiction#cite_note-Behavioral_addictions-30" style="counter-reset: mw-Ref 29;"><span class="mw-reflink-text">[29]</span></a></sup> Any unrelated psychiatric disorders should be kept under control, and differentiated from the contributing factors that cause the addiction.</p>

</section><section data-mw-section-id="24" id="mwAcI"><h4 id="Cannabinoid_addiction">Cannabinoid addiction</h4>

<p id="mwAcM"><span about="#mwt697" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"As of","href":"./Template:As_of"},"params":{"1":{"wt":"2010"}},"i":0}}]}' id="mwAcQ">As of  2010</span><sup class="plainlinks noexcerpt noprint asof-tag update" style="display:none;" about="#mwt697"><a rel="mw:ExtLink" class="external text" href="//en.wikipedia.org/w/index.php?title=Addiction&amp;action=edit"><span typeof="mw:Entity">[</span>update<span typeof="mw:Entity">]</span></a></sup><span typeof="mw:Nowiki" about="#mwt697"></span><link rel="mw:PageProp/Category" href="./Category:Articles_containing_potentially_dated_statements_from_2010" about="#mwt697"/><link rel="mw:PageProp/Category" href="./Category:All_articles_containing_potentially_dated_statements" about="#mwt697" id="mwAcU"/>, there are no effective pharmacological interventions for cannabinoid addiction.<sup about="#mwt1465" class="mw-ref" id="cite_ref-Marijuana_addiction_2010_review_108-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Marijuana addiction 2010 review"},"body":{"id":"mw-reference-text-cite_note-Marijuana_addiction_2010_review-108"}}'><a href="./Addiction#cite_note-Marijuana_addiction_2010_review-108" style="counter-reset: mw-Ref 101;"><span class="mw-reflink-text">[101]</span></a></sup> A 2013 review on cannabinoid addiction noted that the development of <a rel="mw:WikiLink" href="./CB1_receptor" title="CB1 receptor" id="mwAcY" class="mw-redirect">CB1 receptor</a> agonists that have reduced interaction with <a rel="mw:WikiLink" href="./Β-arrestin_2" title="Β-arrestin 2" id="mwAcc" class="mw-redirect">β-arrestin 2</a> signaling might be therapeutically useful.<sup about="#mwt1467" class="mw-ref" id="cite_ref-Cannabinoid_addiction_2013_review_109-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Cannabinoid addiction 2013 review"},"body":{"id":"mw-reference-text-cite_note-Cannabinoid_addiction_2013_review-109"}}'><a href="./Addiction#cite_note-Cannabinoid_addiction_2013_review-109" style="counter-reset: mw-Ref 102;"><span class="mw-reflink-text">[102]</span></a></sup></p>

</section><section data-mw-section-id="25" id="mwAcg"><h4 id="Nicotine_addiction">Nicotine addiction</h4>
<div role="note" class="hatnote navigation-not-searchable" about="#mwt700" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"Further","href":"./Template:Further"},"params":{"1":{"wt":"Smoking cessation"}},"i":0}}]}' id="mwAck">Further information: <a rel="mw:WikiLink" href="./Smoking_cessation" title="Smoking cessation">Smoking cessation</a></div>
<p id="mwAco">Another area in which drug treatment has been widely used is in the treatment of <a rel="mw:WikiLink" href="./Nicotine" title="Nicotine" id="mwAcs">nicotine</a> addiction, which usually involves the use of <a rel="mw:WikiLink" href="./Nicotine_replacement_therapy" title="Nicotine replacement therapy" id="mwAcw">nicotine replacement therapy</a>, <a rel="mw:WikiLink" href="./Nicotinic_receptor_antagonist" title="Nicotinic receptor antagonist" id="mwAc0" class="mw-redirect">nicotinic receptor antagonists</a>, or <a rel="mw:WikiLink" href="./Nicotinic_receptor" title="Nicotinic receptor" id="mwAc4" class="mw-redirect">nicotinic receptor</a> <a rel="mw:WikiLink" href="./Partial_agonist" title="Partial agonist" id="mwAc8">partial agonists</a>.<sup about="#mwt708" class="mw-ref" id="cite_ref-nicotine_addiction_therapies_110-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"nicotine addiction therapies"}}'><a href="./Addiction#cite_note-nicotine_addiction_therapies-110" style="counter-reset: mw-Ref 103;"><span class="mw-reflink-text">[103]</span></a></sup><sup about="#mwt710" class="mw-ref" id="cite_ref-pmid24484986_111-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"pmid24484986"}}'><a href="./Addiction#cite_note-pmid24484986-111" style="counter-reset: mw-Ref 104;"><span class="mw-reflink-text">[104]</span></a></sup>  Examples of drugs that act on nicotinic receptors and have been used for treating nicotine addiction include antagonists like <a rel="mw:WikiLink" href="./Bupropion" title="Bupropion" id="mwAdA">bupropion</a> and the partial agonist <a rel="mw:WikiLink" href="./Varenicline" title="Varenicline" id="mwAdE">varenicline</a>.<sup about="#mwt1469" class="mw-ref" id="cite_ref-nicotine_addiction_therapies_110-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"nicotine addiction therapies"},"body":{"id":"mw-reference-text-cite_note-nicotine_addiction_therapies-110"}}'><a href="./Addiction#cite_note-nicotine_addiction_therapies-110" style="counter-reset: mw-Ref 103;"><span class="mw-reflink-text">[103]</span></a></sup><sup about="#mwt1471" class="mw-ref" id="cite_ref-pmid24484986_111-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"pmid24484986"},"body":{"id":"mw-reference-text-cite_note-pmid24484986-111"}}'><a href="./Addiction#cite_note-pmid24484986-111" style="counter-reset: mw-Ref 104;"><span class="mw-reflink-text">[104]</span></a></sup></p>

</section><section data-mw-section-id="26" id="mwAdI"><h4 id="Opioid_addiction">Opioid addiction</h4>
<div role="note" class="hatnote navigation-not-searchable" about="#mwt754" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"Further","href":"./Template:Further"},"params":{"1":{"wt":"Opioid use disorder"}},"i":0}}]}' id="mwAdM">Further information: <a rel="mw:WikiLink" href="./Opioid_use_disorder" title="Opioid use disorder">Opioid use disorder</a></div>
<p id="mwAdQ">Opioids cause <a rel="mw:WikiLink" href="./Physical_dependence" title="Physical dependence" id="mwAdU">physical dependence</a>, and treatment typically addresses both dependence and addiction.</p>

<p id="mwAdY">Physical dependence is treated using replacement drugs such as <a rel="mw:WikiLink" href="./Suboxone" title="Suboxone" id="mwAdc" class="mw-redirect">suboxone</a> or <a rel="mw:WikiLink" href="./Subutex" title="Subutex" id="mwAdg" class="mw-redirect">subutex</a> (both containing the active ingredients <a rel="mw:WikiLink" href="./Buprenorphine" title="Buprenorphine" id="mwAdk">buprenorphine</a>) and <a rel="mw:WikiLink" href="./Methadone" title="Methadone" id="mwAdo">methadone</a>.<sup about="#mwt1712" class="mw-ref" id="cite_ref-112" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{},"body":{"id":"mw-reference-text-cite_note-112"}}'><a href="./Addiction#cite_note-112" style="counter-reset: mw-Ref 105;"><span class="mw-reflink-text">[105]</span></a></sup><sup about="#mwt1714" class="mw-ref" id="cite_ref-113" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{},"body":{"id":"mw-reference-text-cite_note-113"}}'><a href="./Addiction#cite_note-113" style="counter-reset: mw-Ref 106;"><span class="mw-reflink-text">[106]</span></a></sup> Although these drugs perpetuate physical dependence, the goal of opiate maintenance is to provide a measure of control over both pain and cravings. Use of replacement drugs increases the addicted individual's ability to function normally and eliminates the negative consequences of obtaining controlled substances illicitly. Once a prescribed dosage is stabilized, treatment enters maintenance or tapering phases. In the United States, opiate replacement therapy is tightly regulated in <a rel="mw:WikiLink" href="./Methadone_clinic" title="Methadone clinic" id="mwAds">methadone clinics</a> and under the <a rel="mw:WikiLink" href="./DATA_2000" title="DATA 2000" id="mwAdw" class="mw-redirect">DATA 2000</a> legislation. In some countries, other opioid derivatives such as <a rel="mw:WikiLink" href="./Levomethadyl_acetate" title="Levomethadyl acetate" id="mwAd0" class="mw-redirect">levomethadyl acetate</a>,<sup about="#mwt1716" class="mw-ref" id="cite_ref-114" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{},"body":{"id":"mw-reference-text-cite_note-114"}}'><a href="./Addiction#cite_note-114" style="counter-reset: mw-Ref 107;"><span class="mw-reflink-text">[107]</span></a></sup> <a rel="mw:WikiLink" href="./Dihydrocodeine" title="Dihydrocodeine" id="mwAd4">dihydrocodeine</a>,<sup about="#mwt1718" class="mw-ref" id="cite_ref-115" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{},"body":{"id":"mw-reference-text-cite_note-115"}}'><a href="./Addiction#cite_note-115" style="counter-reset: mw-Ref 108;"><span class="mw-reflink-text">[108]</span></a></sup> <a rel="mw:WikiLink" href="./Dihydroetorphine" title="Dihydroetorphine" id="mwAd8">dihydroetorphine</a><sup about="#mwt1778" class="mw-ref" id="cite_ref-116" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{},"body":{"id":"mw-reference-text-cite_note-116"}}'><a href="./Addiction#cite_note-116" style="counter-reset: mw-Ref 109;"><span class="mw-reflink-text">[109]</span></a></sup> and even <a rel="mw:WikiLink" href="./Heroin" title="Heroin" id="mwAeA">heroin</a><sup about="#mwt1720" class="mw-ref" id="cite_ref-Metrebian1_117-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Metrebian1"},"body":{"id":"mw-reference-text-cite_note-Metrebian1-117"}}'><a href="./Addiction#cite_note-Metrebian1-117" style="counter-reset: mw-Ref 110;"><span class="mw-reflink-text">[110]</span></a></sup><sup about="#mwt1722" class="mw-ref" id="cite_ref-Metrebian2_118-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Metrebian2"},"body":{"id":"mw-reference-text-cite_note-Metrebian2-118"}}'><a href="./Addiction#cite_note-Metrebian2-118" style="counter-reset: mw-Ref 111;"><span class="mw-reflink-text">[111]</span></a></sup> are used as substitute drugs for illegal street opiates, with different prescriptions being given depending on the needs of the individual patient. <a rel="mw:WikiLink" href="./Baclofen" title="Baclofen" id="mwAeE">Baclofen</a> has led to successful reductions of cravings for stimulants, alcohol, and opioids, and also alleviates <a rel="mw:WikiLink" href="./Alcohol_withdrawal_syndrome" title="Alcohol withdrawal syndrome" id="mwAeI">alcohol withdrawal syndrome</a>. Many patients have stated they "became indifferent to alcohol" or "indifferent to cocaine" overnight after starting baclofen therapy.<sup about="#mwt1724" class="mw-ref" id="cite_ref-Kenna_GA,_Nielsen_DM,_Mello_P,_Schiesl_A,_Swift_RM_2007_213–37_119-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Kenna GA, Nielsen DM, Mello P, Schiesl A, Swift RM 2007 213–37"},"body":{"id":"mw-reference-text-cite_note-Kenna_GA,_Nielsen_DM,_Mello_P,_Schiesl_A,_Swift_RM_2007_213–37-119"}}'><a href="./Addiction#cite_note-Kenna_GA,_Nielsen_DM,_Mello_P,_Schiesl_A,_Swift_RM_2007_213–37-119" style="counter-reset: mw-Ref 112;"><span class="mw-reflink-text">[112]</span></a></sup></p>

</section><section data-mw-section-id="27" id="mwAeM"><h4 id="Psychostimulant_addiction">Psychostimulant addiction</h4>
<p id="mwAeQ"><span about="#mwt784" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"As of","href":"./Template:As_of"},"params":{"1":{"wt":"May 2014"}},"i":0}}]}' id="mwAeU">As of  May 2014</span><sup class="plainlinks noexcerpt noprint asof-tag update" style="display:none;" about="#mwt784"><a rel="mw:ExtLink" class="external text" href="//en.wikipedia.org/w/index.php?title=Addiction&amp;action=edit"><span typeof="mw:Entity">[</span>update<span typeof="mw:Entity">]</span></a></sup><span typeof="mw:Nowiki" about="#mwt784"></span><link rel="mw:PageProp/Category" href="./Category:Articles_containing_potentially_dated_statements_from_May_2014" about="#mwt784"/><link rel="mw:PageProp/Category" href="./Category:All_articles_containing_potentially_dated_statements" about="#mwt784" id="mwAeY"/>, there is no effective <a rel="mw:WikiLink" href="./Pharmacotherapy" title="Pharmacotherapy" id="mwAec">pharmacotherapy</a> for any form of psychostimulant addiction.<sup about="#mwt1726" class="mw-ref" id="cite_ref-Reward_system_and_psychostimulants_8-3" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Reward system and psychostimulants"},"body":{"id":"mw-reference-text-cite_note-Reward_system_and_psychostimulants-8"}}'><a href="./Addiction#cite_note-Reward_system_and_psychostimulants-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></sup><sup about="#mwt1728" class="mw-ref" id="cite_ref-pmid24716825_120-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"pmid24716825"},"body":{"id":"mw-reference-text-cite_note-pmid24716825-120"}}'><a href="./Addiction#cite_note-pmid24716825-120" style="counter-reset: mw-Ref 113;"><span class="mw-reflink-text">[113]</span></a></sup><sup about="#mwt1730" class="mw-ref" id="cite_ref-Cochrane_2013_treatments_121-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Cochrane 2013 treatments"},"body":{"id":"mw-reference-text-cite_note-Cochrane_2013_treatments-121"}}'><a href="./Addiction#cite_note-Cochrane_2013_treatments-121" style="counter-reset: mw-Ref 114;"><span class="mw-reflink-text">[114]</span></a></sup><sup about="#mwt1732" class="mw-ref" id="cite_ref-pmid23039267_122-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"pmid23039267"},"body":{"id":"mw-reference-text-cite_note-pmid23039267-122"}}'><a href="./Addiction#cite_note-pmid23039267-122" style="counter-reset: mw-Ref 115;"><span class="mw-reflink-text">[115]</span></a></sup> Reviews from 2015, 2016, and 2018 indicated that <a rel="mw:WikiLink" href="./TAAR1" title="TAAR1" id="mwAeg">TAAR1</a>-<a rel="mw:WikiLink" href="./Selective_agonist" title="Selective agonist" id="mwAek" class="mw-redirect">selective agonists</a> have significant therapeutic potential as a treatment for psychostimulant addictions;<sup about="#mwt794" class="mw-ref" id="cite_ref-Miller+Grandy_2016_123-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Miller+Grandy 2016"}}'><a href="./Addiction#cite_note-Miller+Grandy_2016-123" style="counter-reset: mw-Ref 116;"><span class="mw-reflink-text">[116]</span></a></sup><sup about="#mwt796" class="mw-ref" id="cite_ref-TAAR1_addiction_2015_124-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"TAAR1 addiction 2015"}}'><a href="./Addiction#cite_note-TAAR1_addiction_2015-124" style="counter-reset: mw-Ref 117;"><span class="mw-reflink-text">[117]</span></a></sup><sup about="#mwt1734" class="mw-ref" id="cite_ref-Curable_brain_disorder?_125-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Curable brain disorder?"},"body":{"id":"mw-reference-text-cite_note-Curable_brain_disorder?-125"}}'><a href="./Addiction#cite_note-Curable_brain_disorder?-125" style="counter-reset: mw-Ref 118;"><span class="mw-reflink-text">[118]</span></a></sup> however, <span about="#mwt790" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"As of","href":"./Template:As_of"},"params":{"1":{"wt":"2018"},"lc":{"wt":"y"}},"i":0}}]}' id="mwAeo">as of  2018</span><sup class="plainlinks noexcerpt noprint asof-tag update" style="display:none;" about="#mwt790"><a rel="mw:ExtLink" class="external text" href="//en.wikipedia.org/w/index.php?title=Addiction&amp;action=edit"><span typeof="mw:Entity">[</span>update<span typeof="mw:Entity">]</span></a></sup><span typeof="mw:Nowiki" about="#mwt790"></span><link rel="mw:PageProp/Category" href="./Category:Articles_containing_potentially_dated_statements_from_2018" about="#mwt790"/><link rel="mw:PageProp/Category" href="./Category:All_articles_containing_potentially_dated_statements" about="#mwt790" id="mwAes"/>, the only compounds which are known to function as TAAR1-selective agonists are <a rel="mw:WikiLink" href="./Experimental_drug" title="Experimental drug" id="mwAew">experimental drugs</a>.<sup about="#mwt1780" class="mw-ref" id="cite_ref-Miller+Grandy_2016_123-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Miller+Grandy 2016"},"body":{"id":"mw-reference-text-cite_note-Miller+Grandy_2016-123"}}'><a href="./Addiction#cite_note-Miller+Grandy_2016-123" style="counter-reset: mw-Ref 116;"><span class="mw-reflink-text">[116]</span></a></sup><sup about="#mwt1736" class="mw-ref" id="cite_ref-TAAR1_addiction_2015_124-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"TAAR1 addiction 2015"},"body":{"id":"mw-reference-text-cite_note-TAAR1_addiction_2015-124"}}'><a href="./Addiction#cite_note-TAAR1_addiction_2015-124" style="counter-reset: mw-Ref 117;"><span class="mw-reflink-text">[117]</span></a></sup><sup about="#mwt798" class="mw-ref" id="cite_ref-Curable_brain_disorder?_125-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Curable brain disorder?"}}'><a href="./Addiction#cite_note-Curable_brain_disorder?-125" style="counter-reset: mw-Ref 118;"><span class="mw-reflink-text">[118]</span></a></sup></p>

</section><section data-mw-section-id="28" id="mwAe0"><h4 id="Research">Research</h4>
<table class="box-Expand_section plainlinks metadata ambox mbox-small-left ambox-content" role="presentation" about="#mwt799" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"expand section","href":"./Template:Expand_section"},"params":{"date":{"wt":"April 2016"}},"i":0}}]}' id="mwAe4"><tbody><tr><td class="mbox-image"><figure-inline typeof="mw:Image mw:ExpandedAttrs" about="#mwt1803" data-mw='{"attribs":[["alt",{"html":"alt=&lt;span typeof=\"mw:Entity\" data-parsoid=&apos;{\"src\":\"&amp;amp;#91;\",\"srcContent\":\"[\"}&apos;>[&lt;/span>icon&lt;span typeof=\"mw:Entity\" data-parsoid=&apos;{\"src\":\"&amp;amp;#93;\",\"srcContent\":\"]\"}&apos;>]&lt;/span>","txt":"[icon]"}]]}'><a href="./File:Wiki_letter_w_cropped.svg"><img alt="[icon]" resource="./File:Wiki_letter_w_cropped.svg" src="//upload.wikimedia.org/wikipedia/commons/thumb/1/1c/Wiki_letter_w_cropped.svg/20px-Wiki_letter_w_cropped.svg.png" data-file-width="44" data-file-height="31" data-file-type="drawing" height="14" width="20" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/1/1c/Wiki_letter_w_cropped.svg/40px-Wiki_letter_w_cropped.svg.png 2x, //upload.wikimedia.org/wikipedia/commons/thumb/1/1c/Wiki_letter_w_cropped.svg/30px-Wiki_letter_w_cropped.svg.png 1.5x"/></a></figure-inline></td><td class="mbox-text"><div class="mbox-text-span">This section <b>needs expansion</b>. <small>You can help by <a rel="mw:ExtLink" class="external text" href="//en.wikipedia.org/w/index.php?title=Addiction&amp;action=edit&amp;section=">adding to it</a>.</small>  <small class="date-container"><i>(<span class="date">April 2016</span>)</i></small></div></td></tr></tbody></table><link rel="mw:PageProp/Category" href="./Category:Articles_to_be_expanded_from_April_2016" about="#mwt799"/><link rel="mw:PageProp/Category" href="./Category:All_articles_to_be_expanded" about="#mwt799"/><link rel="mw:PageProp/Category" href="./Category:Articles_using_small_message_boxes" about="#mwt799" id="mwAe8"/>
<p id="mwAfA">Research indicates that vaccines which utilize anti-drug <a rel="mw:WikiLink" href="./Monoclonal_antibodies" title="Monoclonal antibodies" id="mwAfE" class="mw-redirect">monoclonal antibodies</a> can mitigate drug-induced positive reinforcement by preventing the drug from moving across the <a rel="mw:WikiLink" href="./Blood–brain_barrier" title="Blood–brain barrier" id="mwAfI">blood–brain barrier</a>;<sup about="#mwt1738" class="mw-ref" id="cite_ref-Vaccine-antibody_immunotherapy_126-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Vaccine-antibody immunotherapy"},"body":{"id":"mw-reference-text-cite_note-Vaccine-antibody_immunotherapy-126"}}'><a href="./Addiction#cite_note-Vaccine-antibody_immunotherapy-126" style="counter-reset: mw-Ref 119;"><span class="mw-reflink-text">[119]</span></a></sup> however, current vaccine-based therapies are only effective in a relatively small subset of individuals.<sup about="#mwt808" class="mw-ref" id="cite_ref-Vaccine-antibody_immunotherapy_126-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Vaccine-antibody immunotherapy"}}'><a href="./Addiction#cite_note-Vaccine-antibody_immunotherapy-126" style="counter-reset: mw-Ref 119;"><span class="mw-reflink-text">[119]</span></a></sup><sup about="#mwt1740" class="mw-ref" id="cite_ref-Primary_source:_Antibody_level_limitation_127-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Primary source: Antibody level limitation"},"body":{"id":"mw-reference-text-cite_note-Primary_source:_Antibody_level_limitation-127"}}'><a href="./Addiction#cite_note-Primary_source:_Antibody_level_limitation-127" style="counter-reset: mw-Ref 120;"><span class="mw-reflink-text">[120]</span></a></sup> <span about="#mwt806" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"As of","href":"./Template:As_of"},"params":{"1":{"wt":"November 2015"}},"i":0}}]}' id="mwAfM">As of  November 2015</span><sup class="plainlinks noexcerpt noprint asof-tag update" style="display:none;" about="#mwt806"><a rel="mw:ExtLink" class="external text" href="//en.wikipedia.org/w/index.php?title=Addiction&amp;action=edit"><span typeof="mw:Entity">[</span>update<span typeof="mw:Entity">]</span></a></sup><span typeof="mw:Nowiki" about="#mwt806"></span><link rel="mw:PageProp/Category" href="./Category:Articles_containing_potentially_dated_statements_from_November_2015" about="#mwt806"/><link rel="mw:PageProp/Category" href="./Category:All_articles_containing_potentially_dated_statements" about="#mwt806" id="mwAfQ"/>, vaccine-based therapies are being tested in human clinical trials as a treatment for addiction and preventative measure against drug overdoses involving nicotine, cocaine, and methamphetamine.<sup about="#mwt810" class="mw-ref" id="cite_ref-Vaccine-antibody_immunotherapy_126-2" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Vaccine-antibody immunotherapy"}}'><a href="./Addiction#cite_note-Vaccine-antibody_immunotherapy-126" style="counter-reset: mw-Ref 119;"><span class="mw-reflink-text">[119]</span></a></sup></p>

<p id="mwAfU">Since addiction involves abnormalities in <a rel="mw:WikiLink" href="./Glutamate_(neurotransmitter)" title="Glutamate (neurotransmitter)" id="mwAfY">glutamate</a> and <a rel="mw:WikiLink" href="./GABAergic" title="GABAergic" id="mwAfc">GABAergic</a> neurotransmission,<sup about="#mwt824" class="mw-ref" id="cite_ref-ATS_pharmacotherapies_128-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"ATS pharmacotherapies"}}'><a href="./Addiction#cite_note-ATS_pharmacotherapies-128" style="counter-reset: mw-Ref 121;"><span class="mw-reflink-text">[121]</span></a></sup><sup about="#mwt826" class="mw-ref" id="cite_ref-Glutamate_and_GABA_systems_129-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Glutamate and GABA systems"}}'><a href="./Addiction#cite_note-Glutamate_and_GABA_systems-129" style="counter-reset: mw-Ref 122;"><span class="mw-reflink-text">[122]</span></a></sup> receptors associated with these neurotransmitters (e.g., <a rel="mw:WikiLink" href="./AMPA_receptor" title="AMPA receptor" id="mwAfg">AMPA receptors</a>, <a rel="mw:WikiLink" href="./NMDA_receptor" title="NMDA receptor" id="mwAfk">NMDA receptors</a>, and <a rel="mw:WikiLink" href="./GABAB_receptor" title="GABAB receptor" id="mwAfo">GABA<sub id="mwAfs">B</sub> receptors</a>) are potential therapeutic targets for addictions.<sup about="#mwt1742" class="mw-ref" id="cite_ref-ATS_pharmacotherapies_128-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"ATS pharmacotherapies"},"body":{"id":"mw-reference-text-cite_note-ATS_pharmacotherapies-128"}}'><a href="./Addiction#cite_note-ATS_pharmacotherapies-128" style="counter-reset: mw-Ref 121;"><span class="mw-reflink-text">[121]</span></a></sup><sup about="#mwt1744" class="mw-ref" id="cite_ref-Glutamate_and_GABA_systems_129-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Glutamate and GABA systems"},"body":{"id":"mw-reference-text-cite_note-Glutamate_and_GABA_systems-129"}}'><a href="./Addiction#cite_note-Glutamate_and_GABA_systems-129" style="counter-reset: mw-Ref 122;"><span class="mw-reflink-text">[122]</span></a></sup><sup about="#mwt1746" class="mw-ref" id="cite_ref-GABAB_PAMs_130-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"GABAB PAMs"},"body":{"id":"mw-reference-text-cite_note-GABAB_PAMs-130"}}'><a href="./Addiction#cite_note-GABAB_PAMs-130" style="counter-reset: mw-Ref 123;"><span class="mw-reflink-text">[123]</span></a></sup><sup about="#mwt1748" class="mw-ref" id="cite_ref-GABAB_PAMs_2_131-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"GABAB PAMs 2"},"body":{"id":"mw-reference-text-cite_note-GABAB_PAMs_2-131"}}'><a href="./Addiction#cite_note-GABAB_PAMs_2-131" style="counter-reset: mw-Ref 124;"><span class="mw-reflink-text">[124]</span></a></sup>  <a rel="mw:WikiLink" href="./N-acetylcysteine" title="N-acetylcysteine" id="mwAfw" class="mw-redirect">N-acetylcysteine</a>, which affects <a rel="mw:WikiLink" href="./Metabotropic_glutamate_receptor" title="Metabotropic glutamate receptor" id="mwAf0">metabotropic glutamate receptors</a> and NMDA receptors, has shown some benefit in preclinical and clinical studies involving addictions to cocaine, heroin, and cannabinoids.<sup about="#mwt828" class="mw-ref" id="cite_ref-ATS_pharmacotherapies_128-2" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"ATS pharmacotherapies"}}'><a href="./Addiction#cite_note-ATS_pharmacotherapies-128" style="counter-reset: mw-Ref 121;"><span class="mw-reflink-text">[121]</span></a></sup> It may also be useful as an <a rel="mw:WikiLink" href="./Adjunct_therapy" title="Adjunct therapy" id="mwAf4" class="mw-redirect">adjunct therapy</a> for addictions to <a rel="mw:WikiLink" href="./Amphetamine-type_stimulants" title="Amphetamine-type stimulants" id="mwAf8" class="mw-redirect">amphetamine-type stimulants</a>, but more clinical research is required.<sup about="#mwt830" class="mw-ref" id="cite_ref-ATS_pharmacotherapies_128-3" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"ATS pharmacotherapies"}}'><a href="./Addiction#cite_note-ATS_pharmacotherapies-128" style="counter-reset: mw-Ref 121;"><span class="mw-reflink-text">[121]</span></a></sup></p>

<p id="mwAgA">Current medical reviews of research involving lab animals have identified a drug class – class I <a rel="mw:WikiLink" href="./Histone_deacetylase_inhibitor" title="Histone deacetylase inhibitor" id="mwAgE">histone deacetylase inhibitors</a><sup about="#mwt845" class="mw-ref" id="cite_ref-133" rel="dc:references" typeof="mw:Transclusion  mw:Extension/ref" data-mw='{"parts":[{"template":{"target":{"wt":"#tag:ref","function":"tag"},"params":{"1":{"wt":"Inhibitors of class I [[histone deacetylase]] (HDAC) enzymes are drugs that inhibit four specific [[histone-modifying enzyme]]s: [[HDAC1]], [[HDAC2]], [[HDAC3]], and [[HDAC8]]. Most of the animal research with HDAC inhibitors has been conducted with four drugs: [[butyric acid|butyrate salts]] (mainly [[sodium butyrate]]), [[trichostatin A]], [[valproic acid]], and [[vorinostat|SAHA]];&lt;ref name=\"Amphetamine epigenetics\" />&lt;ref name=\"Chromatin states\" /> butyric acid is a naturally occurring [[short-chain fatty acid]] in humans, while the latter two compounds are FDA-approved drugs with [[medical indication]]s unrelated to addiction."},"group":{"wt":"\"note\""}},"i":0}}]}'><a href="./Addiction#cite_note-133" style="counter-reset: mw-Ref 7;" data-mw-group="note"><span class="mw-reflink-text">[note 7]</span></a></sup> – that indirectly inhibits the function and further increases in the expression of accumbal ΔFosB by inducing <a rel="mw:WikiLink" href="./G9a" title="G9a" id="mwAgI" class="mw-redirect">G9a</a> expression in the nucleus accumbens after prolonged use.<sup about="#mwt859" class="mw-ref" id="cite_ref-G9a_reverses_ΔFosB_plasticity_13-5" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"G9a reverses ΔFosB plasticity"}}'><a href="./Addiction#cite_note-G9a_reverses_ΔFosB_plasticity-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></sup><sup about="#mwt1750" class="mw-ref" id="cite_ref-Nestler_2014_epigenetics_67-5" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Nestler 2014 epigenetics"},"body":{"id":"mw-reference-text-cite_note-Nestler_2014_epigenetics-67"}}'><a href="./Addiction#cite_note-Nestler_2014_epigenetics-67" style="counter-reset: mw-Ref 64;"><span class="mw-reflink-text">[64]</span></a></sup><sup about="#mwt1752" class="mw-ref" id="cite_ref-Amphetamine_epigenetics_132-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Amphetamine epigenetics"},"body":{"id":"mw-reference-text-cite_note-Amphetamine_epigenetics-132"}}'><a href="./Addiction#cite_note-Amphetamine_epigenetics-132" style="counter-reset: mw-Ref 125;"><span class="mw-reflink-text">[125]</span></a></sup><sup about="#mwt1754" class="mw-ref" id="cite_ref-Chromatin_states_94-5" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Chromatin states"},"body":{"id":"mw-reference-text-cite_note-Chromatin_states-94"}}'><a href="./Addiction#cite_note-Chromatin_states-94" style="counter-reset: mw-Ref 87;"><span class="mw-reflink-text">[87]</span></a></sup>  These reviews and subsequent preliminary evidence which used <a rel="mw:WikiLink" href="./Oral_administration" title="Oral administration" id="mwAgM">oral administration</a> or <a rel="mw:WikiLink" href="./Intraperitoneal_administration" title="Intraperitoneal administration" id="mwAgQ" class="mw-redirect">intraperitoneal administration</a> of the sodium salt of <a rel="mw:WikiLink" href="./Butyric_acid" title="Butyric acid" id="mwAgU">butyric acid</a> or other class I HDAC inhibitors for an extended period indicate that these drugs have efficacy in reducing addictive behavior in lab animals<sup about="#mwt849" class="mw-ref" id="cite_ref-135" rel="dc:references" typeof="mw:Transclusion  mw:Extension/ref" data-mw='{"parts":[{"template":{"target":{"wt":"#tag:ref","function":"tag"},"params":{"1":{"wt":"Specifically, prolonged administration of a class I HDAC inhibitor appears to reduce an animal&apos;s motivation to acquire and use an addictive drug without affecting an animals motivation to attain other rewards (i.e., it does not appear to cause [[motivational anhedonia]]) and reduce the amount of the drug that is [[self-administration|self-administered]] when it is readily available.&lt;ref name=\"Nestler 2014 epigenetics\" />&lt;ref name=\"Chromatin states\" />&lt;ref name=\"HDACi primaries\" />"},"group":{"wt":"\"note\""}},"i":0}}]}'><a href="./Addiction#cite_note-135" style="counter-reset: mw-Ref 8;" data-mw-group="note"><span class="mw-reflink-text">[note 8]</span></a></sup> that have developed addictions to ethanol, psychostimulants (i.e., amphetamine and cocaine), nicotine, and opiates;<sup about="#mwt861" class="mw-ref" id="cite_ref-Nestler_2014_epigenetics_67-7" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Nestler 2014 epigenetics"}}'><a href="./Addiction#cite_note-Nestler_2014_epigenetics-67" style="counter-reset: mw-Ref 64;"><span class="mw-reflink-text">[64]</span></a></sup><sup about="#mwt863" class="mw-ref" id="cite_ref-Chromatin_states_94-7" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Chromatin states"}}'><a href="./Addiction#cite_note-Chromatin_states-94" style="counter-reset: mw-Ref 87;"><span class="mw-reflink-text">[87]</span></a></sup><sup about="#mwt1782" class="mw-ref" id="cite_ref-HDACi_primaries_134-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"HDACi primaries"},"body":{"id":"mw-reference-text-cite_note-HDACi_primaries-134"}}'><a href="./Addiction#cite_note-HDACi_primaries-134" style="counter-reset: mw-Ref 126;"><span class="mw-reflink-text">[126]</span></a></sup><sup about="#mwt1756" class="mw-ref" id="cite_ref-HDAC_alcoholism_review_136-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"HDAC alcoholism review"},"body":{"id":"mw-reference-text-cite_note-HDAC_alcoholism_review-136"}}'><a href="./Addiction#cite_note-HDAC_alcoholism_review-136" style="counter-reset: mw-Ref 127;"><span class="mw-reflink-text">[127]</span></a></sup> however, few clinical trials involving human addicts and any HDAC class I inhibitors have been conducted to test for treatment efficacy in humans or identify an optimal dosing regimen.<sup about="#mwt857" class="mw-ref" id="cite_ref-138" rel="dc:references" typeof="mw:Transclusion  mw:Extension/ref" data-mw='{"parts":[{"template":{"target":{"wt":"#tag:ref","function":"tag"},"params":{"1":{"wt":"Among the few clinical trials that employed a class I HDAC inhibitor, one utilized [[valproate]] for methamphetamine addiction.&lt;ref name=\"Valproate for methamphetamine addiction primary source\">{{cite journal | vauthors = Kheirabadi GR, Ghavami M, Maracy MR, Salehi M, Sharbafchi MR | title = Effect of add-on valproate on craving in methamphetamine depended patients: A randomized trial | journal = Advanced Biomedical Research | volume = 5 | issue = | pages = 149 | date = 2016 | pmid = 27656618 | pmc = 5025910 | doi = 10.4103/2277-9175.187404 | quote = }}&lt;/ref>"},"group":{"wt":"\"note\""}},"i":0}}]}'><a href="./Addiction#cite_note-138" style="counter-reset: mw-Ref 9;" data-mw-group="note"><span class="mw-reflink-text">[note 9]</span></a></sup></p>

<p id="mwAgY"><a rel="mw:WikiLink" href="./Gene_therapy" title="Gene therapy" id="mwAgc">Gene therapy</a> for addiction is an active area of research. One line of gene therapy research involves the use of <a rel="mw:WikiLink" href="./Viral_vector" title="Viral vector" id="mwAgg">viral vectors</a> to increase the expression of <a rel="mw:WikiLink" href="./Dopamine_D2_receptor" title="Dopamine D2 receptor" id="mwAgk" class="mw-redirect">dopamine D2 receptor</a> proteins in the brain.<sup about="#mwt1758" class="mw-ref" id="cite_ref-139" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{},"body":{"id":"mw-reference-text-cite_note-139"}}'><a href="./Addiction#cite_note-139" style="counter-reset: mw-Ref 129;"><span class="mw-reflink-text">[129]</span></a></sup><sup about="#mwt1760" class="mw-ref" id="cite_ref-140" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{},"body":{"id":"mw-reference-text-cite_note-140"}}'><a href="./Addiction#cite_note-140" style="counter-reset: mw-Ref 130;"><span class="mw-reflink-text">[130]</span></a></sup><sup about="#mwt1762" class="mw-ref" id="cite_ref-141" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{},"body":{"id":"mw-reference-text-cite_note-141"}}'><a href="./Addiction#cite_note-141" style="counter-reset: mw-Ref 131;"><span class="mw-reflink-text">[131]</span></a></sup><sup about="#mwt1764" class="mw-ref" id="cite_ref-142" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{},"body":{"id":"mw-reference-text-cite_note-142"}}'><a href="./Addiction#cite_note-142" style="counter-reset: mw-Ref 132;"><span class="mw-reflink-text">[132]</span></a></sup><sup about="#mwt1766" class="mw-ref" id="cite_ref-143" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{},"body":{"id":"mw-reference-text-cite_note-143"}}'><a href="./Addiction#cite_note-143" style="counter-reset: mw-Ref 133;"><span class="mw-reflink-text">[133]</span></a></sup></p>

</section></section></section><section data-mw-section-id="29" id="mwAgo"><h2 id="Epidemiology">Epidemiology</h2>

<p id="mwAgs">Due to cultural variations, the proportion of individuals who develop a drug or behavioral addiction within a specified time period (i.e., the <a rel="mw:WikiLink" href="./Prevalence" title="Prevalence" id="mwAgw">prevalence</a>) varies over time, by country, and across national <a rel="mw:WikiLink" href="./Demographics" title="Demographics" id="mwAg0" class="mw-redirect">population demographics</a> (e.g., by age group, socioeconomic status, etc.).<sup about="#mwt876" class="mw-ref" id="cite_ref-Transgenerational_epigenetic_inheritance_in_addiction_31-15" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Transgenerational epigenetic inheritance in addiction"}}'><a href="./Addiction#cite_note-Transgenerational_epigenetic_inheritance_in_addiction-31" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></sup></p>

<section data-mw-section-id="30" id="mwAg4"><h3 id="Asia">Asia</h3>
<table class="box-Empty_section plainlinks metadata ambox mbox-small-left ambox-content" role="presentation" about="#mwt877" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"Empty section","href":"./Template:Empty_section"},"params":{"date":{"wt":"December 2015"}},"i":0}}]}' id="mwAg8"><tbody><tr><td class="mbox-image"><figure-inline typeof="mw:Image mw:ExpandedAttrs" about="#mwt1804" data-mw='{"attribs":[["alt",{"html":"alt=&lt;span typeof=\"mw:Entity\" data-parsoid=&apos;{\"src\":\"&amp;amp;#91;\",\"srcContent\":\"[\"}&apos;>[&lt;/span>icon&lt;span typeof=\"mw:Entity\" data-parsoid=&apos;{\"src\":\"&amp;amp;#93;\",\"srcContent\":\"]\"}&apos;>]&lt;/span>","txt":"[icon]"}]]}'><a href="./File:Wiki_letter_w_cropped.svg"><img alt="[icon]" resource="./File:Wiki_letter_w_cropped.svg" src="//upload.wikimedia.org/wikipedia/commons/thumb/1/1c/Wiki_letter_w_cropped.svg/20px-Wiki_letter_w_cropped.svg.png" data-file-width="44" data-file-height="31" data-file-type="drawing" height="14" width="20" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/1/1c/Wiki_letter_w_cropped.svg/40px-Wiki_letter_w_cropped.svg.png 2x, //upload.wikimedia.org/wikipedia/commons/thumb/1/1c/Wiki_letter_w_cropped.svg/30px-Wiki_letter_w_cropped.svg.png 1.5x"/></a></figure-inline></td><td class="mbox-text"><div class="mbox-text-span"><b>This section is empty.</b> <small>You can help by <a rel="mw:ExtLink" class="external text" href="//en.wikipedia.org/w/index.php?title=Addiction&amp;action=edit&amp;section=">adding to it</a>.</small>  <small class="date-container"><i>(<span class="date">December 2015</span>)</i></small></div></td></tr></tbody></table><link rel="mw:PageProp/Category" href="./Category:Articles_to_be_expanded_from_December_2015" about="#mwt877"/><link rel="mw:PageProp/Category" href="./Category:All_articles_to_be_expanded" about="#mwt877"/><link rel="mw:PageProp/Category" href="./Category:Articles_with_empty_sections_from_December_2015" about="#mwt877"/><link rel="mw:PageProp/Category" href="./Category:All_articles_with_empty_sections" about="#mwt877"/><link rel="mw:PageProp/Category" href="./Category:Articles_using_small_message_boxes" about="#mwt877" id="mwAhA"/>

</section><section data-mw-section-id="31" id="mwAhE"><h3 id="Australia">Australia</h3>
<p id="mwAhI">The prevalence of substance abuse disorder among Australians was reported at 5.1% in 2009.<sup about="#mwt1768" class="mw-ref" id="cite_ref-144" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{},"body":{"id":"mw-reference-text-cite_note-144"}}'><a href="./Addiction#cite_note-144" style="counter-reset: mw-Ref 134;"><span class="mw-reflink-text">[134]</span></a></sup></p>

</section><section data-mw-section-id="32" id="mwAhM"><h3 id="Europe">Europe</h3>
<table class="box-Empty_section plainlinks metadata ambox mbox-small-left ambox-content" role="presentation" about="#mwt880" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"Empty section","href":"./Template:Empty_section"},"params":{"date":{"wt":"December 2015"}},"i":0}}]}' id="mwAhQ"><tbody><tr><td class="mbox-image"><figure-inline typeof="mw:Image mw:ExpandedAttrs" about="#mwt1805" data-mw='{"attribs":[["alt",{"html":"alt=&lt;span typeof=\"mw:Entity\" data-parsoid=&apos;{\"src\":\"&amp;amp;#91;\",\"srcContent\":\"[\"}&apos;>[&lt;/span>icon&lt;span typeof=\"mw:Entity\" data-parsoid=&apos;{\"src\":\"&amp;amp;#93;\",\"srcContent\":\"]\"}&apos;>]&lt;/span>","txt":"[icon]"}]]}'><a href="./File:Wiki_letter_w_cropped.svg"><img alt="[icon]" resource="./File:Wiki_letter_w_cropped.svg" src="//upload.wikimedia.org/wikipedia/commons/thumb/1/1c/Wiki_letter_w_cropped.svg/20px-Wiki_letter_w_cropped.svg.png" data-file-width="44" data-file-height="31" data-file-type="drawing" height="14" width="20" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/1/1c/Wiki_letter_w_cropped.svg/40px-Wiki_letter_w_cropped.svg.png 2x, //upload.wikimedia.org/wikipedia/commons/thumb/1/1c/Wiki_letter_w_cropped.svg/30px-Wiki_letter_w_cropped.svg.png 1.5x"/></a></figure-inline></td><td class="mbox-text"><div class="mbox-text-span"><b>This section is empty.</b> <small>You can help by <a rel="mw:ExtLink" class="external text" href="//en.wikipedia.org/w/index.php?title=Addiction&amp;action=edit&amp;section=">adding to it</a>.</small>  <small class="date-container"><i>(<span class="date">December 2015</span>)</i></small></div></td></tr></tbody></table><link rel="mw:PageProp/Category" href="./Category:Articles_to_be_expanded_from_December_2015" about="#mwt880"/><link rel="mw:PageProp/Category" href="./Category:All_articles_to_be_expanded" about="#mwt880"/><link rel="mw:PageProp/Category" href="./Category:Articles_with_empty_sections_from_December_2015" about="#mwt880"/><link rel="mw:PageProp/Category" href="./Category:All_articles_with_empty_sections" about="#mwt880"/><link rel="mw:PageProp/Category" href="./Category:Articles_using_small_message_boxes" about="#mwt880" id="mwAhU"/>

</section><section data-mw-section-id="33" id="mwAhY"><h3 id="United_States">United States</h3>

<p id="mwAhc">Based upon <a rel="mw:WikiLink" href="./Representative_sample" title="Representative sample" id="mwAhg" class="mw-redirect">representative samples</a> of the US youth population in 2011, the <a rel="mw:WikiLink" href="./Lifetime_prevalence" title="Lifetime prevalence" id="mwAhk" class="mw-redirect">lifetime prevalence</a><sup about="#mwt884" class="mw-ref" id="cite_ref-145" rel="dc:references" typeof="mw:Transclusion  mw:Extension/ref" data-mw='{"parts":[{"template":{"target":{"wt":"#tag:ref","function":"tag"},"params":{"1":{"wt":"The lifetime prevalence of an addiction is the percentage of individuals in a population that developed an addiction at some point in their life."},"group":{"wt":"\"note\""}},"i":0}}]}'><a href="./Addiction#cite_note-145" style="counter-reset: mw-Ref 10;" data-mw-group="note"><span class="mw-reflink-text">[note 10]</span></a></sup> of addictions to alcohol and illicit drugs has been estimated to be approximately 8% and 2–3% respectively.<sup about="#mwt887" class="mw-ref" id="cite_ref-Epidem_17-2" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Epidem"}}'><a href="./Addiction#cite_note-Epidem-17" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></sup>  Based upon representative samples of the US adult population in 2011, the <a rel="mw:WikiLink" href="./Period_prevalence" title="Period prevalence" id="mwAho" class="mw-redirect">12 month prevalence</a> of alcohol and illicit drug addictions were estimated at roughly 12% and 2–3% respectively.<sup about="#mwt889" class="mw-ref" id="cite_ref-Epidem_17-3" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Epidem"}}'><a href="./Addiction#cite_note-Epidem-17" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></sup> The lifetime prevalence of <a rel="mw:WikiLink" href="./Prescription_drug" title="Prescription drug" id="mwAhs">prescription drug</a> addictions is currently around 4.7%.<sup about="#mwt1770" class="mw-ref" id="cite_ref-146" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{},"body":{"id":"mw-reference-text-cite_note-146"}}'><a href="./Addiction#cite_note-146" style="counter-reset: mw-Ref 135;"><span class="mw-reflink-text">[135]</span></a></sup></p>

<p id="mwAhw"><span about="#mwt898" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"As of","href":"./Template:As_of"},"params":{"1":{"wt":"2016"},"post":{"wt":","}},"i":0}}]}' id="mwAh0">As of  2016</span><span typeof="mw:Nowiki" about="#mwt898"></span><span about="#mwt898">,</span><sup class="plainlinks noexcerpt noprint asof-tag update" style="display:none;" about="#mwt898"><a rel="mw:ExtLink" class="external text" href="//en.wikipedia.org/w/index.php?title=Addiction&amp;action=edit"><span typeof="mw:Entity">[</span>update<span typeof="mw:Entity">]</span></a></sup><span typeof="mw:Nowiki" about="#mwt898"></span><link rel="mw:PageProp/Category" href="./Category:Articles_containing_potentially_dated_statements_from_2016" about="#mwt898"/><link rel="mw:PageProp/Category" href="./Category:All_articles_containing_potentially_dated_statements" about="#mwt898" id="mwAh4"/> about 22<span typeof="mw:Entity" id="mwAh8"> </span>million people in the United States need treatment for an addiction to alcohol, nicotine, or other drugs.<sup about="#mwt902" class="mw-ref" id="cite_ref-ABAM_18-3" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"ABAM"}}'><a href="./Addiction#cite_note-ABAM-18" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></sup><sup about="#mwt904" class="mw-ref" id="cite_ref-NIDA_Addiction_Medicine_147-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"NIDA Addiction Medicine"}}'><a href="./Addiction#cite_note-NIDA_Addiction_Medicine-147" style="counter-reset: mw-Ref 136;"><span class="mw-reflink-text">[136]</span></a></sup> Only about 10%, or a little over 2<span typeof="mw:Entity" id="mwAiA"> </span>million, receive any form of treatments, and those that do generally do not receive <a rel="mw:WikiLink" href="./Evidence-based_medicine" title="Evidence-based medicine" id="mwAiE">evidence-based care</a>.<sup about="#mwt1772" class="mw-ref" id="cite_ref-ABAM_18-4" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"ABAM"},"body":{"id":"mw-reference-text-cite_note-ABAM-18"}}'><a href="./Addiction#cite_note-ABAM-18" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></sup><sup about="#mwt1774" class="mw-ref" id="cite_ref-NIDA_Addiction_Medicine_147-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"NIDA Addiction Medicine"},"body":{"id":"mw-reference-text-cite_note-NIDA_Addiction_Medicine-147"}}'><a href="./Addiction#cite_note-NIDA_Addiction_Medicine-147" style="counter-reset: mw-Ref 136;"><span class="mw-reflink-text">[136]</span></a></sup> One-third of <a rel="mw:WikiLink" href="./Inpatient_care" title="Inpatient care" id="mwAiI">inpatient</a> hospital costs and 20% of all deaths in the US every year are the result of untreated addictions and risky substance use.<sup about="#mwt906" class="mw-ref" id="cite_ref-ABAM_18-5" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"ABAM"}}'><a href="./Addiction#cite_note-ABAM-18" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></sup><sup about="#mwt908" class="mw-ref" id="cite_ref-NIDA_Addiction_Medicine_147-2" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"NIDA Addiction Medicine"}}'><a href="./Addiction#cite_note-NIDA_Addiction_Medicine-147" style="counter-reset: mw-Ref 136;"><span class="mw-reflink-text">[136]</span></a></sup> In spite of the massive overall economic cost to society, which is greater than the cost of <a rel="mw:WikiLink" href="./Diabetes" title="Diabetes" id="mwAiM" class="mw-redirect">diabetes</a> and all forms of <a rel="mw:WikiLink" href="./Cancer" title="Cancer" id="mwAiQ">cancer</a> combined, most doctors in the US lack the training to effectively address a drug addiction.<sup about="#mwt910" class="mw-ref" id="cite_ref-ABAM_18-6" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"ABAM"}}'><a href="./Addiction#cite_note-ABAM-18" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></sup><sup about="#mwt912" class="mw-ref" id="cite_ref-NIDA_Addiction_Medicine_147-3" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"NIDA Addiction Medicine"}}'><a href="./Addiction#cite_note-NIDA_Addiction_Medicine-147" style="counter-reset: mw-Ref 136;"><span class="mw-reflink-text">[136]</span></a></sup></p>

<p id="mwAiU">Another review listed estimates of lifetime prevalence rates for several behavioral addictions in the United States, including 1–2% for compulsive gambling, 5% for sexual addiction, 2.8% for food addiction, and 5–6% for compulsive shopping.<sup about="#mwt940" class="mw-ref" id="cite_ref-Natural_and_drug_addictions_12-37" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Natural and drug addictions"}}'><a href="./Addiction#cite_note-Natural_and_drug_addictions-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></sup>  A systematic review indicated that the time-invariant prevalence rate for sexual addiction and related compulsive sexual behavior (e.g., compulsive masturbation with or without pornography, compulsive cybersex, etc.) within the United States ranges from 3–6% of the population.<sup about="#mwt1335" class="mw-ref" id="cite_ref-Systematic_review_-_yet_another_DSM_fail_27-3" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Systematic review - yet another DSM fail"},"body":{"id":"mw-reference-text-cite_note-Systematic_review_-_yet_another_DSM_fail-27"}}'><a href="./Addiction#cite_note-Systematic_review_-_yet_another_DSM_fail-27" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></sup></p>

<p id="mwAiY">According to a 2017 poll conducted by the <a rel="mw:WikiLink" href="./Pew_Research_Center" title="Pew Research Center" id="mwAic">Pew Research Center</a>, almost half of US adults know a family member or close friend who has struggled with a drug addiction at some point in their life.<sup about="#mwt1520" class="mw-ref" id="cite_ref-148" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{},"body":{"id":"mw-reference-text-cite_note-148"}}'><a href="./Addiction#cite_note-148" style="counter-reset: mw-Ref 137;"><span class="mw-reflink-text">[137]</span></a></sup></p>

</section><section data-mw-section-id="34" id="mwAig"><h3 id="South_America">South America</h3>
<table class="box-Empty_section plainlinks metadata ambox mbox-small-left ambox-content" role="presentation" about="#mwt995" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"Empty section","href":"./Template:Empty_section"},"params":{"date":{"wt":"November 2017"}},"i":0}}]}' id="mwAik"><tbody><tr><td class="mbox-image"><figure-inline typeof="mw:Image mw:ExpandedAttrs" about="#mwt1555" data-mw='{"attribs":[["alt",{"html":"alt=&lt;span typeof=\"mw:Entity\" data-parsoid=&apos;{\"src\":\"&amp;amp;#91;\",\"srcContent\":\"[\"}&apos;>[&lt;/span>icon&lt;span typeof=\"mw:Entity\" data-parsoid=&apos;{\"src\":\"&amp;amp;#93;\",\"srcContent\":\"]\"}&apos;>]&lt;/span>","txt":"[icon]"}]]}'><a href="./File:Wiki_letter_w_cropped.svg"><img alt="[icon]" resource="./File:Wiki_letter_w_cropped.svg" src="//upload.wikimedia.org/wikipedia/commons/thumb/1/1c/Wiki_letter_w_cropped.svg/20px-Wiki_letter_w_cropped.svg.png" data-file-width="44" data-file-height="31" data-file-type="drawing" height="14" width="20" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/1/1c/Wiki_letter_w_cropped.svg/40px-Wiki_letter_w_cropped.svg.png 2x, //upload.wikimedia.org/wikipedia/commons/thumb/1/1c/Wiki_letter_w_cropped.svg/30px-Wiki_letter_w_cropped.svg.png 1.5x"/></a></figure-inline></td><td class="mbox-text"><div class="mbox-text-span"><b>This section is empty.</b> <small>You can help by <a rel="mw:ExtLink" class="external text" href="//en.wikipedia.org/w/index.php?title=Addiction&amp;action=edit&amp;section=">adding to it</a>.</small>  <small class="date-container"><i>(<span class="date">November 2017</span>)</i></small></div></td></tr></tbody></table><link rel="mw:PageProp/Category" href="./Category:Articles_to_be_expanded_from_November_2017" about="#mwt995"/><link rel="mw:PageProp/Category" href="./Category:All_articles_to_be_expanded" about="#mwt995"/><link rel="mw:PageProp/Category" href="./Category:Articles_with_empty_sections_from_November_2017" about="#mwt995"/><link rel="mw:PageProp/Category" href="./Category:All_articles_with_empty_sections" about="#mwt995"/><link rel="mw:PageProp/Category" href="./Category:Articles_using_small_message_boxes" about="#mwt995" id="mwAio"/>

</section></section><section data-mw-section-id="35" id="mwAis"><h2 id="Personality_theories_of_addiction">Personality theories of addiction</h2>
<div role="note" class="hatnote navigation-not-searchable" about="#mwt998" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"Main","href":"./Template:Main"},"params":{"1":{"wt":"Personality theories of addiction"}},"i":0}}]}' id="mwAiw">Main article: <a rel="mw:WikiLink" href="./Personality_theories_of_addiction" title="Personality theories of addiction">Personality theories of addiction</a></div>
<p id="mwAi0"><a rel="mw:WikiLink" href="./Personality_theories_of_addiction" title="Personality theories of addiction" id="mwAi4">Personality theories of addiction</a> are <a rel="mw:WikiLink" href="./Psychology" title="Psychology" id="mwAi8">psychological</a> models that associate <a rel="mw:WikiLink" href="./Personality_traits" title="Personality traits" id="mwAjA" class="mw-redirect">personality traits</a> or modes of thinking (i.e., <a rel="mw:WikiLink" href="./Affective_science" title="Affective science" id="mwAjE">affective states</a>) with an individual's proclivity for developing an addiction.  Models of addiction risk that have been proposed in psychology literature include an <a rel="mw:WikiLink" href="./Affect_dysregulation" title="Affect dysregulation" id="mwAjI" class="mw-redirect">affect dysregulation</a> model of positive and negative <a rel="mw:WikiLink" href="./Psychological_affect" title="Psychological affect" id="mwAjM" class="mw-redirect">psychological affects</a>, the <a rel="mw:WikiLink" href="./Reinforcement_sensitivity_theory" title="Reinforcement sensitivity theory" id="mwAjQ">reinforcement sensitivity theory</a> model of <a rel="mw:WikiLink" href="./Impulsiveness" title="Impulsiveness" id="mwAjU" class="mw-redirect">impulsiveness</a> and behavioral inhibition, and an impulsivity model of <a rel="mw:WikiLink" href="./Addiction#Sensitization" id="mwAjY">reward sensitization</a> and impulsiveness.<sup about="#mwt1536" class="mw-ref" id="cite_ref-Cheetham_2010_149-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Cheetham_2010"},"body":{"id":"mw-reference-text-cite_note-Cheetham_2010-149"}}'><a href="./Addiction#cite_note-Cheetham_2010-149" style="counter-reset: mw-Ref 138;"><span class="mw-reflink-text">[138]</span></a></sup><sup about="#mwt1538" class="mw-ref" id="cite_ref-Franken_2006_150-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Franken_2006"},"body":{"id":"mw-reference-text-cite_note-Franken_2006-150"}}'><a href="./Addiction#cite_note-Franken_2006-150" style="counter-reset: mw-Ref 139;"><span class="mw-reflink-text">[139]</span></a></sup><sup about="#mwt1540" class="mw-ref" id="cite_ref-pmid18232522_151-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"pmid18232522"},"body":{"id":"mw-reference-text-cite_note-pmid18232522-151"}}'><a href="./Addiction#cite_note-pmid18232522-151" style="counter-reset: mw-Ref 140;"><span class="mw-reflink-text">[140]</span></a></sup><sup about="#mwt1542" class="mw-ref" id="cite_ref-Kimbrel_2007_152-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Kimbrel_2007"},"body":{"id":"mw-reference-text-cite_note-Kimbrel_2007-152"}}'><a href="./Addiction#cite_note-Kimbrel_2007-152" style="counter-reset: mw-Ref 141;"><span class="mw-reflink-text">[141]</span></a></sup><sup about="#mwt1544" class="mw-ref" id="cite_ref-Dawe_153-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Dawe"},"body":{"id":"mw-reference-text-cite_note-Dawe-153"}}'><a href="./Addiction#cite_note-Dawe-153" style="counter-reset: mw-Ref 142;"><span class="mw-reflink-text">[142]</span></a></sup></p>

</section><section data-mw-section-id="36" id="mwAjc"><h2 id="See_also">See also</h2>
<div class="div-col columns column-width" style="-moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em;   " about="#mwt1009" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"col-list","href":"./Template:Col-list"},"params":{"1":{"wt":"\n* {{Portal inline|size=tiny|Addiction}}\n* [[Binge drinking]]\n* [[Binge eating disorder]]\n* [[Discrimination against drug addicts]]\n* [[Pavlovian-instrumental transfer]]\n* [[Philosophy of medicine]]\n"},"colwidth":{"wt":"30em"}},"i":0}}]}' id="mwAjg">
<ul><li><figure-inline class="noviewer" typeof="mw:Image"><a href="./File:Portal-puzzle.svg"><img resource="./File:Portal-puzzle.svg" src="//upload.wikimedia.org/wikipedia/en/thumb/f/fd/Portal-puzzle.svg/16px-Portal-puzzle.svg.png" data-file-width="32" data-file-height="28" data-file-type="drawing" height="14" width="16" srcset="//upload.wikimedia.org/wikipedia/en/thumb/f/fd/Portal-puzzle.svg/32px-Portal-puzzle.svg.png 2x, //upload.wikimedia.org/wikipedia/en/thumb/f/fd/Portal-puzzle.svg/24px-Portal-puzzle.svg.png 1.5x"/></a></figure-inline> <a rel="mw:WikiLink" href="./Portal:Addiction" title="Portal:Addiction">Addiction<span typeof="mw:Entity"> </span>portal</a></li>
<li><a rel="mw:WikiLink" href="./Binge_drinking" title="Binge drinking">Binge drinking</a></li>
<li><a rel="mw:WikiLink" href="./Binge_eating_disorder" title="Binge eating disorder">Binge eating disorder</a></li>
<li><a rel="mw:WikiLink" href="./Discrimination_against_drug_addicts" title="Discrimination against drug addicts">Discrimination against drug addicts</a></li>
<li><a rel="mw:WikiLink" href="./Pavlovian-instrumental_transfer" title="Pavlovian-instrumental transfer">Pavlovian-instrumental transfer</a></li>
<li><a rel="mw:WikiLink" href="./Philosophy_of_medicine" title="Philosophy of medicine">Philosophy of medicine</a></li></ul></div>

</section><section data-mw-section-id="37" id="mwAjk"><h2 id="Notes">Notes</h2>
<div class="reflist " style=" list-style-type: decimal;" about="#mwt1010" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"reflist","href":"./Template:Reflist"},"params":{"group":{"wt":"note"}},"i":0}}]}' id="mwAjo">
<div class="mw-references-wrap" typeof="mw:Extension/references" about="#mwt1546" data-mw='{"name":"references","attrs":{"group":"note","responsive":"1"},"body":{"html":""}}'><ol class="mw-references references" data-mw-group="note"><li about="#cite_note-ΔFosB_behaviors-15" id="cite_note-ΔFosB_behaviors-15"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-ΔFosB_behaviors_15-0" data-mw-group="note"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-ΔFosB_behaviors_15-1" data-mw-group="note"><span class="mw-linkback-text">2 </span></a></span> <span id="mw-reference-text-cite_note-ΔFosB_behaviors-15" class="mw-reference-text">A decrease in aversion sensitivity, in simpler terms, means that an individual's behavior is less likely to be influenced by undesirable outcomes.</span></li><li about="#cite_note-54" id="cite_note-54"><a href="./Addiction#cite_ref-54" data-mw-group="note" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-54" class="mw-reference-text">According to a review of experimental animal models that examined the transgenerational epigenetic inheritance of <a rel="mw:WikiLink" href="./Epigenetic_mark" title="Epigenetic mark" id="mwAjs" class="new">epigenetic marks</a> that occur in addiction, alterations in <a rel="mw:WikiLink" href="./Histone_acetylation" title="Histone acetylation" id="mwAjw" class="mw-redirect">histone acetylation</a> – specifically, di-acetylation of <a rel="mw:WikiLink" href="./Lysine" title="Lysine" id="mwAj0">lysine</a> <a rel="mw:WikiLink" href="./Residue_(amino_acid)" title="Residue (amino acid)" id="mwAj4" class="mw-redirect">residues</a> 9 and 14 on <a rel="mw:WikiLink" href="./Histone_3" title="Histone 3" id="mwAj8" class="mw-redirect">histone 3</a> (i.e., <a rel="mw:WikiLink" href="./H3K9ac2" title="H3K9ac2" id="mwAkA" class="new">H3K9ac2</a> and <a rel="mw:WikiLink" href="./H3K14ac2" title="H3K14ac2" id="mwAkE" class="new">H3K14ac2</a>) in association with <a rel="mw:WikiLink" href="./BDNF" title="BDNF" id="mwAkI" class="mw-redirect">BDNF</a> <a rel="mw:WikiLink" href="./Gene_promoter" title="Gene promoter" id="mwAkM" class="mw-redirect">gene promoters</a> – have been shown to occur within the <a rel="mw:WikiLink" href="./Medial_prefrontal_cortex" title="Medial prefrontal cortex" id="mwAkQ" class="mw-redirect">medial prefrontal cortex</a> (mPFC), <a rel="mw:WikiLink" href="./Testes" title="Testes" id="mwAkU" class="mw-redirect">testes</a>, and <a rel="mw:WikiLink" href="./Sperm" title="Sperm" id="mwAkY">sperm</a> of cocaine-addicted male rats.<sup about="#mwt942" class="mw-ref" id="cite_ref-Transgenerational_epigenetic_inheritance_in_addiction_31-8" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Transgenerational epigenetic inheritance in addiction"}}'><a href="./Addiction#cite_note-Transgenerational_epigenetic_inheritance_in_addiction-31" style="counter-reset: mw-Ref 30;" id="mwAkc"><span class="mw-reflink-text" id="mwAkg">[30]</span></a></sup> These epigenetic alterations in the rat mPFC result in increased BDNF <a rel="mw:WikiLink" href="./Gene_expression" title="Gene expression" id="mwAkk">gene expression</a> within the mPFC, which in turn blunts the <a rel="mw:WikiLink" href="./Reward_system" title="Reward system" id="mwAko">rewarding properties</a> of cocaine and reduces cocaine <a rel="mw:WikiLink" href="./Self-administration" title="Self-administration" id="mwAks">self-administration</a>.<sup about="#mwt944" class="mw-ref" id="cite_ref-Transgenerational_epigenetic_inheritance_in_addiction_31-9" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Transgenerational epigenetic inheritance in addiction"}}'><a href="./Addiction#cite_note-Transgenerational_epigenetic_inheritance_in_addiction-31" style="counter-reset: mw-Ref 30;" id="mwAkw"><span class="mw-reflink-text" id="mwAk0">[30]</span></a></sup> The male but not female offspring of these cocaine-exposed rats inherited both epigenetic marks (i.e., di-acetylation of lysine residues 9 and 14 on histone 3) within mPFC neurons, the corresponding increase in BDNF expression within mPFC neurons, and the behavioral phenotype associated with these effects (i.e., a reduction in cocaine reward, resulting in reduced cocaine-seeking by these male offspring).<sup about="#mwt946" class="mw-ref" id="cite_ref-Transgenerational_epigenetic_inheritance_in_addiction_31-10" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Transgenerational epigenetic inheritance in addiction"}}'><a href="./Addiction#cite_note-Transgenerational_epigenetic_inheritance_in_addiction-31" style="counter-reset: mw-Ref 30;" id="mwAk4"><span class="mw-reflink-text" id="mwAk8">[30]</span></a></sup> Consequently, the transmission of these two cocaine-induced epigenetic alterations (i.e., H3K9ac2 and H3K14ac2) in rats from male fathers to male offspring served to reduce the offspring's risk of developing an addiction to cocaine.<sup about="#mwt948" class="mw-ref" id="cite_ref-Transgenerational_epigenetic_inheritance_in_addiction_31-11" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Transgenerational epigenetic inheritance in addiction"}}'><a href="./Addiction#cite_note-Transgenerational_epigenetic_inheritance_in_addiction-31" style="counter-reset: mw-Ref 30;" id="mwAlA"><span class="mw-reflink-text" id="mwAlE">[30]</span></a></sup> As of  2018,<sup class="plainlinks noexcerpt noprint asof-tag update" style="display:none;" id="mwAlI"><a rel="mw:ExtLink" class="external text" href="//en.wikipedia.org/w/index.php?title=Addiction&amp;action=edit" id="mwAlM"><span typeof="mw:Entity" id="mwAlQ">[</span>update<span typeof="mw:Entity" id="mwAlU">]</span></a></sup><link rel="mw:PageProp/Category" href="./Category:Articles_containing_potentially_dated_statements_from_2018" id="mwAlY"/><link rel="mw:PageProp/Category" href="./Category:All_articles_containing_potentially_dated_statements" id="mwAlc"/> neither the heritability of these epigenetic marks in humans nor the behavioral effects of the marks within human mPFC neurons has been established.<sup about="#mwt950" class="mw-ref" id="cite_ref-Transgenerational_epigenetic_inheritance_in_addiction_31-12" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Transgenerational epigenetic inheritance in addiction"}}'><a href="./Addiction#cite_note-Transgenerational_epigenetic_inheritance_in_addiction-31" style="counter-reset: mw-Ref 30;" id="mwAlg"><span class="mw-reflink-text" id="mwAlk">[30]</span></a></sup></span></li><li about="#cite_note-85" id="cite_note-85"><a href="./Addiction#cite_ref-85" data-mw-group="note" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-85" class="mw-reference-text">In other words, c-Fos <a rel="mw:WikiLink" href="./Gene_repression" title="Gene repression" id="mwAlo" class="mw-redirect">repression</a> allows ΔFosB to more rapidly accumulate within the D1-type medium spiny neurons of the nucleus accumbens because it is selectively induced in this state.<sup about="#mwt1063" class="mw-ref" id="cite_ref-Cellular_basis_3-20" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Cellular basis"}}'><a href="./Addiction#cite_note-Cellular_basis-3" style="counter-reset: mw-Ref 3;" id="mwAls"><span class="mw-reflink-text" id="mwAlw">[3]</span></a></sup> Prior to c-Fos repression, all Fos family proteins (e.g., c-Fos, <a rel="mw:WikiLink" href="./Fra1" title="Fra1" id="mwAl0" class="mw-redirect">Fra1</a>, <a rel="mw:WikiLink" href="./Fra2" title="Fra2" id="mwAl4" class="mw-redirect">Fra2</a>, <a rel="mw:WikiLink" href="./FosB" title="FosB" id="mwAl8" class="mw-redirect">FosB</a>, and ΔFosB) are induced together, with ΔFosB expression increasing to a lesser extent.<sup about="#mwt1065" class="mw-ref" id="cite_ref-Cellular_basis_3-21" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Cellular basis"}}'><a href="./Addiction#cite_note-Cellular_basis-3" style="counter-reset: mw-Ref 3;" id="mwAmA"><span class="mw-reflink-text" id="mwAmE">[3]</span></a></sup></span></li><li about="#cite_note-86" id="cite_note-86"><a href="./Addiction#cite_ref-86" data-mw-group="note" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-86" class="mw-reference-text">According to two medical reviews, ΔFosB has been implicated in causing both increases and decreases in dynorphin expression in different studies;<sup about="#mwt1067" class="mw-ref" id="cite_ref-What_the_ΔFosB?_11-8" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"What the ΔFosB?"}}'><a href="./Addiction#cite_note-What_the_ΔFosB?-11" style="counter-reset: mw-Ref 11;" id="mwAmI"><span class="mw-reflink-text" id="mwAmM">[11]</span></a></sup><sup about="#mwt1069" class="mw-ref" id="cite_ref-pmid18640924_84-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"pmid18640924"}}'><a href="./Addiction#cite_note-pmid18640924-84" style="counter-reset: mw-Ref 81;" id="mwAmQ"><span class="mw-reflink-text" id="mwAmU">[81]</span></a></sup> this table entry reflects only a decrease. </span></li><li about="#cite_note-89" id="cite_note-89"><a href="./Addiction#cite_ref-89" data-mw-group="note" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-89" class="mw-reference-text">Incentive salience, the "<a rel="mw:WikiLink" href="./Motivational_salience" title="Motivational salience" id="mwAmY">motivational salience</a>" for a reward, is a "desire" or "want" attribute, which includes a motivational component, that the brain assigns to a rewarding stimulus.<sup about="#mwt1071" class="mw-ref" id="cite_ref-Incentive_salience_and_motivation_review_87-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Incentive salience and motivation review"}}'><a href="./Addiction#cite_note-Incentive_salience_and_motivation_review-87" style="counter-reset: mw-Ref 82;" id="mwAmc"><span class="mw-reflink-text" id="mwAmg">[82]</span></a></sup><sup about="#mwt1073" class="mw-ref" id="cite_ref-NAcc_function_88-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"NAcc function"}}'><a href="./Addiction#cite_note-NAcc_function-88" style="counter-reset: mw-Ref 83;" id="mwAmk"><span class="mw-reflink-text" id="mwAmo">[83]</span></a></sup> As a consequence, incentive salience acts as a motivational "magnet" for a rewarding stimulus that commands attention, induces approach, and causes the rewarding stimulus to be sought out.<sup about="#mwt1796" class="mw-ref" id="cite_ref-Incentive_salience_and_motivation_review_87-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Incentive salience and motivation review"},"body":{"id":"mw-reference-text-cite_note-Incentive_salience_and_motivation_review-87"}}'><a href="./Addiction#cite_note-Incentive_salience_and_motivation_review-87" style="counter-reset: mw-Ref 82;" id="mwAms"><span class="mw-reflink-text" id="mwAmw">[82]</span></a></sup></span></li><li about="#cite_note-92" id="cite_note-92"><a href="./Addiction#cite_ref-92" data-mw-group="note" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-92" class="mw-reference-text">In simplest terms, this means that when either amphetamine or sex is perceived as more alluring or desirable through reward sensitization, this effect occurs with the other as well.</span></li><li about="#cite_note-133" id="cite_note-133"><a href="./Addiction#cite_ref-133" data-mw-group="note" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-133" class="mw-reference-text">Inhibitors of class I <a rel="mw:WikiLink" href="./Histone_deacetylase" title="Histone deacetylase" id="mwAm0">histone deacetylase</a> (HDAC) enzymes are drugs that inhibit four specific <a rel="mw:WikiLink" href="./Histone-modifying_enzyme" title="Histone-modifying enzyme" id="mwAm4" class="mw-redirect">histone-modifying enzymes</a>: <a rel="mw:WikiLink" href="./HDAC1" title="HDAC1" id="mwAm8">HDAC1</a>, <a rel="mw:WikiLink" href="./HDAC2" title="HDAC2" id="mwAnA" class="mw-redirect">HDAC2</a>, <a rel="mw:WikiLink" href="./HDAC3" title="HDAC3" id="mwAnE">HDAC3</a>, and <a rel="mw:WikiLink" href="./HDAC8" title="HDAC8" id="mwAnI">HDAC8</a>. Most of the animal research with HDAC inhibitors has been conducted with four drugs: <a rel="mw:WikiLink" href="./Butyric_acid" title="Butyric acid" id="mwAnM">butyrate salts</a> (mainly <a rel="mw:WikiLink" href="./Sodium_butyrate" title="Sodium butyrate" id="mwAnQ">sodium butyrate</a>), <a rel="mw:WikiLink" href="./Trichostatin_A" title="Trichostatin A" id="mwAnU">trichostatin A</a>, <a rel="mw:WikiLink" href="./Valproic_acid" title="Valproic acid" id="mwAnY" class="mw-redirect">valproic acid</a>, and <a rel="mw:WikiLink" href="./Vorinostat" title="Vorinostat" id="mwAnc">SAHA</a>;<sup about="#mwt1621" class="mw-ref" id="cite_ref-Amphetamine_epigenetics_132-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Amphetamine epigenetics"}}'><a href="./Addiction#cite_note-Amphetamine_epigenetics-132" style="counter-reset: mw-Ref 125;" id="mwAng"><span class="mw-reflink-text" id="mwAnk">[125]</span></a></sup><sup about="#mwt1623" class="mw-ref" id="cite_ref-Chromatin_states_94-4" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Chromatin states"}}'><a href="./Addiction#cite_note-Chromatin_states-94" style="counter-reset: mw-Ref 87;" id="mwAno"><span class="mw-reflink-text" id="mwAns">[87]</span></a></sup> butyric acid is a naturally occurring <a rel="mw:WikiLink" href="./Short-chain_fatty_acid" title="Short-chain fatty acid" id="mwAnw">short-chain fatty acid</a> in humans, while the latter two compounds are FDA-approved drugs with <a rel="mw:WikiLink" href="./Medical_indication" title="Medical indication" id="mwAn0" class="mw-redirect">medical indications</a> unrelated to addiction.</span></li><li about="#cite_note-135" id="cite_note-135"><a href="./Addiction#cite_ref-135" data-mw-group="note" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-135" class="mw-reference-text">Specifically, prolonged administration of a class I HDAC inhibitor appears to reduce an animal's motivation to acquire and use an addictive drug without affecting an animals motivation to attain other rewards (i.e., it does not appear to cause <a rel="mw:WikiLink" href="./Motivational_anhedonia" title="Motivational anhedonia" id="mwAn4" class="mw-redirect">motivational anhedonia</a>) and reduce the amount of the drug that is <a rel="mw:WikiLink" href="./Self-administration" title="Self-administration" id="mwAn8">self-administered</a> when it is readily available.<sup about="#mwt1625" class="mw-ref" id="cite_ref-Nestler_2014_epigenetics_67-6" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Nestler 2014 epigenetics"}}'><a href="./Addiction#cite_note-Nestler_2014_epigenetics-67" style="counter-reset: mw-Ref 64;" id="mwAoA"><span class="mw-reflink-text" id="mwAoE">[64]</span></a></sup><sup about="#mwt1627" class="mw-ref" id="cite_ref-Chromatin_states_94-6" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Chromatin states"}}'><a href="./Addiction#cite_note-Chromatin_states-94" style="counter-reset: mw-Ref 87;" id="mwAoI"><span class="mw-reflink-text" id="mwAoM">[87]</span></a></sup><sup about="#mwt1629" class="mw-ref" id="cite_ref-HDACi_primaries_134-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"HDACi primaries"}}'><a href="./Addiction#cite_note-HDACi_primaries-134" style="counter-reset: mw-Ref 126;" id="mwAoQ"><span class="mw-reflink-text" id="mwAoU">[126]</span></a></sup></span></li><li about="#cite_note-138" id="cite_note-138"><a href="./Addiction#cite_ref-138" data-mw-group="note" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-138" class="mw-reference-text">Among the few clinical trials that employed a class I HDAC inhibitor, one utilized <a rel="mw:WikiLink" href="./Valproate" title="Valproate" id="mwAoY">valproate</a> for methamphetamine addiction.<sup about="#mwt1864" class="mw-ref" id="cite_ref-Valproate_for_methamphetamine_addiction_primary_source_137-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Valproate for methamphetamine addiction primary source"},"body":{"id":"mw-reference-text-cite_note-Valproate_for_methamphetamine_addiction_primary_source-137"}}'><a href="./Addiction#cite_note-Valproate_for_methamphetamine_addiction_primary_source-137" style="counter-reset: mw-Ref 128;" id="mwAoc"><span class="mw-reflink-text" id="mwAog">[128]</span></a></sup></span></li><li about="#cite_note-145" id="cite_note-145"><a href="./Addiction#cite_ref-145" data-mw-group="note" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-145" class="mw-reference-text">The lifetime prevalence of an addiction is the percentage of individuals in a population that developed an addiction at some point in their life.</span></li></ol></div></div>

<dl id="mwAok"><dt id="mwAoo">Image legend</dt></dl>
<div class="reflist " style=" list-style-type: decimal;" about="#mwt1011" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"reflist","href":"./Template:Reflist"},"params":{"group":{"wt":"Color legend"}},"i":0}}]}' id="mwAos">
<div class="mw-references-wrap" typeof="mw:Extension/references" about="#mwt1548" data-mw='{"name":"references","attrs":{"group":"Color legend","responsive":"1"},"body":{"html":""}}'><ol class="mw-references references" data-mw-group="Color legend"><li about="#cite_note-55" id="cite_note-55"><a href="./Addiction#cite_ref-55" data-mw-group="Color legend" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-55" class="mw-reference-text"><div class="legend" style="-webkit-column-break-inside: avoid;page-break-inside: avoid;break-inside: avoid-column" id="mwAow"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color:
#00ffff; color:black; font-size:100%; text-align:center;" id="mwAo0"><span typeof="mw:Entity" id="mwAo4"> </span></span><span typeof="mw:Entity" id="mwAo8"> </span><a rel="mw:WikiLink" href="./Ion_channel" title="Ion channel" id="mwApA">Ion channel</a></div><div class="legend" style="-webkit-column-break-inside: avoid;page-break-inside: avoid;break-inside: avoid-column" id="mwApE"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color:
#b2df8a; color:black; font-size:100%; text-align:center;" id="mwApI"><span typeof="mw:Entity" id="mwApM"> </span></span><span typeof="mw:Entity" id="mwApQ"> </span><a rel="mw:WikiLink" href="./G_proteins" title="G proteins" id="mwApU" class="mw-redirect">G proteins</a> &amp; <a rel="mw:WikiLink" href="./G_protein-coupled_receptor" title="G protein-coupled receptor" id="mwApY">linked receptors</a></div><div class="legend" style="-webkit-column-break-inside: avoid;page-break-inside: avoid;break-inside: avoid-column" id="mwApc"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color:MediumVioletRed; color:black; font-size:100%; text-align:center;" id="mwApg"><span typeof="mw:Entity" id="mwApk"> </span></span><span typeof="mw:Entity" id="mwApo"> </span>(Text color) <a rel="mw:WikiLink" href="./Transcription_factor" title="Transcription factor" id="mwAps">Transcription factors</a></div></span></li></ol></div></div>

</section><section data-mw-section-id="38" id="mwApw"><h2 id="References">References</h2>
<div class="reflist " style=" list-style-type: decimal;" about="#mwt1012" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"Reflist","href":"./Template:Reflist"},"params":{},"i":0}}]}' id="mwAp0">
<div class="mw-references-wrap mw-references-columns" typeof="mw:Extension/references" about="#mwt1550" data-mw='{"name":"references","attrs":{"group":"","responsive":"1"},"body":{"html":""}}'><ol class="mw-references references"><li about="#cite_note-Surgeon_General_severe_SUD-1" id="cite_note-Surgeon_General_severe_SUD-1"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-Surgeon_General_severe_SUD_1-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-Surgeon_General_severe_SUD_1-1"><span class="mw-linkback-text">2 </span></a></span> <span id="mw-reference-text-cite_note-Surgeon_General_severe_SUD-1" class="mw-reference-text"><cite class="citation web" id="mwAp4"><a rel="mw:ExtLink" class="external text" href="https://addiction.surgeongeneral.gov/sites/default/files/surgeon-generals-report.pdf" id="mwAp8">"Facing Addiction in America: The Surgeon General's Report on Alcohol, Drugs, and Health"</a> <span class="cs1-format" id="mwAqA">(PDF)</span>. <i id="mwAqE">Office of the Surgeon General</i>. US Department of Health and Human Services. November 2016. pp.<span typeof="mw:Entity" id="mwAqI"> </span>35–37, 45, 63, 155, 317, 338<span class="reference-accessdate" id="mwAqM">. Retrieved <span class="nowrap" id="mwAqQ">28 January</span> 2017</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Office+of+the+Surgeon+General&amp;rft.atitle=Facing+Addiction+in+America%3A+The+Surgeon+General%E2%80%99s+Report+on+Alcohol%2C+Drugs%2C+and+Health&amp;rft.pages=35-37%2C+45%2C+63%2C+155%2C+317%2C+338&amp;rft.date=2016-11&amp;rft_id=https%3A%2F%2Faddiction.surgeongeneral.gov%2Fsites%2Fdefault%2Ffiles%2Fsurgeon-generals-report.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" id="mwAqU"></span><style data-mw-deduplicate="TemplateStyles:r879151008" typeof="mw:Extension/templatestyles" about="#mwt1194" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwAqY">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation .cs1-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .citation .cs1-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}</style></span></li><li about="#cite_note-Brain_disease-2" id="cite_note-Brain_disease-2"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-Brain_disease_2-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-Brain_disease_2-1"><span class="mw-linkback-text">2 </span></a><a href="./Addiction#cite_ref-Brain_disease_2-2"><span class="mw-linkback-text">3 </span></a><a href="./Addiction#cite_ref-Brain_disease_2-3"><span class="mw-linkback-text">4 </span></a></span> <span id="mw-reference-text-cite_note-Brain_disease-2" class="mw-reference-text"><cite class="citation journal" id="mwAqc">Volkow ND, Koob GF, McLellan AT (January 2016). "Neurobiologic Advances from the Brain Disease Model of Addiction". <i id="mwAqg">N. Engl. J. Med</i>. <b id="mwAqk">374</b> (4): 363–371. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwAqo">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1056%2FNEJMra1511480" id="mwAqs">10.1056/NEJMra1511480</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwAqw" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwAq0"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/26816013" id="mwAq4">26816013</a>. <q id="mwAq8">Substance-use disorder: A diagnostic term in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) referring to recurrent use of alcohol or other drugs that causes clinically and functionally significant impairment, such as health problems, disability, and failure to meet major responsibilities at work, school, or home. Depending on the level of severity, this disorder is classified as mild, moderate, or severe.<br id="mwArA"/>Addiction: A term used to indicate the most severe, chronic stage of substance-use disorder, in which there is a substantial loss of self-control, as indicated by compulsive drug taking despite the desire to stop taking the drug. In the DSM-5, the term addiction is synonymous with the classification of severe substance-use disorder.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=N.+Engl.+J.+Med.&amp;rft.atitle=Neurobiologic+Advances+from+the+Brain+Disease+Model+of+Addiction&amp;rft.volume=374&amp;rft.issue=4&amp;rft.pages=363-371&amp;rft.date=2016-01&amp;rft_id=info%3Adoi%2F10.1056%2FNEJMra1511480&amp;rft_id=info%3Apmid%2F26816013&amp;rft.aulast=Volkow&amp;rft.aufirst=ND&amp;rft.au=Koob%2C+GF&amp;rft.au=McLellan%2C+AT&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" id="mwArE"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt1222" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwArI"/></span></li><li about="#cite_note-Cellular_basis-3" id="cite_note-Cellular_basis-3"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-Cellular_basis_3-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-Cellular_basis_3-1"><span class="mw-linkback-text">2 </span></a><a href="./Addiction#cite_ref-Cellular_basis_3-2"><span class="mw-linkback-text">3 </span></a><a href="./Addiction#cite_ref-Cellular_basis_3-3"><span class="mw-linkback-text">4 </span></a><a href="./Addiction#cite_ref-Cellular_basis_3-4"><span class="mw-linkback-text">5 </span></a><a href="./Addiction#cite_ref-Cellular_basis_3-5"><span class="mw-linkback-text">6 </span></a><a href="./Addiction#cite_ref-Cellular_basis_3-6"><span class="mw-linkback-text">7 </span></a><a href="./Addiction#cite_ref-Cellular_basis_3-7"><span class="mw-linkback-text">8 </span></a><a href="./Addiction#cite_ref-Cellular_basis_3-8"><span class="mw-linkback-text">9 </span></a><a href="./Addiction#cite_ref-Cellular_basis_3-9"><span class="mw-linkback-text">10 </span></a><a href="./Addiction#cite_ref-Cellular_basis_3-10"><span class="mw-linkback-text">11 </span></a><a href="./Addiction#cite_ref-Cellular_basis_3-11"><span class="mw-linkback-text">12 </span></a><a href="./Addiction#cite_ref-Cellular_basis_3-12"><span class="mw-linkback-text">13 </span></a><a href="./Addiction#cite_ref-Cellular_basis_3-13"><span class="mw-linkback-text">14 </span></a><a href="./Addiction#cite_ref-Cellular_basis_3-14"><span class="mw-linkback-text">15 </span></a><a href="./Addiction#cite_ref-Cellular_basis_3-15"><span class="mw-linkback-text">16 </span></a><a href="./Addiction#cite_ref-Cellular_basis_3-16"><span class="mw-linkback-text">17 </span></a><a href="./Addiction#cite_ref-Cellular_basis_3-17"><span class="mw-linkback-text">18 </span></a><a href="./Addiction#cite_ref-Cellular_basis_3-18"><span class="mw-linkback-text">19 </span></a><a href="./Addiction#cite_ref-Cellular_basis_3-19"><span class="mw-linkback-text">20 </span></a><a href="./Addiction#cite_ref-Cellular_basis_3-20"><span class="mw-linkback-text">21 </span></a><a href="./Addiction#cite_ref-Cellular_basis_3-21"><span class="mw-linkback-text">22 </span></a><a href="./Addiction#cite_ref-Cellular_basis_3-22"><span class="mw-linkback-text">23 </span></a><a href="./Addiction#cite_ref-Cellular_basis_3-23"><span class="mw-linkback-text">24 </span></a></span> <span id="mw-reference-text-cite_note-Cellular_basis-3" class="mw-reference-text"><cite class="citation journal" id="mwArM">Nestler EJ (December 2013). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3898681" id="mwArQ">"Cellular basis of memory for addiction"</a>. <i id="mwArU">Dialogues Clin. Neurosci</i>. <b id="mwArY">15</b> (4): 431–443. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwArc">PMC</a><span typeof="mw:Entity" id="mwArg"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwArk"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3898681" id="mwAro">3898681</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwArs" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwArw"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/24459410" id="mwAr0">24459410</a>. <q id="mwAr4">Despite the importance of numerous psychosocial factors, at its core, drug addiction involves a biological process: the ability of repeated exposure to a drug of abuse to induce changes in a vulnerable brain that drive the compulsive seeking and taking of drugs, and loss of control over drug use, that define a state of addiction.<span typeof="mw:Entity" id="mwAr8"> </span>... A large body of literature has demonstrated that such ΔFosB induction in D1-type [nucleus accumbens] neurons increases an animal's sensitivity to drug as well as natural rewards and promotes drug self-administration, presumably through a process of positive reinforcement<span typeof="mw:Entity" id="mwAsA"> </span>... Another ΔFosB target is cFos: as ΔFosB accumulates with repeated drug exposure it represses c-Fos and contributes to the molecular switch whereby ΔFosB is selectively induced in the chronic drug-treated state.<sup id="mwAsE">41</sup>.<span typeof="mw:Entity" id="mwAsI"> </span>... Moreover, there is increasing evidence that, despite a range of genetic risks for addiction across the population, exposure to sufficiently high doses of a drug for long periods of time can transform someone who has relatively lower genetic loading into an addict.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Dialogues+Clin.+Neurosci.&amp;rft.atitle=Cellular+basis+of+memory+for+addiction&amp;rft.volume=15&amp;rft.issue=4&amp;rft.pages=431-443&amp;rft.date=2013-12&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3898681&amp;rft_id=info%3Apmid%2F24459410&amp;rft.au=Nestler+EJ&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3898681&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" id="mwAsM"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt1216" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwAsQ"/></span></li><li about="#cite_note-Addiction_glossary-4" id="cite_note-Addiction_glossary-4"><a href="./Addiction#cite_ref-Addiction_glossary_4-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-Addiction_glossary-4" class="mw-reference-text"><cite class="citation book" id="mwAsU">Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 15: Reinforcement and Addictive Disorders".  In Sydor A, Brown RY. <i id="mwAsY">Molecular Neuropharmacology: A Foundation for Clinical Neuroscience</i> (2nd ed.). New York: McGraw-Hill Medical. pp.<span typeof="mw:Entity" id="mwAsc"> </span>364–375. <a rel="mw:WikiLink" href="./International_Standard_Book_Number" title="International Standard Book Number" id="mwAsg">ISBN</a><span typeof="mw:Entity" id="mwAsk"> </span><a rel="mw:WikiLink" href="./Special:BookSources/9780071481274" title="Special:BookSources/9780071481274" id="mwAso">9780071481274</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.atitle=Chapter+15%3A+Reinforcement+and+Addictive+Disorders&amp;rft.btitle=Molecular+Neuropharmacology%3A+A+Foundation+for+Clinical+Neuroscience&amp;rft.place=New+York&amp;rft.pages=364-375&amp;rft.edition=2nd&amp;rft.pub=McGraw-Hill+Medical&amp;rft.date=2009&amp;rft.isbn=9780071481274&amp;rft.aulast=Malenka&amp;rft.aufirst=RC&amp;rft.au=Nestler%2C+EJ&amp;rft.au=Hyman%2C+SE&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" id="mwAss"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt1218" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwAsw"/></span></li><li about="#cite_note-Nestler_Labs_Glossary-5" id="cite_note-Nestler_Labs_Glossary-5"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-Nestler_Labs_Glossary_5-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-Nestler_Labs_Glossary_5-1"><span class="mw-linkback-text">2 </span></a><a href="./Addiction#cite_ref-Nestler_Labs_Glossary_5-2"><span class="mw-linkback-text">3 </span></a></span> <span id="mw-reference-text-cite_note-Nestler_Labs_Glossary-5" class="mw-reference-text"><cite class="citation web" id="mwAs0"><a rel="mw:ExtLink" class="external text" href="http://neuroscience.mssm.edu/nestler/glossary.html" id="mwAs4">"Glossary of Terms"</a>. <i id="mwAs8">Mount Sinai School of Medicine</i>. Department of Neuroscience<span class="reference-accessdate" id="mwAtA">. Retrieved <span class="nowrap" id="mwAtE">9 February</span> 2015</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Mount+Sinai+School+of+Medicine&amp;rft.atitle=Glossary+of+Terms&amp;rft_id=http%3A%2F%2Fneuroscience.mssm.edu%2Fnestler%2Fglossary.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" id="mwAtI"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt1220" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwAtM"/></span></li><li about="#cite_note-pmid18790142-6" id="cite_note-pmid18790142-6"><a href="./Addiction#cite_ref-pmid18790142_6-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-pmid18790142-6" class="mw-reference-text"><cite class="citation journal" id="mwAtQ">Angres DH, Bettinardi-Angres K (October 2008). "The disease of addiction: origins, treatment, and recovery". <i id="mwAtU">Disease-a-Month</i>. <b id="mwAtY">54</b> (10): 696–721. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwAtc">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1016%2Fj.disamonth.2008.07.002" id="mwAtg">10.1016/j.disamonth.2008.07.002</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwAtk" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwAto"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18790142" id="mwAts">18790142</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Disease-a-Month&amp;rft.atitle=The+disease+of+addiction%3A+origins%2C+treatment%2C+and+recovery&amp;rft.volume=54&amp;rft.issue=10&amp;rft.pages=696-721&amp;rft.date=2008-10&amp;rft_id=info%3Adoi%2F10.1016%2Fj.disamonth.2008.07.002&amp;rft_id=info%3Apmid%2F18790142&amp;rft.aulast=Angres&amp;rft.aufirst=DH&amp;rft.au=Bettinardi-Angres%2C+K&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" id="mwAtw"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt1146" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwAt0"/></span></li><li about="#cite_note-NHM_addiction-reward-reinforcement-7" id="cite_note-NHM_addiction-reward-reinforcement-7"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-NHM_addiction-reward-reinforcement_7-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-NHM_addiction-reward-reinforcement_7-1"><span class="mw-linkback-text">2 </span></a></span> <span id="mw-reference-text-cite_note-NHM_addiction-reward-reinforcement-7" class="mw-reference-text"><cite class="citation book" about="#mwt127" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite book ","href":"./Template:Cite_book"},"params":{"vauthors":{"wt":"Malenka RC, Nestler EJ, Hyman SE"},"veditors":{"wt":"Sydor A, Brown RY"},"title":{"wt":"Molecular Neuropharmacology: A Foundation for Clinical Neuroscience"},"year":{"wt":"2009"},"publisher":{"wt":"McGraw-Hill Medical"},"location":{"wt":"New York"},"isbn":{"wt":"978-0-07-148127-4"},"pages":{"wt":"364–65, 375"},"edition":{"wt":"2nd"},"chapter":{"wt":"Chapter 15: Reinforcement and Addictive Disorders"},"quote":{"wt":"The defining feature of addiction is compulsive, out-of-control drug use, despite negative consequences.&amp;nbsp;...&lt;br />compulsive eating, shopping, gambling, and sex&amp;nbsp;– so-called \"natural addictions\"&amp;nbsp;– Indeed, addiction to both drugs and behavioral rewards may arise from similar dysregulation of the mesolimbic dopamine system."}},"i":0}}]}' id="mwAt4">Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 15: Reinforcement and Addictive Disorders".  In Sydor A, Brown RY. <i id="mwAt8">Molecular Neuropharmacology: A Foundation for Clinical Neuroscience</i> (2nd ed.). New York: McGraw-Hill Medical. pp.<span typeof="mw:Entity" id="mwAuA"> </span>364–65, 375. <a rel="mw:WikiLink" href="./International_Standard_Book_Number" title="International Standard Book Number" id="mwAuE">ISBN</a><span typeof="mw:Entity" id="mwAuI"> </span><a rel="mw:WikiLink" href="./Special:BookSources/978-0-07-148127-4" title="Special:BookSources/978-0-07-148127-4" id="mwAuM">978-0-07-148127-4</a>. <q id="mwAuQ">The defining feature of addiction is compulsive, out-of-control drug use, despite negative consequences.<span typeof="mw:Entity" id="mwAuU"> </span>...<br id="mwAuY"/>compulsive eating, shopping, gambling, and sex<span typeof="mw:Entity" id="mwAuc"> </span>– so-called "natural addictions"<span typeof="mw:Entity" id="mwAug"> </span>– Indeed, addiction to both drugs and behavioral rewards may arise from similar dysregulation of the mesolimbic dopamine system.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.atitle=Chapter+15%3A+Reinforcement+and+Addictive+Disorders&amp;rft.btitle=Molecular+Neuropharmacology%3A+A+Foundation+for+Clinical+Neuroscience&amp;rft.place=New+York&amp;rft.pages=364-65%2C+375&amp;rft.edition=2nd&amp;rft.pub=McGraw-Hill+Medical&amp;rft.date=2009&amp;rft.isbn=978-0-07-148127-4&amp;rft.aulast=Malenka&amp;rft.aufirst=RC&amp;rft.au=Nestler%2C+EJ&amp;rft.au=Hyman%2C+SE&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt127" id="mwAuk"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt127" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwAuo"/></span></li><li about="#cite_note-Reward_system_and_psychostimulants-8" id="cite_note-Reward_system_and_psychostimulants-8"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-Reward_system_and_psychostimulants_8-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-Reward_system_and_psychostimulants_8-1"><span class="mw-linkback-text">2 </span></a><a href="./Addiction#cite_ref-Reward_system_and_psychostimulants_8-2"><span class="mw-linkback-text">3 </span></a><a href="./Addiction#cite_ref-Reward_system_and_psychostimulants_8-3"><span class="mw-linkback-text">4 </span></a></span> <span id="mw-reference-text-cite_note-Reward_system_and_psychostimulants-8" class="mw-reference-text"><cite class="citation journal" about="#mwt785" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Taylor SB, Lewis CR, Olive MF"},"title":{"wt":"The neurocircuitry of illicit psychostimulant addiction: acute and chronic effects in humans"},"journal":{"wt":"Subst. Abuse Rehabil."},"volume":{"wt":"4"},"pages":{"wt":"29–43"},"date":{"wt":"February 2013"},"pmid":{"wt":"24648786"},"pmc":{"wt":"3931688"},"doi":{"wt":"10.2147/SAR.S39684"},"quote":{"wt":"Initial drug use can be attributed to the ability of the drug to act as a reward (ie, a pleasurable emotional state or positive reinforcer), which can lead to repeated drug use and dependence.&lt;sup>8,9&lt;/sup> A great deal of research has focused on the molecular and neuroanatomical mechanisms of the initial rewarding or reinforcing effect of drugs of abuse.&amp;nbsp;... At present, no pharmacological therapy has been approved by the FDA to treat psychostimulant addiction. Many drugs have been tested, but none have shown conclusive efficacy with tolerable side effects in humans.&lt;sup>172&lt;/sup>&amp;nbsp;...&lt;!--These drugs have included DA-receptor ligands, such as DA receptor agonists, partial agonists, and antagonists, as well as DA-reuptake inhibitors.&lt;sup>173,174&lt;/sup> One newer dopaminergic drug that has shown some promise is the antipsychotic medication aripiprazole, a partial agonist at D2-like receptors, which is currently approved for the treatment of schizophrenia, depression, and bipolar disorder.&lt;sup>175&lt;/sup> Clinical trials have thus far been mixed, with one study finding reduced cocaine craving and use, and another study showing increased cocaine use.&lt;sup>176,177&lt;/sup>&amp;nbsp;...\n\nRecent evidence for dysregulation of glutamatergic signaling in addiction has led to the testing of N-acetylcysteine, a derivative of the amino acid cysteine that normalizes extracellular levels of Glu following cocaine administration.&lt;sup>178,179&lt;/sup> Clinical trials found that N-acetylcysteine treatment attenuates cocaine craving and use and normalizes brain glutamate levels.&lt;sup>180–182&lt;/sup> Other recent studies found trends toward significant reductions in METH use and craving produced by the antidepressant buproprion and the anticonvulsant topiramate, which has glutamate release-inhibiting properties.&lt;sup>183,184&lt;/sup> While these compounds have not demonstrated overwhelming efficacy in reducing psychostimulant use or craving in all subjects tested, trends toward effects were observed and thus merit further investigation.\n\nOther compounds that have been tested, with disappointing results, include β-adrenergic antagonists, opioid-receptor antagonists, 5-HT3-receptor antagonists, antidepressants, and anticonvulsants.&lt;sup>172,185–190&lt;/sup> Despite the lack of past successes, several newer medications are currently being investigated and have shown some initial success, such as the smoking-cessation aid varenicline, the α2 adrenergic agonist clonidine, and the antidepressant mirtazapine.&lt;sup>191–194&lt;/sup> In addition, preclinical evidence strongly suggests potential therapeutic effects of compounds targeting receptors for endocannabinoids, the neuropeptide orexin, and CRF for the prevention of relapse to psychostimulant use.&lt;sup>195–197&lt;/sup>\n\nFuture approaches for the treatment of psychostimulant-induced cognitive deficits and dependence include the use of cognitive enhancers.&lt;sup>198–200&lt;/sup> Two promising examples include prescription stimulants, such as modafinil and methylphenidate, which have shown modest but potential treatment effects in METH users and cocaine users with comorbid attention deficit/hyperactivity disorder, respectively.&lt;sup>201–205&lt;/sup> In addition, galantamine, a cholinergic modulator and cognitive enhancer, has been reported to both decrease cocaine use and improve sustained attention in dependent subjects.&lt;sup>206,207&lt;/sup> Together, these studies indicate that clinical trials of cognitive enhancers in the treatment of psychostimulant addiction are warranted. In addition to the pharmacological trials reviewed above, less conventional strategies that are gaining scientific momentum include vaccine therapies to immunoneutralize drug molecules and impede penetrance across the blood–brain barrier, enzyme conjugates that dramatically increase the metabolic breakdown of abused drugs, pharmacogenetic approaches based on individual genetic polymorphisms in addiction-related genes, and epigenetic modulators of drug-induced changes in gene expression.&lt;sup>208–211&lt;/sup> While still in their relative infancy, these exciting new avenues of research offer a significant expansion of possible biologically based targets for the treatment of psychostimulant addiction.&amp;nbsp;...\n\nThe tremendous need for more effective pharmacological treatments for psychostimulant addiction is a mainstay of contemporary addiction research. However, the recent downsizing of many major pharmaceutical companies away from psychiatric indications (including addiction) due to the lack of efficacy of experimental compounds in humans may require a sea change in the translational research approach.&lt;sup>212,213&lt;/sup> --> A new emphasis on larger-scale biomarker, genetic, and epigenetic research focused on the molecular targets of mental disorders has been recently advocated.&lt;sup>212&lt;/sup> In addition, the integration of cognitive and behavioral modification of circuit-wide neuroplasticity (ie, computer-based training to enhance executive function) may prove to be an effective adjunct-treatment approach for addiction, particularly when combined with cognitive enhancers.&lt;sup>198,213–216&lt;/sup> Furthermore, in order to be effective, all pharmacological or biologically based treatments for addiction need to be integrated into other established forms of addiction rehabilitation, such as cognitive behavioral therapy, individual and group psychotherapy, behavior-modification strategies, twelve-step programs, and residential treatment facilities."}},"i":0}}]}' id="mwAus">Taylor SB, Lewis CR, Olive MF (February 2013). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3931688" id="mwAuw">"The neurocircuitry of illicit psychostimulant addiction: acute and chronic effects in humans"</a>. <i id="mwAu0">Subst. Abuse Rehabil</i>. <b id="mwAu4">4</b>: 29–43. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwAu8">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.2147%2FSAR.S39684" id="mwAvA">10.2147/SAR.S39684</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwAvE">PMC</a><span typeof="mw:Entity" id="mwAvI"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwAvM"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3931688" id="mwAvQ">3931688</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwAvU" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwAvY"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/24648786" id="mwAvc">24648786</a>. <q id="mwAvg">Initial drug use can be attributed to the ability of the drug to act as a reward (ie, a pleasurable emotional state or positive reinforcer), which can lead to repeated drug use and dependence.<sup id="mwAvk">8,9</sup> A great deal of research has focused on the molecular and neuroanatomical mechanisms of the initial rewarding or reinforcing effect of drugs of abuse.<span typeof="mw:Entity" id="mwAvo"> </span>... At present, no pharmacological therapy has been approved by the FDA to treat psychostimulant addiction. Many drugs have been tested, but none have shown conclusive efficacy with tolerable side effects in humans.<sup id="mwAvs">172</sup><span typeof="mw:Entity" id="mwAvw"> </span>... A new emphasis on larger-scale biomarker, genetic, and epigenetic research focused on the molecular targets of mental disorders has been recently advocated.<sup id="mwAv0">212</sup> In addition, the integration of cognitive and behavioral modification of circuit-wide neuroplasticity (ie, computer-based training to enhance executive function) may prove to be an effective adjunct-treatment approach for addiction, particularly when combined with cognitive enhancers.<sup id="mwAv4">198,213–216</sup> Furthermore, in order to be effective, all pharmacological or biologically based treatments for addiction need to be integrated into other established forms of addiction rehabilitation, such as cognitive behavioral therapy, individual and group psychotherapy, behavior-modification strategies, twelve-step programs, and residential treatment facilities.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Subst.+Abuse+Rehabil.&amp;rft.atitle=The+neurocircuitry+of+illicit+psychostimulant+addiction%3A+acute+and+chronic+effects+in+humans&amp;rft.volume=4&amp;rft.pages=29-43&amp;rft.date=2013-02&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3931688&amp;rft_id=info%3Apmid%2F24648786&amp;rft_id=info%3Adoi%2F10.2147%2FSAR.S39684&amp;rft.aulast=Taylor&amp;rft.aufirst=SB&amp;rft.au=Lewis%2C+CR&amp;rft.au=Olive%2C+MF&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3931688&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt785" id="mwAv8"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt785" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwAwA"/></span></li><li about="#cite_note-9" id="cite_note-9"><a href="./Addiction#cite_ref-9" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-9" class="mw-reference-text"><sup about="#mwt745" class="mw-ref" id="cite_ref-Cellular_basis_3-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Cellular basis"}}'><a href="./Addiction#cite_note-Cellular_basis-3" style="counter-reset: mw-Ref 3;" id="mwAwE"><span class="mw-reflink-text" id="mwAwI">[3]</span></a></sup><sup about="#mwt747" class="mw-ref" id="cite_ref-Nestler_Labs_Glossary_5-1" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Nestler Labs Glossary"}}'><a href="./Addiction#cite_note-Nestler_Labs_Glossary-5" style="counter-reset: mw-Ref 5;" id="mwAwM"><span class="mw-reflink-text" id="mwAwQ">[5]</span></a></sup><sup about="#mwt749" class="mw-ref" id="cite_ref-Brain_disease_2-2" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Brain disease"}}'><a href="./Addiction#cite_note-Brain_disease-2" style="counter-reset: mw-Ref 2;" id="mwAwU"><span class="mw-reflink-text" id="mwAwY">[2]</span></a></sup><sup about="#mwt1307" class="mw-ref" id="cite_ref-pmid18790142_6-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"pmid18790142"},"body":{"id":"mw-reference-text-cite_note-pmid18790142-6"}}'><a href="./Addiction#cite_note-pmid18790142-6" style="counter-reset: mw-Ref 6;" id="mwAwc"><span class="mw-reflink-text" id="mwAwg">[6]</span></a></sup><sup about="#mwt751" class="mw-ref" id="cite_ref-NHM_addiction-reward-reinforcement_7-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"NHM addiction-reward-reinforcement"}}'><a href="./Addiction#cite_note-NHM_addiction-reward-reinforcement-7" style="counter-reset: mw-Ref 7;" id="mwAwk"><span class="mw-reflink-text" id="mwAwo">[7]</span></a></sup><sup about="#mwt753" class="mw-ref" id="cite_ref-Reward_system_and_psychostimulants_8-0" rel="dc:references" typeof="mw:Extension/ref" data-mw='{"name":"ref","attrs":{"name":"Reward system and psychostimulants"}}'><a href="./Addiction#cite_note-Reward_system_and_psychostimulants-8" style="counter-reset: mw-Ref 8;" id="mwAws"><span class="mw-reflink-text" id="mwAww">[8]</span></a></sup></span></li><li about="#cite_note-10" id="cite_note-10"><a href="./Addiction#cite_ref-10" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-10" class="mw-reference-text"><cite class="citation web" about="#mwt20" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite web ","href":"./Template:Cite_web"},"params":{"author":{"wt":"American Society for Addiction Medicine"},"title":{"wt":"Definition of Addiction"},"journal":{"wt":""},"volume":{"wt":""},"issue":{"wt":""},"pages":{"wt":""},"year":{"wt":"2012"},"url":{"wt":"http://www.asam.org/for-the-public/definition-of-addiction"}},"i":0}}]}' id="mwAw0">American Society for Addiction Medicine (2012). <a rel="mw:ExtLink" class="external text" href="http://www.asam.org/for-the-public/definition-of-addiction" id="mwAw4">"Definition of Addiction"</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Definition+of+Addiction&amp;rft.date=2012&amp;rft.au=American+Society+for+Addiction+Medicine&amp;rft_id=http%3A%2F%2Fwww.asam.org%2Ffor-the-public%2Fdefinition-of-addiction&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt20" id="mwAw8"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt20" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwAxA"/></span></li><li about="#cite_note-What_the_ΔFosB?-11" id="cite_note-What_the_ΔFosB?-11"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-What_the_ΔFosB?_11-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-What_the_ΔFosB?_11-1"><span class="mw-linkback-text">2 </span></a><a href="./Addiction#cite_ref-What_the_ΔFosB?_11-2"><span class="mw-linkback-text">3 </span></a><a href="./Addiction#cite_ref-What_the_ΔFosB?_11-3"><span class="mw-linkback-text">4 </span></a><a href="./Addiction#cite_ref-What_the_ΔFosB?_11-4"><span class="mw-linkback-text">5 </span></a><a href="./Addiction#cite_ref-What_the_ΔFosB?_11-5"><span class="mw-linkback-text">6 </span></a><a href="./Addiction#cite_ref-What_the_ΔFosB?_11-6"><span class="mw-linkback-text">7 </span></a><a href="./Addiction#cite_ref-What_the_ΔFosB?_11-7"><span class="mw-linkback-text">8 </span></a><a href="./Addiction#cite_ref-What_the_ΔFosB?_11-8"><span class="mw-linkback-text">9 </span></a><a href="./Addiction#cite_ref-What_the_ΔFosB?_11-9"><span class="mw-linkback-text">10 </span></a></span> <span id="mw-reference-text-cite_note-What_the_ΔFosB?-11" class="mw-reference-text"><cite class="citation journal" about="#mwt45" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"author":{"wt":"Ruffle JK"},"title":{"wt":"Molecular neurobiology of addiction: what&apos;s all the (Δ)FosB about?"},"journal":{"wt":"Am. J. Drug Alcohol Abuse"},"volume":{"wt":"40"},"issue":{"wt":"6"},"pages":{"wt":"428–37"},"date":{"wt":"November 2014"},"pmid":{"wt":"25083822"},"doi":{"wt":"10.3109/00952990.2014.933840"},"quote":{"wt":"&lt;br />The strong correlation between chronic drug exposure and ΔFosB provides novel opportunities for targeted therapies in addiction (118), and suggests methods to analyze their efficacy (119). Over the past two decades, research has progressed from identifying ΔFosB induction to investigating its subsequent action (38). It is likely that ΔFosB research will now progress into a new era – the use of ΔFosB as a biomarker.&amp;nbsp;...&lt;br />Conclusions&lt;br />ΔFosB is an essential transcription factor implicated in the molecular and behavioral pathways of addiction following repeated drug exposure. The formation of ΔFosB in multiple brain regions, and the molecular pathway leading to the formation of AP-1 complexes is well understood. The establishment of a functional purpose for ΔFosB has allowed further determination as to some of the key aspects of its molecular cascades, involving effectors such as GluR2 (87,88), Cdk5 (93) and NFkB (100). Moreover, many of these molecular changes identified are now directly linked to the structural, physiological and behavioral changes observed following chronic drug exposure (60,95,97,102). New frontiers of research investigating the molecular roles of ΔFosB have been opened by epigenetic studies, and recent advances have illustrated the role of ΔFosB acting on DNA and histones, truly as a &apos;&apos;molecular switch&apos;&apos; (34). As a consequence of our improved understanding of ΔFosB in addiction, it is possible to evaluate the addictive potential of current medications (119), as well as use it as a biomarker for assessing the efficacy of therapeutic interventions (121,122,124). Some of these proposed interventions have limitations (125) or are in their infancy (75). However, it is hoped that some of these preliminary findings may lead to innovative treatments, which are much needed in addiction."}},"i":0}}]}' id="mwAxE">Ruffle JK (November 2014). "Molecular neurobiology of addiction: what's all the (Δ)FosB about?". <i id="mwAxI">Am. J. Drug Alcohol Abuse</i>. <b id="mwAxM">40</b> (6): 428–37. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwAxQ">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.3109%2F00952990.2014.933840" id="mwAxU">10.3109/00952990.2014.933840</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwAxY" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwAxc"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/25083822" id="mwAxg">25083822</a>. <q id="mwAxk"><br id="mwAxo"/>The strong correlation between chronic drug exposure and ΔFosB provides novel opportunities for targeted therapies in addiction (118), and suggests methods to analyze their efficacy (119). Over the past two decades, research has progressed from identifying ΔFosB induction to investigating its subsequent action (38). It is likely that ΔFosB research will now progress into a new era – the use of ΔFosB as a biomarker.<span typeof="mw:Entity" id="mwAxs"> </span>...<br id="mwAxw"/>Conclusions<br id="mwAx0"/>ΔFosB is an essential transcription factor implicated in the molecular and behavioral pathways of addiction following repeated drug exposure. The formation of ΔFosB in multiple brain regions, and the molecular pathway leading to the formation of AP-1 complexes is well understood. The establishment of a functional purpose for ΔFosB has allowed further determination as to some of the key aspects of its molecular cascades, involving effectors such as GluR2 (87,88), Cdk5 (93) and NFkB (100). Moreover, many of these molecular changes identified are now directly linked to the structural, physiological and behavioral changes observed following chronic drug exposure (60,95,97,102). New frontiers of research investigating the molecular roles of ΔFosB have been opened by epigenetic studies, and recent advances have illustrated the role of ΔFosB acting on DNA and histones, truly as a <i id="mwAx4">molecular switch</i> (34). As a consequence of our improved understanding of ΔFosB in addiction, it is possible to evaluate the addictive potential of current medications (119), as well as use it as a biomarker for assessing the efficacy of therapeutic interventions (121,122,124). Some of these proposed interventions have limitations (125) or are in their infancy (75). However, it is hoped that some of these preliminary findings may lead to innovative treatments, which are much needed in addiction.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Am.+J.+Drug+Alcohol+Abuse&amp;rft.atitle=Molecular+neurobiology+of+addiction%3A+what%27s+all+the+%28%CE%94%29FosB+about%3F&amp;rft.volume=40&amp;rft.issue=6&amp;rft.pages=428-37&amp;rft.date=2014-11&amp;rft_id=info%3Adoi%2F10.3109%2F00952990.2014.933840&amp;rft_id=info%3Apmid%2F25083822&amp;rft.au=Ruffle+JK&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt45" id="mwAx8"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt45" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwAyA"/></span></li><li about="#cite_note-Natural_and_drug_addictions-12" id="cite_note-Natural_and_drug_addictions-12"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-Natural_and_drug_addictions_12-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-Natural_and_drug_addictions_12-1"><span class="mw-linkback-text">2 </span></a><a href="./Addiction#cite_ref-Natural_and_drug_addictions_12-2"><span class="mw-linkback-text">3 </span></a><a href="./Addiction#cite_ref-Natural_and_drug_addictions_12-3"><span class="mw-linkback-text">4 </span></a><a href="./Addiction#cite_ref-Natural_and_drug_addictions_12-4"><span class="mw-linkback-text">5 </span></a><a href="./Addiction#cite_ref-Natural_and_drug_addictions_12-5"><span class="mw-linkback-text">6 </span></a><a href="./Addiction#cite_ref-Natural_and_drug_addictions_12-6"><span class="mw-linkback-text">7 </span></a><a href="./Addiction#cite_ref-Natural_and_drug_addictions_12-7"><span class="mw-linkback-text">8 </span></a><a href="./Addiction#cite_ref-Natural_and_drug_addictions_12-8"><span class="mw-linkback-text">9 </span></a><a href="./Addiction#cite_ref-Natural_and_drug_addictions_12-9"><span class="mw-linkback-text">10 </span></a><a href="./Addiction#cite_ref-Natural_and_drug_addictions_12-10"><span class="mw-linkback-text">11 </span></a><a href="./Addiction#cite_ref-Natural_and_drug_addictions_12-11"><span class="mw-linkback-text">12 </span></a><a href="./Addiction#cite_ref-Natural_and_drug_addictions_12-12"><span class="mw-linkback-text">13 </span></a><a href="./Addiction#cite_ref-Natural_and_drug_addictions_12-13"><span class="mw-linkback-text">14 </span></a><a href="./Addiction#cite_ref-Natural_and_drug_addictions_12-14"><span class="mw-linkback-text">15 </span></a><a href="./Addiction#cite_ref-Natural_and_drug_addictions_12-15"><span class="mw-linkback-text">16 </span></a><a href="./Addiction#cite_ref-Natural_and_drug_addictions_12-16"><span class="mw-linkback-text">17 </span></a><a href="./Addiction#cite_ref-Natural_and_drug_addictions_12-17"><span class="mw-linkback-text">18 </span></a><a href="./Addiction#cite_ref-Natural_and_drug_addictions_12-18"><span class="mw-linkback-text">19 </span></a><a href="./Addiction#cite_ref-Natural_and_drug_addictions_12-19"><span class="mw-linkback-text">20 </span></a><a href="./Addiction#cite_ref-Natural_and_drug_addictions_12-20"><span class="mw-linkback-text">21 </span></a><a href="./Addiction#cite_ref-Natural_and_drug_addictions_12-21"><span class="mw-linkback-text">22 </span></a><a href="./Addiction#cite_ref-Natural_and_drug_addictions_12-22"><span class="mw-linkback-text">23 </span></a><a href="./Addiction#cite_ref-Natural_and_drug_addictions_12-23"><span class="mw-linkback-text">24 </span></a><a href="./Addiction#cite_ref-Natural_and_drug_addictions_12-24"><span class="mw-linkback-text">25 </span></a><a href="./Addiction#cite_ref-Natural_and_drug_addictions_12-25"><span class="mw-linkback-text">26 </span></a><a href="./Addiction#cite_ref-Natural_and_drug_addictions_12-26"><span class="mw-linkback-text">27 </span></a><a href="./Addiction#cite_ref-Natural_and_drug_addictions_12-27"><span class="mw-linkback-text">28 </span></a><a href="./Addiction#cite_ref-Natural_and_drug_addictions_12-28"><span class="mw-linkback-text">29 </span></a><a href="./Addiction#cite_ref-Natural_and_drug_addictions_12-29"><span class="mw-linkback-text">30 </span></a><a href="./Addiction#cite_ref-Natural_and_drug_addictions_12-30"><span class="mw-linkback-text">31 </span></a><a href="./Addiction#cite_ref-Natural_and_drug_addictions_12-31"><span class="mw-linkback-text">32 </span></a><a href="./Addiction#cite_ref-Natural_and_drug_addictions_12-32"><span class="mw-linkback-text">33 </span></a><a href="./Addiction#cite_ref-Natural_and_drug_addictions_12-33"><span class="mw-linkback-text">34 </span></a><a href="./Addiction#cite_ref-Natural_and_drug_addictions_12-34"><span class="mw-linkback-text">35 </span></a><a href="./Addiction#cite_ref-Natural_and_drug_addictions_12-35"><span class="mw-linkback-text">36 </span></a><a href="./Addiction#cite_ref-Natural_and_drug_addictions_12-36"><span class="mw-linkback-text">37 </span></a><a href="./Addiction#cite_ref-Natural_and_drug_addictions_12-37"><span class="mw-linkback-text">38 </span></a></span> <span id="mw-reference-text-cite_note-Natural_and_drug_addictions-12" class="mw-reference-text"><cite class="citation journal" about="#mwt397" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"author":{"wt":"Olsen CM"},"title":{"wt":"Natural rewards, neuroplasticity, and non-drug addictions"},"journal":{"wt":"Neuropharmacology"},"volume":{"wt":"61"},"issue":{"wt":"7"},"pages":{"wt":"1109–22"},"date":{"wt":"December 2011"},"pmid":{"wt":"21459101"},"pmc":{"wt":"3139704"},"doi":{"wt":"10.1016/j.neuropharm.2011.03.010"},"quote":{"wt":"Functional neuroimaging studies in humans have shown that gambling (Breiter et al, 2001), shopping (Knutson et al, 2007), orgasm (Komisaruk et al, 2004), playing video games (Koepp et al, 1998; Hoeft et al, 2008) and the sight of appetizing food (Wang et al, 2004a) activate many of the same brain regions (i.e., the mesocorticolimbic system and extended amygdala) as drugs of abuse (Volkow et al, 2004).&amp;nbsp;... Cross-sensitization is also bidirectional, as a history of amphetamine administration facilitates sexual behavior and enhances the associated increase in NAc DA&amp;nbsp;... As described for food reward, sexual experience can also lead to activation of plasticity-related signaling cascades. The transcription factor delta FosB is increased in the NAc, PFC, dorsal striatum, and VTA following repeated sexual behavior (Wallace et al., 2008; Pitchers et al., 2010b). This natural increase in delta FosB or viral overexpression of delta FosB within the NAc modulates sexual performance, and NAc blockade of delta FosB attenuates this behavior (Hedges et al, 2009; Pitchers et al., 2010b). Further, viral overexpression of delta FosB enhances the conditioned place preference for an environment paired with sexual experience (Hedges et al., 2009).&amp;nbsp;... In some people, there is a transition from \"normal\" to compulsive engagement in natural rewards (such as food or sex), a condition that some have termed behavioral or non-drug addictions (Holden, 2001; Grant et al., 2006a).&amp;nbsp;... In humans, the role of dopamine signaling in incentive-sensitization processes has recently been highlighted by the observation of a dopamine dysregulation syndrome in some patients taking dopaminergic drugs. This syndrome is characterized by a medication-induced increase in (or compulsive) engagement in non-drug rewards such as gambling, shopping, or sex (Evans et al, 2006; Aiken, 2007; Lader, 2008).\""}},"i":0}}]}' id="mwAyE">Olsen CM (December 2011). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3139704" id="mwAyI">"Natural rewards, neuroplasticity, and non-drug addictions"</a>. <i id="mwAyM">Neuropharmacology</i>. <b id="mwAyQ">61</b> (7): 1109–22. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwAyU">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1016%2Fj.neuropharm.2011.03.010" id="mwAyY">10.1016/j.neuropharm.2011.03.010</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwAyc">PMC</a><span typeof="mw:Entity" id="mwAyg"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwAyk"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3139704" id="mwAyo">3139704</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwAys" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwAyw"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21459101" id="mwAy0">21459101</a>. <q id="mwAy4">Functional neuroimaging studies in humans have shown that gambling (Breiter et al, 2001), shopping (Knutson et al, 2007), orgasm (Komisaruk et al, 2004), playing video games (Koepp et al, 1998; Hoeft et al, 2008) and the sight of appetizing food (Wang et al, 2004a) activate many of the same brain regions (i.e., the mesocorticolimbic system and extended amygdala) as drugs of abuse (Volkow et al, 2004).<span typeof="mw:Entity" id="mwAy8"> </span>... Cross-sensitization is also bidirectional, as a history of amphetamine administration facilitates sexual behavior and enhances the associated increase in NAc DA<span typeof="mw:Entity" id="mwAzA"> </span>... As described for food reward, sexual experience can also lead to activation of plasticity-related signaling cascades. The transcription factor delta FosB is increased in the NAc, PFC, dorsal striatum, and VTA following repeated sexual behavior (Wallace et al., 2008; Pitchers et al., 2010b). This natural increase in delta FosB or viral overexpression of delta FosB within the NAc modulates sexual performance, and NAc blockade of delta FosB attenuates this behavior (Hedges et al, 2009; Pitchers et al., 2010b). Further, viral overexpression of delta FosB enhances the conditioned place preference for an environment paired with sexual experience (Hedges et al., 2009).<span typeof="mw:Entity" id="mwAzE"> </span>... In some people, there is a transition from "normal" to compulsive engagement in natural rewards (such as food or sex), a condition that some have termed behavioral or non-drug addictions (Holden, 2001; Grant et al., 2006a).<span typeof="mw:Entity" id="mwAzI"> </span>... In humans, the role of dopamine signaling in incentive-sensitization processes has recently been highlighted by the observation of a dopamine dysregulation syndrome in some patients taking dopaminergic drugs. This syndrome is characterized by a medication-induced increase in (or compulsive) engagement in non-drug rewards such as gambling, shopping, or sex (Evans et al, 2006; Aiken, 2007; Lader, 2008)."</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Neuropharmacology&amp;rft.atitle=Natural+rewards%2C+neuroplasticity%2C+and+non-drug+addictions&amp;rft.volume=61&amp;rft.issue=7&amp;rft.pages=1109-22&amp;rft.date=2011-12&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3139704&amp;rft_id=info%3Apmid%2F21459101&amp;rft_id=info%3Adoi%2F10.1016%2Fj.neuropharm.2011.03.010&amp;rft.au=Olsen+CM&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3139704&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt397" id="mwAzM"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt397" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwAzQ"/><br id="mwAzU"/><!--The following link is outside the template to make it hyperlinked while appearing to be part of the quote.--><a rel="mw:ExtLink" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3139704/table/T1/" id="mwAzY">Table 1: Summary of plasticity observed following exposure to drug or natural reinforcers</a>"</span></li><li about="#cite_note-G9a_reverses_ΔFosB_plasticity-13" id="cite_note-G9a_reverses_ΔFosB_plasticity-13"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-G9a_reverses_ΔFosB_plasticity_13-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-G9a_reverses_ΔFosB_plasticity_13-1"><span class="mw-linkback-text">2 </span></a><a href="./Addiction#cite_ref-G9a_reverses_ΔFosB_plasticity_13-2"><span class="mw-linkback-text">3 </span></a><a href="./Addiction#cite_ref-G9a_reverses_ΔFosB_plasticity_13-3"><span class="mw-linkback-text">4 </span></a><a href="./Addiction#cite_ref-G9a_reverses_ΔFosB_plasticity_13-4"><span class="mw-linkback-text">5 </span></a><a href="./Addiction#cite_ref-G9a_reverses_ΔFosB_plasticity_13-5"><span class="mw-linkback-text">6 </span></a></span> <span id="mw-reference-text-cite_note-G9a_reverses_ΔFosB_plasticity-13" class="mw-reference-text"><cite class="citation journal" about="#mwt46" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Biliński P, Wojtyła A, Kapka-Skrzypczak L, Chwedorowicz R, Cyranka M, Studziński T"},"title":{"wt":"Epigenetic regulation in drug addiction"},"journal":{"wt":"Ann. Agric. Environ. Med."},"volume":{"wt":"19"},"issue":{"wt":"3"},"pages":{"wt":"491–96"},"year":{"wt":"2012"},"pmid":{"wt":"23020045"},"doi":{"wt":""},"quote":{"wt":"For these reasons, ΔFosB is considered a primary and causative transcription factor in creating new neural connections in the reward centre, prefrontal cortex, and other regions of the limbic system. This is reflected in the increased, stable and long-lasting level of sensitivity to cocaine and other drugs, and tendency to relapse even after long periods of abstinence. These newly constructed networks function very efficiently via new pathways as soon as drugs of abuse are further taken&amp;nbsp;... In this way, the induction of CDK5 gene expression occurs together with suppression of the G9A gene coding for dimethyltransferase acting on the histone H3. A feedback mechanism can be observed in the regulation of these 2 crucial factors that determine the adaptive epigenetic response to cocaine. This depends on ΔFosB inhibiting G9a gene expression, i.e. H3K9me2 synthesis which in turn inhibits transcription factors for ΔFosB. For this reason, the observed hyper-expression of G9a, which ensures high levels of the dimethylated form of histone H3, eliminates the neuronal structural and plasticity effects caused by cocaine by means of this feedback which blocks ΔFosB transcription"}},"i":0}}]}' id="mwAzc">Biliński P, Wojtyła A, Kapka-Skrzypczak L, Chwedorowicz R, Cyranka M, Studziński T (2012). "Epigenetic regulation in drug addiction". <i id="mwAzg">Ann. Agric. Environ. Med</i>. <b id="mwAzk">19</b> (3): 491–96. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwAzo" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwAzs"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23020045" id="mwAzw">23020045</a>. <q id="mwAz0">For these reasons, ΔFosB is considered a primary and causative transcription factor in creating new neural connections in the reward centre, prefrontal cortex, and other regions of the limbic system. This is reflected in the increased, stable and long-lasting level of sensitivity to cocaine and other drugs, and tendency to relapse even after long periods of abstinence. These newly constructed networks function very efficiently via new pathways as soon as drugs of abuse are further taken<span typeof="mw:Entity" id="mwAz4"> </span>... In this way, the induction of CDK5 gene expression occurs together with suppression of the G9A gene coding for dimethyltransferase acting on the histone H3. A feedback mechanism can be observed in the regulation of these 2 crucial factors that determine the adaptive epigenetic response to cocaine. This depends on ΔFosB inhibiting G9a gene expression, i.e. H3K9me2 synthesis which in turn inhibits transcription factors for ΔFosB. For this reason, the observed hyper-expression of G9a, which ensures high levels of the dimethylated form of histone H3, eliminates the neuronal structural and plasticity effects caused by cocaine by means of this feedback which blocks ΔFosB transcription</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Ann.+Agric.+Environ.+Med.&amp;rft.atitle=Epigenetic+regulation+in+drug+addiction&amp;rft.volume=19&amp;rft.issue=3&amp;rft.pages=491-96&amp;rft.date=2012&amp;rft_id=info%3Apmid%2F23020045&amp;rft.aulast=Bili%C5%84ski&amp;rft.aufirst=P&amp;rft.au=Wojty%C5%82a%2C+A&amp;rft.au=Kapka-Skrzypczak%2C+L&amp;rft.au=Chwedorowicz%2C+R&amp;rft.au=Cyranka%2C+M&amp;rft.au=Studzi%C5%84ski%2C+T&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt46" id="mwAz8"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt46" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwA0A"/></span></li><li about="#cite_note-Nestler-14" id="cite_note-Nestler-14"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-Nestler_14-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-Nestler_14-1"><span class="mw-linkback-text">2 </span></a><a href="./Addiction#cite_ref-Nestler_14-2"><span class="mw-linkback-text">3 </span></a><a href="./Addiction#cite_ref-Nestler_14-3"><span class="mw-linkback-text">4 </span></a><a href="./Addiction#cite_ref-Nestler_14-4"><span class="mw-linkback-text">5 </span></a><a href="./Addiction#cite_ref-Nestler_14-5"><span class="mw-linkback-text">6 </span></a><a href="./Addiction#cite_ref-Nestler_14-6"><span class="mw-linkback-text">7 </span></a><a href="./Addiction#cite_ref-Nestler_14-7"><span class="mw-linkback-text">8 </span></a><a href="./Addiction#cite_ref-Nestler_14-8"><span class="mw-linkback-text">9 </span></a><a href="./Addiction#cite_ref-Nestler_14-9"><span class="mw-linkback-text">10 </span></a><a href="./Addiction#cite_ref-Nestler_14-10"><span class="mw-linkback-text">11 </span></a><a href="./Addiction#cite_ref-Nestler_14-11"><span class="mw-linkback-text">12 </span></a><a href="./Addiction#cite_ref-Nestler_14-12"><span class="mw-linkback-text">13 </span></a></span> <span id="mw-reference-text-cite_note-Nestler-14" class="mw-reference-text"><cite class="citation journal" about="#mwt398" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Robison AJ, Nestler EJ"},"title":{"wt":"Transcriptional and epigenetic mechanisms of addiction"},"journal":{"wt":"Nat. Rev. Neurosci."},"volume":{"wt":"12"},"issue":{"wt":"11"},"pages":{"wt":"623–37"},"date":{"wt":"November 2011"},"pmid":{"wt":"21989194"},"pmc":{"wt":"3272277"},"doi":{"wt":"10.1038/nrn3111"},"quote":{"wt":"ΔFosB has been linked directly to several addiction-related behaviors&amp;nbsp;...  Importantly, genetic or viral overexpression of ΔJunD, a dominant negative mutant of JunD which antagonizes ΔFosB- and other AP-1-mediated transcriptional activity, in the NAc or OFC blocks these key effects of drug exposure&lt;sup>14,22–24&lt;/sup>. This indicates that ΔFosB is both necessary and sufficient for many of the changes wrought in the brain by chronic drug exposure. ΔFosB is also induced in D1-type NAc MSNs by chronic consumption of several natural rewards, including sucrose, high fat food, sex, wheel running, where it promotes that consumption&lt;sup>14,26–30&lt;/sup>. This implicates ΔFosB in the regulation of natural rewards under normal conditions and perhaps during pathological addictive-like states."}},"i":0}}]}' id="mwA0E">Robison AJ, Nestler EJ (November 2011). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3272277" id="mwA0I">"Transcriptional and epigenetic mechanisms of addiction"</a>. <i id="mwA0M">Nat. Rev. Neurosci</i>. <b id="mwA0Q">12</b> (11): 623–37. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwA0U">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1038%2Fnrn3111" id="mwA0Y">10.1038/nrn3111</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwA0c">PMC</a><span typeof="mw:Entity" id="mwA0g"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwA0k"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3272277" id="mwA0o">3272277</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwA0s" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwA0w"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21989194" id="mwA00">21989194</a>. <q id="mwA04">ΔFosB has been linked directly to several addiction-related behaviors<span typeof="mw:Entity" id="mwA08"> </span>...  Importantly, genetic or viral overexpression of ΔJunD, a dominant negative mutant of JunD which antagonizes ΔFosB- and other AP-1-mediated transcriptional activity, in the NAc or OFC blocks these key effects of drug exposure<sup id="mwA1A">14,22–24</sup>. This indicates that ΔFosB is both necessary and sufficient for many of the changes wrought in the brain by chronic drug exposure. ΔFosB is also induced in D1-type NAc MSNs by chronic consumption of several natural rewards, including sucrose, high fat food, sex, wheel running, where it promotes that consumption<sup id="mwA1E">14,26–30</sup>. This implicates ΔFosB in the regulation of natural rewards under normal conditions and perhaps during pathological addictive-like states.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nat.+Rev.+Neurosci.&amp;rft.atitle=Transcriptional+and+epigenetic+mechanisms+of+addiction&amp;rft.volume=12&amp;rft.issue=11&amp;rft.pages=623-37&amp;rft.date=2011-11&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3272277&amp;rft_id=info%3Apmid%2F21989194&amp;rft_id=info%3Adoi%2F10.1038%2Fnrn3111&amp;rft.aulast=Robison&amp;rft.aufirst=AJ&amp;rft.au=Nestler%2C+EJ&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3272277&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt398" id="mwA1I"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt398" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwA1M"/></span></li><li about="#cite_note-Societal_toll-16" id="cite_note-Societal_toll-16"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-Societal_toll_16-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-Societal_toll_16-1"><span class="mw-linkback-text">2 </span></a></span> <span id="mw-reference-text-cite_note-Societal_toll-16" class="mw-reference-text"><cite class="citation book" about="#mwt86" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite book ","href":"./Template:Cite_book"},"params":{"vauthors":{"wt":"Malenka RC, Nestler EJ, Hyman SE"},"veditors":{"wt":"Sydor A, Brown RY"},"title":{"wt":"Molecular Neuropharmacology: A Foundation for Clinical Neuroscience"},"year":{"wt":"2009"},"publisher":{"wt":"McGraw-Hill Medical"},"location":{"wt":"New York"},"isbn":{"wt":"978-0-07-148127-4"},"page":{"wt":"4"},"edition":{"wt":"2nd"},"chapter":{"wt":"Chapter 1: Basic Principles of Neuropharmacology"},"quote":{"wt":"Drug abuse and addiction exact an astoundingly high financial and human toll on society through direct adverse effects, such as lung cancer and hepatic cirrhosis, and indirect adverse effects&amp;nbsp;–for example, accidents and AIDS&amp;nbsp;– on health and productivity."}},"i":0}}]}' id="mwA1Q">Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 1: Basic Principles of Neuropharmacology".  In Sydor A, Brown RY. <i id="mwA1U">Molecular Neuropharmacology: A Foundation for Clinical Neuroscience</i> (2nd ed.). New York: McGraw-Hill Medical. p.<span typeof="mw:Entity" id="mwA1Y"> </span>4. <a rel="mw:WikiLink" href="./International_Standard_Book_Number" title="International Standard Book Number" id="mwA1c">ISBN</a><span typeof="mw:Entity" id="mwA1g"> </span><a rel="mw:WikiLink" href="./Special:BookSources/978-0-07-148127-4" title="Special:BookSources/978-0-07-148127-4" id="mwA1k">978-0-07-148127-4</a>. <q id="mwA1o">Drug abuse and addiction exact an astoundingly high financial and human toll on society through direct adverse effects, such as lung cancer and hepatic cirrhosis, and indirect adverse effects<span typeof="mw:Entity" id="mwA1s"> </span>–for example, accidents and AIDS<span typeof="mw:Entity" id="mwA1w"> </span>– on health and productivity.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.atitle=Chapter+1%3A+Basic+Principles+of+Neuropharmacology&amp;rft.btitle=Molecular+Neuropharmacology%3A+A+Foundation+for+Clinical+Neuroscience&amp;rft.place=New+York&amp;rft.pages=4&amp;rft.edition=2nd&amp;rft.pub=McGraw-Hill+Medical&amp;rft.date=2009&amp;rft.isbn=978-0-07-148127-4&amp;rft.aulast=Malenka&amp;rft.aufirst=RC&amp;rft.au=Nestler%2C+EJ&amp;rft.au=Hyman%2C+SE&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt86" id="mwA10"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt86" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwA14"/></span></li><li about="#cite_note-Epidem-17" id="cite_note-Epidem-17"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-Epidem_17-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-Epidem_17-1"><span class="mw-linkback-text">2 </span></a><a href="./Addiction#cite_ref-Epidem_17-2"><span class="mw-linkback-text">3 </span></a><a href="./Addiction#cite_ref-Epidem_17-3"><span class="mw-linkback-text">4 </span></a></span> <span id="mw-reference-text-cite_note-Epidem-17" class="mw-reference-text"><cite class="citation journal" about="#mwt87" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Merikangas KR, McClair VL"},"title":{"wt":"Epidemiology of Substance Use Disorders"},"date":{"wt":"June 2012"},"journal":{"wt":"Hum. Genet."},"pages":{"wt":"779–89"},"issue":{"wt":"6"},"volume":{"wt":"131"},"pmc":{"wt":"4408274"},"doi":{"wt":"10.1007/s00439-012-1168-0"},"pmid":{"wt":"22543841"}},"i":0}}]}' id="mwA18">Merikangas KR, McClair VL (June 2012). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4408274" id="mwA2A">"Epidemiology of Substance Use Disorders"</a>. <i id="mwA2E">Hum. Genet</i>. <b id="mwA2I">131</b> (6): 779–89. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwA2M">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1007%2Fs00439-012-1168-0" id="mwA2Q">10.1007/s00439-012-1168-0</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwA2U">PMC</a><span typeof="mw:Entity" id="mwA2Y"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwA2c"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4408274" id="mwA2g">4408274</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwA2k" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwA2o"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22543841" id="mwA2s">22543841</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Hum.+Genet.&amp;rft.atitle=Epidemiology+of+Substance+Use+Disorders&amp;rft.volume=131&amp;rft.issue=6&amp;rft.pages=779-89&amp;rft.date=2012-06&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4408274&amp;rft_id=info%3Apmid%2F22543841&amp;rft_id=info%3Adoi%2F10.1007%2Fs00439-012-1168-0&amp;rft.aulast=Merikangas&amp;rft.aufirst=KR&amp;rft.au=McClair%2C+VL&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4408274&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt87" id="mwA2w"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt87" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwA20"/></span></li><li about="#cite_note-ABAM-18" id="cite_note-ABAM-18"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-ABAM_18-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-ABAM_18-1"><span class="mw-linkback-text">2 </span></a><a href="./Addiction#cite_ref-ABAM_18-2"><span class="mw-linkback-text">3 </span></a><a href="./Addiction#cite_ref-ABAM_18-3"><span class="mw-linkback-text">4 </span></a><a href="./Addiction#cite_ref-ABAM_18-4"><span class="mw-linkback-text">5 </span></a><a href="./Addiction#cite_ref-ABAM_18-5"><span class="mw-linkback-text">6 </span></a><a href="./Addiction#cite_ref-ABAM_18-6"><span class="mw-linkback-text">7 </span></a></span> <span id="mw-reference-text-cite_note-ABAM-18" class="mw-reference-text"><cite class="citation web" about="#mwt899" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite web","href":"./Template:Cite_web"},"params":{"title":{"wt":"American Board of Medical Specialties recognizes the new subspecialty of addiction medicine"},"url":{"wt":"http://www.abam.net/wp-content/uploads/2016/03/1.-News-Release-ADM.pdf"},"website":{"wt":"American Board of Addiction Medicine"},"accessdate":{"wt":"3 April 2016"},"date":{"wt":"14 March 2016"},"quote":{"wt":"Sixteen percent of the non-institutionalized U.S. population age 12 and over – more than 40 million Americans – meets medical criteria for addiction involving nicotine, alcohol or other drugs. This is more than the number of Americans with cancer, diabetes or heart conditions. In 2014, 22.5 million people in the United States needed treatment for addiction involving alcohol or drugs other than nicotine, but only 11.6 percent received any form of inpatient, residential, or outpatient treatment. Of those who do receive treatment, few receive evidence-based care. (There is no information available on how many individuals receive treatment for addiction involving nicotine.)&lt;br />Risky substance use and untreated addiction account for one-third of inpatient hospital costs and 20 percent of all deaths in the United States each year, and cause or contribute to more than 100 other conditions requiring medical care, as well as vehicular crashes, other fatal and non-fatal injuries, overdose deaths, suicides, homicides, domestic discord, the highest incarceration rate in the world and many other costly social consequences. The economic cost to society is greater than the cost of diabetes and all cancers combined. Despite these startling statistics on the prevalence and costs of addiction, few physicians have been trained to prevent or treat it."}},"i":0}}]}' id="mwA24"><a rel="mw:ExtLink" class="external text" href="http://www.abam.net/wp-content/uploads/2016/03/1.-News-Release-ADM.pdf" id="mwA28">"American Board of Medical Specialties recognizes the new subspecialty of addiction medicine"</a> <span class="cs1-format" id="mwA3A">(PDF)</span>. <i id="mwA3E">American Board of Addiction Medicine</i>. 14 March 2016<span class="reference-accessdate" id="mwA3I">. Retrieved <span class="nowrap" id="mwA3M">3 April</span> 2016</span>. <q id="mwA3Q">Sixteen percent of the non-institutionalized U.S. population age 12 and over – more than 40 million Americans – meets medical criteria for addiction involving nicotine, alcohol or other drugs. This is more than the number of Americans with cancer, diabetes or heart conditions. In 2014, 22.5 million people in the United States needed treatment for addiction involving alcohol or drugs other than nicotine, but only 11.6 percent received any form of inpatient, residential, or outpatient treatment. Of those who do receive treatment, few receive evidence-based care. (There is no information available on how many individuals receive treatment for addiction involving nicotine.)<br id="mwA3U"/>Risky substance use and untreated addiction account for one-third of inpatient hospital costs and 20 percent of all deaths in the United States each year, and cause or contribute to more than 100 other conditions requiring medical care, as well as vehicular crashes, other fatal and non-fatal injuries, overdose deaths, suicides, homicides, domestic discord, the highest incarceration rate in the world and many other costly social consequences. The economic cost to society is greater than the cost of diabetes and all cancers combined. Despite these startling statistics on the prevalence and costs of addiction, few physicians have been trained to prevent or treat it.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=American+Board+of+Addiction+Medicine&amp;rft.atitle=American+Board+of+Medical+Specialties+recognizes+the+new+subspecialty+of+addiction+medicine&amp;rft.date=2016-03-14&amp;rft_id=http%3A%2F%2Fwww.abam.net%2Fwp-content%2Fuploads%2F2016%2F03%2F1.-News-Release-ADM.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt899" id="mwA3Y"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt899" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwA3c"/></span></li><li about="#cite_note-INCB_2013-19" id="cite_note-INCB_2013-19"><a href="./Addiction#cite_ref-INCB_2013_19-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-INCB_2013-19" class="mw-reference-text"><cite class="citation book" about="#mwt88" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite book ","href":"./Template:Cite_book"},"params":{"title":{"wt":"International Narcotics Control Board Report: 2013"},"date":{"wt":"2013"},"publisher":{"wt":"United Nations&amp;nbsp;– [[International Narcotics Control Board]]"},"isbn":{"wt":"978-92-1-148274-4"},"url":{"wt":"https://www.incb.org/documents/Publications/AnnualReports/AR2013/English/AR_2013_E.pdf"},"accessdate":{"wt":"28 September 2018"},"chapter-url":{"wt":"https://www.incb.org/documents/Publications/AnnualReports/Thematic_chapters/English/AR_2013_E_Chapter_I.pdf"},"chapter":{"wt":"Economic consequences of drug abuse"}},"i":0}}]}' id="mwA3g"><a rel="mw:ExtLink" class="external text" href="https://www.incb.org/documents/Publications/AnnualReports/Thematic_chapters/English/AR_2013_E_Chapter_I.pdf" id="mwA3k">"Economic consequences of drug abuse"</a> <span class="cs1-format" id="mwA3o">(PDF)</span>. <a rel="mw:ExtLink" class="external text" href="https://www.incb.org/documents/Publications/AnnualReports/AR2013/English/AR_2013_E.pdf" id="mwA3s"><i id="mwA3w">International Narcotics Control Board Report: 2013</i></a> <span class="cs1-format" id="mwA30">(PDF)</span>. United Nations<span typeof="mw:Entity" id="mwA34"> </span>– <a rel="mw:WikiLink" href="./International_Narcotics_Control_Board" title="International Narcotics Control Board" id="mwA38">International Narcotics Control Board</a>. 2013. <a rel="mw:WikiLink" href="./International_Standard_Book_Number" title="International Standard Book Number" id="mwA4A">ISBN</a><span typeof="mw:Entity" id="mwA4E"> </span><a rel="mw:WikiLink" href="./Special:BookSources/978-92-1-148274-4" title="Special:BookSources/978-92-1-148274-4" id="mwA4I">978-92-1-148274-4</a><span class="reference-accessdate" id="mwA4M">. Retrieved <span class="nowrap" id="mwA4Q">28 September</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.atitle=Economic+consequences+of+drug+abuse&amp;rft.btitle=International+Narcotics+Control+Board+Report%3A+2013&amp;rft.pub=United+Nations+%E2%80%93+International+Narcotics+Control+Board&amp;rft.date=2013&amp;rft.isbn=978-92-1-148274-4&amp;rft_id=https%3A%2F%2Fwww.incb.org%2Fdocuments%2FPublications%2FAnnualReports%2FThematic_chapters%2FEnglish%2FAR_2013_E_Chapter_I.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt88" id="mwA4U"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt88" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwA4Y"/></span></li><li about="#cite_note-pmid1501306-20" id="cite_note-pmid1501306-20"><a href="./Addiction#cite_ref-pmid1501306_20-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-pmid1501306-20" class="mw-reference-text"><cite class="citation journal" about="#mwt89" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Morse RM, Flavin DK"},"title":{"wt":"The definition of alcoholism. The Joint Committee of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism"},"journal":{"wt":"JAMA"},"volume":{"wt":"268"},"issue":{"wt":"8"},"pages":{"wt":"1012–14"},"date":{"wt":"August 1992"},"pmid":{"wt":"1501306"},"doi":{"wt":"10.1001/jama.1992.03490080086030"}},"i":0}}]}' id="mwA4c">Morse RM, Flavin DK (August 1992). "The definition of alcoholism. The Joint Committee of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism". <i id="mwA4g">JAMA</i>. <b id="mwA4k">268</b> (8): 1012–14. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwA4o">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1001%2Fjama.1992.03490080086030" id="mwA4s">10.1001/jama.1992.03490080086030</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwA4w" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwA40"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/1501306" id="mwA44">1501306</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=JAMA&amp;rft.atitle=The+definition+of+alcoholism.+The+Joint+Committee+of+the+National+Council+on+Alcoholism+and+Drug+Dependence+and+the+American+Society+of+Addiction+Medicine+to+Study+the+Definition+and+Criteria+for+the+Diagnosis+of+Alcoholism&amp;rft.volume=268&amp;rft.issue=8&amp;rft.pages=1012-14&amp;rft.date=1992-08&amp;rft_id=info%3Adoi%2F10.1001%2Fjama.1992.03490080086030&amp;rft_id=info%3Apmid%2F1501306&amp;rft.aulast=Morse&amp;rft.aufirst=RM&amp;rft.au=Flavin%2C+DK&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt89" id="mwA48"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt89" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwA5A"/></span></li><li about="#cite_note-pmid3278676-21" id="cite_note-pmid3278676-21"><a href="./Addiction#cite_ref-pmid3278676_21-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-pmid3278676-21" class="mw-reference-text"><cite class="citation journal" about="#mwt90" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Marlatt GA, Baer JS, Donovan DM, Kivlahan DR"},"title":{"wt":"Addictive behaviors: etiology and treatment"},"journal":{"wt":"Annu Rev Psychol"},"volume":{"wt":"39"},"issue":{"wt":""},"pages":{"wt":"223–52"},"year":{"wt":"1988"},"pmid":{"wt":"3278676"},"doi":{"wt":"10.1146/annurev.ps.39.020188.001255"}},"i":0}}]}' id="mwA5E">Marlatt GA, Baer JS, Donovan DM, Kivlahan DR (1988). "Addictive behaviors: etiology and treatment". <i id="mwA5I">Annu Rev Psychol</i>. <b id="mwA5M">39</b>: 223–52. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwA5Q">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1146%2Fannurev.ps.39.020188.001255" id="mwA5U">10.1146/annurev.ps.39.020188.001255</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwA5Y" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwA5c"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/3278676" id="mwA5g">3278676</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Annu+Rev+Psychol&amp;rft.atitle=Addictive+behaviors%3A+etiology+and+treatment&amp;rft.volume=39&amp;rft.pages=223-52&amp;rft.date=1988&amp;rft_id=info%3Adoi%2F10.1146%2Fannurev.ps.39.020188.001255&amp;rft_id=info%3Apmid%2F3278676&amp;rft.aulast=Marlatt&amp;rft.aufirst=GA&amp;rft.au=Baer%2C+JS&amp;rft.au=Donovan%2C+DM&amp;rft.au=Kivlahan%2C+DR&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt90" id="mwA5k"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt90" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwA5o"/></span></li><li about="#cite_note-Addiction-dependence_distinction-22" id="cite_note-Addiction-dependence_distinction-22"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-Addiction-dependence_distinction_22-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-Addiction-dependence_distinction_22-1"><span class="mw-linkback-text">2 </span></a></span> <span id="mw-reference-text-cite_note-Addiction-dependence_distinction-22" class="mw-reference-text"><cite class="citation web" about="#mwt103" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite web","href":"./Template:Cite_web"},"params":{"author":{"wt":"American Psychiatric Association"},"title":{"wt":"Substance-Related and Addictive Disorders"},"url":{"wt":"http://www.dsm5.org/documents/substance%20use%20disorder%20fact%20sheet.pdf"},"publisher":{"wt":"American Psychiatric Publishing"},"accessdate":{"wt":"10 July 2015"},"pages":{"wt":"1–2"},"date":{"wt":"2013"},"quote":{"wt":"Additionally, the diagnosis of dependence caused much confusion. Most people link dependence with \"addiction\" when in fact dependence can be a normal body response to a substance."},"deadurl":{"wt":"yes"},"archiveurl":{"wt":"https://web.archive.org/web/20150815050402/http://www.dsm5.org/Documents/Substance%20Use%20Disorder%20Fact%20Sheet.pdf"},"archivedate":{"wt":"15 August 2015"}},"i":0}}]}' id="mwA5s">American Psychiatric Association (2013). <a rel="mw:ExtLink" class="external text" href="https://web.archive.org/web/20150815050402/http://www.dsm5.org/Documents/Substance%20Use%20Disorder%20Fact%20Sheet.pdf" id="mwA5w">"Substance-Related and Addictive Disorders"</a> <span class="cs1-format" id="mwA50">(PDF)</span>. American Psychiatric Publishing. pp.<span typeof="mw:Entity" id="mwA54"> </span>1–2. Archived from <a rel="mw:ExtLink" class="external text" href="http://www.dsm5.org/documents/substance%20use%20disorder%20fact%20sheet.pdf" id="mwA58">the original</a> <span class="cs1-format" id="mwA6A">(PDF)</span> on 15 August 2015<span class="reference-accessdate" id="mwA6E">. Retrieved <span class="nowrap" id="mwA6I">10 July</span> 2015</span>. <q id="mwA6M">Additionally, the diagnosis of dependence caused much confusion. Most people link dependence with "addiction" when in fact dependence can be a normal body response to a substance.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Substance-Related+and+Addictive+Disorders&amp;rft.pages=1-2&amp;rft.pub=American+Psychiatric+Publishing&amp;rft.date=2013&amp;rft.au=American+Psychiatric+Association&amp;rft_id=http%3A%2F%2Fwww.dsm5.org%2Fdocuments%2Fsubstance%2520use%2520disorder%2520fact%2520sheet.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt103" id="mwA6Q"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt103" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwA6U"/></span></li><li about="#cite_note-NHMH_3e_terms-DSM_flaw-23" id="cite_note-NHMH_3e_terms-DSM_flaw-23"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-NHMH_3e_terms-DSM_flaw_23-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-NHMH_3e_terms-DSM_flaw_23-1"><span class="mw-linkback-text">2 </span></a></span> <span id="mw-reference-text-cite_note-NHMH_3e_terms-DSM_flaw-23" class="mw-reference-text"><cite class="citation book" about="#mwt638" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite book ","href":"./Template:Cite_book"},"params":{"vauthors":{"wt":"Malenka RC, Nestler EJ, Hyman SE, Holtzman DM"},"title":{"wt":"Molecular Neuropharmacology: A Foundation for Clinical Neuroscience"},"year":{"wt":"2015"},"publisher":{"wt":"McGraw-Hill Medical"},"location":{"wt":"New York"},"isbn":{"wt":"978-0-07-182770-6"},"edition":{"wt":"3rd"},"chapter":{"wt":"Chapter 16: Reinforcement and Addictive Disorders"},"quote":{"wt":"The official diagnosis of drug addiction by the Diagnostic and Statistic Manual of Mental Disorders (2013), which uses the term substance use disorder, is flawed. Criteria used to make the diagnosis of substance use disorders include tolerance and somatic dependence/withdrawal, even though these processes are not integral to addiction as noted. It is ironic and unfortunate that the manual still avoids use of the term addiction as an official diagnosis, even though addiction provides the best description of the clinical syndrome."}},"i":0}}]}' id="mwA6Y">Malenka RC, Nestler EJ, Hyman SE, Holtzman DM (2015). "Chapter 16: Reinforcement and Addictive Disorders". <i id="mwA6c">Molecular Neuropharmacology: A Foundation for Clinical Neuroscience</i> (3rd ed.). New York: McGraw-Hill Medical. <a rel="mw:WikiLink" href="./International_Standard_Book_Number" title="International Standard Book Number" id="mwA6g">ISBN</a><span typeof="mw:Entity" id="mwA6k"> </span><a rel="mw:WikiLink" href="./Special:BookSources/978-0-07-182770-6" title="Special:BookSources/978-0-07-182770-6" id="mwA6o">978-0-07-182770-6</a>. <q id="mwA6s">The official diagnosis of drug addiction by the Diagnostic and Statistic Manual of Mental Disorders (2013), which uses the term substance use disorder, is flawed. Criteria used to make the diagnosis of substance use disorders include tolerance and somatic dependence/withdrawal, even though these processes are not integral to addiction as noted. It is ironic and unfortunate that the manual still avoids use of the term addiction as an official diagnosis, even though addiction provides the best description of the clinical syndrome.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.atitle=Chapter+16%3A+Reinforcement+and+Addictive+Disorders&amp;rft.btitle=Molecular+Neuropharmacology%3A+A+Foundation+for+Clinical+Neuroscience&amp;rft.place=New+York&amp;rft.edition=3rd&amp;rft.pub=McGraw-Hill+Medical&amp;rft.date=2015&amp;rft.isbn=978-0-07-182770-6&amp;rft.aulast=Malenka&amp;rft.aufirst=RC&amp;rft.au=Nestler%2C+EJ&amp;rft.au=Hyman%2C+SE&amp;rft.au=Holtzman%2C+DM&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt638" id="mwA6w"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt638" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwA60"/></span></li><li about="#cite_note-Cognitive_-_stimulus-24" id="cite_note-Cognitive_-_stimulus-24"><a href="./Addiction#cite_ref-Cognitive_-_stimulus_24-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-Cognitive_-_stimulus-24" class="mw-reference-text"><cite class="citation journal" about="#mwt112" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Washburn DA"},"title":{"wt":"The Stroop effect at 80: The competition between stimulus control and cognitive control"},"journal":{"wt":"J Exp Anal Behav"},"volume":{"wt":"105"},"issue":{"wt":"1"},"pages":{"wt":"3–13"},"year":{"wt":"2016"},"pmid":{"wt":"26781048"},"doi":{"wt":"10.1002/jeab.194"},"quote":{"wt":"Today, arguably more than at any time in history, the constructs of attention, executive functioning, and cognitive control seem to be pervasive and preeminent in research and theory. Even within the cognitive framework, however, there has long been an understanding that behavior is multiply determined, and that many responses are relatively automatic, unattended, contention-scheduled, and habitual. Indeed, the cognitive flexibility, response inhibition, and self-regulation that appear to be hallmarks of cognitive control are noteworthy only in contrast to responses that are relatively rigid, associative, and involuntary."}},"i":0}}]}' id="mwA64">Washburn DA (2016). "The Stroop effect at 80: The competition between stimulus control and cognitive control". <i id="mwA68">J Exp Anal Behav</i>. <b id="mwA7A">105</b> (1): 3–13. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwA7E">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1002%2Fjeab.194" id="mwA7I">10.1002/jeab.194</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwA7M" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwA7Q"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/26781048" id="mwA7U">26781048</a>. <q id="mwA7Y">Today, arguably more than at any time in history, the constructs of attention, executive functioning, and cognitive control seem to be pervasive and preeminent in research and theory. Even within the cognitive framework, however, there has long been an understanding that behavior is multiply determined, and that many responses are relatively automatic, unattended, contention-scheduled, and habitual. Indeed, the cognitive flexibility, response inhibition, and self-regulation that appear to be hallmarks of cognitive control are noteworthy only in contrast to responses that are relatively rigid, associative, and involuntary.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J+Exp+Anal+Behav&amp;rft.atitle=The+Stroop+effect+at+80%3A+The+competition+between+stimulus+control+and+cognitive+control&amp;rft.volume=105&amp;rft.issue=1&amp;rft.pages=3-13&amp;rft.date=2016&amp;rft_id=info%3Adoi%2F10.1002%2Fjeab.194&amp;rft_id=info%3Apmid%2F26781048&amp;rft.aulast=Washburn&amp;rft.aufirst=DA&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt112" id="mwA7c"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt112" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwA7g"/></span></li><li about="#cite_note-Executive_functions-25" id="cite_note-Executive_functions-25"><a href="./Addiction#cite_ref-Executive_functions_25-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-Executive_functions-25" class="mw-reference-text"><cite class="citation journal" about="#mwt113" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"author":{"wt":"Diamond A"},"title":{"wt":"Executive functions"},"journal":{"wt":"Annu Rev Psychol"},"volume":{"wt":"64"},"issue":{"wt":""},"pages":{"wt":"135–68"},"year":{"wt":"2013"},"pmid":{"wt":"23020641"},"pmc":{"wt":"4084861"},"doi":{"wt":"10.1146/annurev-psych-113011-143750"},"quote":{"wt":"Core EFs are inhibition [response inhibition (self-control&amp;nbsp;– resisting temptations and resisting acting impulsively) and interference control (selective attention and cognitive inhibition)], working memory, and cognitive flexibility (including creatively thinking \"outside the box,\" seeing anything from different perspectives, and quickly and flexibly adapting to changed circumstances).&amp;nbsp;... EFs and prefrontal cortex are the first to suffer, and suffer disproportionately, if something is not right in your life. They suffer first, and most, if you are stressed (Arnsten 1998, Liston et al. 2009, Oaten &amp; Cheng 2005), sad (Hirt et al. 2008, von Hecker &amp; Meiser 2005), lonely (Baumeister et al. 2002, Cacioppo &amp; Patrick 2008, Campbell et al. 2006, Tun et al. 2012), sleep deprived (Barnes et al. 2012, Huang et al. 2007), or not physically fit (Best 2010, Chaddock et al. 2011, Hillman et al. 2008). Any of these can cause you to appear to have a disorder of EFs, such as ADHD, when you do not. You can see the deleterious effects of stress, sadness, loneliness, and lack of physical health or fitness at the physiological and neuroanatomical level in prefrontal cortex and at the behavioral level in worse EFs (poorer reasoning and problem solving, forgetting things, and impaired ability to exercise discipline and self-control).&amp;nbsp;...&lt;br />EFs can be improved (Diamond &amp; Lee 2011, Klingberg 2010).&amp;nbsp;... At any age across the life cycle EFs can be improved, including in the elderly and in infants. There has been much work with excellent results on improving EFs in the elderly by improving physical fitness (Erickson &amp; Kramer 2009, Voss et al. 2011)&amp;nbsp;... Inhibitory control (one of the core EFs) involves being able to control one&apos;s attention, behavior, thoughts, and/or emotions to override a strong internal predisposition or external lure, and instead do what&apos;s more appropriate or needed. Without inhibitory control we would be at the mercy of impulses, old habits of thought or action (conditioned responses), and/or stimuli in the environment that pull us this way or that. Thus, inhibitory control makes it possible for us to change and for us to choose how we react and how we behave rather than being unthinking creatures of habit. It doesn’t make it easy. Indeed, we usually are creatures of habit and our behavior is under the control of environmental stimuli far more than we usually realize, but having the ability to exercise inhibitory control creates the possibility of change and choice.&amp;nbsp;... The subthalamic nucleus appears to play a critical role in preventing such impulsive or premature responding (Frank 2006)."}},"i":0}}]}' id="mwA7k">Diamond A (2013). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4084861" id="mwA7o">"Executive functions"</a>. <i id="mwA7s">Annu Rev Psychol</i>. <b id="mwA7w">64</b>: 135–68. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwA70">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1146%2Fannurev-psych-113011-143750" id="mwA74">10.1146/annurev-psych-113011-143750</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwA78">PMC</a><span typeof="mw:Entity" id="mwA8A"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwA8E"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4084861" id="mwA8I">4084861</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwA8M" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwA8Q"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23020641" id="mwA8U">23020641</a>. <q id="mwA8Y">Core EFs are inhibition [response inhibition (self-control<span typeof="mw:Entity" id="mwA8c"> </span>– resisting temptations and resisting acting impulsively) and interference control (selective attention and cognitive inhibition)], working memory, and cognitive flexibility (including creatively thinking "outside the box," seeing anything from different perspectives, and quickly and flexibly adapting to changed circumstances).<span typeof="mw:Entity" id="mwA8g"> </span>... EFs and prefrontal cortex are the first to suffer, and suffer disproportionately, if something is not right in your life. They suffer first, and most, if you are stressed (Arnsten 1998, Liston et al. 2009, Oaten &amp; Cheng 2005), sad (Hirt et al. 2008, von Hecker &amp; Meiser 2005), lonely (Baumeister et al. 2002, Cacioppo &amp; Patrick 2008, Campbell et al. 2006, Tun et al. 2012), sleep deprived (Barnes et al. 2012, Huang et al. 2007), or not physically fit (Best 2010, Chaddock et al. 2011, Hillman et al. 2008). Any of these can cause you to appear to have a disorder of EFs, such as ADHD, when you do not. You can see the deleterious effects of stress, sadness, loneliness, and lack of physical health or fitness at the physiological and neuroanatomical level in prefrontal cortex and at the behavioral level in worse EFs (poorer reasoning and problem solving, forgetting things, and impaired ability to exercise discipline and self-control).<span typeof="mw:Entity" id="mwA8k"> </span>...<br id="mwA8o"/>EFs can be improved (Diamond &amp; Lee 2011, Klingberg 2010).<span typeof="mw:Entity" id="mwA8s"> </span>... At any age across the life cycle EFs can be improved, including in the elderly and in infants. There has been much work with excellent results on improving EFs in the elderly by improving physical fitness (Erickson &amp; Kramer 2009, Voss et al. 2011)<span typeof="mw:Entity" id="mwA8w"> </span>... Inhibitory control (one of the core EFs) involves being able to control one's attention, behavior, thoughts, and/or emotions to override a strong internal predisposition or external lure, and instead do what's more appropriate or needed. Without inhibitory control we would be at the mercy of impulses, old habits of thought or action (conditioned responses), and/or stimuli in the environment that pull us this way or that. Thus, inhibitory control makes it possible for us to change and for us to choose how we react and how we behave rather than being unthinking creatures of habit. It doesn’t make it easy. Indeed, we usually are creatures of habit and our behavior is under the control of environmental stimuli far more than we usually realize, but having the ability to exercise inhibitory control creates the possibility of change and choice.<span typeof="mw:Entity" id="mwA80"> </span>... The subthalamic nucleus appears to play a critical role in preventing such impulsive or premature responding (Frank 2006).</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Annu+Rev+Psychol&amp;rft.atitle=Executive+functions&amp;rft.volume=64&amp;rft.pages=135-68&amp;rft.date=2013&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4084861&amp;rft_id=info%3Apmid%2F23020641&amp;rft_id=info%3Adoi%2F10.1146%2Fannurev-psych-113011-143750&amp;rft.au=Diamond+A&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4084861&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt113" id="mwA84"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt113" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwA88"/></span></li><li about="#cite_note-NHM-Cognitive_Control-26" id="cite_note-NHM-Cognitive_Control-26"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-NHM-Cognitive_Control_26-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-NHM-Cognitive_Control_26-1"><span class="mw-linkback-text">2 </span></a></span> <span id="mw-reference-text-cite_note-NHM-Cognitive_Control-26" class="mw-reference-text"><cite class="citation book" about="#mwt114" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite book ","href":"./Template:Cite_book"},"params":{"vauthors":{"wt":"Malenka RC, Nestler EJ, Hyman SE"},"veditors":{"wt":"Sydor A, Brown RY"},"title":{"wt":"Molecular Neuropharmacology: A Foundation for Clinical Neuroscience"},"year":{"wt":"2009"},"publisher":{"wt":"McGraw-Hill Medical"},"location":{"wt":"New York"},"isbn":{"wt":"978-0-07-148127-4"},"pages":{"wt":"313–21"},"edition":{"wt":"2nd"},"chapter":{"wt":"Chapter 13: Higher Cognitive Function and Behavioral Control"},"quote":{"wt":"{{bull}} Executive function, the cognitive control of behavior, depends on the prefrontal cortex, which is highly developed in higher primates and especially humans.&lt;br />{{bull}} Working memory is a short-term, capacity-limited cognitive buffer that stores information and permits its manipulation to guide decision-making and behavior.&amp;nbsp;...&lt;br />These diverse inputs and back projections to both cortical and subcortical structures put the prefrontal cortex in a position to exert what is often called \"top-down\" control or cognitive control of behavior.&amp;nbsp;... The prefrontal cortex receives inputs not only from other cortical regions, including association cortex, but also, via the thalamus, inputs from subcortical structures subserving emotion and motivation, such as the amygdala (Chapter 14) and ventral striatum (or nucleus accumbens; Chapter 15).&amp;nbsp;...&lt;br />In conditions in which prepotent responses tend to dominate behavior, such as in drug addiction, where drug cues can elicit drug seeking (Chapter 15), or in attention deficit hyperactivity disorder (ADHD; described below), significant negative consequences can result.&amp;nbsp;... ADHD can be conceptualized as a disorder of executive function; specifically, ADHD is characterized by reduced ability to exert and maintain cognitive control of behavior. Compared with healthy individuals, those with ADHD have diminished ability to suppress inappropriate prepotent responses to stimuli (impaired response inhibition) and diminished ability to inhibit responses to irrelevant stimuli (impaired interference suppression).&amp;nbsp;... &lt;!--Inhibitory control brain structures-->Functional neuroimaging in humans demonstrates activation of the prefrontal cortex and caudate nucleus (part of the striatum) in tasks that demand inhibitory control of behavior. Subjects with ADHD exhibit less activation of the medial prefrontal cortex than healthy controls even when they succeed in such tasks and utilize different circuits.&amp;nbsp;... Early results with structural MRI show thinning of the cerebral cortex in ADHD subjects compared with age-matched controls in prefrontal cortex and posterior parietal cortex, areas involved in working memory and attention."}},"i":0}}]}' id="mwA9A">Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 13: Higher Cognitive Function and Behavioral Control".  In Sydor A, Brown RY. <i id="mwA9E">Molecular Neuropharmacology: A Foundation for Clinical Neuroscience</i> (2nd ed.). New York: McGraw-Hill Medical. pp.<span typeof="mw:Entity" id="mwA9I"> </span>313–21. <a rel="mw:WikiLink" href="./International_Standard_Book_Number" title="International Standard Book Number" id="mwA9M">ISBN</a><span typeof="mw:Entity" id="mwA9Q"> </span><a rel="mw:WikiLink" href="./Special:BookSources/978-0-07-148127-4" title="Special:BookSources/978-0-07-148127-4" id="mwA9U">978-0-07-148127-4</a>. <q id="mwA9Y"><span typeof="mw:Entity" id="mwA9c"> </span><span typeof="mw:Entity" id="mwA9g">•</span><span typeof="mw:Entity" id="mwA9k"> </span> Executive function, the cognitive control of behavior, depends on the prefrontal cortex, which is highly developed in higher primates and especially humans.<br id="mwA9o"/><span typeof="mw:Entity" id="mwA9s"> </span><span typeof="mw:Entity" id="mwA9w">•</span><span typeof="mw:Entity" id="mwA90"> </span> Working memory is a short-term, capacity-limited cognitive buffer that stores information and permits its manipulation to guide decision-making and behavior.<span typeof="mw:Entity" id="mwA94"> </span>...<br id="mwA98"/>These diverse inputs and back projections to both cortical and subcortical structures put the prefrontal cortex in a position to exert what is often called "top-down" control or cognitive control of behavior.<span typeof="mw:Entity" id="mwA-A"> </span>... The prefrontal cortex receives inputs not only from other cortical regions, including association cortex, but also, via the thalamus, inputs from subcortical structures subserving emotion and motivation, such as the amygdala (Chapter 14) and ventral striatum (or nucleus accumbens; Chapter 15).<span typeof="mw:Entity" id="mwA-E"> </span>...<br id="mwA-I"/>In conditions in which prepotent responses tend to dominate behavior, such as in drug addiction, where drug cues can elicit drug seeking (Chapter 15), or in attention deficit hyperactivity disorder (ADHD; described below), significant negative consequences can result.<span typeof="mw:Entity" id="mwA-M"> </span>... ADHD can be conceptualized as a disorder of executive function; specifically, ADHD is characterized by reduced ability to exert and maintain cognitive control of behavior. Compared with healthy individuals, those with ADHD have diminished ability to suppress inappropriate prepotent responses to stimuli (impaired response inhibition) and diminished ability to inhibit responses to irrelevant stimuli (impaired interference suppression).<span typeof="mw:Entity" id="mwA-Q"> </span>... Functional neuroimaging in humans demonstrates activation of the prefrontal cortex and caudate nucleus (part of the striatum) in tasks that demand inhibitory control of behavior. Subjects with ADHD exhibit less activation of the medial prefrontal cortex than healthy controls even when they succeed in such tasks and utilize different circuits.<span typeof="mw:Entity" id="mwA-U"> </span>... Early results with structural MRI show thinning of the cerebral cortex in ADHD subjects compared with age-matched controls in prefrontal cortex and posterior parietal cortex, areas involved in working memory and attention.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.atitle=Chapter+13%3A+Higher+Cognitive+Function+and+Behavioral+Control&amp;rft.btitle=Molecular+Neuropharmacology%3A+A+Foundation+for+Clinical+Neuroscience&amp;rft.place=New+York&amp;rft.pages=313-21&amp;rft.edition=2nd&amp;rft.pub=McGraw-Hill+Medical&amp;rft.date=2009&amp;rft.isbn=978-0-07-148127-4&amp;rft.aulast=Malenka&amp;rft.aufirst=RC&amp;rft.au=Nestler%2C+EJ&amp;rft.au=Hyman%2C+SE&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt114" id="mwA-Y"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt114" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwA-c"/></span></li><li about="#cite_note-Systematic_review_-_yet_another_DSM_fail-27" id="cite_note-Systematic_review_-_yet_another_DSM_fail-27"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-Systematic_review_-_yet_another_DSM_fail_27-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-Systematic_review_-_yet_another_DSM_fail_27-1"><span class="mw-linkback-text">2 </span></a><a href="./Addiction#cite_ref-Systematic_review_-_yet_another_DSM_fail_27-2"><span class="mw-linkback-text">3 </span></a><a href="./Addiction#cite_ref-Systematic_review_-_yet_another_DSM_fail_27-3"><span class="mw-linkback-text">4 </span></a></span> <span id="mw-reference-text-cite_note-Systematic_review_-_yet_another_DSM_fail-27" class="mw-reference-text"><cite class="citation journal" about="#mwt931" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Karila L, Wéry A, Weinstein A, Cottencin O, Petit A, Reynaud M, Billieux J"},"title":{"wt":"Sexual addiction or hypersexual disorder: different terms for the same problem? A review of the literature"},"journal":{"wt":"Curr. Pharm. Des."},"volume":{"wt":"20"},"issue":{"wt":"25"},"pages":{"wt":"4012–20"},"year":{"wt":"2014"},"pmid":{"wt":"24001295"},"doi":{"wt":"10.2174/13816128113199990619"},"quote":{"wt":"Sexual addiction, which is also known as hypersexual disorder, has largely been ignored by psychiatrists, even though the condition causes serious psychosocial problems for many people. A lack of empirical evidence on sexual addiction is the result of the disease&apos;s complete absence from versions of the Diagnostic and Statistical Manual of Mental Disorders.&amp;nbsp;...  Existing prevalence rates of sexual addiction-related disorders range from 3% to 6%. Sexual addiction/hypersexual disorder is used as an umbrella construct to encompass various types of problematic behaviors, including excessive masturbation, cybersex, pornography use, sexual behavior with consenting adults, telephone sex, strip club visitation, and other behaviors. The adverse consequences of sexual addiction are similar to the consequences of other addictive disorders. Addictive, somatic and psychiatric disorders coexist with sexual addiction. In recent years, research on sexual addiction has proliferated, and screening instruments have increasingly been developed to diagnose or quantify sexual addiction disorders. In our systematic review of the existing measures, 22 questionnaires were identified. As with other behavioral addictions, the appropriate treatment of sexual addiction should combine pharmacological and psychological approaches."}},"i":0}}]}' id="mwA-g">Karila L, Wéry A, Weinstein A, Cottencin O, Petit A, Reynaud M, Billieux J (2014). "Sexual addiction or hypersexual disorder: different terms for the same problem? A review of the literature". <i id="mwA-k">Curr. Pharm. Des</i>. <b id="mwA-o">20</b> (25): 4012–20. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwA-s">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.2174%2F13816128113199990619" id="mwA-w">10.2174/13816128113199990619</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwA-0" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwA-4"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/24001295" id="mwA-8">24001295</a>. <q id="mwA_A">Sexual addiction, which is also known as hypersexual disorder, has largely been ignored by psychiatrists, even though the condition causes serious psychosocial problems for many people. A lack of empirical evidence on sexual addiction is the result of the disease's complete absence from versions of the Diagnostic and Statistical Manual of Mental Disorders.<span typeof="mw:Entity" id="mwA_E"> </span>...  Existing prevalence rates of sexual addiction-related disorders range from 3% to 6%. Sexual addiction/hypersexual disorder is used as an umbrella construct to encompass various types of problematic behaviors, including excessive masturbation, cybersex, pornography use, sexual behavior with consenting adults, telephone sex, strip club visitation, and other behaviors. The adverse consequences of sexual addiction are similar to the consequences of other addictive disorders. Addictive, somatic and psychiatric disorders coexist with sexual addiction. In recent years, research on sexual addiction has proliferated, and screening instruments have increasingly been developed to diagnose or quantify sexual addiction disorders. In our systematic review of the existing measures, 22 questionnaires were identified. As with other behavioral addictions, the appropriate treatment of sexual addiction should combine pharmacological and psychological approaches.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Curr.+Pharm.+Des.&amp;rft.atitle=Sexual+addiction+or+hypersexual+disorder%3A+different+terms+for+the+same+problem%3F+A+review+of+the+literature&amp;rft.volume=20&amp;rft.issue=25&amp;rft.pages=4012-20&amp;rft.date=2014&amp;rft_id=info%3Adoi%2F10.2174%2F13816128113199990619&amp;rft_id=info%3Apmid%2F24001295&amp;rft.aulast=Karila&amp;rft.aufirst=L&amp;rft.au=W%C3%A9ry%2C+A&amp;rft.au=Weinstein%2C+A&amp;rft.au=Cottencin%2C+O&amp;rft.au=Petit%2C+A&amp;rft.au=Reynaud%2C+M&amp;rft.au=Billieux%2C+J&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt931" id="mwA_I"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt931" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwA_M"/></span></li><li about="#cite_note-Amph-Sex_X-sensitization_through_D1_signaling-28" id="cite_note-Amph-Sex_X-sensitization_through_D1_signaling-28"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-Amph-Sex_X-sensitization_through_D1_signaling_28-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-Amph-Sex_X-sensitization_through_D1_signaling_28-1"><span class="mw-linkback-text">2 </span></a><a href="./Addiction#cite_ref-Amph-Sex_X-sensitization_through_D1_signaling_28-2"><span class="mw-linkback-text">3 </span></a><a href="./Addiction#cite_ref-Amph-Sex_X-sensitization_through_D1_signaling_28-3"><span class="mw-linkback-text">4 </span></a><a href="./Addiction#cite_ref-Amph-Sex_X-sensitization_through_D1_signaling_28-4"><span class="mw-linkback-text">5 </span></a></span> <span id="mw-reference-text-cite_note-Amph-Sex_X-sensitization_through_D1_signaling-28" class="mw-reference-text"><!--Supplemental primary source--><cite class="citation journal" about="#mwt399" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Pitchers KK, Vialou V, Nestler EJ, Laviolette SR, Lehman MN, Coolen LM"},"title":{"wt":"Natural and drug rewards act on common neural plasticity mechanisms with ΔFosB as a key mediator"},"journal":{"wt":"[[The Journal of Neuroscience]]"},"volume":{"wt":"33"},"issue":{"wt":"8"},"pages":{"wt":"3434–42"},"date":{"wt":"February 2013"},"pmid":{"wt":"23426671"},"pmc":{"wt":"3865508"},"doi":{"wt":"10.1523/JNEUROSCI.4881-12.2013"},"quote":{"wt":"Drugs of abuse induce neuroplasticity in the natural reward pathway, specifically the nucleus accumbens (NAc), thereby causing development and expression of addictive behavior.&amp;nbsp;... Together, these findings demonstrate that drugs of abuse and natural reward behaviors act on common molecular and cellular mechanisms of plasticity that control vulnerability to drug addiction, and that this increased vulnerability is mediated by ΔFosB and its downstream transcriptional targets.&amp;nbsp;... Sexual behavior is highly rewarding (Tenk et al., 2009), and sexual experience causes sensitized drug-related behaviors, including cross-sensitization to amphetamine (Amph)-induced locomotor activity (Bradley and Meisel, 2001; Pitchers et al., 2010a) and enhanced Amph reward (Pitchers et al., 2010a). Moreover, sexual experience induces neural plasticity in the NAc similar to that induced by psychostimulant exposure, including increased dendritic spine density (Meisel and Mullins, 2006; Pitchers et al., 2010a), altered glutamate receptor trafficking, and decreased synaptic strength in prefrontal cortex-responding NAc shell neurons (Pitchers et al., 2012). Finally, periods of abstinence from sexual experience were found to be critical for enhanced Amph reward, NAc spinogenesis (Pitchers et al., 2010a), and glutamate receptor trafficking (Pitchers et al., 2012). These findings suggest that natural and drug reward experiences share common mechanisms of neural plasticity"}},"i":0}}]}' id="mwA_Q">Pitchers KK, Vialou V, Nestler EJ, Laviolette SR, Lehman MN, Coolen LM (February 2013). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3865508" id="mwA_U">"Natural and drug rewards act on common neural plasticity mechanisms with ΔFosB as a key mediator"</a>. <i id="mwA_Y"><a rel="mw:WikiLink" href="./The_Journal_of_Neuroscience" title="The Journal of Neuroscience" id="mwA_c">The Journal of Neuroscience</a></i>. <b id="mwA_g">33</b> (8): 3434–42. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwA_k">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1523%2FJNEUROSCI.4881-12.2013" id="mwA_o">10.1523/JNEUROSCI.4881-12.2013</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwA_s">PMC</a><span typeof="mw:Entity" id="mwA_w"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwA_0"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3865508" id="mwA_4">3865508</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwA_8" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBAA"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23426671" id="mwBAE">23426671</a>. <q id="mwBAI">Drugs of abuse induce neuroplasticity in the natural reward pathway, specifically the nucleus accumbens (NAc), thereby causing development and expression of addictive behavior.<span typeof="mw:Entity" id="mwBAM"> </span>... Together, these findings demonstrate that drugs of abuse and natural reward behaviors act on common molecular and cellular mechanisms of plasticity that control vulnerability to drug addiction, and that this increased vulnerability is mediated by ΔFosB and its downstream transcriptional targets.<span typeof="mw:Entity" id="mwBAQ"> </span>... Sexual behavior is highly rewarding (Tenk et al., 2009), and sexual experience causes sensitized drug-related behaviors, including cross-sensitization to amphetamine (Amph)-induced locomotor activity (Bradley and Meisel, 2001; Pitchers et al., 2010a) and enhanced Amph reward (Pitchers et al., 2010a). Moreover, sexual experience induces neural plasticity in the NAc similar to that induced by psychostimulant exposure, including increased dendritic spine density (Meisel and Mullins, 2006; Pitchers et al., 2010a), altered glutamate receptor trafficking, and decreased synaptic strength in prefrontal cortex-responding NAc shell neurons (Pitchers et al., 2012). Finally, periods of abstinence from sexual experience were found to be critical for enhanced Amph reward, NAc spinogenesis (Pitchers et al., 2010a), and glutamate receptor trafficking (Pitchers et al., 2012). These findings suggest that natural and drug reward experiences share common mechanisms of neural plasticity</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Journal+of+Neuroscience&amp;rft.atitle=Natural+and+drug+rewards+act+on+common+neural+plasticity+mechanisms+with+%CE%94FosB+as+a+key+mediator&amp;rft.volume=33&amp;rft.issue=8&amp;rft.pages=3434-42&amp;rft.date=2013-02&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3865508&amp;rft_id=info%3Apmid%2F23426671&amp;rft_id=info%3Adoi%2F10.1523%2FJNEUROSCI.4881-12.2013&amp;rft.aulast=Pitchers&amp;rft.aufirst=KK&amp;rft.au=Vialou%2C+V&amp;rft.au=Nestler%2C+EJ&amp;rft.au=Laviolette%2C+SR&amp;rft.au=Lehman%2C+MN&amp;rft.au=Coolen%2C+LM&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3865508&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt399" id="mwBAU"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt399" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBAY"/></span></li><li about="#cite_note-Amph-Sex_X-sensitization_through_NMDA_signaling-29" id="cite_note-Amph-Sex_X-sensitization_through_NMDA_signaling-29"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-Amph-Sex_X-sensitization_through_NMDA_signaling_29-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-Amph-Sex_X-sensitization_through_NMDA_signaling_29-1"><span class="mw-linkback-text">2 </span></a><a href="./Addiction#cite_ref-Amph-Sex_X-sensitization_through_NMDA_signaling_29-2"><span class="mw-linkback-text">3 </span></a><a href="./Addiction#cite_ref-Amph-Sex_X-sensitization_through_NMDA_signaling_29-3"><span class="mw-linkback-text">4 </span></a><a href="./Addiction#cite_ref-Amph-Sex_X-sensitization_through_NMDA_signaling_29-4"><span class="mw-linkback-text">5 </span></a></span> <span id="mw-reference-text-cite_note-Amph-Sex_X-sensitization_through_NMDA_signaling-29" class="mw-reference-text"><!--Supplemental primary source--><cite class="citation journal" about="#mwt400" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Beloate LN, Weems PW, Casey GR, Webb IC, Coolen LM"},"title":{"wt":"Nucleus accumbens NMDA receptor activation regulates amphetamine cross-sensitization and deltaFosB expression following sexual experience in male rats"},"journal":{"wt":"Neuropharmacology"},"volume":{"wt":"101"},"issue":{"wt":""},"pages":{"wt":"154–64"},"date":{"wt":"February 2016"},"pmid":{"wt":"26391065"},"doi":{"wt":"10.1016/j.neuropharm.2015.09.023"},"quote":{"wt":""}},"i":0}}]}' id="mwBAc">Beloate LN, Weems PW, Casey GR, Webb IC, Coolen LM (February 2016). "Nucleus accumbens NMDA receptor activation regulates amphetamine cross-sensitization and deltaFosB expression following sexual experience in male rats". <i id="mwBAg">Neuropharmacology</i>. <b id="mwBAk">101</b>: 154–64. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBAo">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1016%2Fj.neuropharm.2015.09.023" id="mwBAs">10.1016/j.neuropharm.2015.09.023</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBAw" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBA0"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/26391065" id="mwBA4">26391065</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Neuropharmacology&amp;rft.atitle=Nucleus+accumbens+NMDA+receptor+activation+regulates+amphetamine+cross-sensitization+and+deltaFosB+expression+following+sexual+experience+in+male+rats&amp;rft.volume=101&amp;rft.pages=154-64&amp;rft.date=2016-02&amp;rft_id=info%3Adoi%2F10.1016%2Fj.neuropharm.2015.09.023&amp;rft_id=info%3Apmid%2F26391065&amp;rft.aulast=Beloate&amp;rft.aufirst=LN&amp;rft.au=Weems%2C+PW&amp;rft.au=Casey%2C+GR&amp;rft.au=Webb%2C+IC&amp;rft.au=Coolen%2C+LM&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt400" id="mwBA8"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt400" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBBA"/></span></li><li about="#cite_note-Behavioral_addictions-30" id="cite_note-Behavioral_addictions-30"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-Behavioral_addictions_30-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-Behavioral_addictions_30-1"><span class="mw-linkback-text">2 </span></a><a href="./Addiction#cite_ref-Behavioral_addictions_30-2"><span class="mw-linkback-text">3 </span></a></span> <span id="mw-reference-text-cite_note-Behavioral_addictions-30" class="mw-reference-text"><cite class="citation journal" id="mwBBE">Grant JE, Potenza MN, Weinstein A, Gorelick DA (September 2010). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3164585" id="mwBBI">"Introduction to behavioral addictions"</a>. <i id="mwBBM">Am. J. Drug Alcohol Abuse</i>. <b id="mwBBQ">36</b> (5): 233–241. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBBU">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.3109%2F00952990.2010.491884" id="mwBBY">10.3109/00952990.2010.491884</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwBBc">PMC</a><span typeof="mw:Entity" id="mwBBg"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwBBk"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3164585" id="mwBBo">3164585</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBBs" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBBw"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/20560821" id="mwBB0">20560821</a>. <q id="mwBB4">Naltrexone, a mu-opioid receptor antagonist approved by the US Food and Drug Administration for the treatment of alcoholism and opioid dependence, has shown efficacy in controlled clinical trials for the treatment of pathological gambling and kleptomania (76–79), and promise in uncontrolled studies of compulsive buying (80), compulsive sexual behavior (81), internet addiction (82), and pathologic skin picking (83).<span typeof="mw:Entity" id="mwBB8"> </span>... Topiramate, an anti-convulsant which blocks the AMPA subtype of glutamate receptor (among other actions), has shown promise in open-label studies of pathological gambling, compulsive buying, and compulsive skin picking (85), as well as efficacy in reducing alcohol (86), cigarette (87), and cocaine (88) use. N-acetyl cysteine, an amino acid that restores extracellular glutamate concentration in the nucleus accumbens, reduced gambling urges and behavior in one study of pathological gamblers (89), and reduces cocaine craving (90) and cocaine use (91) in cocaine addicts. These studies suggest that glutamatergic modulation of dopaminergic tone in the nucleus accumbens may be a mechanism common to behavioral addiction and substance use disorders (92).</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Am.+J.+Drug+Alcohol+Abuse&amp;rft.atitle=Introduction+to+behavioral+addictions&amp;rft.volume=36&amp;rft.issue=5&amp;rft.pages=233-241&amp;rft.date=2010-09&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3164585&amp;rft_id=info%3Apmid%2F20560821&amp;rft_id=info%3Adoi%2F10.3109%2F00952990.2010.491884&amp;rft.aulast=Grant&amp;rft.aufirst=JE&amp;rft.au=Potenza%2C+MN&amp;rft.au=Weinstein%2C+A&amp;rft.au=Gorelick%2C+DA&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3164585&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" id="mwBCA"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt1857" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBCE"/></span></li><li about="#cite_note-Transgenerational_epigenetic_inheritance_in_addiction-31" id="cite_note-Transgenerational_epigenetic_inheritance_in_addiction-31"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-Transgenerational_epigenetic_inheritance_in_addiction_31-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-Transgenerational_epigenetic_inheritance_in_addiction_31-1"><span class="mw-linkback-text">2 </span></a><a href="./Addiction#cite_ref-Transgenerational_epigenetic_inheritance_in_addiction_31-2"><span class="mw-linkback-text">3 </span></a><a href="./Addiction#cite_ref-Transgenerational_epigenetic_inheritance_in_addiction_31-3"><span class="mw-linkback-text">4 </span></a><a href="./Addiction#cite_ref-Transgenerational_epigenetic_inheritance_in_addiction_31-4"><span class="mw-linkback-text">5 </span></a><a href="./Addiction#cite_ref-Transgenerational_epigenetic_inheritance_in_addiction_31-5"><span class="mw-linkback-text">6 </span></a><a href="./Addiction#cite_ref-Transgenerational_epigenetic_inheritance_in_addiction_31-6"><span class="mw-linkback-text">7 </span></a><a href="./Addiction#cite_ref-Transgenerational_epigenetic_inheritance_in_addiction_31-7"><span class="mw-linkback-text">8 </span></a><a href="./Addiction#cite_ref-Transgenerational_epigenetic_inheritance_in_addiction_31-8"><span class="mw-linkback-text">9 </span></a><a href="./Addiction#cite_ref-Transgenerational_epigenetic_inheritance_in_addiction_31-9"><span class="mw-linkback-text">10 </span></a><a href="./Addiction#cite_ref-Transgenerational_epigenetic_inheritance_in_addiction_31-10"><span class="mw-linkback-text">11 </span></a><a href="./Addiction#cite_ref-Transgenerational_epigenetic_inheritance_in_addiction_31-11"><span class="mw-linkback-text">12 </span></a><a href="./Addiction#cite_ref-Transgenerational_epigenetic_inheritance_in_addiction_31-12"><span class="mw-linkback-text">13 </span></a><a href="./Addiction#cite_ref-Transgenerational_epigenetic_inheritance_in_addiction_31-13"><span class="mw-linkback-text">14 </span></a><a href="./Addiction#cite_ref-Transgenerational_epigenetic_inheritance_in_addiction_31-14"><span class="mw-linkback-text">15 </span></a><a href="./Addiction#cite_ref-Transgenerational_epigenetic_inheritance_in_addiction_31-15"><span class="mw-linkback-text">16 </span></a></span> <span id="mw-reference-text-cite_note-Transgenerational_epigenetic_inheritance_in_addiction-31" class="mw-reference-text"><cite class="citation journal" about="#mwt298" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Vassoler FM, Sadri-Vakili G"},"title":{"wt":"Mechanisms of transgenerational inheritance of addictive-like behaviors"},"journal":{"wt":"Neuroscience"},"volume":{"wt":"264"},"issue":{"wt":""},"pages":{"wt":"198–206"},"year":{"wt":"2014"},"pmid":{"wt":"23920159"},"pmc":{"wt":"3872494"},"doi":{"wt":"10.1016/j.neuroscience.2013.07.064"},"quote":{"wt":"However, the components that are responsible for the heritability of characteristics that make an individual more susceptible to drug addiction in humans remain largely unknown given that patterns of inheritance cannot be explained by simple genetic mechanisms (Cloninger et al., 1981; Schuckit et al., 1972). The environment also plays a large role in the development of addiction as evidenced by great societal variability in drug use patterns between countries and across time (UNODC, 2012). Therefore, both genetics and the environment contribute to an individual&apos;s vulnerability to become addicted following an initial exposure to drugs of abuse.&amp;nbsp;...&lt;br />The evidence presented here demonstrates that rapid environmental adaptation occurs following exposure to a number of stimuli. Epigenetic mechanisms represent the key components by which the environment can influence genetics, and they provide the missing link between genetic heritability and environmental influences on the behavioral and physiological phenotypes of the offspring."}},"i":0}}]}' id="mwBCI">Vassoler FM, Sadri-Vakili G (2014). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3872494" id="mwBCM">"Mechanisms of transgenerational inheritance of addictive-like behaviors"</a>. <i id="mwBCQ">Neuroscience</i>. <b id="mwBCU">264</b>: 198–206. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBCY">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1016%2Fj.neuroscience.2013.07.064" id="mwBCc">10.1016/j.neuroscience.2013.07.064</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwBCg">PMC</a><span typeof="mw:Entity" id="mwBCk"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwBCo"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3872494" id="mwBCs">3872494</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBCw" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBC0"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23920159" id="mwBC4">23920159</a>. <q id="mwBC8">However, the components that are responsible for the heritability of characteristics that make an individual more susceptible to drug addiction in humans remain largely unknown given that patterns of inheritance cannot be explained by simple genetic mechanisms (Cloninger et al., 1981; Schuckit et al., 1972). The environment also plays a large role in the development of addiction as evidenced by great societal variability in drug use patterns between countries and across time (UNODC, 2012). Therefore, both genetics and the environment contribute to an individual's vulnerability to become addicted following an initial exposure to drugs of abuse.<span typeof="mw:Entity" id="mwBDA"> </span>...<br id="mwBDE"/>The evidence presented here demonstrates that rapid environmental adaptation occurs following exposure to a number of stimuli. Epigenetic mechanisms represent the key components by which the environment can influence genetics, and they provide the missing link between genetic heritability and environmental influences on the behavioral and physiological phenotypes of the offspring.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Neuroscience&amp;rft.atitle=Mechanisms+of+transgenerational+inheritance+of+addictive-like+behaviors&amp;rft.volume=264&amp;rft.pages=198-206&amp;rft.date=2014&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3872494&amp;rft_id=info%3Apmid%2F23920159&amp;rft_id=info%3Adoi%2F10.1016%2Fj.neuroscience.2013.07.064&amp;rft.aulast=Vassoler&amp;rft.aufirst=FM&amp;rft.au=Sadri-Vakili%2C+G&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3872494&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt298" id="mwBDI"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt298" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBDM"/></span></li><li about="#cite_note-Kendler94-32" id="cite_note-Kendler94-32"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-Kendler94_32-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-Kendler94_32-1"><span class="mw-linkback-text">2 </span></a></span> <span id="mw-reference-text-cite_note-Kendler94-32" class="mw-reference-text"><cite class="citation journal" about="#mwt213" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Kendler KS, Neale MC, Heath AC, Kessler RC, Eaves LJ"},"title":{"wt":"A twin-family study of alcoholism in women"},"journal":{"wt":"Am J Psychiatry"},"volume":{"wt":"151"},"issue":{"wt":"5"},"pages":{"wt":"707–15"},"date":{"wt":"May 1994"},"pmid":{"wt":"8166312"},"doi":{"wt":"10.1176/ajp.151.5.707"}},"i":0}}]}' id="mwBDQ">Kendler KS, Neale MC, Heath AC, Kessler RC, Eaves LJ (May 1994). "A twin-family study of alcoholism in women". <i id="mwBDU">Am J Psychiatry</i>. <b id="mwBDY">151</b> (5): 707–15. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBDc">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1176%2Fajp.151.5.707" id="mwBDg">10.1176/ajp.151.5.707</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBDk" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBDo"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/8166312" id="mwBDs">8166312</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Am+J+Psychiatry&amp;rft.atitle=A+twin-family+study+of+alcoholism+in+women&amp;rft.volume=151&amp;rft.issue=5&amp;rft.pages=707-15&amp;rft.date=1994-05&amp;rft_id=info%3Adoi%2F10.1176%2Fajp.151.5.707&amp;rft_id=info%3Apmid%2F8166312&amp;rft.aulast=Kendler&amp;rft.aufirst=KS&amp;rft.au=Neale%2C+MC&amp;rft.au=Heath%2C+AC&amp;rft.au=Kessler%2C+RC&amp;rft.au=Eaves%2C+LJ&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt213" id="mwBDw"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt213" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBD0"/></span></li><li about="#cite_note-pmid23454283-33" id="cite_note-pmid23454283-33"><a href="./Addiction#cite_ref-pmid23454283_33-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-pmid23454283-33" class="mw-reference-text"><cite class="citation journal" about="#mwt221" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Clarke TK, Crist RC, Kampman KM, Dackis CA, Pettinati HM, O&apos;Brien CP, Oslin DW, Ferraro TN, Lohoff FW, Berrettini WH"},"title":{"wt":"Low frequency genetic variants in the μ-opioid receptor (OPRM1) affect risk for addiction to heroin and cocaine"},"journal":{"wt":"Neuroscience Letters"},"volume":{"wt":"542"},"issue":{"wt":""},"pages":{"wt":"71–75"},"year":{"wt":"2013"},"pmid":{"wt":"23454283"},"doi":{"wt":"10.1016/j.neulet.2013.02.018"},"pmc":{"wt":"3640707"}},"i":0}}]}' id="mwBD4">Clarke TK, Crist RC, Kampman KM, Dackis CA, Pettinati HM, O'Brien CP, Oslin DW, Ferraro TN, Lohoff FW, Berrettini WH (2013). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3640707" id="mwBD8">"Low frequency genetic variants in the μ-opioid receptor (OPRM1) affect risk for addiction to heroin and cocaine"</a>. <i id="mwBEA">Neuroscience Letters</i>. <b id="mwBEE">542</b>: 71–75. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBEI">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1016%2Fj.neulet.2013.02.018" id="mwBEM">10.1016/j.neulet.2013.02.018</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwBEQ">PMC</a><span typeof="mw:Entity" id="mwBEU"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwBEY"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3640707" id="mwBEc">3640707</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBEg" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBEk"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23454283" id="mwBEo">23454283</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Neuroscience+Letters&amp;rft.atitle=Low+frequency+genetic+variants+in+the+%CE%BC-opioid+receptor+%28OPRM1%29+affect+risk+for+addiction+to+heroin+and+cocaine&amp;rft.volume=542&amp;rft.pages=71-75&amp;rft.date=2013&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3640707&amp;rft_id=info%3Apmid%2F23454283&amp;rft_id=info%3Adoi%2F10.1016%2Fj.neulet.2013.02.018&amp;rft.aulast=Clarke&amp;rft.aufirst=TK&amp;rft.au=Crist%2C+RC&amp;rft.au=Kampman%2C+KM&amp;rft.au=Dackis%2C+CA&amp;rft.au=Pettinati%2C+HM&amp;rft.au=O%27Brien%2C+CP&amp;rft.au=Oslin%2C+DW&amp;rft.au=Ferraro%2C+TN&amp;rft.au=Lohoff%2C+FW&amp;rft.au=Berrettini%2C+WH&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3640707&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt221" id="mwBEs"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt221" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBEw"/></span></li><li about="#cite_note-34" id="cite_note-34"><a href="./Addiction#cite_ref-34" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-34" class="mw-reference-text"><cite class="citation journal" about="#mwt223" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal","href":"./Template:Cite_journal"},"params":{"last1":{"wt":"Hall"},"first1":{"wt":"F. Scott"},"author2":{"wt":"Drgonova, Jana"},"author3":{"wt":"Jain, Siddharth"},"author4":{"wt":"Uhl, George R."},"title":{"wt":"Implications of genome wide association studies for addiction: Are our a priori assumptions all wrong?"},"journal":{"wt":"Pharmacology &amp; Therapeutics"},"date":{"wt":"December 2013"},"volume":{"wt":"140"},"issue":{"wt":"3"},"pages":{"wt":"267–79"},"doi":{"wt":"10.1016/j.pharmthera.2013.07.006"},"pmid":{"wt":"23872493"},"pmc":{"wt":"3797854"}},"i":0}}]}' id="mwBE0">Hall, F. Scott; Drgonova, Jana; Jain, Siddharth; Uhl, George R. (December 2013). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3797854" id="mwBE4">"Implications of genome wide association studies for addiction: Are our a priori assumptions all wrong?"</a>. <i id="mwBE8">Pharmacology &amp; Therapeutics</i>. <b id="mwBFA">140</b> (3): 267–79. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBFE">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1016%2Fj.pharmthera.2013.07.006" id="mwBFI">10.1016/j.pharmthera.2013.07.006</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwBFM">PMC</a><span typeof="mw:Entity" id="mwBFQ"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwBFU"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3797854" id="mwBFY">3797854</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBFc" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBFg"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23872493" id="mwBFk">23872493</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Pharmacology+%26+Therapeutics&amp;rft.atitle=Implications+of+genome+wide+association+studies+for+addiction%3A+Are+our+a+priori+assumptions+all+wrong%3F&amp;rft.volume=140&amp;rft.issue=3&amp;rft.pages=267-79&amp;rft.date=2013-12&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3797854&amp;rft_id=info%3Apmid%2F23872493&amp;rft_id=info%3Adoi%2F10.1016%2Fj.pharmthera.2013.07.006&amp;rft.aulast=Hall&amp;rft.aufirst=F.+Scott&amp;rft.au=Drgonova%2C+Jana&amp;rft.au=Jain%2C+Siddharth&amp;rft.au=Uhl%2C+George+R.&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3797854&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt223" id="mwBFo"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt223" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBFs"/></span></li><li about="#cite_note-Crowe1991-35" id="cite_note-Crowe1991-35"><a href="./Addiction#cite_ref-Crowe1991_35-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-Crowe1991-35" class="mw-reference-text"><cite class="citation journal" about="#mwt227" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal","href":"./Template:Cite_journal"},"params":{"last1":{"wt":"Crowe"},"first1":{"wt":"J.R"},"title":{"wt":"Genetics of alcoholism"},"journal":{"wt":"Alcohol Health and Research World"},"pages":{"wt":"1–11"},"url":{"wt":"http://psycnet.apa.org/record/1993-22020-001"},"accessdate":{"wt":"13 December 2017"}},"i":0}}]}' id="mwBFw">Crowe, J.R. <a rel="mw:ExtLink" class="external text" href="http://psycnet.apa.org/record/1993-22020-001" id="mwBF0">"Genetics of alcoholism"</a>. <i id="mwBF4">Alcohol Health and Research World</i>: 1–11<span class="reference-accessdate" id="mwBF8">. Retrieved <span class="nowrap" id="mwBGA">13 December</span> 2017</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Alcohol+Health+and+Research+World&amp;rft.atitle=Genetics+of+alcoholism&amp;rft.pages=1-11&amp;rft.aulast=Crowe&amp;rft.aufirst=J.R&amp;rft_id=http%3A%2F%2Fpsycnet.apa.org%2Frecord%2F1993-22020-001&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt227" id="mwBGE"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt227" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBGI"/></span></li><li about="#cite_note-36" id="cite_note-36"><a href="./Addiction#cite_ref-36" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-36" class="mw-reference-text"><cite class="citation news" about="#mwt228" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"Cite news","href":"./Template:Cite_news"},"params":{"url":{"wt":"https://www.addictionsandrecovery.org/is-addiction-a-disease.htm"},"title":{"wt":"The Genetics of Addiction – Is Addiction a Disease?"},"last":{"wt":"Life"},"first":{"wt":"Dr. Steven Melemis, I Want to Change My"},"work":{"wt":"I Want to Change My Life"},"access-date":{"wt":"17 September 2018"}},"i":0}}]}' id="mwBGM">Life, Dr. Steven Melemis, I Want to Change My. <a rel="mw:ExtLink" class="external text" href="https://www.addictionsandrecovery.org/is-addiction-a-disease.htm" id="mwBGQ">"The Genetics of Addiction – Is Addiction a Disease?"</a>. <i id="mwBGU">I Want to Change My Life</i><span class="reference-accessdate" id="mwBGY">. Retrieved <span class="nowrap" id="mwBGc">17 September</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=I+Want+to+Change+My+Life&amp;rft.atitle=The+Genetics+of+Addiction+%E2%80%93+Is+Addiction+a+Disease%3F&amp;rft.aulast=Life&amp;rft.aufirst=Dr.+Steven+Melemis%2C+I+Want+to+Change+My&amp;rft_id=https%3A%2F%2Fwww.addictionsandrecovery.org%2Fis-addiction-a-disease.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt228" id="mwBGg"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt228" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBGk"/></span></li><li about="#cite_note-37" id="cite_note-37"><a href="./Addiction#cite_ref-37" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-37" class="mw-reference-text"><cite class="citation news" about="#mwt229" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"Cite news","href":"./Template:Cite_news"},"params":{"url":{"wt":"https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates"},"title":{"wt":"Overdose Death Rates"},"last":{"wt":"Abuse"},"first":{"wt":"National Institute on Drug"},"date":{"wt":"9 August 2018"},"access-date":{"wt":"17 September 2018"}},"i":0}}]}' id="mwBGo">Abuse, National Institute on Drug (9 August 2018). <a rel="mw:ExtLink" class="external text" href="https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates" id="mwBGs">"Overdose Death Rates"</a><span class="reference-accessdate" id="mwBGw">. Retrieved <span class="nowrap" id="mwBG0">17 September</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Overdose+Death+Rates&amp;rft.date=2018-08-09&amp;rft.aulast=Abuse&amp;rft.aufirst=National+Institute+on+Drug&amp;rft_id=https%3A%2F%2Fwww.drugabuse.gov%2Frelated-topics%2Ftrends-statistics%2Foverdose-death-rates&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt229" id="mwBG4"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt229" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBG8"/></span></li><li about="#cite_note-Abuse-38" id="cite_note-Abuse-38"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-Abuse_38-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-Abuse_38-1"><span class="mw-linkback-text">2 </span></a></span> <span id="mw-reference-text-cite_note-Abuse-38" class="mw-reference-text"><cite class="citation news" about="#mwt234" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"Cite news","href":"./Template:Cite_news"},"params":{"url":{"wt":"https://www.drugabuse.gov/publications/preventing-drug-abuse-among-children-adolescents/chapter-1-risk-factors-protective-factors/what-are-risk-factors"},"title":{"wt":"What are risk factors and protective factors?"},"last":{"wt":"Abuse"},"first":{"wt":"National Institute on Drug"},"access-date":{"wt":"13 December 2017"}},"i":0}}]}' id="mwBHA">Abuse, National Institute on Drug. <a rel="mw:ExtLink" class="external text" href="https://www.drugabuse.gov/publications/preventing-drug-abuse-among-children-adolescents/chapter-1-risk-factors-protective-factors/what-are-risk-factors" id="mwBHE">"What are risk factors and protective factors?"</a><span class="reference-accessdate" id="mwBHI">. Retrieved <span class="nowrap" id="mwBHM">13 December</span> 2017</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=What+are+risk+factors+and+protective+factors%3F&amp;rft.aulast=Abuse&amp;rft.aufirst=National+Institute+on+Drug&amp;rft_id=https%3A%2F%2Fwww.drugabuse.gov%2Fpublications%2Fpreventing-drug-abuse-among-children-adolescents%2Fchapter-1-risk-factors-protective-factors%2Fwhat-are-risk-factors&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt234" id="mwBHQ"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt234" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBHU"/></span></li><li about="#cite_note-SAMHSA_ACE-39" id="cite_note-SAMHSA_ACE-39"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-SAMHSA_ACE_39-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-SAMHSA_ACE_39-1"><span class="mw-linkback-text">2 </span></a></span> <span id="mw-reference-text-cite_note-SAMHSA_ACE-39" class="mw-reference-text"><cite class="citation web" about="#mwt246" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite web ","href":"./Template:Cite_web"},"params":{"title":{"wt":"Adverse Childhood Experiences"},"publisher":{"wt":"Substance Abuse and Mental Health Services Administration"},"location":{"wt":"Rockville, Maryland, United States"},"website":{"wt":"samhsa.gov"},"url":{"wt":"http://www.samhsa.gov/capt/practicing-effective-prevention/prevention-behavioral-health/adverse-childhood-experiences"},"accessdate":{"wt":"26 September 2016"}},"i":0}}]}' id="mwBHY"><a rel="mw:ExtLink" class="external text" href="http://www.samhsa.gov/capt/practicing-effective-prevention/prevention-behavioral-health/adverse-childhood-experiences" id="mwBHc">"Adverse Childhood Experiences"</a>. <i id="mwBHg">samhsa.gov</i>. Rockville, Maryland, United States: Substance Abuse and Mental Health Services Administration<span class="reference-accessdate" id="mwBHk">. Retrieved <span class="nowrap" id="mwBHo">26 September</span> 2016</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=samhsa.gov&amp;rft.atitle=Adverse+Childhood+Experiences&amp;rft_id=http%3A%2F%2Fwww.samhsa.gov%2Fcapt%2Fpracticing-effective-prevention%2Fprevention-behavioral-health%2Fadverse-childhood-experiences&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt246" id="mwBHs"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt246" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBHw"/></span></li><li about="#cite_note-Enoch2011-40" id="cite_note-Enoch2011-40"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-Enoch2011_40-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-Enoch2011_40-1"><span class="mw-linkback-text">2 </span></a></span> <span id="mw-reference-text-cite_note-Enoch2011-40" class="mw-reference-text"><cite class="citation journal" about="#mwt247" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal","href":"./Template:Cite_journal"},"params":{"last1":{"wt":"Enoch"},"first1":{"wt":"Mary"},"title":{"wt":"The role of early life stress as a predictor for alcohol and drug dependence"},"journal":{"wt":"Psychopharmacology"},"pages":{"wt":"17–31"},"pmid":{"wt":"20596857"},"doi":{"wt":"10.1007/s00213-010-1916-6"},"pmc":{"wt":"3005022"},"volume":{"wt":"214"},"issue":{"wt":"1"},"year":{"wt":"2011"}},"i":0}}]}' id="mwBH0">Enoch, Mary (2011). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3005022" id="mwBH4">"The role of early life stress as a predictor for alcohol and drug dependence"</a>. <i id="mwBH8">Psychopharmacology</i>. <b id="mwBIA">214</b> (1): 17–31. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBIE">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1007%2Fs00213-010-1916-6" id="mwBII">10.1007/s00213-010-1916-6</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwBIM">PMC</a><span typeof="mw:Entity" id="mwBIQ"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwBIU"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3005022" id="mwBIY">3005022</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBIc" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBIg"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/20596857" id="mwBIk">20596857</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Psychopharmacology&amp;rft.atitle=The+role+of+early+life+stress+as+a+predictor+for+alcohol+and+drug+dependence&amp;rft.volume=214&amp;rft.issue=1&amp;rft.pages=17-31&amp;rft.date=2011&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3005022&amp;rft_id=info%3Apmid%2F20596857&amp;rft_id=info%3Adoi%2F10.1007%2Fs00213-010-1916-6&amp;rft.aulast=Enoch&amp;rft.aufirst=Mary&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3005022&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt247" id="mwBIo"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt247" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBIs"/></span></li><li about="#cite_note-41" id="cite_note-41"><a href="./Addiction#cite_ref-41" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-41" class="mw-reference-text"><cite class="citation web" about="#mwt248" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"Cite web ","href":"./Template:Cite_web"},"params":{"url":{"wt":"https://learn.genetics.utah.edu/content/addiction/environment/"},"title":{"wt":"Environmental Risk Factors"},"website":{"wt":"learn.genetics.utah.edu"},"access-date":{"wt":"17 September 2018"}},"i":0}}]}' id="mwBIw"><a rel="mw:ExtLink" class="external text" href="https://learn.genetics.utah.edu/content/addiction/environment/" id="mwBI0">"Environmental Risk Factors"</a>. <i id="mwBI4">learn.genetics.utah.edu</i><span class="reference-accessdate" id="mwBI8">. Retrieved <span class="nowrap" id="mwBJA">17 September</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=learn.genetics.utah.edu&amp;rft.atitle=Environmental+Risk+Factors&amp;rft_id=https%3A%2F%2Flearn.genetics.utah.edu%2Fcontent%2Faddiction%2Fenvironment%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt248" id="mwBJE"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt248" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBJI"/></span></li><li about="#cite_note-42" id="cite_note-42"><a href="./Addiction#cite_ref-42" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-42" class="mw-reference-text"><cite class="citation journal" about="#mwt259" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Spear LP"},"title":{"wt":"The adolescent brain and age-related behavioral manifestations"},"journal":{"wt":"Neuroscience and Biobehavioral Reviews"},"volume":{"wt":"24"},"issue":{"wt":"4"},"pages":{"wt":"417–63"},"date":{"wt":"June 2000"},"pmid":{"wt":"10817843"},"doi":{"wt":"10.1016/s0149-7634(00)00014-2"},"citeseerx":{"wt":"10.1.1.461.3295"}},"i":0}}]}' id="mwBJM">Spear LP (June 2000). "The adolescent brain and age-related behavioral manifestations". <i id="mwBJQ">Neuroscience and Biobehavioral Reviews</i>. <b id="mwBJU">24</b> (4): 417–63. <a rel="mw:WikiLink" href="./CiteSeerX" title="CiteSeerX" id="mwBJY">CiteSeerX</a><span typeof="mw:Entity" id="mwBJc"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwBJg"><a rel="mw:ExtLink" class="external text" href="//citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.461.3295" id="mwBJk">10.1.1.461.3295</a></span>. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBJo">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1016%2Fs0149-7634%2800%2900014-2" id="mwBJs">10.1016/s0149-7634(00)00014-2</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBJw" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBJ0"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/10817843" id="mwBJ4">10817843</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Neuroscience+and+Biobehavioral+Reviews&amp;rft.atitle=The+adolescent+brain+and+age-related+behavioral+manifestations&amp;rft.volume=24&amp;rft.issue=4&amp;rft.pages=417-63&amp;rft.date=2000-06&amp;rft_id=%2F%2Fciteseerx.ist.psu.edu%2Fviewdoc%2Fsummary%3Fdoi%3D10.1.1.461.3295&amp;rft_id=info%3Apmid%2F10817843&amp;rft_id=info%3Adoi%2F10.1016%2Fs0149-7634%2800%2900014-2&amp;rft.aulast=Spear&amp;rft.aufirst=LP&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt259" id="mwBJ8"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt259" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBKA"/></span></li><li about="#cite_note-43" id="cite_note-43"><a href="./Addiction#cite_ref-43" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-43" class="mw-reference-text"><cite class="citation journal" about="#mwt260" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Hammond CJ, Mayes LC, Potenza MN"},"title":{"wt":"Neurobiology of adolescent substance use and addictive behaviors: treatment implications"},"journal":{"wt":"Adolescent Medicine"},"volume":{"wt":"25"},"issue":{"wt":"1"},"pages":{"wt":"15–32"},"date":{"wt":"April 2014"},"pmid":{"wt":"25022184"},"pmc":{"wt":"4446977"}},"i":0}}]}' id="mwBKE">Hammond CJ, Mayes LC, Potenza MN (April 2014). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4446977" id="mwBKI">"Neurobiology of adolescent substance use and addictive behaviors: treatment implications"</a>. <i id="mwBKM">Adolescent Medicine</i>. <b id="mwBKQ">25</b> (1): 15–32. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwBKU">PMC</a><span typeof="mw:Entity" id="mwBKY"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwBKc"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4446977" id="mwBKg">4446977</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBKk" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBKo"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/25022184" id="mwBKs">25022184</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Adolescent+Medicine&amp;rft.atitle=Neurobiology+of+adolescent+substance+use+and+addictive+behaviors%3A+treatment+implications&amp;rft.volume=25&amp;rft.issue=1&amp;rft.pages=15-32&amp;rft.date=2014-04&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4446977&amp;rft_id=info%3Apmid%2F25022184&amp;rft.aulast=Hammond&amp;rft.aufirst=CJ&amp;rft.au=Mayes%2C+LC&amp;rft.au=Potenza%2C+MN&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4446977&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt260" id="mwBKw"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt260" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBK0"/></span></li><li about="#cite_note-44" id="cite_note-44"><a href="./Addiction#cite_ref-44" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-44" class="mw-reference-text"><cite class="citation journal" about="#mwt261" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Catalano RF, Hawkins JD, Wells EA, Miller J, Brewer D"},"title":{"wt":"Evaluation of the effectiveness of adolescent drug abuse treatment, assessment of risks for relapse, and promising approaches for relapse prevention"},"journal":{"wt":"The International Journal of the Addictions"},"volume":{"wt":"25"},"issue":{"wt":"9A–10A"},"pages":{"wt":"1085–140"},"pmid":{"wt":"2131328"},"year":{"wt":"1990"},"doi":{"wt":"10.3109/10826089109081039"}},"i":0}}]}' id="mwBK4">Catalano RF, Hawkins JD, Wells EA, Miller J, Brewer D (1990). "Evaluation of the effectiveness of adolescent drug abuse treatment, assessment of risks for relapse, and promising approaches for relapse prevention". <i id="mwBK8">The International Journal of the Addictions</i>. <b id="mwBLA">25</b> (9A–10A): 1085–140. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBLE">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.3109%2F10826089109081039" id="mwBLI">10.3109/10826089109081039</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBLM" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBLQ"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/2131328" id="mwBLU">2131328</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+International+Journal+of+the+Addictions&amp;rft.atitle=Evaluation+of+the+effectiveness+of+adolescent+drug+abuse+treatment%2C+assessment+of+risks+for+relapse%2C+and+promising+approaches+for+relapse+prevention&amp;rft.volume=25&amp;rft.issue=9A%E2%80%9310A&amp;rft.pages=1085-140&amp;rft.date=1990&amp;rft_id=info%3Adoi%2F10.3109%2F10826089109081039&amp;rft_id=info%3Apmid%2F2131328&amp;rft.aulast=Catalano&amp;rft.aufirst=RF&amp;rft.au=Hawkins%2C+JD&amp;rft.au=Wells%2C+EA&amp;rft.au=Miller%2C+J&amp;rft.au=Brewer%2C+D&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt261" id="mwBLY"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt261" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBLc"/></span></li><li about="#cite_note-45" id="cite_note-45"><a href="./Addiction#cite_ref-45" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-45" class="mw-reference-text"><cite class="citation journal" about="#mwt262" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Perepletchikova F, Krystal JH, Kaufman J"},"title":{"wt":"Practitioner review: adolescent alcohol use disorders: assessment and treatment issues"},"journal":{"wt":"Journal of Child Psychology and Psychiatry, and Allied Disciplines"},"volume":{"wt":"49"},"issue":{"wt":"11"},"pages":{"wt":"1131–54"},"date":{"wt":"November 2008"},"pmid":{"wt":"19017028"},"pmc":{"wt":"4113213"},"doi":{"wt":"10.1111/j.1469-7610.2008.01934.x"}},"i":0}}]}' id="mwBLg">Perepletchikova F, Krystal JH, Kaufman J (November 2008). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4113213" id="mwBLk">"Practitioner review: adolescent alcohol use disorders: assessment and treatment issues"</a>. <i id="mwBLo">Journal of Child Psychology and Psychiatry, and Allied Disciplines</i>. <b id="mwBLs">49</b> (11): 1131–54. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBLw">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1111%2Fj.1469-7610.2008.01934.x" id="mwBL0">10.1111/j.1469-7610.2008.01934.x</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwBL4">PMC</a><span typeof="mw:Entity" id="mwBL8"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwBMA"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4113213" id="mwBME">4113213</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBMI" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBMM"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19017028" id="mwBMQ">19017028</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Child+Psychology+and+Psychiatry%2C+and+Allied+Disciplines&amp;rft.atitle=Practitioner+review%3A+adolescent+alcohol+use+disorders%3A+assessment+and+treatment+issues&amp;rft.volume=49&amp;rft.issue=11&amp;rft.pages=1131-54&amp;rft.date=2008-11&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4113213&amp;rft_id=info%3Apmid%2F19017028&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1469-7610.2008.01934.x&amp;rft.aulast=Perepletchikova&amp;rft.aufirst=F&amp;rft.au=Krystal%2C+JH&amp;rft.au=Kaufman%2C+J&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4113213&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt262" id="mwBMU"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt262" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBMY"/></span></li><li about="#cite_note-46" id="cite_note-46"><a href="./Addiction#cite_ref-46" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-46" class="mw-reference-text"><cite class="citation web" about="#mwt266" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite web","href":"./Template:Cite_web"},"params":{"url":{"wt":"http://alcoholrehab.com/drug-addiction/age-and-substance-abuse/"},"title":{"wt":"Age and Substance Abuse – Alcohol Rehab"},"publisher":{"wt":""}},"i":0}}]}' id="mwBMc"><a rel="mw:ExtLink" class="external text" href="http://alcoholrehab.com/drug-addiction/age-and-substance-abuse/" id="mwBMg">"Age and Substance Abuse – Alcohol Rehab"</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Age+and+Substance+Abuse+%E2%80%93+Alcohol+Rehab&amp;rft_id=http%3A%2F%2Falcoholrehab.com%2Fdrug-addiction%2Fage-and-substance-abuse%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt266" id="mwBMk"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt266" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBMo"/></span></li><li about="#cite_note-Drug_use_trends-47" id="cite_note-Drug_use_trends-47"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-Drug_use_trends_47-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-Drug_use_trends_47-1"><span class="mw-linkback-text">2 </span></a><a href="./Addiction#cite_ref-Drug_use_trends_47-2"><span class="mw-linkback-text">3 </span></a></span> <span id="mw-reference-text-cite_note-Drug_use_trends-47" class="mw-reference-text"><cite class="citation web" about="#mwt272" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite web","href":"./Template:Cite_web"},"params":{"title":{"wt":"Nationwide Trends"},"url":{"wt":"http://www.drugabuse.gov/publications/drugfacts/nationwide-trends"},"publisher":{"wt":"National Institute on Drug Abuse"},"accessdate":{"wt":"15 December 2017"},"date":{"wt":"June 2015"}},"i":0}}]}' id="mwBMs"><a rel="mw:ExtLink" class="external text" href="http://www.drugabuse.gov/publications/drugfacts/nationwide-trends" id="mwBMw">"Nationwide Trends"</a>. National Institute on Drug Abuse. June 2015<span class="reference-accessdate" id="mwBM0">. Retrieved <span class="nowrap" id="mwBM4">15 December</span> 2017</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Nationwide+Trends&amp;rft.pub=National+Institute+on+Drug+Abuse&amp;rft.date=2015-06&amp;rft_id=http%3A%2F%2Fwww.drugabuse.gov%2Fpublications%2Fdrugfacts%2Fnationwide-trends&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt272" id="mwBM8"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt272" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBNA"/></span></li><li about="#cite_note-:0-48" id="cite_note-:0-48"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-:0_48-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-:0_48-1"><span class="mw-linkback-text">2 </span></a></span> <span id="mw-reference-text-cite_note-:0-48" class="mw-reference-text"><cite class="citation news" about="#mwt273" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"Cite news","href":"./Template:Cite_news"},"params":{"url":{"wt":"https://www.addictioncenter.com/addiction/addiction-statistics/"},"title":{"wt":"Addiction Statistics – Facts on Drug and Alcohol Addiction"},"work":{"wt":"AddictionCenter"},"access-date":{"wt":"17 September 2018"}},"i":0}}]}' id="mwBNE"><a rel="mw:ExtLink" class="external text" href="https://www.addictioncenter.com/addiction/addiction-statistics/" id="mwBNI">"Addiction Statistics – Facts on Drug and Alcohol Addiction"</a>. <i id="mwBNM">AddictionCenter</i><span class="reference-accessdate" id="mwBNQ">. Retrieved <span class="nowrap" id="mwBNU">17 September</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=AddictionCenter&amp;rft.atitle=Addiction+Statistics+%E2%80%93+Facts+on+Drug+and+Alcohol+Addiction&amp;rft_id=https%3A%2F%2Fwww.addictioncenter.com%2Faddiction%2Faddiction-statistics%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt273" id="mwBNY"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt273" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBNc"/></span></li><li about="#cite_note-49" id="cite_note-49"><a href="./Addiction#cite_ref-49" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-49" class="mw-reference-text"><cite class="citation web" about="#mwt285" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"Cite web","href":"./Template:Cite_web"},"params":{"url":{"wt":"https://www.samhsa.gov/capt/practicing-effective-prevention/prevention-behavioral-health/risk-protective-factors"},"title":{"wt":"Risk and Protective Factors"},"last":{"wt":"SAMHSA"},"date":{"wt":""},"publisher":{"wt":"Substance Abuse and Mental Health Administration"},"access-date":{"wt":"19 December 2016"}},"i":0}}]}' id="mwBNg">SAMHSA. <a rel="mw:ExtLink" class="external text" href="https://www.samhsa.gov/capt/practicing-effective-prevention/prevention-behavioral-health/risk-protective-factors" id="mwBNk">"Risk and Protective Factors"</a>. Substance Abuse and Mental Health Administration<span class="reference-accessdate" id="mwBNo">. Retrieved <span class="nowrap" id="mwBNs">19 December</span> 2016</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Risk+and+Protective+Factors&amp;rft.pub=Substance+Abuse+and+Mental+Health+Administration&amp;rft.au=SAMHSA&amp;rft_id=https%3A%2F%2Fwww.samhsa.gov%2Fcapt%2Fpracticing-effective-prevention%2Fprevention-behavioral-health%2Frisk-protective-factors&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt285" id="mwBNw"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt285" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBN0"/></span></li><li about="#cite_note-50" id="cite_note-50"><a href="./Addiction#cite_ref-50" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-50" class="mw-reference-text"><cite class="citation web" about="#mwt286" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"Cite web","href":"./Template:Cite_web"},"params":{"url":{"wt":"http://www.recoveryanswers.org/pressrelease/infographic-risk-factors-addiction/"},"title":{"wt":"Infographic – Risk Factors of Addiction {{!}} Recovery Research Institute"},"website":{"wt":"www.recoveryanswers.org"},"access-date":{"wt":"19 December 2016"}},"i":0}}]}' id="mwBN4"><a rel="mw:ExtLink" class="external text" href="http://www.recoveryanswers.org/pressrelease/infographic-risk-factors-addiction/" id="mwBN8">"Infographic – Risk Factors of Addiction | Recovery Research Institute"</a>. <i id="mwBOA">www.recoveryanswers.org</i><span class="reference-accessdate" id="mwBOE">. Retrieved <span class="nowrap" id="mwBOI">19 December</span> 2016</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.recoveryanswers.org&amp;rft.atitle=Infographic+%E2%80%93+Risk+Factors+of+Addiction+%7C+Recovery+Research+Institute&amp;rft_id=http%3A%2F%2Fwww.recoveryanswers.org%2Fpressrelease%2Finfographic-risk-factors-addiction%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt286" id="mwBOM"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt286" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBOQ"/></span></li><li about="#cite_note-51" id="cite_note-51"><a href="./Addiction#cite_ref-51" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-51" class="mw-reference-text"><cite class="citation web" about="#mwt287" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"Cite web","href":"./Template:Cite_web"},"params":{"url":{"wt":"http://www.mayoclinic.org/diseases-conditions/drug-addiction/basics/risk-factors/con-20020970"},"title":{"wt":"Drug addiction Risk factors – Mayo Clinic"},"website":{"wt":"www.mayoclinic.org"},"access-date":{"wt":"19 December 2016"}},"i":0}}]}' id="mwBOU"><a rel="mw:ExtLink" class="external text" href="http://www.mayoclinic.org/diseases-conditions/drug-addiction/basics/risk-factors/con-20020970" id="mwBOY">"Drug addiction Risk factors – Mayo Clinic"</a>. <i id="mwBOc">www.mayoclinic.org</i><span class="reference-accessdate" id="mwBOg">. Retrieved <span class="nowrap" id="mwBOk">19 December</span> 2016</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.mayoclinic.org&amp;rft.atitle=Drug+addiction+Risk+factors+%E2%80%93+Mayo+Clinic&amp;rft_id=http%3A%2F%2Fwww.mayoclinic.org%2Fdiseases-conditions%2Fdrug-addiction%2Fbasics%2Frisk-factors%2Fcon-20020970&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt287" id="mwBOo"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt287" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBOs"/></span></li><li about="#cite_note-52" id="cite_note-52"><a href="./Addiction#cite_ref-52" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-52" class="mw-reference-text"><cite class="citation news" about="#mwt289" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"Cite news","href":"./Template:Cite_news"},"params":{"url":{"wt":"https://www.dualdiagnosis.org/mental-health-and-addiction/the-connection/"},"title":{"wt":"The Connection Between Mental Illness and Substance Abuse {{!}} Dual Diagnosis"},"work":{"wt":"Dual Diagnosis"},"access-date":{"wt":"17 September 2018"}},"i":0}}]}' id="mwBOw"><a rel="mw:ExtLink" class="external text" href="https://www.dualdiagnosis.org/mental-health-and-addiction/the-connection/" id="mwBO0">"The Connection Between Mental Illness and Substance Abuse | Dual Diagnosis"</a>. <i id="mwBO4">Dual Diagnosis</i><span class="reference-accessdate" id="mwBO8">. Retrieved <span class="nowrap" id="mwBPA">17 September</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Dual+Diagnosis&amp;rft.atitle=The+Connection+Between+Mental+Illness+and+Substance+Abuse+%7C+Dual+Diagnosis&amp;rft_id=https%3A%2F%2Fwww.dualdiagnosis.org%2Fmental-health-and-addiction%2Fthe-connection%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt289" id="mwBPE"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt289" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBPI"/></span></li><li about="#cite_note-pmid26572641-53" id="cite_note-pmid26572641-53"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-pmid26572641_53-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-pmid26572641_53-1"><span class="mw-linkback-text">2 </span></a><a href="./Addiction#cite_ref-pmid26572641_53-2"><span class="mw-linkback-text">3 </span></a></span> <span id="mw-reference-text-cite_note-pmid26572641-53" class="mw-reference-text"><cite class="citation journal" about="#mwt299" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Yuan TF, Li A, Sun X, Ouyang H, Campos C, Rocha NB, Arias-Carrión O, Machado S, Hou G, So KF"},"title":{"wt":"Transgenerational Inheritance of Paternal Neurobehavioral Phenotypes: Stress, Addiction, Ageing and Metabolism"},"journal":{"wt":"Mol. Neurobiol."},"volume":{"wt":"53"},"issue":{"wt":"9"},"pages":{"wt":"6367–76"},"year":{"wt":"2015"},"pmid":{"wt":"26572641"},"doi":{"wt":"10.1007/s12035-015-9526-2"},"url":{"wt":""},"hdl":{"wt":"10400.22/7331"}},"i":0}}]}' id="mwBPM">Yuan TF, Li A, Sun X, Ouyang H, Campos C, Rocha NB, Arias-Carrión O, Machado S, Hou G, So KF (2015). "Transgenerational Inheritance of Paternal Neurobehavioral Phenotypes: Stress, Addiction, Ageing and Metabolism". <i id="mwBPQ">Mol. Neurobiol</i>. <b id="mwBPU">53</b> (9): 6367–76. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBPY">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1007%2Fs12035-015-9526-2" id="mwBPc">10.1007/s12035-015-9526-2</a>. <a rel="mw:WikiLink" href="./Handle_System" title="Handle System" id="mwBPg">hdl</a>:<a rel="mw:ExtLink" class="external text" href="//hdl.handle.net/10400.22%2F7331" id="mwBPk">10400.22/7331</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBPo" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBPs"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/26572641" id="mwBPw">26572641</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Mol.+Neurobiol.&amp;rft.atitle=Transgenerational+Inheritance+of+Paternal+Neurobehavioral+Phenotypes%3A+Stress%2C+Addiction%2C+Ageing+and+Metabolism&amp;rft.volume=53&amp;rft.issue=9&amp;rft.pages=6367-76&amp;rft.date=2015&amp;rft_id=info%3Ahdl%2F10400.22%2F7331&amp;rft_id=info%3Apmid%2F26572641&amp;rft_id=info%3Adoi%2F10.1007%2Fs12035-015-9526-2&amp;rft.aulast=Yuan&amp;rft.aufirst=TF&amp;rft.au=Li%2C+A&amp;rft.au=Sun%2C+X&amp;rft.au=Ouyang%2C+H&amp;rft.au=Campos%2C+C&amp;rft.au=Rocha%2C+NB&amp;rft.au=Arias-Carri%C3%B3n%2C+O&amp;rft.au=Machado%2C+S&amp;rft.au=Hou%2C+G&amp;rft.au=So%2C+KF&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt299" id="mwBP0"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt299" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBP4"/></span></li><li about="#cite_note-Nestler-Renthal_Figure_2-56" id="cite_note-Nestler-Renthal_Figure_2-56"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-Nestler-Renthal_Figure_2_56-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-Nestler-Renthal_Figure_2_56-1"><span class="mw-linkback-text">2 </span></a><a href="./Addiction#cite_ref-Nestler-Renthal_Figure_2_56-2"><span class="mw-linkback-text">3 </span></a></span> <span id="mw-reference-text-cite_note-Nestler-Renthal_Figure_2-56" class="mw-reference-text"><cite class="citation journal" id="mwBP8">Renthal W, Nestler EJ (September 2009). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2834246" id="mwBQA">"Chromatin regulation in drug addiction and depression"</a>. <i id="mwBQE">Dialogues Clin. Neurosci</i>. <b id="mwBQI">11</b> (3): 257–268. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwBQM">PMC</a><span typeof="mw:Entity" id="mwBQQ"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwBQU"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2834246" id="mwBQY">2834246</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBQc" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBQg"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19877494" id="mwBQk">19877494</a>. <q id="mwBQo">[Psychostimulants] increase cAMP levels in striatum, which activates protein kinase A (PKA) and leads to phosphorylation of its targets. This includes the cAMP response element binding protein (CREB), the phosphorylation of which induces its association with the histone acetyltransferase, CREB binding protein (CBP) to acetylate histones and facilitate gene activation. This is known to occur on many genes including fosB and <span class="nowrap" id="mwBQs">c-fos</span> in response to psychostimulant exposure. ΔFosB is also upregulated by chronic psychostimulant treatments, and is known to activate certain genes (eg, cdk5) and repress others (eg, <span class="nowrap" id="mwBQw">c-fos</span>) where it recruits HDAC1 as a corepressor.<span typeof="mw:Entity" id="mwBQ0"> </span>... Chronic exposure to psychostimulants increases glutamatergic [signaling] from the prefrontal cortex to the NAc. Glutamatergic signaling elevates Ca2+ levels in NAc postsynaptic elements where it activates CaMK (calcium/calmodulin protein kinases) signaling, which, in addition to phosphorylating CREB, also phosphorylates HDAC5.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Dialogues+Clin.+Neurosci.&amp;rft.atitle=Chromatin+regulation+in+drug+addiction+and+depression&amp;rft.volume=11&amp;rft.issue=3&amp;rft.pages=257-268&amp;rft.date=2009-09&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2834246&amp;rft_id=info%3Apmid%2F19877494&amp;rft.au=Renthal+W%2C+Nestler+EJ&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2834246&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" id="mwBQ4"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt1498" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBQ8"/><br id="mwBRA"/><a rel="mw:ExtLink" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2834246/figure/DialoguesClinNeurosci-11-257-g002/" id="mwBRE">Figure 2: Psychostimulant-induced signaling events</a></span></li><li about="#cite_note-Glutamate-dopamine_cotransmission_review-57" id="cite_note-Glutamate-dopamine_cotransmission_review-57"><a href="./Addiction#cite_ref-Glutamate-dopamine_cotransmission_review_57-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-Glutamate-dopamine_cotransmission_review-57" class="mw-reference-text"><cite class="citation journal" id="mwBRI">Broussard JI (January 2012). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3250102" id="mwBRM">"Co-transmission of dopamine and glutamate"</a>. <i id="mwBRQ">J. Gen. Physiol</i>. <b id="mwBRU">139</b> (1): 93–96. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBRY">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1085%2Fjgp.201110659" id="mwBRc">10.1085/jgp.201110659</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwBRg">PMC</a><span typeof="mw:Entity" id="mwBRk"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwBRo"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3250102" id="mwBRs">3250102</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBRw" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBR0"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22200950" id="mwBR4">22200950</a>. <q id="mwBR8">Coincident and convergent input often induces plasticity on a postsynaptic neuron. The NAc integrates processed information about the environment from basolateral amygdala, hippocampus, and prefrontal cortex (PFC), as well as projections from midbrain dopamine neurons. Previous studies have demonstrated how dopamine modulates this integrative process. For example, high frequency stimulation potentiates hippocampal inputs to the NAc while simultaneously depressing PFC synapses (Goto and Grace, 2005). The converse was also shown to be true; stimulation at PFC potentiates PFC–NAc synapses but depresses hippocampal–NAc synapses. In light of the new functional evidence of midbrain dopamine/glutamate co-transmission (references above), new experiments of NAc function will have to test whether midbrain glutamatergic inputs bias or filter either limbic or cortical inputs to guide goal-directed behavior.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J.+Gen.+Physiol.&amp;rft.atitle=Co-transmission+of+dopamine+and+glutamate&amp;rft.volume=139&amp;rft.issue=1&amp;rft.pages=93-96&amp;rft.date=2012-01&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3250102&amp;rft_id=info%3Apmid%2F22200950&amp;rft_id=info%3Adoi%2F10.1085%2Fjgp.201110659&amp;rft.aulast=Broussard&amp;rft.aufirst=JI&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3250102&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" id="mwBSA"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt1492" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBSE"/></span></li><li about="#cite_note-Amphetamine_KEGG_ΔFosB-58" id="cite_note-Amphetamine_KEGG_ΔFosB-58"><a href="./Addiction#cite_ref-Amphetamine_KEGG_ΔFosB_58-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-Amphetamine_KEGG_ΔFosB-58" class="mw-reference-text"><cite class="citation web" id="mwBSI">Kanehisa Laboratories (10 October 2014). <a rel="mw:ExtLink" class="external text" href="http://www.genome.jp/kegg-bin/show_pathway?hsa05031+2354" id="mwBSM">"Amphetamine – Homo sapiens (human)"</a>. <i id="mwBSQ">KEGG Pathway</i><span class="reference-accessdate" id="mwBSU">. Retrieved <span class="nowrap" id="mwBSY">31 October</span> 2014</span>. <q id="mwBSc">Most addictive drugs increase extracellular concentrations of dopamine (DA) in nucleus accumbens (NAc) and medial prefrontal cortex (mPFC), projection areas of mesocorticolimbic DA neurons and key components of the "brain reward circuit". Amphetamine achieves this elevation in extracellular levels of DA by promoting efflux from synaptic terminals.<span typeof="mw:Entity" id="mwBSg"> </span>... Chronic exposure to amphetamine induces a unique transcription factor delta FosB, which plays an essential role in long-term adaptive changes in the brain.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=KEGG+Pathway&amp;rft.atitle=Amphetamine+%E2%80%93+Homo+sapiens+%28human%29&amp;rft.date=2014-10-10&amp;rft.au=Kanehisa+Laboratories&amp;rft_id=http%3A%2F%2Fwww.genome.jp%2Fkegg-bin%2Fshow_pathway%3Fhsa05031%2B2354&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" id="mwBSk"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt1494" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBSo"/></span></li><li about="#cite_note-Meth_cAMP/calcium-dependent_cascade-59" id="cite_note-Meth_cAMP/calcium-dependent_cascade-59"><a href="./Addiction#cite_ref-Meth_cAMP/calcium-dependent_cascade_59-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-Meth_cAMP/calcium-dependent_cascade-59" class="mw-reference-text"><cite class="citation journal" id="mwBSs">Cadet JL, Brannock C, Jayanthi S, Krasnova IN (2015). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4359351" id="mwBSw">"Transcriptional and epigenetic substrates of methamphetamine addiction and withdrawal: evidence from a long-access self-administration model in the rat"</a>. <i id="mwBS0">Mol. Neurobiol</i>. <b id="mwBS4">51</b> (2): 696–717. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBS8">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1007%2Fs12035-014-8776-8" id="mwBTA">10.1007/s12035-014-8776-8</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwBTE">PMC</a><span typeof="mw:Entity" id="mwBTI"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwBTM"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4359351" id="mwBTQ">4359351</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBTU" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBTY"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/24939695" id="mwBTc">24939695</a>. <q id="mwBTg"><a rel="mw:ExtLink" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359351/figure/Fig1/" id="mwBTk">Figure 1</a></q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Mol.+Neurobiol.&amp;rft.atitle=Transcriptional+and+epigenetic+substrates+of+methamphetamine+addiction+and+withdrawal%3A+evidence+from+a+long-access+self-administration+model+in+the+rat&amp;rft.volume=51&amp;rft.issue=2&amp;rft.pages=696-717&amp;rft.date=2015&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4359351&amp;rft_id=info%3Apmid%2F24939695&amp;rft_id=info%3Adoi%2F10.1007%2Fs12035-014-8776-8&amp;rft.aulast=Cadet&amp;rft.aufirst=JL&amp;rft.au=Brannock%2C+C&amp;rft.au=Jayanthi%2C+S&amp;rft.au=Krasnova%2C+IN&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4359351&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" id="mwBTo"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt1496" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBTs"/></span></li><li about="#cite_note-Nestler1-60" id="cite_note-Nestler1-60"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-Nestler1_60-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-Nestler1_60-1"><span class="mw-linkback-text">2 </span></a><a href="./Addiction#cite_ref-Nestler1_60-2"><span class="mw-linkback-text">3 </span></a></span> <span id="mw-reference-text-cite_note-Nestler1-60" class="mw-reference-text"><cite class="citation journal" id="mwBTw">Robison AJ, Nestler EJ (November 2011). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3272277" id="mwBT0">"Transcriptional and epigenetic mechanisms of addiction"</a>. <i id="mwBT4">Nat. Rev. Neurosci</i>. <b id="mwBT8">12</b> (11): 623–637. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBUA">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1038%2Fnrn3111" id="mwBUE">10.1038/nrn3111</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwBUI">PMC</a><span typeof="mw:Entity" id="mwBUM"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwBUQ"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3272277" id="mwBUU">3272277</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBUY" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBUc"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21989194" id="mwBUg">21989194</a>. <q id="mwBUk">ΔFosB serves as one of the master control proteins governing this structural plasticity.<span typeof="mw:Entity" id="mwBUo"> </span>... ΔFosB also represses G9a expression, leading to reduced repressive histone methylation at the cdk5 gene. The net result is gene activation and increased CDK5 expression.<span typeof="mw:Entity" id="mwBUs"> </span>... In contrast, ΔFosB binds to the <span class="nowrap" id="mwBUw">c-fos</span> gene and recruits several co-repressors, including HDAC1 (histone deacetylase 1) and SIRT 1 (sirtuin 1).<span typeof="mw:Entity" id="mwBU0"> </span>... The net result is <span class="nowrap" id="mwBU4">c-fos</span> gene repression.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nat.+Rev.+Neurosci.&amp;rft.atitle=Transcriptional+and+epigenetic+mechanisms+of+addiction&amp;rft.volume=12&amp;rft.issue=11&amp;rft.pages=623-637&amp;rft.date=2011-11&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3272277&amp;rft_id=info%3Apmid%2F21989194&amp;rft_id=info%3Adoi%2F10.1038%2Fnrn3111&amp;rft.au=Robison+AJ%2C+Nestler+EJ&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3272277&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" id="mwBU8"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt1502" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBVA"/><br id="mwBVE"/><a rel="mw:ExtLink" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3272277/figure/F4/" id="mwBVI">Figure 4: Epigenetic basis of drug regulation of gene expression</a></span></li><li about="#cite_note-Nestler2-61" id="cite_note-Nestler2-61"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-Nestler2_61-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-Nestler2_61-1"><span class="mw-linkback-text">2 </span></a><a href="./Addiction#cite_ref-Nestler2_61-2"><span class="mw-linkback-text">3 </span></a><a href="./Addiction#cite_ref-Nestler2_61-3"><span class="mw-linkback-text">4 </span></a></span> <span id="mw-reference-text-cite_note-Nestler2-61" class="mw-reference-text"><cite class="citation journal" id="mwBVM">Nestler EJ (December 2012). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3569166" id="mwBVQ">"Transcriptional mechanisms of drug addiction"</a>. <i id="mwBVU">Clin. Psychopharmacol. Neurosci</i>. <b id="mwBVY">10</b> (3): 136–143. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBVc">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.9758%2Fcpn.2012.10.3.136" id="mwBVg">10.9758/cpn.2012.10.3.136</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwBVk">PMC</a><span typeof="mw:Entity" id="mwBVo"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwBVs"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3569166" id="mwBVw">3569166</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBV0" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBV4"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23430970" id="mwBV8">23430970</a>. <q id="mwBWA">The 35-37 kD ΔFosB isoforms accumulate with chronic drug exposure due to their extraordinarily long half-lives.<span typeof="mw:Entity" id="mwBWE"> </span>... As a result of its stability, the ΔFosB protein persists in neurons for at least several weeks after cessation of drug exposure.<span typeof="mw:Entity" id="mwBWI"> </span>... ΔFosB overexpression in nucleus accumbens induces NFκB<span typeof="mw:Entity" id="mwBWM"> </span>...  In contrast, the ability of ΔFosB to repress the <span class="nowrap" id="mwBWQ">c-Fos</span> gene occurs in concert with the recruitment of a histone deacetylase and presumably several other repressive proteins such as a repressive histone methyltransferase</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clin.+Psychopharmacol.+Neurosci.&amp;rft.atitle=Transcriptional+mechanisms+of+drug+addiction&amp;rft.volume=10&amp;rft.issue=3&amp;rft.pages=136-143&amp;rft.date=2012-12&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3569166&amp;rft_id=info%3Apmid%2F23430970&amp;rft_id=info%3Adoi%2F10.9758%2Fcpn.2012.10.3.136&amp;rft.au=Nestler+EJ&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3569166&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" id="mwBWU"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt1504" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBWY"/></span></li><li about="#cite_note-{{nowrap|c-Fos}}_repression-62" id="cite_note-{{nowrap|c-Fos}}_repression-62"><a href="./Addiction#cite_ref-{{nowrap|c-Fos}}_repression_62-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-{{nowrap|c-Fos}}_repression-62" class="mw-reference-text"><cite class="citation journal" id="mwBWc">Nestler EJ (October 2008). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2607320" id="mwBWg">"Review. Transcriptional mechanisms of addiction: role of DeltaFosB"</a>. <i id="mwBWk">Philos. Trans. R. Soc. Lond., B, Biol. Sci</i>. <b id="mwBWo">363</b> (1507): 3245–3255. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBWs">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1098%2Frstb.2008.0067" id="mwBWw">10.1098/rstb.2008.0067</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwBW0">PMC</a><span typeof="mw:Entity" id="mwBW4"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwBW8"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2607320" id="mwBXA">2607320</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBXE" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBXI"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18640924" id="mwBXM">18640924</a>. <q id="mwBXQ">Recent evidence has shown that ΔFosB also represses the <span class="nowrap" id="mwBXU">c-fos</span> gene that helps create the molecular switch—from the induction of several short-lived Fos family proteins after acute drug exposure to the predominant accumulation of ΔFosB after chronic drug exposure</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Philos.+Trans.+R.+Soc.+Lond.%2C+B%2C+Biol.+Sci.&amp;rft.atitle=Review.+Transcriptional+mechanisms+of+addiction%3A+role+of+DeltaFosB&amp;rft.volume=363&amp;rft.issue=1507&amp;rft.pages=3245-3255&amp;rft.date=2008-10&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2607320&amp;rft_id=info%3Apmid%2F18640924&amp;rft_id=info%3Adoi%2F10.1098%2Frstb.2008.0067&amp;rft.au=Nestler+EJ&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2607320&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" id="mwBXY"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt1500" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBXc"/></span></li><li about="#cite_note-Nestler,_Hyman,_and_Malenka_2-63" id="cite_note-Nestler,_Hyman,_and_Malenka_2-63"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-Nestler,_Hyman,_and_Malenka_2_63-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-Nestler,_Hyman,_and_Malenka_2_63-1"><span class="mw-linkback-text">2 </span></a></span> <span id="mw-reference-text-cite_note-Nestler,_Hyman,_and_Malenka_2-63" class="mw-reference-text"><cite class="citation journal" about="#mwt351" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Hyman SE, Malenka RC, Nestler EJ"},"title":{"wt":"Neural mechanisms of addiction: the role of reward-related learning and memory"},"journal":{"wt":"Annu. Rev. Neurosci."},"volume":{"wt":"29"},"issue":{"wt":""},"pages":{"wt":"565–98"},"year":{"wt":"2006"},"pmid":{"wt":"16776597"},"doi":{"wt":"10.1146/annurev.neuro.29.051605.113009"},"url":{"wt":""}},"i":0}}]}' id="mwBXg">Hyman SE, Malenka RC, Nestler EJ (2006). "Neural mechanisms of addiction: the role of reward-related learning and memory". <i id="mwBXk">Annu. Rev. Neurosci</i>. <b id="mwBXo">29</b>: 565–98. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBXs">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1146%2Fannurev.neuro.29.051605.113009" id="mwBXw">10.1146/annurev.neuro.29.051605.113009</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBX0" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBX4"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16776597" id="mwBX8">16776597</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Annu.+Rev.+Neurosci.&amp;rft.atitle=Neural+mechanisms+of+addiction%3A+the+role+of+reward-related+learning+and+memory&amp;rft.volume=29&amp;rft.pages=565-98&amp;rft.date=2006&amp;rft_id=info%3Adoi%2F10.1146%2Fannurev.neuro.29.051605.113009&amp;rft_id=info%3Apmid%2F16776597&amp;rft.aulast=Hyman&amp;rft.aufirst=SE&amp;rft.au=Malenka%2C+RC&amp;rft.au=Nestler%2C+EJ&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt351" id="mwBYA"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt351" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBYE"/></span></li><li about="#cite_note-Addiction_genetics-64" id="cite_note-Addiction_genetics-64"><a href="./Addiction#cite_ref-Addiction_genetics_64-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-Addiction_genetics-64" class="mw-reference-text"><cite class="citation journal" about="#mwt352" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Steiner H, Van Waes V"},"title":{"wt":"Addiction-related gene regulation: risks of exposure to cognitive enhancers vs. other psychostimulants"},"journal":{"wt":"Prog. Neurobiol."},"volume":{"wt":"100"},"issue":{"wt":""},"pages":{"wt":"60–80"},"date":{"wt":"January 2013"},"pmid":{"wt":"23085425"},"pmc":{"wt":"3525776"},"doi":{"wt":"10.1016/j.pneurobio.2012.10.001"},"url":{"wt":""}},"i":0}}]}' id="mwBYI">Steiner H, Van Waes V (January 2013). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3525776" id="mwBYM">"Addiction-related gene regulation: risks of exposure to cognitive enhancers vs. other psychostimulants"</a>. <i id="mwBYQ">Prog. Neurobiol</i>. <b id="mwBYU">100</b>: 60–80. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBYY">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1016%2Fj.pneurobio.2012.10.001" id="mwBYc">10.1016/j.pneurobio.2012.10.001</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwBYg">PMC</a><span typeof="mw:Entity" id="mwBYk"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwBYo"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3525776" id="mwBYs">3525776</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBYw" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBY0"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23085425" id="mwBY4">23085425</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Prog.+Neurobiol.&amp;rft.atitle=Addiction-related+gene+regulation%3A+risks+of+exposure+to+cognitive+enhancers+vs.+other+psychostimulants&amp;rft.volume=100&amp;rft.pages=60-80&amp;rft.date=2013-01&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3525776&amp;rft_id=info%3Apmid%2F23085425&amp;rft_id=info%3Adoi%2F10.1016%2Fj.pneurobio.2012.10.001&amp;rft.aulast=Steiner&amp;rft.aufirst=H&amp;rft.au=Van+Waes%2C+V&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3525776&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt352" id="mwBY8"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt352" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBZA"/></span></li><li about="#cite_note-Alcoholism_ΔFosB-65" id="cite_note-Alcoholism_ΔFosB-65"><a href="./Addiction#cite_ref-Alcoholism_ΔFosB_65-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-Alcoholism_ΔFosB-65" class="mw-reference-text"><cite class="citation web" about="#mwt353" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite web ","href":"./Template:Cite_web"},"params":{"title":{"wt":"Alcoholism – Homo sapiens (human)"},"url":{"wt":"http://www.genome.jp/kegg-bin/show_pathway?hsa05034+2354"},"work":{"wt":"KEGG Pathway"},"accessdate":{"wt":"10 April 2014"},"author":{"wt":"Kanehisa Laboratories"},"date":{"wt":"2 August 2013"}},"i":0}}]}' id="mwBZE">Kanehisa Laboratories (2 August 2013). <a rel="mw:ExtLink" class="external text" href="http://www.genome.jp/kegg-bin/show_pathway?hsa05034+2354" id="mwBZI">"Alcoholism – Homo sapiens (human)"</a>. <i id="mwBZM">KEGG Pathway</i><span class="reference-accessdate" id="mwBZQ">. Retrieved <span class="nowrap" id="mwBZU">10 April</span> 2014</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=KEGG+Pathway&amp;rft.atitle=Alcoholism+%E2%80%93+Homo+sapiens+%28human%29&amp;rft.date=2013-08-02&amp;rft.au=Kanehisa+Laboratories&amp;rft_id=http%3A%2F%2Fwww.genome.jp%2Fkegg-bin%2Fshow_pathway%3Fhsa05034%2B2354&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt353" id="mwBZY"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt353" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBZc"/></span></li><li about="#cite_note-MPH_ΔFosB-66" id="cite_note-MPH_ΔFosB-66"><a href="./Addiction#cite_ref-MPH_ΔFosB_66-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-MPH_ΔFosB-66" class="mw-reference-text"><cite class="citation journal" about="#mwt354" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Kim Y, Teylan MA, Baron M, Sands A, Nairn AC, Greengard P"},"title":{"wt":"Methylphenidate-induced dendritic spine formation and DeltaFosB expression in nucleus accumbens"},"journal":{"wt":"Proc. Natl. Acad. Sci. USA"},"volume":{"wt":"106"},"issue":{"wt":"8"},"pages":{"wt":"2915–20"},"date":{"wt":"February 2009"},"pmid":{"wt":"19202072"},"pmc":{"wt":"2650365"},"doi":{"wt":"10.1073/pnas.0813179106"},"quote":{"wt":"&lt;!--Despite decades of clinical use of methylphenidate for ADHD, concerns have been raised that long-term treatment of children with this medication may result in subsequent drug abuse and addiction.&amp;nbsp;... Thus, although oral administration of clinical doses of methylphenidate is not associated with euphoria or with abuse problems, nontherapeutic use of high doses or i.v. administration may lead to addiction (39, 40).-->"}},"i":0}}]}' id="mwBZg">Kim Y, Teylan MA, Baron M, Sands A, Nairn AC, Greengard P (February 2009). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2650365" id="mwBZk">"Methylphenidate-induced dendritic spine formation and DeltaFosB expression in nucleus accumbens"</a>. <i id="mwBZo">Proc. Natl. Acad. Sci. USA</i>. <b id="mwBZs">106</b> (8): 2915–20. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBZw">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1073%2Fpnas.0813179106" id="mwBZ0">10.1073/pnas.0813179106</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwBZ4">PMC</a><span typeof="mw:Entity" id="mwBZ8"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwBaA"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2650365" id="mwBaE">2650365</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBaI" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBaM"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19202072" id="mwBaQ">19202072</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Proc.+Natl.+Acad.+Sci.+USA&amp;rft.atitle=Methylphenidate-induced+dendritic+spine+formation+and+DeltaFosB+expression+in+nucleus+accumbens&amp;rft.volume=106&amp;rft.issue=8&amp;rft.pages=2915-20&amp;rft.date=2009-02&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2650365&amp;rft_id=info%3Apmid%2F19202072&amp;rft_id=info%3Adoi%2F10.1073%2Fpnas.0813179106&amp;rft.aulast=Kim&amp;rft.aufirst=Y&amp;rft.au=Teylan%2C+MA&amp;rft.au=Baron%2C+M&amp;rft.au=Sands%2C+A&amp;rft.au=Nairn%2C+AC&amp;rft.au=Greengard%2C+P&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2650365&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt354" id="mwBaU"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt354" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBaY"/></span></li><li about="#cite_note-Nestler_2014_epigenetics-67" id="cite_note-Nestler_2014_epigenetics-67"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-Nestler_2014_epigenetics_67-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-Nestler_2014_epigenetics_67-1"><span class="mw-linkback-text">2 </span></a><a href="./Addiction#cite_ref-Nestler_2014_epigenetics_67-2"><span class="mw-linkback-text">3 </span></a><a href="./Addiction#cite_ref-Nestler_2014_epigenetics_67-3"><span class="mw-linkback-text">4 </span></a><a href="./Addiction#cite_ref-Nestler_2014_epigenetics_67-4"><span class="mw-linkback-text">5 </span></a><a href="./Addiction#cite_ref-Nestler_2014_epigenetics_67-5"><span class="mw-linkback-text">6 </span></a><a href="./Addiction#cite_ref-Nestler_2014_epigenetics_67-6"><span class="mw-linkback-text">7 </span></a><a href="./Addiction#cite_ref-Nestler_2014_epigenetics_67-7"><span class="mw-linkback-text">8 </span></a></span> <span id="mw-reference-text-cite_note-Nestler_2014_epigenetics-67" class="mw-reference-text"><cite class="citation journal" about="#mwt846" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"vcite2 journal ","href":"./Template:Vcite2_journal"},"params":{"vauthors":{"wt":"Nestler EJ"},"title":{"wt":"Epigenetic mechanisms of drug addiction"},"journal":{"wt":"Neuropharmacology"},"volume":{"wt":"76 Pt B"},"issue":{"wt":""},"pages":{"wt":"259–68"},"date":{"wt":"January 2014"},"pmid":{"wt":"23643695"},"pmc":{"wt":"3766384"},"doi":{"wt":"10.1016/j.neuropharm.2013.04.004"},"quote":{"wt":"Short-term increases in histone acetylation generally promote behavioral responses to the drugs, while sustained increases oppose cocaine&apos;s effects, based on the actions of systemic or intra-NAc administration of HDAC inhibitors.&amp;nbsp;...  Genetic or pharmacological blockade of G9a in the NAc potentiates behavioral responses to cocaine and opiates, whereas increasing G9a function exerts the opposite effect (Maze et al., 2010; Sun et al., 2012a). Such drug-induced downregulation of G9a and H3K9me2 also sensitizes animals to the deleterious effects of subsequent chronic stress (Covington et al., 2011). Downregulation of G9a increases the dendritic arborization of NAc neurons, and is associated with increased expression of numerous proteins implicated in synaptic function, which directly connects altered G9a/H3K9me2 in the synaptic plasticity associated with addiction (Maze et al., 2010).&lt;br />G9a appears to be a critical control point for epigenetic regulation in NAc, as we know it functions in two negative feedback loops. It opposes the induction of ΔFosB, a long-lasting transcription factor important for drug addiction (Robison and Nestler, 2011), while ΔFosB in turn suppresses G9a expression (Maze et al., 2010; Sun et al., 2012a).&amp;nbsp;... Also, G9a is induced in NAc upon prolonged HDAC inhibition, which explains the paradoxical attenuation of cocaine&apos;s behavioral effects seen under these conditions, as noted above (Kennedy et al., 2013). GABAA receptor subunit genes are among those that are controlled by this feedback loop. Thus, chronic cocaine, or prolonged HDAC inhibition, induces several GABAA receptor subunits in NAc, which is associated with increased frequency of inhibitory postsynaptic currents (IPSCs). In striking contrast, combined exposure to cocaine and HDAC inhibition, which triggers the induction of G9a and increased global levels of H3K9me2, leads to blockade of GABAA receptor and IPSC regulation."}},"i":0}}]}' id="mwBac">Nestler EJ (January 2014). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3766384" id="mwBag">"Epigenetic mechanisms of drug addiction"</a>. <i id="mwBak">Neuropharmacology</i>. 76 Pt B: 259–68. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBao">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1016%2Fj.neuropharm.2013.04.004" id="mwBas">10.1016/j.neuropharm.2013.04.004</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwBaw">PMC</a><span typeof="mw:Entity" id="mwBa0"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwBa4"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3766384" id="mwBa8">3766384</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBbA" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBbE"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23643695" id="mwBbI">23643695</a>. <q id="mwBbM">Short-term increases in histone acetylation generally promote behavioral responses to the drugs, while sustained increases oppose cocaine's effects, based on the actions of systemic or intra-NAc administration of HDAC inhibitors.<span typeof="mw:Entity" id="mwBbQ"> </span>...  Genetic or pharmacological blockade of G9a in the NAc potentiates behavioral responses to cocaine and opiates, whereas increasing G9a function exerts the opposite effect (Maze et al., 2010; Sun et al., 2012a). Such drug-induced downregulation of G9a and H3K9me2 also sensitizes animals to the deleterious effects of subsequent chronic stress (Covington et al., 2011). Downregulation of G9a increases the dendritic arborization of NAc neurons, and is associated with increased expression of numerous proteins implicated in synaptic function, which directly connects altered G9a/H3K9me2 in the synaptic plasticity associated with addiction (Maze et al., 2010).<br id="mwBbU"/>G9a appears to be a critical control point for epigenetic regulation in NAc, as we know it functions in two negative feedback loops. It opposes the induction of ΔFosB, a long-lasting transcription factor important for drug addiction (Robison and Nestler, 2011), while ΔFosB in turn suppresses G9a expression (Maze et al., 2010; Sun et al., 2012a).<span typeof="mw:Entity" id="mwBbY"> </span>... Also, G9a is induced in NAc upon prolonged HDAC inhibition, which explains the paradoxical attenuation of cocaine's behavioral effects seen under these conditions, as noted above (Kennedy et al., 2013). GABAA receptor subunit genes are among those that are controlled by this feedback loop. Thus, chronic cocaine, or prolonged HDAC inhibition, induces several GABAA receptor subunits in NAc, which is associated with increased frequency of inhibitory postsynaptic currents (IPSCs). In striking contrast, combined exposure to cocaine and HDAC inhibition, which triggers the induction of G9a and increased global levels of H3K9me2, leads to blockade of GABAA receptor and IPSC regulation.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Neuropharmacology&amp;rft.atitle=Epigenetic+mechanisms+of+drug+addiction&amp;rft.volume=76+Pt+B&amp;rft.pages=259-68&amp;rft.date=2014-01&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3766384&amp;rft_id=info%3Apmid%2F23643695&amp;rft_id=info%3Adoi%2F10.1016%2Fj.neuropharm.2013.04.004&amp;rft.aulast=Nestler&amp;rft.aufirst=EJ&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3766384&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt846" id="mwBbc"></span><link rel="mw:PageProp/Category" href="./Category:CS1:_long_volume_value" about="#mwt846" id="mwBbg"/><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt846" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBbk"/></span></li><li about="#cite_note-ΔFosB_reward-68" id="cite_note-ΔFosB_reward-68"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-ΔFosB_reward_68-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-ΔFosB_reward_68-1"><span class="mw-linkback-text">2 </span></a><a href="./Addiction#cite_ref-ΔFosB_reward_68-2"><span class="mw-linkback-text">3 </span></a><a href="./Addiction#cite_ref-ΔFosB_reward_68-3"><span class="mw-linkback-text">4 </span></a></span> <span id="mw-reference-text-cite_note-ΔFosB_reward-68" class="mw-reference-text"><cite class="citation journal" about="#mwt396" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Blum K, Werner T, Carnes S, Carnes P, Bowirrat A, Giordano J, Oscar-Berman M, Gold M"},"title":{"wt":"Sex, drugs, and rock &apos;n&apos; roll: hypothesizing common mesolimbic activation as a function of reward gene polymorphisms"},"journal":{"wt":"Journal of Psychoactive Drugs"},"volume":{"wt":"44"},"issue":{"wt":"1"},"pages":{"wt":"38–55"},"year":{"wt":"2012"},"pmid":{"wt":"22641964"},"pmc":{"wt":"4040958"},"doi":{"wt":"10.1080/02791072.2012.662112"},"quote":{"wt":"It has been found that deltaFosB gene in the NAc is critical for reinforcing effects of sexual reward. Pitchers and colleagues (2010) reported that sexual experience was shown to cause DeltaFosB accumulation in several limbic brain regions including the NAc, medial pre-frontal cortex, VTA, caudate, and putamen, but not the medial preoptic nucleus. Next, the induction of c-Fos, a downstream (repressed) target of DeltaFosB, was measured in sexually experienced and naive animals. The number of mating-induced c-Fos-IR cells was significantly decreased in sexually experienced animals compared to sexually naive controls. Finally, DeltaFosB levels and its activity in the NAc were manipulated using viral-mediated gene transfer to study its potential role in mediating sexual experience and experience-induced facilitation of sexual performance. Animals with DeltaFosB overexpression displayed enhanced facilitation of sexual performance with sexual experience relative to controls. In contrast, the expression of DeltaJunD, a dominant-negative binding partner of DeltaFosB, attenuated sexual experience-induced facilitation of sexual performance, and stunted long-term maintenance of facilitation compared to DeltaFosB overexpressing group. Together, these findings support a critical role for DeltaFosB expression in the NAc in the reinforcing effects of sexual behavior and sexual experience-induced facilitation of sexual performance.&amp;nbsp;... both drug addiction and sexual addiction represent pathological forms of neuroplasticity along with the emergence of aberrant behaviors involving a cascade of neurochemical changes mainly in the brain&apos;s rewarding circuitry."}},"i":0}}]}' id="mwBbo">Blum K, Werner T, Carnes S, Carnes P, Bowirrat A, Giordano J, Oscar-Berman M, Gold M (2012). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4040958" id="mwBbs">"Sex, drugs, and rock 'n' roll: hypothesizing common mesolimbic activation as a function of reward gene polymorphisms"</a>. <i id="mwBbw">Journal of Psychoactive Drugs</i>. <b id="mwBb0">44</b> (1): 38–55. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBb4">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1080%2F02791072.2012.662112" id="mwBb8">10.1080/02791072.2012.662112</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwBcA">PMC</a><span typeof="mw:Entity" id="mwBcE"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwBcI"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4040958" id="mwBcM">4040958</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBcQ" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBcU"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22641964" id="mwBcY">22641964</a>. <q id="mwBcc">It has been found that deltaFosB gene in the NAc is critical for reinforcing effects of sexual reward. Pitchers and colleagues (2010) reported that sexual experience was shown to cause DeltaFosB accumulation in several limbic brain regions including the NAc, medial pre-frontal cortex, VTA, caudate, and putamen, but not the medial preoptic nucleus. Next, the induction of c-Fos, a downstream (repressed) target of DeltaFosB, was measured in sexually experienced and naive animals. The number of mating-induced c-Fos-IR cells was significantly decreased in sexually experienced animals compared to sexually naive controls. Finally, DeltaFosB levels and its activity in the NAc were manipulated using viral-mediated gene transfer to study its potential role in mediating sexual experience and experience-induced facilitation of sexual performance. Animals with DeltaFosB overexpression displayed enhanced facilitation of sexual performance with sexual experience relative to controls. In contrast, the expression of DeltaJunD, a dominant-negative binding partner of DeltaFosB, attenuated sexual experience-induced facilitation of sexual performance, and stunted long-term maintenance of facilitation compared to DeltaFosB overexpressing group. Together, these findings support a critical role for DeltaFosB expression in the NAc in the reinforcing effects of sexual behavior and sexual experience-induced facilitation of sexual performance.<span typeof="mw:Entity" id="mwBcg"> </span>... both drug addiction and sexual addiction represent pathological forms of neuroplasticity along with the emergence of aberrant behaviors involving a cascade of neurochemical changes mainly in the brain's rewarding circuitry.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Psychoactive+Drugs&amp;rft.atitle=Sex%2C+drugs%2C+and+rock+%27n%27+roll%3A+hypothesizing+common+mesolimbic+activation+as+a+function+of+reward+gene+polymorphisms&amp;rft.volume=44&amp;rft.issue=1&amp;rft.pages=38-55&amp;rft.date=2012&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4040958&amp;rft_id=info%3Apmid%2F22641964&amp;rft_id=info%3Adoi%2F10.1080%2F02791072.2012.662112&amp;rft.aulast=Blum&amp;rft.aufirst=K&amp;rft.au=Werner%2C+T&amp;rft.au=Carnes%2C+S&amp;rft.au=Carnes%2C+P&amp;rft.au=Bowirrat%2C+A&amp;rft.au=Giordano%2C+J&amp;rft.au=Oscar-Berman%2C+M&amp;rft.au=Gold%2C+M&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4040958&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt396" id="mwBck"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt396" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBco"/></span></li><li about="#cite_note-Malenka_2009_04-69" id="cite_note-Malenka_2009_04-69"><a href="./Addiction#cite_ref-Malenka_2009_04_69-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-Malenka_2009_04-69" class="mw-reference-text"><cite class="citation book" about="#mwt418" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite book ","href":"./Template:Cite_book"},"params":{"vauthors":{"wt":"Malenka RC, Nestler EJ, Hyman SE"},"veditors":{"wt":"Sydor A, Brown RY"},"title":{"wt":"Molecular Neuropharmacology: A Foundation for Clinical Neuroscience"},"year":{"wt":"2009"},"publisher":{"wt":"McGraw-Hill Medical"},"location":{"wt":"New York"},"isbn":{"wt":"978-0-07-148127-4"},"pages":{"wt":"384–85"},"edition":{"wt":"2nd"},"chapter":{"wt":"Chapter 15: Reinforcement and addictive disorders"}},"i":0}}]}' id="mwBcs">Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 15: Reinforcement and addictive disorders".  In Sydor A, Brown RY. <i id="mwBcw">Molecular Neuropharmacology: A Foundation for Clinical Neuroscience</i> (2nd ed.). New York: McGraw-Hill Medical. pp.<span typeof="mw:Entity" id="mwBc0"> </span>384–85. <a rel="mw:WikiLink" href="./International_Standard_Book_Number" title="International Standard Book Number" id="mwBc4">ISBN</a><span typeof="mw:Entity" id="mwBc8"> </span><a rel="mw:WikiLink" href="./Special:BookSources/978-0-07-148127-4" title="Special:BookSources/978-0-07-148127-4" id="mwBdA">978-0-07-148127-4</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.atitle=Chapter+15%3A+Reinforcement+and+addictive+disorders&amp;rft.btitle=Molecular+Neuropharmacology%3A+A+Foundation+for+Clinical+Neuroscience&amp;rft.place=New+York&amp;rft.pages=384-85&amp;rft.edition=2nd&amp;rft.pub=McGraw-Hill+Medical&amp;rft.date=2009&amp;rft.isbn=978-0-07-148127-4&amp;rft.aulast=Malenka&amp;rft.aufirst=RC&amp;rft.au=Nestler%2C+EJ&amp;rft.au=Hyman%2C+SE&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt418" id="mwBdE"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt418" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBdI"/></span></li><li about="#cite_note-Salamone-70" id="cite_note-Salamone-70"><a href="./Addiction#cite_ref-Salamone_70-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-Salamone-70" class="mw-reference-text"><cite class="citation journal" about="#mwt424" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal","href":"./Template:Cite_journal"},"params":{"last":{"wt":"Salamone"},"first":{"wt":"J.D."},"title":{"wt":"Complex motor and sensorimotor function of striatal and accumbens dopamine: Involvement in instrumental behavior processes"},"journal":{"wt":"Psychopharmacology"},"year":{"wt":"1992"},"volume":{"wt":"107"},"issue":{"wt":"2–3"},"pages":{"wt":"160–74"},"doi":{"wt":"10.1007/bf02245133"},"pmid":{"wt":"1615120"}},"i":0}}]}' id="mwBdM">Salamone, J.D. (1992). "Complex motor and sensorimotor function of striatal and accumbens dopamine: Involvement in instrumental behavior processes". <i id="mwBdQ">Psychopharmacology</i>. <b id="mwBdU">107</b> (2–3): 160–74. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBdY">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1007%2Fbf02245133" id="mwBdc">10.1007/bf02245133</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBdg" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBdk"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/1615120" id="mwBdo">1615120</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Psychopharmacology&amp;rft.atitle=Complex+motor+and+sensorimotor+function+of+striatal+and+accumbens+dopamine%3A+Involvement+in+instrumental+behavior+processes&amp;rft.volume=107&amp;rft.issue=2%E2%80%933&amp;rft.pages=160-74&amp;rft.date=1992&amp;rft_id=info%3Adoi%2F10.1007%2Fbf02245133&amp;rft_id=info%3Apmid%2F1615120&amp;rft.aulast=Salamone&amp;rft.aufirst=J.D.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt424" id="mwBds"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt424" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBdw"/></span></li><li about="#cite_note-Kauer-71" id="cite_note-Kauer-71"><a href="./Addiction#cite_ref-Kauer_71-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-Kauer-71" class="mw-reference-text"><cite class="citation journal" about="#mwt425" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal","href":"./Template:Cite_journal"},"params":{"last":{"wt":"Kauer"},"first":{"wt":"J.A."},"author2":{"wt":"R.C. Malenka"},"title":{"wt":"Synaptic plasticity and addiction"},"journal":{"wt":"Nature Reviews Neuroscience"},"year":{"wt":"2007"},"issue":{"wt":"11"},"pages":{"wt":"844–58"},"doi":{"wt":"10.1038/nrn2234"},"pmid":{"wt":"17948030"},"volume":{"wt":"8"}},"i":0}}]}' id="mwBd0">Kauer, J.A.; R.C. Malenka (2007). "Synaptic plasticity and addiction". <i id="mwBd4">Nature Reviews Neuroscience</i>. <b id="mwBd8">8</b> (11): 844–58. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBeA">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1038%2Fnrn2234" id="mwBeE">10.1038/nrn2234</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBeI" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBeM"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17948030" id="mwBeQ">17948030</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nature+Reviews+Neuroscience&amp;rft.atitle=Synaptic+plasticity+and+addiction&amp;rft.volume=8&amp;rft.issue=11&amp;rft.pages=844-58&amp;rft.date=2007&amp;rft_id=info%3Adoi%2F10.1038%2Fnrn2234&amp;rft_id=info%3Apmid%2F17948030&amp;rft.aulast=Kauer&amp;rft.aufirst=J.A.&amp;rft.au=R.C.+Malenka&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt425" id="mwBeU"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt425" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBeY"/></span></li><li about="#cite_note-Witten-72" id="cite_note-Witten-72"><a href="./Addiction#cite_ref-Witten_72-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-Witten-72" class="mw-reference-text"><cite class="citation journal" about="#mwt426" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal","href":"./Template:Cite_journal"},"params":{"last":{"wt":"Witten"},"first":{"wt":"I"},"author2":{"wt":"S.-C. Lin"},"author3":{"wt":"M Brodsky"},"title":{"wt":"Cholinergic interneurons control local circuit activity and cocaine conditioning"},"journal":{"wt":"Science"},"year":{"wt":"2010"},"volume":{"wt":"330"},"issue":{"wt":"6011"},"pages":{"wt":"1677–81"},"doi":{"wt":"10.1126/science.1193771"},"pmid":{"wt":"21164015"},"pmc":{"wt":"3142356"},"bibcode":{"wt":"2010Sci...330.1677W"}},"i":0}}]}' id="mwBec">Witten, I; S.-C. Lin; M Brodsky (2010). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3142356" id="mwBeg">"Cholinergic interneurons control local circuit activity and cocaine conditioning"</a>. <i id="mwBek">Science</i>. <b id="mwBeo">330</b> (6011): 1677–81. <a rel="mw:WikiLink" href="./Bibcode" title="Bibcode" id="mwBes">Bibcode</a>:<a rel="mw:ExtLink" class="external text" href="http://adsabs.harvard.edu/abs/2010Sci...330.1677W" id="mwBew">2010Sci...330.1677W</a>. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBe0">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1126%2Fscience.1193771" id="mwBe4">10.1126/science.1193771</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwBe8">PMC</a><span typeof="mw:Entity" id="mwBfA"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwBfE"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3142356" id="mwBfI">3142356</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBfM" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBfQ"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21164015" id="mwBfU">21164015</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Science&amp;rft.atitle=Cholinergic+interneurons+control+local+circuit+activity+and+cocaine+conditioning&amp;rft.volume=330&amp;rft.issue=6011&amp;rft.pages=1677-81&amp;rft.date=2010&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3142356&amp;rft_id=info%3Apmid%2F21164015&amp;rft_id=info%3Adoi%2F10.1126%2Fscience.1193771&amp;rft_id=info%3Abibcode%2F2010Sci...330.1677W&amp;rft.aulast=Witten&amp;rft.aufirst=I&amp;rft.au=S.-C.+Lin&amp;rft.au=M+Brodsky&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3142356&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt426" id="mwBfY"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt426" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBfc"/></span></li><li about="#cite_note-pmid11572966-73" id="cite_note-pmid11572966-73"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-pmid11572966_73-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-pmid11572966_73-1"><span class="mw-linkback-text">2 </span></a></span> <span id="mw-reference-text-cite_note-pmid11572966-73" class="mw-reference-text"><cite class="citation journal" id="mwBfg">Nestler EJ, Barrot M, Self DW (September 2001). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC58680" id="mwBfk">"DeltaFosB: a sustained molecular switch for addiction"</a>. <i id="mwBfo">Proc. Natl. Acad. Sci. U.S.A</i>. <b id="mwBfs">98</b> (20): 11042–46. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBfw">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1073%2Fpnas.191352698" id="mwBf0">10.1073/pnas.191352698</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwBf4">PMC</a><span typeof="mw:Entity" id="mwBf8"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwBgA"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC58680" id="mwBgE">58680</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBgI" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBgM"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/11572966" id="mwBgQ">11572966</a>. <q id="mwBgU">Although the ΔFosB signal is relatively long-lived, it is not permanent. ΔFosB degrades gradually and can no longer be detected in brain after 1–2 months of drug withdrawal<span typeof="mw:Entity" id="mwBgY"> </span>... Indeed, ΔFosB is the longest-lived adaptation known to occur in adult brain, not only in response to drugs of abuse, but to any other perturbation (that doesn't involve lesions) as well.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Proc.+Natl.+Acad.+Sci.+U.S.A.&amp;rft.atitle=DeltaFosB%3A+a+sustained+molecular+switch+for+addiction&amp;rft.volume=98&amp;rft.issue=20&amp;rft.pages=11042-46&amp;rft.date=2001-09&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC58680&amp;rft_id=info%3Apmid%2F11572966&amp;rft_id=info%3Adoi%2F10.1073%2Fpnas.191352698&amp;rft.aulast=Nestler&amp;rft.aufirst=EJ&amp;rft.au=Barrot%2C+M&amp;rft.au=Self%2C+DW&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC58680&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" id="mwBgc"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt1788" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBgg"/></span></li><li about="#cite_note-Jones_and_Bonci-74" id="cite_note-Jones_and_Bonci-74"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-Jones_and_Bonci_74-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-Jones_and_Bonci_74-1"><span class="mw-linkback-text">2 </span></a></span> <span id="mw-reference-text-cite_note-Jones_and_Bonci-74" class="mw-reference-text"><cite class="citation journal" about="#mwt448" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Jones S, Bonci A"},"title":{"wt":"Synaptic plasticity and drug addiction"},"journal":{"wt":"Current Opinion in Pharmacology"},"volume":{"wt":"5"},"issue":{"wt":"1"},"pages":{"wt":"20–25"},"year":{"wt":"2005"},"pmid":{"wt":"15661621"},"doi":{"wt":"10.1016/j.coph.2004.08.011"}},"i":0}}]}' id="mwBgk">Jones S, Bonci A (2005). "Synaptic plasticity and drug addiction". <i id="mwBgo">Current Opinion in Pharmacology</i>. <b id="mwBgs">5</b> (1): 20–25. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBgw">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1016%2Fj.coph.2004.08.011" id="mwBg0">10.1016/j.coph.2004.08.011</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBg4" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBg8"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15661621" id="mwBhA">15661621</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Current+Opinion+in+Pharmacology&amp;rft.atitle=Synaptic+plasticity+and+drug+addiction&amp;rft.volume=5&amp;rft.issue=1&amp;rft.pages=20-25&amp;rft.date=2005&amp;rft_id=info%3Adoi%2F10.1016%2Fj.coph.2004.08.011&amp;rft_id=info%3Apmid%2F15661621&amp;rft.aulast=Jones&amp;rft.aufirst=S&amp;rft.au=Bonci%2C+A&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt448" id="mwBhE"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt448" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBhI"/></span></li><li about="#cite_note-Eisch_and_Harburg-75" id="cite_note-Eisch_and_Harburg-75"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-Eisch_and_Harburg_75-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-Eisch_and_Harburg_75-1"><span class="mw-linkback-text">2 </span></a></span> <span id="mw-reference-text-cite_note-Eisch_and_Harburg-75" class="mw-reference-text"><cite class="citation journal" about="#mwt449" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Eisch AJ, Harburg GC"},"title":{"wt":"Opiates, psychostimulants, and adult hippocampal neurogenesis: Insights for addiction and stem cell biology"},"journal":{"wt":"Hippocampus"},"volume":{"wt":"16"},"issue":{"wt":"3"},"pages":{"wt":"271–86"},"year":{"wt":"2006"},"pmid":{"wt":"16411230"},"doi":{"wt":"10.1002/hipo.20161"}},"i":0}}]}' id="mwBhM">Eisch AJ, Harburg GC (2006). "Opiates, psychostimulants, and adult hippocampal neurogenesis: Insights for addiction and stem cell biology". <i id="mwBhQ">Hippocampus</i>. <b id="mwBhU">16</b> (3): 271–86. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBhY">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1002%2Fhipo.20161" id="mwBhc">10.1002/hipo.20161</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBhg" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBhk"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16411230" id="mwBho">16411230</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Hippocampus&amp;rft.atitle=Opiates%2C+psychostimulants%2C+and+adult+hippocampal+neurogenesis%3A+Insights+for+addiction+and+stem+cell+biology&amp;rft.volume=16&amp;rft.issue=3&amp;rft.pages=271-86&amp;rft.date=2006&amp;rft_id=info%3Adoi%2F10.1002%2Fhipo.20161&amp;rft_id=info%3Apmid%2F16411230&amp;rft.aulast=Eisch&amp;rft.aufirst=AJ&amp;rft.au=Harburg%2C+GC&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt449" id="mwBhs"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt449" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBhw"/></span></li><li about="#cite_note-Rang-76" id="cite_note-Rang-76"><a href="./Addiction#cite_ref-Rang_76-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-Rang-76" class="mw-reference-text"><cite class="citation book" about="#mwt450" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite book ","href":"./Template:Cite_book"},"params":{"author":{"wt":"Rang, H.P."},"title":{"wt":"Pharmacology"},"publisher":{"wt":"Churchill Livingstone"},"location":{"wt":"Edinburgh"},"year":{"wt":"2003"},"page":{"wt":"596"},"isbn":{"wt":"978-0-443-07145-4"}},"i":0}}]}' id="mwBh0">Rang, H.P. (2003). <i id="mwBh4">Pharmacology</i>. Edinburgh: Churchill Livingstone. p.<span typeof="mw:Entity" id="mwBh8"> </span>596. <a rel="mw:WikiLink" href="./International_Standard_Book_Number" title="International Standard Book Number" id="mwBiA">ISBN</a><span typeof="mw:Entity" id="mwBiE"> </span><a rel="mw:WikiLink" href="./Special:BookSources/978-0-443-07145-4" title="Special:BookSources/978-0-443-07145-4" id="mwBiI">978-0-443-07145-4</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Pharmacology&amp;rft.place=Edinburgh&amp;rft.pages=596&amp;rft.pub=Churchill+Livingstone&amp;rft.date=2003&amp;rft.isbn=978-0-443-07145-4&amp;rft.au=Rang%2C+H.P.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt450" id="mwBiM"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt450" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBiQ"/></span></li><li about="#cite_note-Kourrich-77" id="cite_note-Kourrich-77"><a href="./Addiction#cite_ref-Kourrich_77-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-Kourrich-77" class="mw-reference-text"><cite class="citation journal" about="#mwt455" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Kourrich S, Rothwell PE, Klug JR, Thomas MJ"},"title":{"wt":"Cocaine experience controls bidirectional synaptic plasticity in the nucleus accumbens"},"journal":{"wt":"J. Neurosci."},"volume":{"wt":"27"},"issue":{"wt":"30"},"pages":{"wt":"7921–28"},"year":{"wt":"2007"},"pmid":{"wt":"17652583"},"doi":{"wt":"10.1523/JNEUROSCI.1859-07.2007"}},"i":0}}]}' id="mwBiU">Kourrich S, Rothwell PE, Klug JR, Thomas MJ (2007). "Cocaine experience controls bidirectional synaptic plasticity in the nucleus accumbens". <i id="mwBiY">J. Neurosci</i>. <b id="mwBic">27</b> (30): 7921–28. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBig">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1523%2FJNEUROSCI.1859-07.2007" id="mwBik">10.1523/JNEUROSCI.1859-07.2007</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBio" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBis"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17652583" id="mwBiw">17652583</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J.+Neurosci.&amp;rft.atitle=Cocaine+experience+controls+bidirectional+synaptic+plasticity+in+the+nucleus+accumbens&amp;rft.volume=27&amp;rft.issue=30&amp;rft.pages=7921-28&amp;rft.date=2007&amp;rft_id=info%3Adoi%2F10.1523%2FJNEUROSCI.1859-07.2007&amp;rft_id=info%3Apmid%2F17652583&amp;rft.aulast=Kourrich&amp;rft.aufirst=S&amp;rft.au=Rothwell%2C+PE&amp;rft.au=Klug%2C+JR&amp;rft.au=Thomas%2C+MJ&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt455" id="mwBi0"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt455" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBi4"/></span></li><li about="#cite_note-Kalivas_and_Volkow-78" id="cite_note-Kalivas_and_Volkow-78"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-Kalivas_and_Volkow_78-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-Kalivas_and_Volkow_78-1"><span class="mw-linkback-text">2 </span></a></span> <span id="mw-reference-text-cite_note-Kalivas_and_Volkow-78" class="mw-reference-text"><cite class="citation journal" about="#mwt465" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Kalivas PW, Volkow ND"},"title":{"wt":"The neural basis of addiction: a pathology of motivation and choice"},"journal":{"wt":"The American Journal of Psychiatry"},"volume":{"wt":"162"},"issue":{"wt":"8"},"pages":{"wt":"1403–13"},"date":{"wt":"August 2005"},"pmid":{"wt":"16055761"},"doi":{"wt":"10.1176/appi.ajp.162.8.1403"}},"i":0}}]}' id="mwBi8">Kalivas PW, Volkow ND (August 2005). "The neural basis of addiction: a pathology of motivation and choice". <i id="mwBjA">The American Journal of Psychiatry</i>. <b id="mwBjE">162</b> (8): 1403–13. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBjI">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1176%2Fappi.ajp.162.8.1403" id="mwBjM">10.1176/appi.ajp.162.8.1403</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBjQ" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBjU"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16055761" id="mwBjY">16055761</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+American+Journal+of+Psychiatry&amp;rft.atitle=The+neural+basis+of+addiction%3A+a+pathology+of+motivation+and+choice&amp;rft.volume=162&amp;rft.issue=8&amp;rft.pages=1403-13&amp;rft.date=2005-08&amp;rft_id=info%3Adoi%2F10.1176%2Fappi.ajp.162.8.1403&amp;rft_id=info%3Apmid%2F16055761&amp;rft.aulast=Kalivas&amp;rft.aufirst=PW&amp;rft.au=Volkow%2C+ND&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt465" id="mwBjc"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt465" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBjg"/></span></li><li about="#cite_note-Floresco-79" id="cite_note-Floresco-79"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-Floresco_79-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-Floresco_79-1"><span class="mw-linkback-text">2 </span></a></span> <span id="mw-reference-text-cite_note-Floresco-79" class="mw-reference-text"><cite class="citation journal" about="#mwt466" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Floresco SB, Ghods-Sharifi S"},"title":{"wt":"Amygdala-prefrontal cortical circuitry regulates effort-based decision making"},"journal":{"wt":"Cerebral Cortex"},"volume":{"wt":"17"},"issue":{"wt":"2"},"pages":{"wt":"251–60"},"date":{"wt":"February 2007"},"pmid":{"wt":"16495432"},"doi":{"wt":"10.1093/cercor/bhj143"},"citeseerx":{"wt":"10.1.1.335.4681"}},"i":0}}]}' id="mwBjk">Floresco SB, Ghods-Sharifi S (February 2007). "Amygdala-prefrontal cortical circuitry regulates effort-based decision making". <i id="mwBjo">Cerebral Cortex</i>. <b id="mwBjs">17</b> (2): 251–60. <a rel="mw:WikiLink" href="./CiteSeerX" title="CiteSeerX" id="mwBjw">CiteSeerX</a><span typeof="mw:Entity" id="mwBj0"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwBj4"><a rel="mw:ExtLink" class="external text" href="//citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.335.4681" id="mwBj8">10.1.1.335.4681</a></span>. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBkA">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1093%2Fcercor%2Fbhj143" id="mwBkE">10.1093/cercor/bhj143</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBkI" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBkM"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16495432" id="mwBkQ">16495432</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cerebral+Cortex&amp;rft.atitle=Amygdala-prefrontal+cortical+circuitry+regulates+effort-based+decision+making&amp;rft.volume=17&amp;rft.issue=2&amp;rft.pages=251-60&amp;rft.date=2007-02&amp;rft_id=%2F%2Fciteseerx.ist.psu.edu%2Fviewdoc%2Fsummary%3Fdoi%3D10.1.1.335.4681&amp;rft_id=info%3Apmid%2F16495432&amp;rft_id=info%3Adoi%2F10.1093%2Fcercor%2Fbhj143&amp;rft.aulast=Floresco&amp;rft.aufirst=SB&amp;rft.au=Ghods-Sharifi%2C+S&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt466" id="mwBkU"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt466" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBkY"/></span></li><li about="#cite_note-80" id="cite_note-80"><a href="./Addiction#cite_ref-80" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-80" class="mw-reference-text"><cite class="citation journal" about="#mwt467" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Perry CJ, Zbukvic I, Kim JH, Lawrence AJ"},"title":{"wt":"Role of cues and contexts on drug-seeking behaviour"},"journal":{"wt":"British Journal of Pharmacology"},"volume":{"wt":"171"},"issue":{"wt":"20"},"pages":{"wt":"4636–72"},"date":{"wt":"October 2014"},"pmid":{"wt":"24749941"},"pmc":{"wt":"4209936"},"doi":{"wt":"10.1111/bph.12735"}},"i":0}}]}' id="mwBkc">Perry CJ, Zbukvic I, Kim JH, Lawrence AJ (October 2014). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4209936" id="mwBkg">"Role of cues and contexts on drug-seeking behaviour"</a>. <i id="mwBkk">British Journal of Pharmacology</i>. <b id="mwBko">171</b> (20): 4636–72. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBks">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1111%2Fbph.12735" id="mwBkw">10.1111/bph.12735</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwBk0">PMC</a><span typeof="mw:Entity" id="mwBk4"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwBk8"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4209936" id="mwBlA">4209936</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBlE" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBlI"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/24749941" id="mwBlM">24749941</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=British+Journal+of+Pharmacology&amp;rft.atitle=Role+of+cues+and+contexts+on+drug-seeking+behaviour&amp;rft.volume=171&amp;rft.issue=20&amp;rft.pages=4636-72&amp;rft.date=2014-10&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4209936&amp;rft_id=info%3Apmid%2F24749941&amp;rft_id=info%3Adoi%2F10.1111%2Fbph.12735&amp;rft.aulast=Perry&amp;rft.aufirst=CJ&amp;rft.au=Zbukvic%2C+I&amp;rft.au=Kim%2C+JH&amp;rft.au=Lawrence%2C+AJ&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4209936&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt467" id="mwBlQ"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt467" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBlU"/></span></li><li about="#cite_note-arch-81" id="cite_note-arch-81"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-arch_81-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-arch_81-1"><span class="mw-linkback-text">2 </span></a><a href="./Addiction#cite_ref-arch_81-2"><span class="mw-linkback-text">3 </span></a></span> <span id="mw-reference-text-cite_note-arch-81" class="mw-reference-text"><cite class="citation journal" about="#mwt478" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Volkow ND, Fowler JS, Wang GJ, Swanson JM, Telang F"},"title":{"wt":"Dopamine in drug abuse and addiction: results of imaging studies and treatment implications"},"journal":{"wt":"Arch. Neurol."},"volume":{"wt":"64"},"issue":{"wt":"11"},"pages":{"wt":"1575–79"},"year":{"wt":"2007"},"pmid":{"wt":"17998440"},"doi":{"wt":"10.1001/archneur.64.11.1575"},"url":{"wt":""}},"i":0}}]}' id="mwBlY">Volkow ND, Fowler JS, Wang GJ, Swanson JM, Telang F (2007). "Dopamine in drug abuse and addiction: results of imaging studies and treatment implications". <i id="mwBlc">Arch. Neurol</i>. <b id="mwBlg">64</b> (11): 1575–79. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBlk">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1001%2Farchneur.64.11.1575" id="mwBlo">10.1001/archneur.64.11.1575</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBls" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBlw"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17998440" id="mwBl0">17998440</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Arch.+Neurol.&amp;rft.atitle=Dopamine+in+drug+abuse+and+addiction%3A+results+of+imaging+studies+and+treatment+implications&amp;rft.volume=64&amp;rft.issue=11&amp;rft.pages=1575-79&amp;rft.date=2007&amp;rft_id=info%3Adoi%2F10.1001%2Farchneur.64.11.1575&amp;rft_id=info%3Apmid%2F17998440&amp;rft.aulast=Volkow&amp;rft.aufirst=ND&amp;rft.au=Fowler%2C+JS&amp;rft.au=Wang%2C+GJ&amp;rft.au=Swanson%2C+JM&amp;rft.au=Telang%2C+F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt478" id="mwBl4"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt478" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBl8"/></span></li><li about="#cite_note-drugs-brain-82" id="cite_note-drugs-brain-82"><a href="./Addiction#cite_ref-drugs-brain_82-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-drugs-brain-82" class="mw-reference-text"><cite class="citation web" about="#mwt479" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite web","href":"./Template:Cite_web"},"params":{"url":{"wt":"http://www.drugabuse.gov/publications/science-addiction/drugs-brain"},"title":{"wt":"Drugs, Brains, and Behavior: The Science of Addiction"},"publisher":{"wt":"National Institute on Drug Abuse"}},"i":0}}]}' id="mwBmA"><a rel="mw:ExtLink" class="external text" href="http://www.drugabuse.gov/publications/science-addiction/drugs-brain" id="mwBmE">"Drugs, Brains, and Behavior: The Science of Addiction"</a>. National Institute on Drug Abuse.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Drugs%2C+Brains%2C+and+Behavior%3A+The+Science+of+Addiction&amp;rft.pub=National+Institute+on+Drug+Abuse&amp;rft_id=http%3A%2F%2Fwww.drugabuse.gov%2Fpublications%2Fscience-addiction%2Fdrugs-brain&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt479" id="mwBmI"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt479" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBmM"/></span></li><li about="#cite_note-addict-83" id="cite_note-addict-83"><a href="./Addiction#cite_ref-addict_83-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-addict-83" class="mw-reference-text"><cite class="citation web" about="#mwt480" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite web","href":"./Template:Cite_web"},"params":{"url":{"wt":"http://www.drugabuse.gov/infofacts/understand.html"},"title":{"wt":"Understanding Drug Abuse and Addiction"},"publisher":{"wt":"National Institute on Drug Abuse"},"date":{"wt":"November 2012"}},"i":0}}]}' id="mwBmQ"><a rel="mw:ExtLink" class="external text" href="http://www.drugabuse.gov/infofacts/understand.html" id="mwBmU">"Understanding Drug Abuse and Addiction"</a>. National Institute on Drug Abuse. November 2012.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Understanding+Drug+Abuse+and+Addiction&amp;rft.pub=National+Institute+on+Drug+Abuse&amp;rft.date=2012-11&amp;rft_id=http%3A%2F%2Fwww.drugabuse.gov%2Finfofacts%2Funderstand.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt480" id="mwBmY"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt480" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBmc"/></span></li><li about="#cite_note-pmid18640924-84" id="cite_note-pmid18640924-84"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-pmid18640924_84-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-pmid18640924_84-1"><span class="mw-linkback-text">2 </span></a><a href="./Addiction#cite_ref-pmid18640924_84-2"><span class="mw-linkback-text">3 </span></a></span> <span id="mw-reference-text-cite_note-pmid18640924-84" class="mw-reference-text"><cite class="citation journal" about="#mwt496" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"author":{"wt":"Nestler EJ"},"title":{"wt":"Review. Transcriptional mechanisms of addiction: role of DeltaFosB"},"journal":{"wt":"Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences"},"volume":{"wt":"363"},"issue":{"wt":"1507"},"pages":{"wt":"3245–55"},"date":{"wt":"October 2008"},"pmid":{"wt":"18640924"},"doi":{"wt":"10.1098/rstb.2008.0067"},"url":{"wt":""},"pmc":{"wt":"2607320"},"quote":{"wt":"Recent evidence has shown that ΔFosB also represses the c-fos gene that helps create the molecular switch – from the induction of several short-lived Fos family proteins after acute drug exposure to the predominant accumulation of ΔFosB after chronic drug exposure&amp;nbsp;– cited earlier (Renthal et al. in press). The mechanism responsible for ΔFosB repression of c-fos expression is complex and is covered below.&amp;nbsp;...&lt;br />Examples of validated targets for ΔFosB in nucleus accumbens&amp;nbsp;... GluR2&amp;nbsp;... dynorphin&amp;nbsp;... Cdk5&amp;nbsp;... NFκB&amp;nbsp;... c-Fos"}},"i":0}}]}' id="mwBmg">Nestler EJ (October 2008). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2607320" id="mwBmk">"Review. Transcriptional mechanisms of addiction: role of DeltaFosB"</a>. <i id="mwBmo">Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences</i>. <b id="mwBms">363</b> (1507): 3245–55. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBmw">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1098%2Frstb.2008.0067" id="mwBm0">10.1098/rstb.2008.0067</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwBm4">PMC</a><span typeof="mw:Entity" id="mwBm8"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwBnA"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2607320" id="mwBnE">2607320</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBnI" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBnM"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18640924" id="mwBnQ">18640924</a>. <q id="mwBnU">Recent evidence has shown that ΔFosB also represses the c-fos gene that helps create the molecular switch – from the induction of several short-lived Fos family proteins after acute drug exposure to the predominant accumulation of ΔFosB after chronic drug exposure<span typeof="mw:Entity" id="mwBnY"> </span>– cited earlier (Renthal et al. in press). The mechanism responsible for ΔFosB repression of c-fos expression is complex and is covered below.<span typeof="mw:Entity" id="mwBnc"> </span>...<br id="mwBng"/>Examples of validated targets for ΔFosB in nucleus accumbens<span typeof="mw:Entity" id="mwBnk"> </span>... GluR2<span typeof="mw:Entity" id="mwBno"> </span>... dynorphin<span typeof="mw:Entity" id="mwBns"> </span>... Cdk5<span typeof="mw:Entity" id="mwBnw"> </span>... NFκB<span typeof="mw:Entity" id="mwBn0"> </span>... c-Fos</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Philosophical+Transactions+of+the+Royal+Society+of+London.+Series+B%2C+Biological+Sciences&amp;rft.atitle=Review.+Transcriptional+mechanisms+of+addiction%3A+role+of+DeltaFosB&amp;rft.volume=363&amp;rft.issue=1507&amp;rft.pages=3245-55&amp;rft.date=2008-10&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2607320&amp;rft_id=info%3Apmid%2F18640924&amp;rft_id=info%3Adoi%2F10.1098%2Frstb.2008.0067&amp;rft.au=Nestler+EJ&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2607320&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt496" id="mwBn4"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt496" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBn8"/><br id="mwBoA"/><a rel="mw:ExtLink" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2607320/table/tbl3/" id="mwBoE">Table 3</a></span></li><li about="#cite_note-Incentive_salience_and_motivation_review-87" id="cite_note-Incentive_salience_and_motivation_review-87"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-Incentive_salience_and_motivation_review_87-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-Incentive_salience_and_motivation_review_87-1"><span class="mw-linkback-text">2 </span></a><a href="./Addiction#cite_ref-Incentive_salience_and_motivation_review_87-2"><span class="mw-linkback-text">3 </span></a><a href="./Addiction#cite_ref-Incentive_salience_and_motivation_review_87-3"><span class="mw-linkback-text">4 </span></a><a href="./Addiction#cite_ref-Incentive_salience_and_motivation_review_87-4"><span class="mw-linkback-text">5 </span></a><a href="./Addiction#cite_ref-Incentive_salience_and_motivation_review_87-5"><span class="mw-linkback-text">6 </span></a></span> <span id="mw-reference-text-cite_note-Incentive_salience_and_motivation_review-87" class="mw-reference-text"><cite class="citation journal" id="mwBoI">Berridge KC (April 2012). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3325516" id="mwBoM">"From prediction error to incentive salience: mesolimbic computation of reward motivation"</a>. <i id="mwBoQ">Eur. J. Neurosci</i>. <b id="mwBoU">35</b> (7): 1124–43. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBoY">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1111%2Fj.1460-9568.2012.07990.x" id="mwBoc">10.1111/j.1460-9568.2012.07990.x</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwBog">PMC</a><span typeof="mw:Entity" id="mwBok"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwBoo"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3325516" id="mwBos">3325516</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBow" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBo0"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22487042" id="mwBo4">22487042</a>. <q id="mwBo8">Here I discuss how mesocorticolimbic mechanisms generate the motivation component of incentive salience. Incentive salience takes Pavlovian learning and memory as one input and as an equally important input takes neurobiological state factors (e.g. drug states, appetite states, satiety states) that can vary independently of learning. Neurobiological state changes can produce unlearned fluctuations or even reversals in the ability of a previously learned reward cue to trigger motivation. Such fluctuations in cue-triggered motivation can dramatically depart from all previously learned values about the associated reward outcome.<span typeof="mw:Entity" id="mwBpA"> </span>... Associative learning and prediction are important contributors to motivation for rewards. Learning gives incentive value to arbitrary cues such as a Pavlovian conditioned stimulus (CS) that is associated with a reward (unconditioned stimulus or UCS). Learned cues for reward are often potent triggers of desires. For example, learned cues can trigger normal appetites in everyone, and can sometimes trigger compulsive urges and relapse in addicts.<br id="mwBpE"/>Cue-triggered ‘wanting’ for the UCS<br id="mwBpI"/>A brief CS encounter (or brief UCS encounter) often primes a pulse of elevated motivation to obtain and consume more reward UCS. This is a signature feature of incentive salience.<br id="mwBpM"/>Cue as attractive motivational magnets<br id="mwBpQ"/>When a Pavlovian CS+ is attributed with incentive salience it not only triggers ‘wanting’ for its UCS, but often the cue itself becomes highly attractive – even to an irrational degree. This cue attraction is another signature feature of incentive salience<span typeof="mw:Entity" id="mwBpU"> </span>... Two recognizable features of incentive salience are often visible that can be used in neuroscience experiments: (i) UCS-directed ‘wanting’ – CS-triggered pulses of intensified ‘wanting’ for the UCS reward; and (ii) CS-directed ‘wanting’ – motivated attraction to the Pavlovian cue, which makes the arbitrary CS stimulus into a motivational magnet.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Eur.+J.+Neurosci.&amp;rft.atitle=From+prediction+error+to+incentive+salience%3A+mesolimbic+computation+of+reward+motivation&amp;rft.volume=35&amp;rft.issue=7&amp;rft.pages=1124-43&amp;rft.date=2012-04&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3325516&amp;rft_id=info%3Apmid%2F22487042&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1460-9568.2012.07990.x&amp;rft.aulast=Berridge&amp;rft.aufirst=KC&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3325516&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" id="mwBpY"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt1786" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBpc"/></span></li><li about="#cite_note-NAcc_function-88" id="cite_note-NAcc_function-88"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-NAcc_function_88-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-NAcc_function_88-1"><span class="mw-linkback-text">2 </span></a></span> <span id="mw-reference-text-cite_note-NAcc_function-88" class="mw-reference-text"><cite class="citation book" about="#mwt534" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite book ","href":"./Template:Cite_book"},"params":{"vauthors":{"wt":"Malenka RC, Nestler EJ, Hyman SE"},"veditors":{"wt":"Sydor A, Brown RY"},"title":{"wt":"Molecular Neuropharmacology: A Foundation for Clinical Neuroscience"},"year":{"wt":"2009"},"publisher":{"wt":"McGraw-Hill Medical"},"location":{"wt":"New York"},"isbn":{"wt":"978-0-07-148127-4"},"pages":{"wt":"147–48, 366–67, 375–76"},"edition":{"wt":"2nd"},"quote":{"wt":"VTA DA neurons play a critical role in motivation, reward-related behavior (Chapter 15), attention, and multiple forms of memory. This organization of the DA system, wide projection from a limited number of cell bodies, permits coordinated responses to potent new rewards. Thus, acting in diverse terminal fields, dopamine confers motivational salience (\"wanting\") on the reward itself or associated cues (nucleus accumbens shell region), updates the value placed on different goals in light of this new experience (orbital prefrontal cortex), helps consolidate multiple forms of memory (amygdala and hippocampus), and encodes new motor programs that will facilitate obtaining this reward in the future (nucleus accumbens core region and dorsal striatum). In this example, dopamine modulates the processing of sensorimotor information in diverse neural circuits to maximize the ability of the organism to obtain future rewards.&amp;nbsp;...&lt;br />The brain reward circuitry that is targeted by addictive drugs normally mediates the pleasure and strengthening of behaviors associated with natural reinforcers, such as food, water, and sexual contact. Dopamine neurons in the VTA are activated by food and water, and dopamine release in the NAc is stimulated by the presence of natural reinforcers, such as food, water, or a sexual partner.&amp;nbsp;...&lt;br />The NAc and VTA are central components of the circuitry underlying reward and memory of reward. As previously mentioned, the activity of dopaminergic neurons in the VTA appears to be linked to reward prediction. The NAc is involved in learning associated with reinforcement and the modulation of motoric responses to stimuli that satisfy internal homeostatic needs. The shell of the NAc appears to be particularly important to initial drug actions within reward circuitry; addictive drugs appear to have a greater effect on dopamine release in the shell than in the core of the NAc.&amp;nbsp;... If motivational drive is described in terms of wanting, and hedonic evaluation in terms of liking, it appears that wanting can be dissociated from liking and that dopamine may influence these phenomena differently. Differences between wanting and liking are confirmed in reports by human addicts, who state that their desire for drugs (wanting) increases with continued use even when pleasure (liking) decreases because of tolerance."}},"i":0}}]}' id="mwBpg">Malenka RC, Nestler EJ, Hyman SE (2009).  Sydor A, Brown RY, eds. <i id="mwBpk">Molecular Neuropharmacology: A Foundation for Clinical Neuroscience</i> (2nd ed.). New York: McGraw-Hill Medical. pp.<span typeof="mw:Entity" id="mwBpo"> </span>147–48, 366–67, 375–76. <a rel="mw:WikiLink" href="./International_Standard_Book_Number" title="International Standard Book Number" id="mwBps">ISBN</a><span typeof="mw:Entity" id="mwBpw"> </span><a rel="mw:WikiLink" href="./Special:BookSources/978-0-07-148127-4" title="Special:BookSources/978-0-07-148127-4" id="mwBp0">978-0-07-148127-4</a>. <q id="mwBp4">VTA DA neurons play a critical role in motivation, reward-related behavior (Chapter 15), attention, and multiple forms of memory. This organization of the DA system, wide projection from a limited number of cell bodies, permits coordinated responses to potent new rewards. Thus, acting in diverse terminal fields, dopamine confers motivational salience ("wanting") on the reward itself or associated cues (nucleus accumbens shell region), updates the value placed on different goals in light of this new experience (orbital prefrontal cortex), helps consolidate multiple forms of memory (amygdala and hippocampus), and encodes new motor programs that will facilitate obtaining this reward in the future (nucleus accumbens core region and dorsal striatum). In this example, dopamine modulates the processing of sensorimotor information in diverse neural circuits to maximize the ability of the organism to obtain future rewards.<span typeof="mw:Entity" id="mwBp8"> </span>...<br id="mwBqA"/>The brain reward circuitry that is targeted by addictive drugs normally mediates the pleasure and strengthening of behaviors associated with natural reinforcers, such as food, water, and sexual contact. Dopamine neurons in the VTA are activated by food and water, and dopamine release in the NAc is stimulated by the presence of natural reinforcers, such as food, water, or a sexual partner.<span typeof="mw:Entity" id="mwBqE"> </span>...<br id="mwBqI"/>The NAc and VTA are central components of the circuitry underlying reward and memory of reward. As previously mentioned, the activity of dopaminergic neurons in the VTA appears to be linked to reward prediction. The NAc is involved in learning associated with reinforcement and the modulation of motoric responses to stimuli that satisfy internal homeostatic needs. The shell of the NAc appears to be particularly important to initial drug actions within reward circuitry; addictive drugs appear to have a greater effect on dopamine release in the shell than in the core of the NAc.<span typeof="mw:Entity" id="mwBqM"> </span>... If motivational drive is described in terms of wanting, and hedonic evaluation in terms of liking, it appears that wanting can be dissociated from liking and that dopamine may influence these phenomena differently. Differences between wanting and liking are confirmed in reports by human addicts, who state that their desire for drugs (wanting) increases with continued use even when pleasure (liking) decreases because of tolerance.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Molecular+Neuropharmacology%3A+A+Foundation+for+Clinical+Neuroscience&amp;rft.place=New+York&amp;rft.pages=147-48%2C+366-67%2C+375-76&amp;rft.edition=2nd&amp;rft.pub=McGraw-Hill+Medical&amp;rft.date=2009&amp;rft.isbn=978-0-07-148127-4&amp;rft.aulast=Malenka&amp;rft.aufirst=RC&amp;rft.au=Nestler%2C+EJ&amp;rft.au=Hyman%2C+SE&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt534" id="mwBqQ"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt534" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBqU"/></span></li><li about="#cite_note-Reinforcement_in_addiction-90" id="cite_note-Reinforcement_in_addiction-90"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-Reinforcement_in_addiction_90-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-Reinforcement_in_addiction_90-1"><span class="mw-linkback-text">2 </span></a><a href="./Addiction#cite_ref-Reinforcement_in_addiction_90-2"><span class="mw-linkback-text">3 </span></a><a href="./Addiction#cite_ref-Reinforcement_in_addiction_90-3"><span class="mw-linkback-text">4 </span></a></span> <span id="mw-reference-text-cite_note-Reinforcement_in_addiction-90" class="mw-reference-text"><cite class="citation book" about="#mwt553" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"Cite book ","href":"./Template:Cite_book"},"params":{"vauthors":{"wt":"Edwards S"},"title":{"wt":"Reinforcement principles for addiction medicine; from recreational drug use to psychiatric disorder"},"journal":{"wt":"Prog. Brain Res."},"volume":{"wt":"223"},"issue":{"wt":""},"pages":{"wt":"63–76"},"year":{"wt":"2016"},"pmid":{"wt":"26806771"},"doi":{"wt":"10.1016/bs.pbr.2015.07.005"},"quote":{"wt":"An important dimension of reinforcement highly relevant to the addiction process (and particularly relapse) is secondary reinforcement (Stewart, 1992). Secondary reinforcers (in many cases also considered conditioned reinforcers) likely drive the majority of reinforcement processes in humans. In the specific case of drug addition, cues and contexts that are intimately and repeatedly associated with drug use will often themselves become reinforcing&amp;nbsp;... A fundamental piece of Robinson and Berridge&apos;s incentive-sensitization theory of addiction posits that the incentive value or attractive nature of such secondary reinforcement processes, in addition to the primary reinforcers themselves, may persist and even become sensitized over time in league with the development of drug addiction (Robinson and Berridge, 1993)."},"series":{"wt":"Progress in Brain Research"},"isbn":{"wt":"978-0-444-63545-7"}},"i":0}}]}' id="mwBqY">Edwards S (2016). <i id="mwBqc">Reinforcement principles for addiction medicine; from recreational drug use to psychiatric disorder</i>. <i id="mwBqg">Prog. Brain Res</i>. Progress in Brain Research. <b id="mwBqk">223</b>. pp.<span typeof="mw:Entity" id="mwBqo"> </span>63–76. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBqs">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1016%2Fbs.pbr.2015.07.005" id="mwBqw">10.1016/bs.pbr.2015.07.005</a>. <a rel="mw:WikiLink" href="./International_Standard_Book_Number" title="International Standard Book Number" id="mwBq0">ISBN</a><span typeof="mw:Entity" id="mwBq4"> </span><a rel="mw:WikiLink" href="./Special:BookSources/978-0-444-63545-7" title="Special:BookSources/978-0-444-63545-7" id="mwBq8">978-0-444-63545-7</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBrA" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBrE"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/26806771" id="mwBrI">26806771</a>. <q id="mwBrM">An important dimension of reinforcement highly relevant to the addiction process (and particularly relapse) is secondary reinforcement (Stewart, 1992). Secondary reinforcers (in many cases also considered conditioned reinforcers) likely drive the majority of reinforcement processes in humans. In the specific case of drug addition, cues and contexts that are intimately and repeatedly associated with drug use will often themselves become reinforcing<span typeof="mw:Entity" id="mwBrQ"> </span>... A fundamental piece of Robinson and Berridge's incentive-sensitization theory of addiction posits that the incentive value or attractive nature of such secondary reinforcement processes, in addition to the primary reinforcers themselves, may persist and even become sensitized over time in league with the development of drug addiction (Robinson and Berridge, 1993).</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Reinforcement+principles+for+addiction+medicine%3B+from+recreational+drug+use+to+psychiatric+disorder&amp;rft.series=Progress+in+Brain+Research&amp;rft.pages=63-76&amp;rft.date=2016&amp;rft_id=info%3Apmid%2F26806771&amp;rft_id=info%3Adoi%2F10.1016%2Fbs.pbr.2015.07.005&amp;rft.isbn=978-0-444-63545-7&amp;rft.aulast=Edwards&amp;rft.aufirst=S&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt553" id="mwBrU"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt553" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBrY"/></span></li><li about="#cite_note-Pleasure_system_-_incentive_sensitization-91" id="cite_note-Pleasure_system_-_incentive_sensitization-91"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-Pleasure_system_-_incentive_sensitization_91-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-Pleasure_system_-_incentive_sensitization_91-1"><span class="mw-linkback-text">2 </span></a></span> <span id="mw-reference-text-cite_note-Pleasure_system_-_incentive_sensitization-91" class="mw-reference-text"><cite class="citation journal" about="#mwt554" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Berridge KC, Kringelbach ML"},"title":{"wt":"Pleasure systems in the brain"},"journal":{"wt":"Neuron"},"volume":{"wt":"86"},"issue":{"wt":"3"},"pages":{"wt":"646–64"},"date":{"wt":"May 2015"},"pmid":{"wt":"25950633"},"doi":{"wt":"10.1016/j.neuron.2015.02.018"},"pmc":{"wt":"4425246"}},"i":0}}]}' id="mwBrc">Berridge KC, Kringelbach ML (May 2015). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4425246" id="mwBrg">"Pleasure systems in the brain"</a>. <i id="mwBrk">Neuron</i>. <b id="mwBro">86</b> (3): 646–64. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBrs">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1016%2Fj.neuron.2015.02.018" id="mwBrw">10.1016/j.neuron.2015.02.018</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwBr0">PMC</a><span typeof="mw:Entity" id="mwBr4"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwBr8"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4425246" id="mwBsA">4425246</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBsE" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBsI"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/25950633" id="mwBsM">25950633</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Neuron&amp;rft.atitle=Pleasure+systems+in+the+brain&amp;rft.volume=86&amp;rft.issue=3&amp;rft.pages=646-64&amp;rft.date=2015-05&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4425246&amp;rft_id=info%3Apmid%2F25950633&amp;rft_id=info%3Adoi%2F10.1016%2Fj.neuron.2015.02.018&amp;rft.aulast=Berridge&amp;rft.aufirst=KC&amp;rft.au=Kringelbach%2C+ML&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4425246&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt554" id="mwBsQ"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt554" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBsU"/></span></li><li about="#cite_note-RGS_opioid-93" id="cite_note-RGS_opioid-93"><a href="./Addiction#cite_ref-RGS_opioid_93-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-RGS_opioid-93" class="mw-reference-text"><cite class="citation journal" about="#mwt591" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Traynor J"},"title":{"wt":"μ-Opioid receptors and regulators of G protein signaling (RGS) proteins: from a symposium on new concepts in mu-opioid pharmacology"},"journal":{"wt":"Drug Alcohol Depend"},"volume":{"wt":"121"},"issue":{"wt":"3"},"pages":{"wt":"173–80"},"date":{"wt":"March 2012"},"pmid":{"wt":"22129844"},"pmc":{"wt":"3288798"},"doi":{"wt":"10.1016/j.drugalcdep.2011.10.027"},"quote":{"wt":""}},"i":0}}]}' id="mwBsY">Traynor J (March 2012). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3288798" id="mwBsc">"μ-Opioid receptors and regulators of G protein signaling (RGS) proteins: from a symposium on new concepts in mu-opioid pharmacology"</a>. <i id="mwBsg">Drug Alcohol Depend</i>. <b id="mwBsk">121</b> (3): 173–80. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBso">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1016%2Fj.drugalcdep.2011.10.027" id="mwBss">10.1016/j.drugalcdep.2011.10.027</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwBsw">PMC</a><span typeof="mw:Entity" id="mwBs0"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwBs4"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3288798" id="mwBs8">3288798</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBtA" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBtE"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22129844" id="mwBtI">22129844</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Drug+Alcohol+Depend&amp;rft.atitle=%CE%BC-Opioid+receptors+and+regulators+of+G+protein+signaling+%28RGS%29+proteins%3A+from+a+symposium+on+new+concepts+in+mu-opioid+pharmacology&amp;rft.volume=121&amp;rft.issue=3&amp;rft.pages=173-80&amp;rft.date=2012-03&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3288798&amp;rft_id=info%3Apmid%2F22129844&amp;rft_id=info%3Adoi%2F10.1016%2Fj.drugalcdep.2011.10.027&amp;rft.aulast=Traynor&amp;rft.aufirst=J&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3288798&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt591" id="mwBtM"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt591" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBtQ"/></span></li><li about="#cite_note-Chromatin_states-94" id="cite_note-Chromatin_states-94"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-Chromatin_states_94-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-Chromatin_states_94-1"><span class="mw-linkback-text">2 </span></a><a href="./Addiction#cite_ref-Chromatin_states_94-2"><span class="mw-linkback-text">3 </span></a><a href="./Addiction#cite_ref-Chromatin_states_94-3"><span class="mw-linkback-text">4 </span></a><a href="./Addiction#cite_ref-Chromatin_states_94-4"><span class="mw-linkback-text">5 </span></a><a href="./Addiction#cite_ref-Chromatin_states_94-5"><span class="mw-linkback-text">6 </span></a><a href="./Addiction#cite_ref-Chromatin_states_94-6"><span class="mw-linkback-text">7 </span></a><a href="./Addiction#cite_ref-Chromatin_states_94-7"><span class="mw-linkback-text">8 </span></a></span> <span id="mw-reference-text-cite_note-Chromatin_states-94" class="mw-reference-text"><cite class="citation journal" about="#mwt848" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"vcite2 journal ","href":"./Template:Vcite2_journal"},"params":{"vauthors":{"wt":"Walker DM, Cates HM, Heller EA, Nestler EJ"},"title":{"wt":"Regulation of chromatin states by drugs of abuse"},"journal":{"wt":"Curr. Opin. Neurobiol."},"volume":{"wt":"30"},"issue":{"wt":""},"pages":{"wt":"112–21"},"date":{"wt":"February 2015"},"pmid":{"wt":"25486626"},"doi":{"wt":"10.1016/j.conb.2014.11.002"},"quote":{"wt":"Studies investigating general HDAC inhibition on behavioral outcomes have produced varying results but it seems that the effects are specific to the timing of exposure (either before, during or after exposure to drugs of abuse) as well as the length of exposure"},"pmc":{"wt":"4293340"}},"i":0}}]}' id="mwBtU">Walker DM, Cates HM, Heller EA, Nestler EJ (February 2015). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4293340" id="mwBtY">"Regulation of chromatin states by drugs of abuse"</a>. <i id="mwBtc">Curr. Opin. Neurobiol</i>. <b id="mwBtg">30</b>: 112–21. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBtk">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1016%2Fj.conb.2014.11.002" id="mwBto">10.1016/j.conb.2014.11.002</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwBts">PMC</a><span typeof="mw:Entity" id="mwBtw"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwBt0"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4293340" id="mwBt4">4293340</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBt8" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBuA"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/25486626" id="mwBuE">25486626</a>. <q id="mwBuI">Studies investigating general HDAC inhibition on behavioral outcomes have produced varying results but it seems that the effects are specific to the timing of exposure (either before, during or after exposure to drugs of abuse) as well as the length of exposure</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Curr.+Opin.+Neurobiol.&amp;rft.atitle=Regulation+of+chromatin+states+by+drugs+of+abuse&amp;rft.volume=30&amp;rft.pages=112-21&amp;rft.date=2015-02&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4293340&amp;rft_id=info%3Apmid%2F25486626&amp;rft_id=info%3Adoi%2F10.1016%2Fj.conb.2014.11.002&amp;rft.aulast=Walker&amp;rft.aufirst=DM&amp;rft.au=Cates%2C+HM&amp;rft.au=Heller%2C+EA&amp;rft.au=Nestler%2C+EJ&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4293340&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt848" id="mwBuM"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt848" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBuQ"/></span></li><li about="#cite_note-95" id="cite_note-95"><a href="./Addiction#cite_ref-95" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-95" class="mw-reference-text"><cite class="citation journal" about="#mwt631" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Petry NM, Rehbein F, Gentile DA, Lemmens JS, Rumpf HJ, Mößle T, Bischof G, Tao R, Fung DS, Borges G, Auriacombe M, González Ibáñez A, Tam P, O&apos;Brien CP"},"title":{"wt":"An international consensus for assessing internet gaming disorder using the new DSM-5 approach"},"journal":{"wt":"Addiction"},"volume":{"wt":"109"},"issue":{"wt":"9"},"pages":{"wt":"1399–406"},"date":{"wt":"September 2014"},"pmid":{"wt":"24456155"},"doi":{"wt":"10.1111/add.12457"}},"i":0}}]}' id="mwBuU">Petry NM, Rehbein F, Gentile DA, Lemmens JS, Rumpf HJ, Mößle T, Bischof G, Tao R, Fung DS, Borges G, Auriacombe M, González Ibáñez A, Tam P, O'Brien CP (September 2014). "An international consensus for assessing internet gaming disorder using the new DSM-5 approach". <i id="mwBuY">Addiction</i>. <b id="mwBuc">109</b> (9): 1399–406. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBug">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1111%2Fadd.12457" id="mwBuk">10.1111/add.12457</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBuo" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBus"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/24456155" id="mwBuw">24456155</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Addiction&amp;rft.atitle=An+international+consensus+for+assessing+internet+gaming+disorder+using+the+new+DSM-5+approach&amp;rft.volume=109&amp;rft.issue=9&amp;rft.pages=1399-406&amp;rft.date=2014-09&amp;rft_id=info%3Adoi%2F10.1111%2Fadd.12457&amp;rft_id=info%3Apmid%2F24456155&amp;rft.aulast=Petry&amp;rft.aufirst=NM&amp;rft.au=Rehbein%2C+F&amp;rft.au=Gentile%2C+DA&amp;rft.au=Lemmens%2C+JS&amp;rft.au=Rumpf%2C+HJ&amp;rft.au=M%C3%B6%C3%9Fle%2C+T&amp;rft.au=Bischof%2C+G&amp;rft.au=Tao%2C+R&amp;rft.au=Fung%2C+DS&amp;rft.au=Borges%2C+G&amp;rft.au=Auriacombe%2C+M&amp;rft.au=Gonz%C3%A1lez+Ib%C3%A1%C3%B1ez%2C+A&amp;rft.au=Tam%2C+P&amp;rft.au=O%27Brien%2C+CP&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt631" id="mwBu0"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt631" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBu4"/></span></li><li about="#cite_note-pmid10511013-96" id="cite_note-pmid10511013-96"><a href="./Addiction#cite_ref-pmid10511013_96-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-pmid10511013-96" class="mw-reference-text"><cite class="citation journal" about="#mwt635" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Torres G, Horowitz JM"},"title":{"wt":"Drugs of abuse and brain gene expression"},"journal":{"wt":"Psychosom Med"},"volume":{"wt":"61"},"issue":{"wt":"5"},"pages":{"wt":"630–50"},"year":{"wt":"1999"},"pmid":{"wt":"10511013"},"doi":{"wt":"10.1097/00006842-199909000-00007"},"citeseerx":{"wt":"10.1.1.326.4903"}},"i":0}}]}' id="mwBu8">Torres G, Horowitz JM (1999). "Drugs of abuse and brain gene expression". <i id="mwBvA">Psychosom Med</i>. <b id="mwBvE">61</b> (5): 630–50. <a rel="mw:WikiLink" href="./CiteSeerX" title="CiteSeerX" id="mwBvI">CiteSeerX</a><span typeof="mw:Entity" id="mwBvM"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwBvQ"><a rel="mw:ExtLink" class="external text" href="//citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.326.4903" id="mwBvU">10.1.1.326.4903</a></span>. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBvY">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1097%2F00006842-199909000-00007" id="mwBvc">10.1097/00006842-199909000-00007</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBvg" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBvk"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/10511013" id="mwBvo">10511013</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Psychosom+Med&amp;rft.atitle=Drugs+of+abuse+and+brain+gene+expression&amp;rft.volume=61&amp;rft.issue=5&amp;rft.pages=630-50&amp;rft.date=1999&amp;rft_id=%2F%2Fciteseerx.ist.psu.edu%2Fviewdoc%2Fsummary%3Fdoi%3D10.1.1.326.4903&amp;rft_id=info%3Apmid%2F10511013&amp;rft_id=info%3Adoi%2F10.1097%2F00006842-199909000-00007&amp;rft.aulast=Torres&amp;rft.aufirst=G&amp;rft.au=Horowitz%2C+JM&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt635" id="mwBvs"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt635" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBvw"/></span></li><li about="#cite_note-DSM-V_Insel-97" id="cite_note-DSM-V_Insel-97"><a href="./Addiction#cite_ref-DSM-V_Insel_97-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-DSM-V_Insel-97" class="mw-reference-text"><cite class="citation web" about="#mwt639" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite web","href":"./Template:Cite_web"},"params":{"author1":{"wt":"Thomas Insel"},"title":{"wt":"Transforming Diagnosis"},"url":{"wt":"http://www.nimh.nih.gov/about/director/2013/transforming-diagnosis.shtml"},"publisher":{"wt":"National Institute of Mental Health"},"accessdate":{"wt":"17 June 2015"}},"i":0}}]}' id="mwBv0">Thomas Insel. <a rel="mw:ExtLink" class="external text" href="http://www.nimh.nih.gov/about/director/2013/transforming-diagnosis.shtml" id="mwBv4">"Transforming Diagnosis"</a>. National Institute of Mental Health<span class="reference-accessdate" id="mwBv8">. Retrieved <span class="nowrap" id="mwBwA">17 June</span> 2015</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Transforming+Diagnosis&amp;rft.pub=National+Institute+of+Mental+Health&amp;rft.au=Thomas+Insel&amp;rft_id=http%3A%2F%2Fwww.nimh.nih.gov%2Fabout%2Fdirector%2F2013%2Ftransforming-diagnosis.shtml&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt639" id="mwBwE"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt639" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBwI"/></span></li><li about="#cite_note-German_meta-analysis-98" id="cite_note-German_meta-analysis-98"><a href="./Addiction#cite_ref-German_meta-analysis_98-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-German_meta-analysis-98" class="mw-reference-text"><cite class="citation journal" about="#mwt645" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Walter M, Dürsteler KM, Petitjean SA, Wiesbeck GA, Euler S, Sollberger D, Lang UE, Vogel M"},"title":{"wt":"[Psychosocial Treatment of Addictive Disorders – An Overview of Psychotherapeutic Options and their Efficacy]"},"language":{"wt":"German"},"journal":{"wt":"Fortschr Neurol Psychiatr"},"volume":{"wt":"83"},"issue":{"wt":"4"},"pages":{"wt":"201–10"},"year":{"wt":"2015"},"pmid":{"wt":"25893493"},"doi":{"wt":"10.1055/s-0034-1399338"},"quote":{"wt":"Addictive disorders are chronic relapsing conditions marked by compulsive and often uncontrolled use of psychotropic substances or stimuli. In this review, we present and discuss the current specific psychosocial interventions for addictive disorders and their effectiveness. In particular cognitive behavioral therapy, motivational interviewing, relapse prevention, the community reinforcement approach, and contingency management were found to be effective. For these psychotherapeutic treatments, mostly moderate effect sizes have been found. Their effectiveness seems to be highest in cannabis dependence. Empirical evidence for dependence on \"hard\" drugs is largest for contingency management, while for alcohol dependence motivational interviewing and the community reinforcement approach show the largest effect sizes. Presumably, combinations of different approaches as well as online interventions will bring further progress in the psychosocial treatment of addictive disorders in the future."}},"i":0}}]}' id="mwBwM">Walter M, Dürsteler KM, Petitjean SA, Wiesbeck GA, Euler S, Sollberger D, Lang UE, Vogel M (2015). "[Psychosocial Treatment of Addictive Disorders – An Overview of Psychotherapeutic Options and their Efficacy]". <i id="mwBwQ">Fortschr Neurol Psychiatr</i> (in German). <b id="mwBwU">83</b> (4): 201–10. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBwY">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1055%2Fs-0034-1399338" id="mwBwc">10.1055/s-0034-1399338</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBwg" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBwk"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/25893493" id="mwBwo">25893493</a>. <q id="mwBws">Addictive disorders are chronic relapsing conditions marked by compulsive and often uncontrolled use of psychotropic substances or stimuli. In this review, we present and discuss the current specific psychosocial interventions for addictive disorders and their effectiveness. In particular cognitive behavioral therapy, motivational interviewing, relapse prevention, the community reinforcement approach, and contingency management were found to be effective. For these psychotherapeutic treatments, mostly moderate effect sizes have been found. Their effectiveness seems to be highest in cannabis dependence. Empirical evidence for dependence on "hard" drugs is largest for contingency management, while for alcohol dependence motivational interviewing and the community reinforcement approach show the largest effect sizes. Presumably, combinations of different approaches as well as online interventions will bring further progress in the psychosocial treatment of addictive disorders in the future.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Fortschr+Neurol+Psychiatr&amp;rft.atitle=%5BPsychosocial+Treatment+of+Addictive+Disorders+%E2%80%93+An+Overview+of+Psychotherapeutic+Options+and+their+Efficacy%5D&amp;rft.volume=83&amp;rft.issue=4&amp;rft.pages=201-10&amp;rft.date=2015&amp;rft_id=info%3Adoi%2F10.1055%2Fs-0034-1399338&amp;rft_id=info%3Apmid%2F25893493&amp;rft.aulast=Walter&amp;rft.aufirst=M&amp;rft.au=D%C3%BCrsteler%2C+KM&amp;rft.au=Petitjean%2C+SA&amp;rft.au=Wiesbeck%2C+GA&amp;rft.au=Euler%2C+S&amp;rft.au=Sollberger%2C+D&amp;rft.au=Lang%2C+UE&amp;rft.au=Vogel%2C+M&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt645" id="mwBww"></span><link rel="mw:PageProp/Category" href="./Category:CS1_German-language_sources_(de)" about="#mwt645" id="mwBw0"/><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt645" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwBw4"/></span></li><li about="#cite_note-Addiction_review_2016-99" id="cite_note-Addiction_review_2016-99"><a href="./Addiction#cite_ref-Addiction_review_2016_99-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-Addiction_review_2016-99" class="mw-reference-text"><cite class="citation journal" about="#mwt659" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Carroll ME, Smethells JR"},"title":{"wt":"Sex Differences in Behavioral Dyscontrol: Role in Drug Addiction and Novel Treatments"},"journal":{"wt":"Front. Psychiatry"},"volume":{"wt":"6"},"issue":{"wt":""},"pages":{"wt":"175"},"date":{"wt":"February 2016"},"pmid":{"wt":"26903885"},"pmc":{"wt":"4745113"},"doi":{"wt":"10.3389/fpsyt.2015.00175"},"quote":{"wt":"Environmental Enrichment&amp;nbsp;...&lt;br />In humans, non-drug rewards delivered in a contingency management (CM) format successfully reduced drug dependence&amp;nbsp;... In general, CM programs promote drug abstinence through a combination of positive reinforcement for drug-free urine samples. For instance, voucher-based reinforcement therapy in which medication compliance, therapy session attendance, and negative drug screenings reinforced with vouchers to local business (e.g., movie theater, restaurants, etc.) directly reinforces drug abstinence, provides competing reinforcers, enriches the environment, and it is a robust treatment across a broad range of abused drugs (189).&amp;nbsp;...&lt;br />Physical Exercise&lt;br />There is accelerating evidence that physical exercise is a useful treatment for preventing and reducing drug addiction&amp;nbsp;... In some individuals, exercise has its own rewarding effects, and a behavioral economic interaction may occur, such that physical and social rewards of exercise can substitute for the rewarding effects of drug abuse.&amp;nbsp;... The value of this form of treatment for drug addiction in laboratory animals and humans is that exercise, if it can substitute for the rewarding effects of drugs, could be self-maintained over an extended period of time. Work to date in [laboratory animals and humans] regarding exercise as a treatment for drug addiction supports this hypothesis.&amp;nbsp;... However, a &lt;abbr title=\"randomized controlled trial\">RTC&lt;/abbr> study was recently reported by Rawson et al. (226), whereby they used 8 weeks of exercise as a post-residential treatment for METH addiction, showed a significant reduction in use (confirmed by urine screens) in participants who had been using meth 18 days or less a month.&amp;nbsp;... &apos;&apos;&apos;Animal and human research on physical exercise as a treatment for stimulant addiction indicates that this is one of the most promising treatments on the horizon.&apos;&apos;&apos; [emphasis added]"}},"i":0}}]}' id="mwBw8">Carroll ME, Smethells JR (February 2016). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4745113" id="mwBxA">"Sex Differences in Behavioral Dyscontrol: Role in Drug Addiction and Novel Treatments"</a>. <i id="mwBxE">Front. Psychiatry</i>. <b id="mwBxI">6</b>: 175. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBxM">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.3389%2Ffpsyt.2015.00175" id="mwBxQ">10.3389/fpsyt.2015.00175</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwBxU">PMC</a><span typeof="mw:Entity" id="mwBxY"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwBxc"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4745113" id="mwBxg">4745113</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBxk" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBxo"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/26903885" id="mwBxs">26903885</a>. <q id="mwBxw">Environmental Enrichment<span typeof="mw:Entity" id="mwBx0"> </span>...<br id="mwBx4"/>In humans, non-drug rewards delivered in a contingency management (CM) format successfully reduced drug dependence<span typeof="mw:Entity" id="mwBx8"> </span>... In general, CM programs promote drug abstinence through a combination of positive reinforcement for drug-free urine samples. For instance, voucher-based reinforcement therapy in which medication compliance, therapy session attendance, and negative drug screenings reinforced with vouchers to local business (e.g., movie theater, restaurants, etc.) directly reinforces drug abstinence, provides competing reinforcers, enriches the environment, and it is a robust treatment across a broad range of abused drugs (189).<span typeof="mw:Entity" id="mwByA"> </span>...<br id="mwByE"/>Physical Exercise<br id="mwByI"/>There is accelerating evidence that physical exercise is a useful treatment for preventing and reducing drug addiction<span typeof="mw:Entity" id="mwByM"> </span>... In some individuals, exercise has its own rewarding effects, and a behavioral economic interaction may occur, such that physical and social rewards of exercise can substitute for the rewarding effects of drug abuse.<span typeof="mw:Entity" id="mwByQ"> </span>... The value of this form of treatment for drug addiction in laboratory animals and humans is that exercise, if it can substitute for the rewarding effects of drugs, could be self-maintained over an extended period of time. Work to date in [laboratory animals and humans] regarding exercise as a treatment for drug addiction supports this hypothesis.<span typeof="mw:Entity" id="mwByU"> </span>... However, a <abbr title="randomized controlled trial" id="mwByY">RTC</abbr> study was recently reported by Rawson et al. (226), whereby they used 8 weeks of exercise as a post-residential treatment for METH addiction, showed a significant reduction in use (confirmed by urine screens) in participants who had been using meth 18 days or less a month.<span typeof="mw:Entity" id="mwByc"> </span>... <b id="mwByg">Animal and human research on physical exercise as a treatment for stimulant addiction indicates that this is one of the most promising treatments on the horizon.</b> [emphasis added]</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Front.+Psychiatry&amp;rft.atitle=Sex+Differences+in+Behavioral+Dyscontrol%3A+Role+in+Drug+Addiction+and+Novel+Treatments&amp;rft.volume=6&amp;rft.pages=175&amp;rft.date=2016-02&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4745113&amp;rft_id=info%3Apmid%2F26903885&amp;rft_id=info%3Adoi%2F10.3389%2Ffpsyt.2015.00175&amp;rft.aulast=Carroll&amp;rft.aufirst=ME&amp;rft.au=Smethells%2C+JR&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4745113&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt659" id="mwByk"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt659" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwByo"/></span></li><li about="#cite_note-Running_vs_addiction-100" id="cite_note-Running_vs_addiction-100"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-Running_vs_addiction_100-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-Running_vs_addiction_100-1"><span class="mw-linkback-text">2 </span></a><a href="./Addiction#cite_ref-Running_vs_addiction_100-2"><span class="mw-linkback-text">3 </span></a><a href="./Addiction#cite_ref-Running_vs_addiction_100-3"><span class="mw-linkback-text">4 </span></a></span> <span id="mw-reference-text-cite_note-Running_vs_addiction-100" class="mw-reference-text"><cite class="citation journal" about="#mwt660" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Lynch WJ, Peterson AB, Sanchez V, Abel J, Smith MA"},"title":{"wt":"Exercise as a novel treatment for drug addiction: a neurobiological and stage-dependent hypothesis"},"journal":{"wt":"Neurosci Biobehav Rev"},"volume":{"wt":"37"},"issue":{"wt":"8"},"pages":{"wt":"1622–44"},"date":{"wt":"September 2013"},"pmid":{"wt":"23806439"},"pmc":{"wt":"3788047"},"doi":{"wt":"10.1016/j.neubiorev.2013.06.011"},"quote":{"wt":"[exercise] efficacy may be related to its ability to normalize glutamatergic and dopaminergic signaling and reverse drug-induced changes in chromatin via epigenetic interactions with brain-derived neurotrophic factor (BDNF) in the reward pathway.&amp;nbsp;... these data show that exercise can affect dopaminergic signaling at many different levels, which may underlie its ability to modify vulnerability during drug use initiation. Exercise also produces neuroadaptations that may influence an individual&apos;s vulnerability to initiate drug use. Consistent with this idea, chronic moderate levels of forced treadmill running blocks not only subsequent methamphetamine-induced conditioned place preference, but also stimulant-induced increases in dopamine release in the NAc (Chen et al., 2008) and striatum (Marques et al., 2008).&amp;nbsp;... [These] findings indicate the efficacy of exercise at reducing drug intake in drug-dependent individuals&amp;nbsp;... wheel running [reduces] methamphetamine self-administration under extended access conditions (Engelmann et al., 2013)&amp;nbsp;... These findings suggest that exercise may \"magnitude\"-dependently prevent the development of an addicted phenotype possibly by blocking/reversing behavioral and neuro-adaptive changes that develop during and following extended access to the drug.&amp;nbsp;... Exercise has been proposed as a treatment for drug addiction that may reduce drug craving and risk of relapse. Although few clinical studies have investigated the efficacy of exercise for preventing relapse, the few studies that have been conducted generally report a reduction in drug craving and better treatment outcomes (see Table 4).&amp;nbsp;... Taken together, these data suggest that the potential benefits of exercise during relapse, particularly for relapse to psychostimulants, may be mediated via chromatin remodeling and possibly lead to greater treatment outcomes."}},"i":0}}]}' id="mwBys">Lynch WJ, Peterson AB, Sanchez V, Abel J, Smith MA (September 2013). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3788047" id="mwByw">"Exercise as a novel treatment for drug addiction: a neurobiological and stage-dependent hypothesis"</a>. <i id="mwBy0">Neurosci Biobehav Rev</i>. <b id="mwBy4">37</b> (8): 1622–44. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwBy8">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1016%2Fj.neubiorev.2013.06.011" id="mwBzA">10.1016/j.neubiorev.2013.06.011</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwBzE">PMC</a><span typeof="mw:Entity" id="mwBzI"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwBzM"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3788047" id="mwBzQ">3788047</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwBzU" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwBzY"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23806439" id="mwBzc">23806439</a>. <q id="mwBzg">[exercise] efficacy may be related to its ability to normalize glutamatergic and dopaminergic signaling and reverse drug-induced changes in chromatin via epigenetic interactions with brain-derived neurotrophic factor (BDNF) in the reward pathway.<span typeof="mw:Entity" id="mwBzk"> </span>... these data show that exercise can affect dopaminergic signaling at many different levels, which may underlie its ability to modify vulnerability during drug use initiation. Exercise also produces neuroadaptations that may influence an individual's vulnerability to initiate drug use. Consistent with this idea, chronic moderate levels of forced treadmill running blocks not only subsequent methamphetamine-induced conditioned place preference, but also stimulant-induced increases in dopamine release in the NAc (Chen et al., 2008) and striatum (Marques et al., 2008).<span typeof="mw:Entity" id="mwBzo"> </span>... [These] findings indicate the efficacy of exercise at reducing drug intake in drug-dependent individuals<span typeof="mw:Entity" id="mwBzs"> </span>... wheel running [reduces] methamphetamine self-administration under extended access conditions (Engelmann et al., 2013)<span typeof="mw:Entity" id="mwBzw"> </span>... These findings suggest that exercise may "magnitude"-dependently prevent the development of an addicted phenotype possibly by blocking/reversing behavioral and neuro-adaptive changes that develop during and following extended access to the drug.<span typeof="mw:Entity" id="mwBz0"> </span>... Exercise has been proposed as a treatment for drug addiction that may reduce drug craving and risk of relapse. Although few clinical studies have investigated the efficacy of exercise for preventing relapse, the few studies that have been conducted generally report a reduction in drug craving and better treatment outcomes (see Table 4).<span typeof="mw:Entity" id="mwBz4"> </span>... Taken together, these data suggest that the potential benefits of exercise during relapse, particularly for relapse to psychostimulants, may be mediated via chromatin remodeling and possibly lead to greater treatment outcomes.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Neurosci+Biobehav+Rev&amp;rft.atitle=Exercise+as+a+novel+treatment+for+drug+addiction%3A+a+neurobiological+and+stage-dependent+hypothesis&amp;rft.volume=37&amp;rft.issue=8&amp;rft.pages=1622-44&amp;rft.date=2013-09&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3788047&amp;rft_id=info%3Apmid%2F23806439&amp;rft_id=info%3Adoi%2F10.1016%2Fj.neubiorev.2013.06.011&amp;rft.aulast=Lynch&amp;rft.aufirst=WJ&amp;rft.au=Peterson%2C+AB&amp;rft.au=Sanchez%2C+V&amp;rft.au=Abel%2C+J&amp;rft.au=Smith%2C+MA&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3788047&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt660" id="mwBz8"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt660" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwB0A"/></span></li><li about="#cite_note-Exercise_Rev_3-101" id="cite_note-Exercise_Rev_3-101"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-Exercise_Rev_3_101-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-Exercise_Rev_3_101-1"><span class="mw-linkback-text">2 </span></a></span> <span id="mw-reference-text-cite_note-Exercise_Rev_3-101" class="mw-reference-text"><cite class="citation journal" about="#mwt663" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Linke SE, Ussher M"},"title":{"wt":"Exercise-based treatments for substance use disorders: evidence, theory, and practicality"},"journal":{"wt":"Am J Drug Alcohol Abuse"},"volume":{"wt":"41"},"issue":{"wt":"1"},"pages":{"wt":"7–15"},"year":{"wt":"2015"},"pmid":{"wt":"25397661"},"doi":{"wt":"10.3109/00952990.2014.976708"},"quote":{"wt":"The limited research conducted suggests that exercise may be an effective adjunctive treatment for SUDs. In contrast to the scarce intervention trials to date, a relative abundance of literature on the theoretical and practical reasons supporting the investigation of this topic has been published.&amp;nbsp;... numerous theoretical and practical reasons support exercise-based treatments for SUDs, including psychological, behavioral, neurobiological, nearly universal safety profile, and overall positive health effects."},"pmc":{"wt":"4831948"}},"i":0}}]}' id="mwB0E">Linke SE, Ussher M (2015). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4831948" id="mwB0I">"Exercise-based treatments for substance use disorders: evidence, theory, and practicality"</a>. <i id="mwB0M">Am J Drug Alcohol Abuse</i>. <b id="mwB0Q">41</b> (1): 7–15. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwB0U">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.3109%2F00952990.2014.976708" id="mwB0Y">10.3109/00952990.2014.976708</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwB0c">PMC</a><span typeof="mw:Entity" id="mwB0g"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwB0k"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4831948" id="mwB0o">4831948</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwB0s" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwB0w"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/25397661" id="mwB00">25397661</a>. <q id="mwB04">The limited research conducted suggests that exercise may be an effective adjunctive treatment for SUDs. In contrast to the scarce intervention trials to date, a relative abundance of literature on the theoretical and practical reasons supporting the investigation of this topic has been published.<span typeof="mw:Entity" id="mwB08"> </span>... numerous theoretical and practical reasons support exercise-based treatments for SUDs, including psychological, behavioral, neurobiological, nearly universal safety profile, and overall positive health effects.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Am+J+Drug+Alcohol+Abuse&amp;rft.atitle=Exercise-based+treatments+for+substance+use+disorders%3A+evidence%2C+theory%2C+and+practicality&amp;rft.volume=41&amp;rft.issue=1&amp;rft.pages=7-15&amp;rft.date=2015&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4831948&amp;rft_id=info%3Apmid%2F25397661&amp;rft_id=info%3Adoi%2F10.3109%2F00952990.2014.976708&amp;rft.aulast=Linke&amp;rft.aufirst=SE&amp;rft.au=Ussher%2C+M&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4831948&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt663" id="mwB1A"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt663" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwB1E"/></span></li><li about="#cite_note-Exercise,_addiction_prevention,_and_ΔFosB-102" id="cite_note-Exercise,_addiction_prevention,_and_ΔFosB-102"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-Exercise,_addiction_prevention,_and_ΔFosB_102-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-Exercise,_addiction_prevention,_and_ΔFosB_102-1"><span class="mw-linkback-text">2 </span></a></span> <span id="mw-reference-text-cite_note-Exercise,_addiction_prevention,_and_ΔFosB-102" class="mw-reference-text"><cite class="citation journal" about="#mwt661" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Zhou Y, Zhao M, Zhou C, Li R"},"title":{"wt":"Sex differences in drug addiction and response to exercise intervention: From human to animal studies"},"journal":{"wt":"Front. Neuroendocrinol."},"volume":{"wt":"40"},"issue":{"wt":""},"pages":{"wt":"24–41"},"date":{"wt":"July 2015"},"pmid":{"wt":"26182835"},"doi":{"wt":"10.1016/j.yfrne.2015.07.001"},"quote":{"wt":"Collectively, these findings demonstrate that exercise may serve as a substitute or competition for drug abuse by changing ΔFosB or cFos immunoreactivity in the reward system to protect against later or previous drug use.&amp;nbsp;... As briefly reviewed above, a large number of human and rodent studies clearly show that there are sex differences in drug addiction and exercise. The sex differences are also found in the effectiveness of exercise on drug addiction prevention and treatment, as well as underlying neurobiological mechanisms. The postulate that exercise serves as an ideal intervention for drug addiction has been widely recognized and used in human and animal rehabilitation.&amp;nbsp;... In particular, more studies on the neurobiological mechanism of exercise and its roles in preventing and treating drug addiction are needed."},"pmc":{"wt":"4712120"}},"i":0}}]}' id="mwB1I">Zhou Y, Zhao M, Zhou C, Li R (July 2015). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4712120" id="mwB1M">"Sex differences in drug addiction and response to exercise intervention: From human to animal studies"</a>. <i id="mwB1Q">Front. Neuroendocrinol</i>. <b id="mwB1U">40</b>: 24–41. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwB1Y">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1016%2Fj.yfrne.2015.07.001" id="mwB1c">10.1016/j.yfrne.2015.07.001</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwB1g">PMC</a><span typeof="mw:Entity" id="mwB1k"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwB1o"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4712120" id="mwB1s">4712120</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwB1w" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwB10"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/26182835" id="mwB14">26182835</a>. <q id="mwB18">Collectively, these findings demonstrate that exercise may serve as a substitute or competition for drug abuse by changing ΔFosB or cFos immunoreactivity in the reward system to protect against later or previous drug use.<span typeof="mw:Entity" id="mwB2A"> </span>... As briefly reviewed above, a large number of human and rodent studies clearly show that there are sex differences in drug addiction and exercise. The sex differences are also found in the effectiveness of exercise on drug addiction prevention and treatment, as well as underlying neurobiological mechanisms. The postulate that exercise serves as an ideal intervention for drug addiction has been widely recognized and used in human and animal rehabilitation.<span typeof="mw:Entity" id="mwB2E"> </span>... In particular, more studies on the neurobiological mechanism of exercise and its roles in preventing and treating drug addiction are needed.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Front.+Neuroendocrinol.&amp;rft.atitle=Sex+differences+in+drug+addiction+and+response+to+exercise+intervention%3A+From+human+to+animal+studies&amp;rft.volume=40&amp;rft.pages=24-41&amp;rft.date=2015-07&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4712120&amp;rft_id=info%3Apmid%2F26182835&amp;rft_id=info%3Adoi%2F10.1016%2Fj.yfrne.2015.07.001&amp;rft.aulast=Zhou&amp;rft.aufirst=Y&amp;rft.au=Zhao%2C+M&amp;rft.au=Zhou%2C+C&amp;rft.au=Li%2C+R&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4712120&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt661" id="mwB2I"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt661" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwB2M"/></span></li><li about="#cite_note-103" id="cite_note-103"><a href="./Addiction#cite_ref-103" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-103" class="mw-reference-text"><cite class="citation journal" about="#mwt688" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Soyka M, Roesner S"},"title":{"wt":"New pharmacological approaches for the treatment of alcoholism"},"journal":{"wt":"Expert Opinion on Pharmacotherapy"},"volume":{"wt":"7"},"issue":{"wt":"17"},"pages":{"wt":"2341–53"},"date":{"wt":"December 2006"},"pmid":{"wt":"17109610"},"doi":{"wt":"10.1517/14656566.7.17.2341"}},"i":0}}]}' id="mwB2Q">Soyka M, Roesner S (December 2006). "New pharmacological approaches for the treatment of alcoholism". <i id="mwB2U">Expert Opinion on Pharmacotherapy</i>. <b id="mwB2Y">7</b> (17): 2341–53. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwB2c">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1517%2F14656566.7.17.2341" id="mwB2g">10.1517/14656566.7.17.2341</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwB2k" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwB2o"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17109610" id="mwB2s">17109610</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Expert+Opinion+on+Pharmacotherapy&amp;rft.atitle=New+pharmacological+approaches+for+the+treatment+of+alcoholism&amp;rft.volume=7&amp;rft.issue=17&amp;rft.pages=2341-53&amp;rft.date=2006-12&amp;rft_id=info%3Adoi%2F10.1517%2F14656566.7.17.2341&amp;rft_id=info%3Apmid%2F17109610&amp;rft.aulast=Soyka&amp;rft.aufirst=M&amp;rft.au=Roesner%2C+S&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt688" id="mwB2w"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt688" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwB20"/></span></li><li about="#cite_note-104" id="cite_note-104"><a href="./Addiction#cite_ref-104" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-104" class="mw-reference-text"><cite class="citation journal" about="#mwt689" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Pettinati HM, Rabinowitz AR"},"title":{"wt":"Choosing the right medication for the treatment of alcoholism"},"journal":{"wt":"Current Psychiatry Reports"},"volume":{"wt":"8"},"issue":{"wt":"5"},"pages":{"wt":"383–88"},"date":{"wt":"October 2006"},"pmid":{"wt":"16968619"},"doi":{"wt":"10.1007/s11920-006-0040-0"}},"i":0}}]}' id="mwB24">Pettinati HM, Rabinowitz AR (October 2006). "Choosing the right medication for the treatment of alcoholism". <i id="mwB28">Current Psychiatry Reports</i>. <b id="mwB3A">8</b> (5): 383–88. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwB3E">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1007%2Fs11920-006-0040-0" id="mwB3I">10.1007/s11920-006-0040-0</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwB3M" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwB3Q"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16968619" id="mwB3U">16968619</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Current+Psychiatry+Reports&amp;rft.atitle=Choosing+the+right+medication+for+the+treatment+of+alcoholism&amp;rft.volume=8&amp;rft.issue=5&amp;rft.pages=383-88&amp;rft.date=2006-10&amp;rft_id=info%3Adoi%2F10.1007%2Fs11920-006-0040-0&amp;rft_id=info%3Apmid%2F16968619&amp;rft.aulast=Pettinati&amp;rft.aufirst=HM&amp;rft.au=Rabinowitz%2C+AR&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt689" id="mwB3Y"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt689" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwB3c"/></span></li><li about="#cite_note-105" id="cite_note-105"><a href="./Addiction#cite_ref-105" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-105" class="mw-reference-text"><cite class="citation journal" about="#mwt690" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Bouza C, Angeles M, Magro A, Muñoz A, Amate JM"},"title":{"wt":"Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review"},"journal":{"wt":"Addiction"},"volume":{"wt":"99"},"issue":{"wt":"7"},"pages":{"wt":"811–28"},"date":{"wt":"July 2004"},"pmid":{"wt":"15200577"},"doi":{"wt":"10.1111/j.1360-0443.2004.00763.x"}},"i":0}}]}' id="mwB3g">Bouza C, Angeles M, Magro A, Muñoz A, Amate JM (July 2004). "Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review". <i id="mwB3k">Addiction</i>. <b id="mwB3o">99</b> (7): 811–28. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwB3s">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1111%2Fj.1360-0443.2004.00763.x" id="mwB3w">10.1111/j.1360-0443.2004.00763.x</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwB30" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwB34"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15200577" id="mwB38">15200577</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Addiction&amp;rft.atitle=Efficacy+and+safety+of+naltrexone+and+acamprosate+in+the+treatment+of+alcohol+dependence%3A+a+systematic+review&amp;rft.volume=99&amp;rft.issue=7&amp;rft.pages=811-28&amp;rft.date=2004-07&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1360-0443.2004.00763.x&amp;rft_id=info%3Apmid%2F15200577&amp;rft.aulast=Bouza&amp;rft.aufirst=C&amp;rft.au=Angeles%2C+M&amp;rft.au=Magro%2C+A&amp;rft.au=Mu%C3%B1oz%2C+A&amp;rft.au=Amate%2C+JM&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt690" id="mwB4A"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt690" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwB4E"/></span></li><li about="#cite_note-106" id="cite_note-106"><a href="./Addiction#cite_ref-106" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-106" class="mw-reference-text"><cite class="citation journal" about="#mwt691" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Williams SH"},"title":{"wt":"Medications for treating alcohol dependence"},"journal":{"wt":"American Family Physician"},"volume":{"wt":"72"},"issue":{"wt":"9"},"pages":{"wt":"1775–80"},"date":{"wt":"November 2005"},"pmid":{"wt":"16300039"}},"i":0}}]}' id="mwB4I">Williams SH (November 2005). "Medications for treating alcohol dependence". <i id="mwB4M">American Family Physician</i>. <b id="mwB4Q">72</b> (9): 1775–80. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwB4U" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwB4Y"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16300039" id="mwB4c">16300039</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=American+Family+Physician&amp;rft.atitle=Medications+for+treating+alcohol+dependence&amp;rft.volume=72&amp;rft.issue=9&amp;rft.pages=1775-80&amp;rft.date=2005-11&amp;rft_id=info%3Apmid%2F16300039&amp;rft.aulast=Williams&amp;rft.aufirst=SH&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt691" id="mwB4g"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt691" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwB4k"/></span></li><li about="#cite_note-107" id="cite_note-107"><a href="./Addiction#cite_ref-107" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-107" class="mw-reference-text"><cite class="citation journal" about="#mwt692" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Rösner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M"},"title":{"wt":"Opioid antagonists for alcohol dependence"},"journal":{"wt":"The Cochrane Database of Systematic Reviews"},"issue":{"wt":"12"},"pages":{"wt":"CD001867"},"date":{"wt":"December 2010"},"pmid":{"wt":"21154349"},"doi":{"wt":"10.1002/14651858.CD001867.pub2"}},"i":0}}]}' id="mwB4o">Rösner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M (December 2010). "Opioid antagonists for alcohol dependence". <i id="mwB4s">The Cochrane Database of Systematic Reviews</i> (12): CD001867. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwB4w">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1002%2F14651858.CD001867.pub2" id="mwB40">10.1002/14651858.CD001867.pub2</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwB44" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwB48"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21154349" id="mwB5A">21154349</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Cochrane+Database+of+Systematic+Reviews&amp;rft.atitle=Opioid+antagonists+for+alcohol+dependence&amp;rft.issue=12&amp;rft.pages=CD001867&amp;rft.date=2010-12&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD001867.pub2&amp;rft_id=info%3Apmid%2F21154349&amp;rft.aulast=R%C3%B6sner&amp;rft.aufirst=S&amp;rft.au=Hackl-Herrwerth%2C+A&amp;rft.au=Leucht%2C+S&amp;rft.au=Vecchi%2C+S&amp;rft.au=Srisurapanont%2C+M&amp;rft.au=Soyka%2C+M&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt692" id="mwB5E"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt692" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwB5I"/></span></li><li about="#cite_note-Marijuana_addiction_2010_review-108" id="cite_note-Marijuana_addiction_2010_review-108"><a href="./Addiction#cite_ref-Marijuana_addiction_2010_review_108-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-Marijuana_addiction_2010_review-108" class="mw-reference-text"><cite class="citation journal" about="#mwt698" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Sofuoglu M, Sugarman DE, Carroll KM"},"title":{"wt":"Cognitive function as an emerging treatment target for marijuana addiction"},"journal":{"wt":"Exp Clin Psychopharmacol"},"volume":{"wt":"18"},"issue":{"wt":"2"},"pages":{"wt":"109–19"},"date":{"wt":"April 2010"},"pmid":{"wt":"20384422"},"pmc":{"wt":"2909584"},"doi":{"wt":"10.1037/a0019295"},"quote":{"wt":"Cannabis is the most widely used illicit substance in the world, and demand for effective treatment is increasing. However, abstinence rates following behavioral therapies have been modest, and there are no effective pharmacotherapies for the treatment of cannabis addiction."}},"i":0}}]}' id="mwB5M">Sofuoglu M, Sugarman DE, Carroll KM (April 2010). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2909584" id="mwB5Q">"Cognitive function as an emerging treatment target for marijuana addiction"</a>. <i id="mwB5U">Exp Clin Psychopharmacol</i>. <b id="mwB5Y">18</b> (2): 109–19. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwB5c">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1037%2Fa0019295" id="mwB5g">10.1037/a0019295</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwB5k">PMC</a><span typeof="mw:Entity" id="mwB5o"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwB5s"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2909584" id="mwB5w">2909584</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwB50" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwB54"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/20384422" id="mwB58">20384422</a>. <q id="mwB6A">Cannabis is the most widely used illicit substance in the world, and demand for effective treatment is increasing. However, abstinence rates following behavioral therapies have been modest, and there are no effective pharmacotherapies for the treatment of cannabis addiction.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Exp+Clin+Psychopharmacol&amp;rft.atitle=Cognitive+function+as+an+emerging+treatment+target+for+marijuana+addiction&amp;rft.volume=18&amp;rft.issue=2&amp;rft.pages=109-19&amp;rft.date=2010-04&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2909584&amp;rft_id=info%3Apmid%2F20384422&amp;rft_id=info%3Adoi%2F10.1037%2Fa0019295&amp;rft.aulast=Sofuoglu&amp;rft.aufirst=M&amp;rft.au=Sugarman%2C+DE&amp;rft.au=Carroll%2C+KM&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2909584&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt698" id="mwB6E"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt698" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwB6I"/></span></li><li about="#cite_note-Cannabinoid_addiction_2013_review-109" id="cite_note-Cannabinoid_addiction_2013_review-109"><a href="./Addiction#cite_ref-Cannabinoid_addiction_2013_review_109-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-Cannabinoid_addiction_2013_review-109" class="mw-reference-text"><cite class="citation journal" about="#mwt699" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Fratta W, Fattore L"},"title":{"wt":"Molecular mechanisms of cannabinoid addiction"},"journal":{"wt":"Curr. Opin. Neurobiol."},"volume":{"wt":"23"},"issue":{"wt":"4"},"pages":{"wt":"487–92"},"date":{"wt":"August 2013"},"pmid":{"wt":"23490548"},"doi":{"wt":"10.1016/j.conb.2013.02.002"},"quote":{"wt":"14. Nguyen PT, Schmid CL, Raehal KM, Selley DE, Bohn LM, Sim-Selley LJ: b-Arrestin2 regulates cannabinoid CB1 receptor signaling and adaptation in a central nervous system region dependent manner. Biol Psychiatry 2012, 71:714–24.&lt;br />A pioneering study revealing both positive and negative modulatory effects of beta-arrestin2 on THC tolerance. By demonstrating that tolerance to antinociception is reduced whereas tolerance to catalepsy is enhanced in beta-arrestin2 knockout mice, authors suggest that development of cannabinoid agonists that minimize interactions between CB1Rs and beta-arrestin2 might produce improved cannabinoid analgesics with reduced motor suppression, and be therapeutically beneficial."}},"i":0}}]}' id="mwB6M">Fratta W, Fattore L (August 2013). "Molecular mechanisms of cannabinoid addiction". <i id="mwB6Q">Curr. Opin. Neurobiol</i>. <b id="mwB6U">23</b> (4): 487–92. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwB6Y">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1016%2Fj.conb.2013.02.002" id="mwB6c">10.1016/j.conb.2013.02.002</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwB6g" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwB6k"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23490548" id="mwB6o">23490548</a>. <q id="mwB6s">14. Nguyen PT, Schmid CL, Raehal KM, Selley DE, Bohn LM, Sim-Selley LJ: b-Arrestin2 regulates cannabinoid CB1 receptor signaling and adaptation in a central nervous system region dependent manner. Biol Psychiatry 2012, 71:714–24.<br id="mwB6w"/>A pioneering study revealing both positive and negative modulatory effects of beta-arrestin2 on THC tolerance. By demonstrating that tolerance to antinociception is reduced whereas tolerance to catalepsy is enhanced in beta-arrestin2 knockout mice, authors suggest that development of cannabinoid agonists that minimize interactions between CB1Rs and beta-arrestin2 might produce improved cannabinoid analgesics with reduced motor suppression, and be therapeutically beneficial.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Curr.+Opin.+Neurobiol.&amp;rft.atitle=Molecular+mechanisms+of+cannabinoid+addiction&amp;rft.volume=23&amp;rft.issue=4&amp;rft.pages=487-92&amp;rft.date=2013-08&amp;rft_id=info%3Adoi%2F10.1016%2Fj.conb.2013.02.002&amp;rft_id=info%3Apmid%2F23490548&amp;rft.aulast=Fratta&amp;rft.aufirst=W&amp;rft.au=Fattore%2C+L&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt699" id="mwB60"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt699" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwB64"/></span></li><li about="#cite_note-nicotine_addiction_therapies-110" id="cite_note-nicotine_addiction_therapies-110"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-nicotine_addiction_therapies_110-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-nicotine_addiction_therapies_110-1"><span class="mw-linkback-text">2 </span></a></span> <span id="mw-reference-text-cite_note-nicotine_addiction_therapies-110" class="mw-reference-text"><cite class="citation journal" about="#mwt705" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Garwood CL, Potts LA"},"title":{"wt":"Emerging pharmacotherapies for smoking cessation"},"journal":{"wt":"Am J Health Syst Pharm"},"volume":{"wt":"64"},"issue":{"wt":"16"},"pages":{"wt":"1693–98"},"year":{"wt":"2007"},"pmid":{"wt":"17687057"},"doi":{"wt":"10.2146/ajhp060427"}},"i":0}}]}' id="mwB68">Garwood CL, Potts LA (2007). "Emerging pharmacotherapies for smoking cessation". <i id="mwB7A">Am J Health Syst Pharm</i>. <b id="mwB7E">64</b> (16): 1693–98. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwB7I">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.2146%2Fajhp060427" id="mwB7M">10.2146/ajhp060427</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwB7Q" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwB7U"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17687057" id="mwB7Y">17687057</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Am+J+Health+Syst+Pharm&amp;rft.atitle=Emerging+pharmacotherapies+for+smoking+cessation&amp;rft.volume=64&amp;rft.issue=16&amp;rft.pages=1693-98&amp;rft.date=2007&amp;rft_id=info%3Adoi%2F10.2146%2Fajhp060427&amp;rft_id=info%3Apmid%2F17687057&amp;rft.aulast=Garwood&amp;rft.aufirst=CL&amp;rft.au=Potts%2C+LA&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt705" id="mwB7c"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt705" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwB7g"/></span></li><li about="#cite_note-pmid24484986-111" id="cite_note-pmid24484986-111"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-pmid24484986_111-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-pmid24484986_111-1"><span class="mw-linkback-text">2 </span></a></span> <span id="mw-reference-text-cite_note-pmid24484986-111" class="mw-reference-text"><cite class="citation book" about="#mwt706" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"Cite book ","href":"./Template:Cite_book"},"params":{"vauthors":{"wt":"Crooks PA, Bardo MT, Dwoskin LP"},"title":{"wt":"Nicotinic receptor antagonists as treatments for nicotine abuse"},"journal":{"wt":"Adv. Pharmacol."},"volume":{"wt":"69"},"issue":{"wt":""},"pages":{"wt":"513–51"},"year":{"wt":"2014"},"pmid":{"wt":"24484986"},"pmc":{"wt":"4110698"},"doi":{"wt":"10.1016/B978-0-12-420118-7.00013-5"},"url":{"wt":""},"series":{"wt":"Advances in Pharmacology"},"isbn":{"wt":"978-0-12-420118-7"}},"i":0}}]}' id="mwB7k">Crooks PA, Bardo MT, Dwoskin LP (2014). <i id="mwB7o">Nicotinic receptor antagonists as treatments for nicotine abuse</i>. <i id="mwB7s">Adv. Pharmacol</i>. Advances in Pharmacology. <b id="mwB7w">69</b>. pp.<span typeof="mw:Entity" id="mwB70"> </span>513–51. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwB74">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1016%2FB978-0-12-420118-7.00013-5" id="mwB78">10.1016/B978-0-12-420118-7.00013-5</a>. <a rel="mw:WikiLink" href="./International_Standard_Book_Number" title="International Standard Book Number" id="mwB8A">ISBN</a><span typeof="mw:Entity" id="mwB8E"> </span><a rel="mw:WikiLink" href="./Special:BookSources/978-0-12-420118-7" title="Special:BookSources/978-0-12-420118-7" id="mwB8I">978-0-12-420118-7</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwB8M">PMC</a><span typeof="mw:Entity" id="mwB8Q"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwB8U"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4110698" id="mwB8Y">4110698</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwB8c" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwB8g"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/24484986" id="mwB8k">24484986</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Nicotinic+receptor+antagonists+as+treatments+for+nicotine+abuse&amp;rft.series=Advances+in+Pharmacology&amp;rft.pages=513-51&amp;rft.date=2014&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4110698&amp;rft_id=info%3Apmid%2F24484986&amp;rft_id=info%3Adoi%2F10.1016%2FB978-0-12-420118-7.00013-5&amp;rft.isbn=978-0-12-420118-7&amp;rft.aulast=Crooks&amp;rft.aufirst=PA&amp;rft.au=Bardo%2C+MT&amp;rft.au=Dwoskin%2C+LP&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt706" id="mwB8o"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt706" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwB8s"/></span></li><li about="#cite_note-112" id="cite_note-112"><a href="./Addiction#cite_ref-112" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-112" class="mw-reference-text"><cite class="citation journal" about="#mwt766" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE"},"title":{"wt":"A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence"},"journal":{"wt":"N. Engl. J. Med."},"volume":{"wt":"343"},"issue":{"wt":"18"},"pages":{"wt":"1290–97"},"year":{"wt":"2000"},"pmid":{"wt":"11058673"},"doi":{"wt":"10.1056/NEJM200011023431802"}},"i":0}}]}' id="mwB8w">Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE (2000). "A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence". <i id="mwB80">N. Engl. J. Med</i>. <b id="mwB84">343</b> (18): 1290–97. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwB88">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1056%2FNEJM200011023431802" id="mwB9A">10.1056/NEJM200011023431802</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwB9E" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwB9I"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/11058673" id="mwB9M">11058673</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=N.+Engl.+J.+Med.&amp;rft.atitle=A+comparison+of+levomethadyl+acetate%2C+buprenorphine%2C+and+methadone+for+opioid+dependence&amp;rft.volume=343&amp;rft.issue=18&amp;rft.pages=1290-97&amp;rft.date=2000&amp;rft_id=info%3Adoi%2F10.1056%2FNEJM200011023431802&amp;rft_id=info%3Apmid%2F11058673&amp;rft.aulast=Johnson&amp;rft.aufirst=RE&amp;rft.au=Chutuape%2C+MA&amp;rft.au=Strain%2C+EC&amp;rft.au=Walsh%2C+SL&amp;rft.au=Stitzer%2C+ML&amp;rft.au=Bigelow%2C+GE&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt766" id="mwB9Q"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt766" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwB9U"/></span></li><li about="#cite_note-113" id="cite_note-113"><a href="./Addiction#cite_ref-113" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-113" class="mw-reference-text"><cite class="citation journal" about="#mwt767" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Connock M, Juarez-Garcia A, Jowett S"},"title":{"wt":"Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation"},"journal":{"wt":"Health Technol Assess"},"volume":{"wt":"11"},"issue":{"wt":"9"},"pages":{"wt":"1–171, iii–iv"},"year":{"wt":"2007"},"pmid":{"wt":"17313907"},"display-authors":{"wt":"etal"},"doi":{"wt":"10.3310/hta11090"}},"i":0}}]}' id="mwB9Y">Connock M, Juarez-Garcia A, Jowett S,  et al. (2007). "Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation". <i id="mwB9c">Health Technol Assess</i>. <b id="mwB9g">11</b> (9): 1–171, iii–iv. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwB9k">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.3310%2Fhta11090" id="mwB9o">10.3310/hta11090</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwB9s" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwB9w"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17313907" id="mwB90">17313907</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Health+Technol+Assess&amp;rft.atitle=Methadone+and+buprenorphine+for+the+management+of+opioid+dependence%3A+a+systematic+review+and+economic+evaluation&amp;rft.volume=11&amp;rft.issue=9&amp;rft.pages=1-171%2C+iii-iv&amp;rft.date=2007&amp;rft_id=info%3Adoi%2F10.3310%2Fhta11090&amp;rft_id=info%3Apmid%2F17313907&amp;rft.aulast=Connock&amp;rft.aufirst=M&amp;rft.au=Juarez-Garcia%2C+A&amp;rft.au=Jowett%2C+S&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt767" id="mwB94"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt767" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwB98"/></span></li><li about="#cite_note-114" id="cite_note-114"><a href="./Addiction#cite_ref-114" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-114" class="mw-reference-text"><cite class="citation journal" about="#mwt768" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Marsch LA, Stephens MA, Mudric T, Strain EC, Bigelow GE, Johnson RE"},"title":{"wt":"Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence"},"journal":{"wt":"Exp Clin Psychopharmacol"},"volume":{"wt":"13"},"issue":{"wt":"4"},"pages":{"wt":"293–302"},"year":{"wt":"2005"},"pmid":{"wt":"16366759"},"doi":{"wt":"10.1037/1064-1297.13.4.293"}},"i":0}}]}' id="mwB-A">Marsch LA, Stephens MA, Mudric T, Strain EC, Bigelow GE, Johnson RE (2005). "Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence". <i id="mwB-E">Exp Clin Psychopharmacol</i>. <b id="mwB-I">13</b> (4): 293–302. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwB-M">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1037%2F1064-1297.13.4.293" id="mwB-Q">10.1037/1064-1297.13.4.293</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwB-U" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwB-Y"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16366759" id="mwB-c">16366759</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Exp+Clin+Psychopharmacol&amp;rft.atitle=Predictors+of+outcome+in+LAAM%2C+buprenorphine%2C+and+methadone+treatment+for+opioid+dependence&amp;rft.volume=13&amp;rft.issue=4&amp;rft.pages=293-302&amp;rft.date=2005&amp;rft_id=info%3Adoi%2F10.1037%2F1064-1297.13.4.293&amp;rft_id=info%3Apmid%2F16366759&amp;rft.aulast=Marsch&amp;rft.aufirst=LA&amp;rft.au=Stephens%2C+MA&amp;rft.au=Mudric%2C+T&amp;rft.au=Strain%2C+EC&amp;rft.au=Bigelow%2C+GE&amp;rft.au=Johnson%2C+RE&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt768" id="mwB-g"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt768" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwB-k"/></span></li><li about="#cite_note-115" id="cite_note-115"><a href="./Addiction#cite_ref-115" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-115" class="mw-reference-text"><cite class="citation journal" about="#mwt769" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Robertson JR, Raab GM, Bruce M, McKenzie JS, Storkey HR, Salter A"},"title":{"wt":"Addressing the efficacy of dihydrocodeine versus methadone as an alternative maintenance treatment for opiate dependence: A randomized controlled trial"},"journal":{"wt":"[[Addiction (journal)|Addiction]]"},"volume":{"wt":"101"},"issue":{"wt":"12"},"pages":{"wt":"1752–59"},"year":{"wt":"2006"},"pmid":{"wt":"17156174"},"doi":{"wt":"10.1111/j.1360-0443.2006.01603.x"}},"i":0}}]}' id="mwB-o">Robertson JR, Raab GM, Bruce M, McKenzie JS, Storkey HR, Salter A (2006). "Addressing the efficacy of dihydrocodeine versus methadone as an alternative maintenance treatment for opiate dependence: A randomized controlled trial". <i id="mwB-s"><a rel="mw:WikiLink" href="./Addiction_(journal)" title="Addiction (journal)" id="mwB-w">Addiction</a></i>. <b id="mwB-0">101</b> (12): 1752–59. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwB-4">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1111%2Fj.1360-0443.2006.01603.x" id="mwB-8">10.1111/j.1360-0443.2006.01603.x</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwB_A" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwB_E"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17156174" id="mwB_I">17156174</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Addiction&amp;rft.atitle=Addressing+the+efficacy+of+dihydrocodeine+versus+methadone+as+an+alternative+maintenance+treatment+for+opiate+dependence%3A+A+randomized+controlled+trial&amp;rft.volume=101&amp;rft.issue=12&amp;rft.pages=1752-59&amp;rft.date=2006&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1360-0443.2006.01603.x&amp;rft_id=info%3Apmid%2F17156174&amp;rft.aulast=Robertson&amp;rft.aufirst=JR&amp;rft.au=Raab%2C+GM&amp;rft.au=Bruce%2C+M&amp;rft.au=McKenzie%2C+JS&amp;rft.au=Storkey%2C+HR&amp;rft.au=Salter%2C+A&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt769" id="mwB_M"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt769" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwB_Q"/></span></li><li about="#cite_note-116" id="cite_note-116"><a href="./Addiction#cite_ref-116" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-116" class="mw-reference-text"><cite class="citation journal" about="#mwt770" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"author":{"wt":"Qin Bo-Yi"},"title":{"wt":"Advances in dihydroetorphine: From analgesia to detoxification"},"journal":{"wt":"Drug Development Research"},"volume":{"wt":"39"},"issue":{"wt":"2"},"pages":{"wt":"131–34"},"year":{"wt":"1998"},"doi":{"wt":"10.1002/(SICI)1098-2299(199610)39:2&lt;131::AID-DDR3>3.0.CO;2-Q"}},"i":0}}]}' id="mwB_U">Qin Bo-Yi (1998). "Advances in dihydroetorphine: From analgesia to detoxification". <i id="mwB_Y">Drug Development Research</i>. <b id="mwB_c">39</b> (2): 131–34. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwB_g">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1002%2F%28SICI%291098-2299%28199610%2939%3A2%3C131%3A%3AAID-DDR3%3E3.0.CO%3B2-Q" id="mwB_k">10.1002/(SICI)1098-2299(199610)39:2<span typeof="mw:Entity" id="mwB_o">&lt;</span>131::AID-DDR3<span typeof="mw:Entity" id="mwB_s">></span>3.0.CO;2-Q</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Drug+Development+Research&amp;rft.atitle=Advances+in+dihydroetorphine%3A+From+analgesia+to+detoxification&amp;rft.volume=39&amp;rft.issue=2&amp;rft.pages=131-34&amp;rft.date=1998&amp;rft_id=info%3Adoi%2F10.1002%2F%28SICI%291098-2299%28199610%2939%3A2%3C131%3A%3AAID-DDR3%3E3.0.CO%3B2-Q&amp;rft.au=Qin+Bo-Yi&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt770" id="mwB_w"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt770" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwB_0"/> <a rel="mw:ExtLink" class="external text" href="https://archive.today/20121210055522/http://www3.interscience.wiley.com/cgi-bin/abstract/67067/ABSTRACT?CRETRY=1&amp;SRETRY=0" id="mwB_4">Link</a></span></li><li about="#cite_note-Metrebian1-117" id="cite_note-Metrebian1-117"><a href="./Addiction#cite_ref-Metrebian1_117-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-Metrebian1-117" class="mw-reference-text"><cite class="citation journal" about="#mwt771" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Metrebian N, Shanahan W, Wells B, Stimson GV"},"title":{"wt":"Feasibility of prescribing injectable heroin and methadone to opiate-dependent drug users: associated health gains and harm reductions"},"journal":{"wt":"Med. J. Aust."},"volume":{"wt":"168"},"issue":{"wt":"12"},"pages":{"wt":"596–600"},"year":{"wt":"1998"},"pmid":{"wt":"9673620"}},"i":0}}]}' id="mwB_8">Metrebian N, Shanahan W, Wells B, Stimson GV (1998). "Feasibility of prescribing injectable heroin and methadone to opiate-dependent drug users: associated health gains and harm reductions". <i id="mwCAA">Med. J. Aust</i>. <b id="mwCAE">168</b> (12): 596–600. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwCAI" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwCAM"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/9673620" id="mwCAQ">9673620</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Med.+J.+Aust.&amp;rft.atitle=Feasibility+of+prescribing+injectable+heroin+and+methadone+to+opiate-dependent+drug+users%3A+associated+health+gains+and+harm+reductions&amp;rft.volume=168&amp;rft.issue=12&amp;rft.pages=596-600&amp;rft.date=1998&amp;rft_id=info%3Apmid%2F9673620&amp;rft.aulast=Metrebian&amp;rft.aufirst=N&amp;rft.au=Shanahan%2C+W&amp;rft.au=Wells%2C+B&amp;rft.au=Stimson%2C+GV&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt771" id="mwCAU"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt771" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwCAY"/></span></li><li about="#cite_note-Metrebian2-118" id="cite_note-Metrebian2-118"><a href="./Addiction#cite_ref-Metrebian2_118-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-Metrebian2-118" class="mw-reference-text"><cite class="citation journal" about="#mwt772" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Metrebian N, Mott J, Carnwath Z, Carnwath T, Stimson GV, Sell L"},"title":{"wt":"Pathways into receiving a prescription for diamorphine (heroin) for the treatment of opiate dependence in the United kingdom"},"journal":{"wt":"Eur Addict Res"},"volume":{"wt":"13"},"issue":{"wt":"3"},"pages":{"wt":"144–47"},"year":{"wt":"2007"},"pmid":{"wt":"17570910"},"doi":{"wt":"10.1159/000101550"}},"i":0}}]}' id="mwCAc">Metrebian N, Mott J, Carnwath Z, Carnwath T, Stimson GV, Sell L (2007). "Pathways into receiving a prescription for diamorphine (heroin) for the treatment of opiate dependence in the United kingdom". <i id="mwCAg">Eur Addict Res</i>. <b id="mwCAk">13</b> (3): 144–47. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwCAo">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1159%2F000101550" id="mwCAs">10.1159/000101550</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwCAw" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwCA0"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17570910" id="mwCA4">17570910</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Eur+Addict+Res&amp;rft.atitle=Pathways+into+receiving+a+prescription+for+diamorphine+%28heroin%29+for+the+treatment+of+opiate+dependence+in+the+United+kingdom&amp;rft.volume=13&amp;rft.issue=3&amp;rft.pages=144-47&amp;rft.date=2007&amp;rft_id=info%3Adoi%2F10.1159%2F000101550&amp;rft_id=info%3Apmid%2F17570910&amp;rft.aulast=Metrebian&amp;rft.aufirst=N&amp;rft.au=Mott%2C+J&amp;rft.au=Carnwath%2C+Z&amp;rft.au=Carnwath%2C+T&amp;rft.au=Stimson%2C+GV&amp;rft.au=Sell%2C+L&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt772" id="mwCA8"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt772" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwCBA"/></span></li><li about="#cite_note-Kenna_GA,_Nielsen_DM,_Mello_P,_Schiesl_A,_Swift_RM_2007_213–37-119" id="cite_note-Kenna_GA,_Nielsen_DM,_Mello_P,_Schiesl_A,_Swift_RM_2007_213–37-119"><a href="./Addiction#cite_ref-Kenna_GA,_Nielsen_DM,_Mello_P,_Schiesl_A,_Swift_RM_2007_213–37_119-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-Kenna_GA,_Nielsen_DM,_Mello_P,_Schiesl_A,_Swift_RM_2007_213–37-119" class="mw-reference-text"><cite class="citation journal" about="#mwt773" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Kenna GA, Nielsen DM, Mello P, Schiesl A, Swift RM"},"title":{"wt":"Pharmacotherapy of dual substance abuse and dependence"},"journal":{"wt":"CNS Drugs"},"volume":{"wt":"21"},"issue":{"wt":"3"},"pages":{"wt":"213–37"},"year":{"wt":"2007"},"pmid":{"wt":"17338593"},"doi":{"wt":"10.2165/00023210-200721030-00003"}},"i":0}}]}' id="mwCBE">Kenna GA, Nielsen DM, Mello P, Schiesl A, Swift RM (2007). "Pharmacotherapy of dual substance abuse and dependence". <i id="mwCBI">CNS Drugs</i>. <b id="mwCBM">21</b> (3): 213–37. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwCBQ">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.2165%2F00023210-200721030-00003" id="mwCBU">10.2165/00023210-200721030-00003</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwCBY" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwCBc"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17338593" id="mwCBg">17338593</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=CNS+Drugs&amp;rft.atitle=Pharmacotherapy+of+dual+substance+abuse+and+dependence&amp;rft.volume=21&amp;rft.issue=3&amp;rft.pages=213-37&amp;rft.date=2007&amp;rft_id=info%3Adoi%2F10.2165%2F00023210-200721030-00003&amp;rft_id=info%3Apmid%2F17338593&amp;rft.aulast=Kenna&amp;rft.aufirst=GA&amp;rft.au=Nielsen%2C+DM&amp;rft.au=Mello%2C+P&amp;rft.au=Schiesl%2C+A&amp;rft.au=Swift%2C+RM&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt773" id="mwCBk"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt773" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwCBo"/></span></li><li about="#cite_note-pmid24716825-120" id="cite_note-pmid24716825-120"><a href="./Addiction#cite_ref-pmid24716825_120-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-pmid24716825-120" class="mw-reference-text"><cite class="citation journal" about="#mwt786" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Stoops WW, Rush CR"},"title":{"wt":"Combination pharmacotherapies for stimulant use disorder: a review of clinical findings and recommendations for future research"},"journal":{"wt":"Expert Rev Clin Pharmacol"},"volume":{"wt":"7"},"issue":{"wt":"3"},"pages":{"wt":"363–74"},"date":{"wt":"May 2014"},"pmid":{"wt":"24716825"},"doi":{"wt":"10.1586/17512433.2014.909283"},"quote":{"wt":"Despite concerted efforts to identify a pharmacotherapy for managing stimulant use disorders, no widely effective medications have been approved."},"pmc":{"wt":"4017926"}},"i":0}}]}' id="mwCBs">Stoops WW, Rush CR (May 2014). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4017926" id="mwCBw">"Combination pharmacotherapies for stimulant use disorder: a review of clinical findings and recommendations for future research"</a>. <i id="mwCB0">Expert Rev Clin Pharmacol</i>. <b id="mwCB4">7</b> (3): 363–74. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwCB8">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1586%2F17512433.2014.909283" id="mwCCA">10.1586/17512433.2014.909283</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwCCE">PMC</a><span typeof="mw:Entity" id="mwCCI"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwCCM"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4017926" id="mwCCQ">4017926</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwCCU" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwCCY"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/24716825" id="mwCCc">24716825</a>. <q id="mwCCg">Despite concerted efforts to identify a pharmacotherapy for managing stimulant use disorders, no widely effective medications have been approved.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Expert+Rev+Clin+Pharmacol&amp;rft.atitle=Combination+pharmacotherapies+for+stimulant+use+disorder%3A+a+review+of+clinical+findings+and+recommendations+for+future+research&amp;rft.volume=7&amp;rft.issue=3&amp;rft.pages=363-74&amp;rft.date=2014-05&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4017926&amp;rft_id=info%3Apmid%2F24716825&amp;rft_id=info%3Adoi%2F10.1586%2F17512433.2014.909283&amp;rft.aulast=Stoops&amp;rft.aufirst=WW&amp;rft.au=Rush%2C+CR&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4017926&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt786" id="mwCCk"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt786" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwCCo"/></span></li><li about="#cite_note-Cochrane_2013_treatments-121" id="cite_note-Cochrane_2013_treatments-121"><a href="./Addiction#cite_ref-Cochrane_2013_treatments_121-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-Cochrane_2013_treatments-121" class="mw-reference-text"><cite class="citation journal" about="#mwt787" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Perez-Mana C, Castells X, Torrens M, Capella D, Farre M"},"title":{"wt":"Efficacy of psychostimulant drugs for amphetamine abuse or dependence"},"journal":{"wt":"Cochrane Database Syst. Rev."},"volume":{"wt":"9"},"issue":{"wt":"9"},"pages":{"wt":"CD009695"},"date":{"wt":"September 2013"},"pmid":{"wt":"23996457"},"doi":{"wt":"10.1002/14651858.CD009695.pub2"},"quote":{"wt":"To date, no pharmacological treatment has been approved for [addiction], and psychotherapy remains the mainstay of treatment.&amp;nbsp;... Results of this review do not support the use of psychostimulant medications at the tested doses as a replacement therapy"}},"i":0}}]}' id="mwCCs">Perez-Mana C, Castells X, Torrens M, Capella D, Farre M (September 2013). "Efficacy of psychostimulant drugs for amphetamine abuse or dependence". <i id="mwCCw">Cochrane Database Syst. Rev</i>. <b id="mwCC0">9</b> (9): CD009695. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwCC4">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1002%2F14651858.CD009695.pub2" id="mwCC8">10.1002/14651858.CD009695.pub2</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwCDA" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwCDE"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23996457" id="mwCDI">23996457</a>. <q id="mwCDM">To date, no pharmacological treatment has been approved for [addiction], and psychotherapy remains the mainstay of treatment.<span typeof="mw:Entity" id="mwCDQ"> </span>... Results of this review do not support the use of psychostimulant medications at the tested doses as a replacement therapy</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cochrane+Database+Syst.+Rev.&amp;rft.atitle=Efficacy+of+psychostimulant+drugs+for+amphetamine+abuse+or+dependence&amp;rft.volume=9&amp;rft.issue=9&amp;rft.pages=CD009695&amp;rft.date=2013-09&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD009695.pub2&amp;rft_id=info%3Apmid%2F23996457&amp;rft.aulast=Perez-Mana&amp;rft.aufirst=C&amp;rft.au=Castells%2C+X&amp;rft.au=Torrens%2C+M&amp;rft.au=Capella%2C+D&amp;rft.au=Farre%2C+M&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt787" id="mwCDU"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt787" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwCDY"/></span></li><li about="#cite_note-pmid23039267-122" id="cite_note-pmid23039267-122"><a href="./Addiction#cite_ref-pmid23039267_122-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-pmid23039267-122" class="mw-reference-text"><cite class="citation journal" about="#mwt788" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Forray A, Sofuoglu M"},"title":{"wt":"Future pharmacological treatments for substance use disorders"},"journal":{"wt":"Br. J. Clin. Pharmacol."},"volume":{"wt":"77"},"issue":{"wt":"2"},"pages":{"wt":"382–400"},"date":{"wt":"February 2014"},"pmid":{"wt":"23039267"},"pmc":{"wt":"4014020"},"doi":{"wt":"10.1111/j.1365-2125.2012.04474.x"}},"i":0}}]}' id="mwCDc">Forray A, Sofuoglu M (February 2014). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4014020" id="mwCDg">"Future pharmacological treatments for substance use disorders"</a>. <i id="mwCDk">Br. J. Clin. Pharmacol</i>. <b id="mwCDo">77</b> (2): 382–400. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwCDs">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1111%2Fj.1365-2125.2012.04474.x" id="mwCDw">10.1111/j.1365-2125.2012.04474.x</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwCD0">PMC</a><span typeof="mw:Entity" id="mwCD4"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwCD8"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4014020" id="mwCEA">4014020</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwCEE" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwCEI"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23039267" id="mwCEM">23039267</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Br.+J.+Clin.+Pharmacol.&amp;rft.atitle=Future+pharmacological+treatments+for+substance+use+disorders&amp;rft.volume=77&amp;rft.issue=2&amp;rft.pages=382-400&amp;rft.date=2014-02&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4014020&amp;rft_id=info%3Apmid%2F23039267&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1365-2125.2012.04474.x&amp;rft.aulast=Forray&amp;rft.aufirst=A&amp;rft.au=Sofuoglu%2C+M&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4014020&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt788" id="mwCEQ"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt788" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwCEU"/></span></li><li about="#cite_note-Miller+Grandy_2016-123" id="cite_note-Miller+Grandy_2016-123"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-Miller+Grandy_2016_123-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-Miller+Grandy_2016_123-1"><span class="mw-linkback-text">2 </span></a></span> <span id="mw-reference-text-cite_note-Miller+Grandy_2016-123" class="mw-reference-text"><cite class="citation journal" about="#mwt791" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Grandy DK, Miller GM, Li JX"},"title":{"wt":"\"TAARgeting Addiction\" – The Alamo Bears Witness to Another Revolution: An Overview of the Plenary Symposium of the 2015 Behavior, Biology and Chemistry Conference"},"journal":{"wt":"Drug Alcohol Depend."},"volume":{"wt":"159"},"issue":{"wt":""},"pages":{"wt":"9–16"},"date":{"wt":"February 2016"},"pmid":{"wt":"26644139"},"doi":{"wt":"10.1016/j.drugalcdep.2015.11.014"},"quote":{"wt":"When considered together with the rapidly growing literature in the field a compelling case emerges in support of developing TAAR1-selective agonists as medications for preventing relapse to psychostimulant abuse."},"pmc":{"wt":"4724540"}},"i":0}}]}' id="mwCEY">Grandy DK, Miller GM, Li JX (February 2016). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4724540" id="mwCEc">"<span class="cs1-kern-left" id="mwCEg">"</span>TAARgeting Addiction" – The Alamo Bears Witness to Another Revolution: An Overview of the Plenary Symposium of the 2015 Behavior, Biology and Chemistry Conference"</a>. <i id="mwCEk">Drug Alcohol Depend</i>. <b id="mwCEo">159</b>: 9–16. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwCEs">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1016%2Fj.drugalcdep.2015.11.014" id="mwCEw">10.1016/j.drugalcdep.2015.11.014</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwCE0">PMC</a><span typeof="mw:Entity" id="mwCE4"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwCE8"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4724540" id="mwCFA">4724540</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwCFE" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwCFI"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/26644139" id="mwCFM">26644139</a>. <q id="mwCFQ">When considered together with the rapidly growing literature in the field a compelling case emerges in support of developing TAAR1-selective agonists as medications for preventing relapse to psychostimulant abuse.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Drug+Alcohol+Depend.&amp;rft.atitle=%22TAARgeting+Addiction%22+%E2%80%93+The+Alamo+Bears+Witness+to+Another+Revolution%3A+An+Overview+of+the+Plenary+Symposium+of+the+2015+Behavior%2C+Biology+and+Chemistry+Conference&amp;rft.volume=159&amp;rft.pages=9-16&amp;rft.date=2016-02&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4724540&amp;rft_id=info%3Apmid%2F26644139&amp;rft_id=info%3Adoi%2F10.1016%2Fj.drugalcdep.2015.11.014&amp;rft.aulast=Grandy&amp;rft.aufirst=DK&amp;rft.au=Miller%2C+GM&amp;rft.au=Li%2C+JX&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4724540&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt791" id="mwCFU"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt791" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwCFY"/></span></li><li about="#cite_note-TAAR1_addiction_2015-124" id="cite_note-TAAR1_addiction_2015-124"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-TAAR1_addiction_2015_124-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-TAAR1_addiction_2015_124-1"><span class="mw-linkback-text">2 </span></a></span> <span id="mw-reference-text-cite_note-TAAR1_addiction_2015-124" class="mw-reference-text"><cite class="citation journal" about="#mwt792" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Jing L, Li JX"},"title":{"wt":"Trace amine-associated receptor 1: A promising target for the treatment of psychostimulant addiction"},"journal":{"wt":"Eur. J. Pharmacol."},"volume":{"wt":"761"},"issue":{"wt":""},"pages":{"wt":"345–52"},"date":{"wt":"August 2015"},"pmid":{"wt":"26092759"},"doi":{"wt":"10.1016/j.ejphar.2015.06.019"},"quote":{"wt":"Taken together, the data reviewed here strongly support that TAAR1 is implicated in the functional regulation of monoaminergic systems, especially dopaminergic system, and that TAAR1 serves as a homeostatic \"brake\" system that is involved in the modulation of dopaminergic activity. Existing data provided robust preclinical evidence supporting the development of TAAR1 agonists as potential treatment for psychostimulant abuse and addiction.&amp;nbsp;... Given that TAAR1 is primarily located in the intracellular compartments and existing TAAR1 agonists are proposed to get access to the receptors by translocation to the cell interior (Miller, 2011), future drug design and development efforts may need to take strategies of drug delivery into consideration (Rajendran et al., 2010)."},"pmc":{"wt":"4532615"}},"i":0}}]}' id="mwCFc">Jing L, Li JX (August 2015). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4532615" id="mwCFg">"Trace amine-associated receptor 1: A promising target for the treatment of psychostimulant addiction"</a>. <i id="mwCFk">Eur. J. Pharmacol</i>. <b id="mwCFo">761</b>: 345–52. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwCFs">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1016%2Fj.ejphar.2015.06.019" id="mwCFw">10.1016/j.ejphar.2015.06.019</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwCF0">PMC</a><span typeof="mw:Entity" id="mwCF4"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwCF8"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4532615" id="mwCGA">4532615</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwCGE" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwCGI"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/26092759" id="mwCGM">26092759</a>. <q id="mwCGQ">Taken together, the data reviewed here strongly support that TAAR1 is implicated in the functional regulation of monoaminergic systems, especially dopaminergic system, and that TAAR1 serves as a homeostatic "brake" system that is involved in the modulation of dopaminergic activity. Existing data provided robust preclinical evidence supporting the development of TAAR1 agonists as potential treatment for psychostimulant abuse and addiction.<span typeof="mw:Entity" id="mwCGU"> </span>... Given that TAAR1 is primarily located in the intracellular compartments and existing TAAR1 agonists are proposed to get access to the receptors by translocation to the cell interior (Miller, 2011), future drug design and development efforts may need to take strategies of drug delivery into consideration (Rajendran et al., 2010).</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Eur.+J.+Pharmacol.&amp;rft.atitle=Trace+amine-associated+receptor+1%3A+A+promising+target+for+the+treatment+of+psychostimulant+addiction&amp;rft.volume=761&amp;rft.pages=345-52&amp;rft.date=2015-08&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4532615&amp;rft_id=info%3Apmid%2F26092759&amp;rft_id=info%3Adoi%2F10.1016%2Fj.ejphar.2015.06.019&amp;rft.aulast=Jing&amp;rft.aufirst=L&amp;rft.au=Li%2C+JX&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4532615&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt792" id="mwCGY"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt792" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwCGc"/></span></li><li about="#cite_note-Curable_brain_disorder?-125" id="cite_note-Curable_brain_disorder?-125"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-Curable_brain_disorder?_125-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-Curable_brain_disorder?_125-1"><span class="mw-linkback-text">2 </span></a></span> <span id="mw-reference-text-cite_note-Curable_brain_disorder?-125" class="mw-reference-text"><cite class="citation journal" about="#mwt789" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Liu JF, Li JX"},"title":{"wt":"Drug addiction: a curable mental disorder?"},"journal":{"wt":"Acta Pharmacologica Sinica"},"volume":{"wt":"39"},"issue":{"wt":"12"},"pages":{"wt":"1823–1829"},"date":{"wt":"December 2018"},"pmid":{"wt":"30382181"},"doi":{"wt":"10.1038/s41401-018-0180-x"},"url":{"wt":""}},"i":0}}]}' id="mwCGg">Liu JF, Li JX (December 2018). "Drug addiction: a curable mental disorder?". <i id="mwCGk">Acta Pharmacologica Sinica</i>. <b id="mwCGo">39</b> (12): 1823–1829. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwCGs">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1038%2Fs41401-018-0180-x" id="mwCGw">10.1038/s41401-018-0180-x</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwCG0" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwCG4"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/30382181" id="mwCG8">30382181</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Acta+Pharmacologica+Sinica&amp;rft.atitle=Drug+addiction%3A+a+curable+mental+disorder%3F&amp;rft.volume=39&amp;rft.issue=12&amp;rft.pages=1823-1829&amp;rft.date=2018-12&amp;rft_id=info%3Adoi%2F10.1038%2Fs41401-018-0180-x&amp;rft_id=info%3Apmid%2F30382181&amp;rft.aulast=Liu&amp;rft.aufirst=JF&amp;rft.au=Li%2C+JX&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt789" id="mwCHA"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt789" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwCHE"/></span></li><li about="#cite_note-Vaccine-antibody_immunotherapy-126" id="cite_note-Vaccine-antibody_immunotherapy-126"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-Vaccine-antibody_immunotherapy_126-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-Vaccine-antibody_immunotherapy_126-1"><span class="mw-linkback-text">2 </span></a><a href="./Addiction#cite_ref-Vaccine-antibody_immunotherapy_126-2"><span class="mw-linkback-text">3 </span></a></span> <span id="mw-reference-text-cite_note-Vaccine-antibody_immunotherapy-126" class="mw-reference-text"><cite class="citation journal" about="#mwt804" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Zalewska-Kaszubska J"},"title":{"wt":"Is immunotherapy an opportunity for effective treatment of drug addiction?"},"journal":{"wt":"Vaccine"},"volume":{"wt":"33"},"issue":{"wt":"48"},"pages":{"wt":"6545–51"},"date":{"wt":"November 2015"},"pmid":{"wt":"26432911"},"doi":{"wt":"10.1016/j.vaccine.2015.09.079"},"url":{"wt":""}},"i":0}}]}' id="mwCHI">Zalewska-Kaszubska J (November 2015). "Is immunotherapy an opportunity for effective treatment of drug addiction?". <i id="mwCHM">Vaccine</i>. <b id="mwCHQ">33</b> (48): 6545–51. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwCHU">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1016%2Fj.vaccine.2015.09.079" id="mwCHY">10.1016/j.vaccine.2015.09.079</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwCHc" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwCHg"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/26432911" id="mwCHk">26432911</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Vaccine&amp;rft.atitle=Is+immunotherapy+an+opportunity+for+effective+treatment+of+drug+addiction%3F&amp;rft.volume=33&amp;rft.issue=48&amp;rft.pages=6545-51&amp;rft.date=2015-11&amp;rft_id=info%3Adoi%2F10.1016%2Fj.vaccine.2015.09.079&amp;rft_id=info%3Apmid%2F26432911&amp;rft.aulast=Zalewska-Kaszubska&amp;rft.aufirst=J&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt804" id="mwCHo"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt804" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwCHs"/></span></li><li about="#cite_note-Primary_source:_Antibody_level_limitation-127" id="cite_note-Primary_source:_Antibody_level_limitation-127"><a href="./Addiction#cite_ref-Primary_source:_Antibody_level_limitation_127-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-Primary_source:_Antibody_level_limitation-127" class="mw-reference-text"><cite class="citation journal" about="#mwt805" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Laudenbach M, Baruffaldi F, Vervacke JS, Distefano MD, Titcombe PJ, Mueller DL, Tubo NJ, Griffith TS, Pravetoni M"},"title":{"wt":"The frequency of naive and early-activated hapten-specific B cell subsets dictates the efficacy of a therapeutic vaccine against prescription opioid abuse"},"journal":{"wt":"J. Immunol."},"volume":{"wt":"194"},"issue":{"wt":"12"},"pages":{"wt":"5926–36"},"date":{"wt":"June 2015"},"pmid":{"wt":"25972483"},"pmc":{"wt":"4458396"},"doi":{"wt":"10.4049/jimmunol.1500385"},"quote":{"wt":"Translation of therapeutic vaccines for addiction, cancer, or other chronic noncommunicable diseases has been slow because only a small subset of immunized subjects achieved effective Ab levels."}},"i":0}}]}' id="mwCHw">Laudenbach M, Baruffaldi F, Vervacke JS, Distefano MD, Titcombe PJ, Mueller DL, Tubo NJ, Griffith TS, Pravetoni M (June 2015). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4458396" id="mwCH0">"The frequency of naive and early-activated hapten-specific B cell subsets dictates the efficacy of a therapeutic vaccine against prescription opioid abuse"</a>. <i id="mwCH4">J. Immunol</i>. <b id="mwCH8">194</b> (12): 5926–36. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwCIA">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.4049%2Fjimmunol.1500385" id="mwCIE">10.4049/jimmunol.1500385</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwCII">PMC</a><span typeof="mw:Entity" id="mwCIM"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwCIQ"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4458396" id="mwCIU">4458396</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwCIY" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwCIc"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/25972483" id="mwCIg">25972483</a>. <q id="mwCIk">Translation of therapeutic vaccines for addiction, cancer, or other chronic noncommunicable diseases has been slow because only a small subset of immunized subjects achieved effective Ab levels.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J.+Immunol.&amp;rft.atitle=The+frequency+of+naive+and+early-activated+hapten-specific+B+cell+subsets+dictates+the+efficacy+of+a+therapeutic+vaccine+against+prescription+opioid+abuse&amp;rft.volume=194&amp;rft.issue=12&amp;rft.pages=5926-36&amp;rft.date=2015-06&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4458396&amp;rft_id=info%3Apmid%2F25972483&amp;rft_id=info%3Adoi%2F10.4049%2Fjimmunol.1500385&amp;rft.aulast=Laudenbach&amp;rft.aufirst=M&amp;rft.au=Baruffaldi%2C+F&amp;rft.au=Vervacke%2C+JS&amp;rft.au=Distefano%2C+MD&amp;rft.au=Titcombe%2C+PJ&amp;rft.au=Mueller%2C+DL&amp;rft.au=Tubo%2C+NJ&amp;rft.au=Griffith%2C+TS&amp;rft.au=Pravetoni%2C+M&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4458396&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt805" id="mwCIo"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt805" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwCIs"/></span></li><li about="#cite_note-ATS_pharmacotherapies-128" id="cite_note-ATS_pharmacotherapies-128"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-ATS_pharmacotherapies_128-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-ATS_pharmacotherapies_128-1"><span class="mw-linkback-text">2 </span></a><a href="./Addiction#cite_ref-ATS_pharmacotherapies_128-2"><span class="mw-linkback-text">3 </span></a><a href="./Addiction#cite_ref-ATS_pharmacotherapies_128-3"><span class="mw-linkback-text">4 </span></a></span> <span id="mw-reference-text-cite_note-ATS_pharmacotherapies-128" class="mw-reference-text"><cite class="citation journal" about="#mwt819" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Cao DN, Shi JJ, Hao W, Wu N, Li J"},"title":{"wt":"Advances and challenges in pharmacotherapeutics for amphetamine-type stimulants addiction"},"journal":{"wt":"Eur. J. Pharmacol."},"volume":{"wt":"780"},"issue":{"wt":""},"pages":{"wt":"129–35"},"date":{"wt":"March 2016"},"pmid":{"wt":"27018393"},"doi":{"wt":"10.1016/j.ejphar.2016.03.040"},"quote":{"wt":""}},"i":0}}]}' id="mwCIw">Cao DN, Shi JJ, Hao W, Wu N, Li J (March 2016). "Advances and challenges in pharmacotherapeutics for amphetamine-type stimulants addiction". <i id="mwCI0">Eur. J. Pharmacol</i>. <b id="mwCI4">780</b>: 129–35. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwCI8">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1016%2Fj.ejphar.2016.03.040" id="mwCJA">10.1016/j.ejphar.2016.03.040</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwCJE" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwCJI"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/27018393" id="mwCJM">27018393</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Eur.+J.+Pharmacol.&amp;rft.atitle=Advances+and+challenges+in+pharmacotherapeutics+for+amphetamine-type+stimulants+addiction&amp;rft.volume=780&amp;rft.pages=129-35&amp;rft.date=2016-03&amp;rft_id=info%3Adoi%2F10.1016%2Fj.ejphar.2016.03.040&amp;rft_id=info%3Apmid%2F27018393&amp;rft.aulast=Cao&amp;rft.aufirst=DN&amp;rft.au=Shi%2C+JJ&amp;rft.au=Hao%2C+W&amp;rft.au=Wu%2C+N&amp;rft.au=Li%2C+J&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt819" id="mwCJQ"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt819" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwCJU"/></span></li><li about="#cite_note-Glutamate_and_GABA_systems-129" id="cite_note-Glutamate_and_GABA_systems-129"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-Glutamate_and_GABA_systems_129-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-Glutamate_and_GABA_systems_129-1"><span class="mw-linkback-text">2 </span></a></span> <span id="mw-reference-text-cite_note-Glutamate_and_GABA_systems-129" class="mw-reference-text"><cite class="citation journal" about="#mwt820" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Moeller SJ, London ED, Northoff G"},"title":{"wt":"Neuroimaging markers of glutamatergic and GABAergic systems in drug addiction: Relationships to resting-state functional connectivity"},"journal":{"wt":"Neurosci Biobehav Rev"},"volume":{"wt":"61"},"issue":{"wt":""},"pages":{"wt":"35–52"},"date":{"wt":"February 2016"},"pmid":{"wt":"26657968"},"pmc":{"wt":"4731270"},"doi":{"wt":"10.1016/j.neubiorev.2015.11.010"},"url":{"wt":""}},"i":0}}]}' id="mwCJY">Moeller SJ, London ED, Northoff G (February 2016). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4731270" id="mwCJc">"Neuroimaging markers of glutamatergic and GABAergic systems in drug addiction: Relationships to resting-state functional connectivity"</a>. <i id="mwCJg">Neurosci Biobehav Rev</i>. <b id="mwCJk">61</b>: 35–52. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwCJo">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1016%2Fj.neubiorev.2015.11.010" id="mwCJs">10.1016/j.neubiorev.2015.11.010</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwCJw">PMC</a><span typeof="mw:Entity" id="mwCJ0"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwCJ4"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4731270" id="mwCJ8">4731270</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwCKA" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwCKE"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/26657968" id="mwCKI">26657968</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Neurosci+Biobehav+Rev&amp;rft.atitle=Neuroimaging+markers+of+glutamatergic+and+GABAergic+systems+in+drug+addiction%3A+Relationships+to+resting-state+functional+connectivity&amp;rft.volume=61&amp;rft.pages=35-52&amp;rft.date=2016-02&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4731270&amp;rft_id=info%3Apmid%2F26657968&amp;rft_id=info%3Adoi%2F10.1016%2Fj.neubiorev.2015.11.010&amp;rft.aulast=Moeller&amp;rft.aufirst=SJ&amp;rft.au=London%2C+ED&amp;rft.au=Northoff%2C+G&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4731270&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt820" id="mwCKM"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt820" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwCKQ"/></span></li><li about="#cite_note-GABAB_PAMs-130" id="cite_note-GABAB_PAMs-130"><a href="./Addiction#cite_ref-GABAB_PAMs_130-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-GABAB_PAMs-130" class="mw-reference-text"><cite class="citation journal" about="#mwt821" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Agabio R, Colombo G"},"title":{"wt":"[GABAB receptor as therapeutic target for drug addiction: from baclofen to positive allosteric modulators]"},"language":{"wt":"Polish"},"journal":{"wt":"Psychiatr. Pol."},"volume":{"wt":"49"},"issue":{"wt":"2"},"pages":{"wt":"215–23"},"date":{"wt":"April 2015"},"pmid":{"wt":"26093587"},"doi":{"wt":"10.12740/PP/33911"},"url":{"wt":""}},"i":0}}]}' id="mwCKU">Agabio R, Colombo G (April 2015). "[GABAB receptor as therapeutic target for drug addiction: from baclofen to positive allosteric modulators]". <i id="mwCKY">Psychiatr. Pol.</i> (in Polish). <b id="mwCKc">49</b> (2): 215–23. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwCKg">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.12740%2FPP%2F33911" id="mwCKk">10.12740/PP/33911</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwCKo" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwCKs"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/26093587" id="mwCKw">26093587</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Psychiatr.+Pol.&amp;rft.atitle=%5BGABAB+receptor+as+therapeutic+target+for+drug+addiction%3A+from+baclofen+to+positive+allosteric+modulators%5D&amp;rft.volume=49&amp;rft.issue=2&amp;rft.pages=215-23&amp;rft.date=2015-04&amp;rft_id=info%3Adoi%2F10.12740%2FPP%2F33911&amp;rft_id=info%3Apmid%2F26093587&amp;rft.aulast=Agabio&amp;rft.aufirst=R&amp;rft.au=Colombo%2C+G&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt821" id="mwCK0"></span><link rel="mw:PageProp/Category" href="./Category:CS1_Polish-language_sources_(pl)" about="#mwt821" id="mwCK4"/><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt821" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwCK8"/></span></li><li about="#cite_note-GABAB_PAMs_2-131" id="cite_note-GABAB_PAMs_2-131"><a href="./Addiction#cite_ref-GABAB_PAMs_2_131-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-GABAB_PAMs_2-131" class="mw-reference-text"><cite class="citation journal" about="#mwt822" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Filip M, Frankowska M, Sadakierska-Chudy A, Suder A, Szumiec L, Mierzejewski P, Bienkowski P, Przegaliński E, Cryan JF"},"title":{"wt":"GABAB receptors as a therapeutic strategy in substance use disorders: focus on positive allosteric modulators"},"journal":{"wt":"Neuropharmacology"},"volume":{"wt":"88"},"issue":{"wt":""},"pages":{"wt":"36–47"},"date":{"wt":"January 2015"},"pmid":{"wt":"24971600"},"doi":{"wt":"10.1016/j.neuropharm.2014.06.016"},"quote":{"wt":""}},"i":0}}]}' id="mwCLA">Filip M, Frankowska M, Sadakierska-Chudy A, Suder A, Szumiec L, Mierzejewski P, Bienkowski P, Przegaliński E, Cryan JF (January 2015). "GABAB receptors as a therapeutic strategy in substance use disorders: focus on positive allosteric modulators". <i id="mwCLE">Neuropharmacology</i>. <b id="mwCLI">88</b>: 36–47. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwCLM">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1016%2Fj.neuropharm.2014.06.016" id="mwCLQ">10.1016/j.neuropharm.2014.06.016</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwCLU" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwCLY"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/24971600" id="mwCLc">24971600</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Neuropharmacology&amp;rft.atitle=GABAB+receptors+as+a+therapeutic+strategy+in+substance+use+disorders%3A+focus+on+positive+allosteric+modulators&amp;rft.volume=88&amp;rft.pages=36-47&amp;rft.date=2015-01&amp;rft_id=info%3Adoi%2F10.1016%2Fj.neuropharm.2014.06.016&amp;rft_id=info%3Apmid%2F24971600&amp;rft.aulast=Filip&amp;rft.aufirst=M&amp;rft.au=Frankowska%2C+M&amp;rft.au=Sadakierska-Chudy%2C+A&amp;rft.au=Suder%2C+A&amp;rft.au=Szumiec%2C+L&amp;rft.au=Mierzejewski%2C+P&amp;rft.au=Bienkowski%2C+P&amp;rft.au=Przegali%C5%84ski%2C+E&amp;rft.au=Cryan%2C+JF&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt822" id="mwCLg"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt822" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwCLk"/></span></li><li about="#cite_note-Amphetamine_epigenetics-132" id="cite_note-Amphetamine_epigenetics-132"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-Amphetamine_epigenetics_132-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-Amphetamine_epigenetics_132-1"><span class="mw-linkback-text">2 </span></a></span> <span id="mw-reference-text-cite_note-Amphetamine_epigenetics-132" class="mw-reference-text"><cite class="citation journal" about="#mwt847" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"McCowan TJ, Dhasarathy A, Carvelli L"},"title":{"wt":"The Epigenetic Mechanisms of Amphetamine"},"journal":{"wt":"J. Addict. Prev."},"volume":{"wt":"2015"},"issue":{"wt":"Suppl 1"},"pages":{"wt":""},"date":{"wt":"February 2015"},"pmid":{"wt":"27453897"},"pmc":{"wt":"4955852"},"doi":{"wt":""},"quote":{"wt":"Epigenetic modifications caused by addictive drugs play an important role in neuronal plasticity and in drug-induced behavioral responses. Although few studies have investigated the effects of AMPH on gene regulation (Table 1), current data suggest that AMPH acts at multiple levels to alter histone/DNA interaction and to recruit transcription factors which ultimately cause repression of some genes and activation of other genes. Importantly, some studies have also correlated the epigenetic regulation induced by AMPH with the behavioral outcomes caused by this drug, suggesting therefore that epigenetics remodeling underlies the behavioral changes induced by AMPH. If this proves to be true, the use of specific drugs that inhibit histone acetylation, methylation or DNA methylation might be an important therapeutic alternative to prevent and/or reverse AMPH addiction and mitigate the side effects generate by AMPH when used to treat ADHD."}},"i":0}}]}' id="mwCLo">McCowan TJ, Dhasarathy A, Carvelli L (February 2015). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4955852" id="mwCLs">"The Epigenetic Mechanisms of Amphetamine"</a>. <i id="mwCLw">J. Addict. Prev</i>. <b id="mwCL0">2015</b> (Suppl 1). <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwCL4">PMC</a><span typeof="mw:Entity" id="mwCL8"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwCMA"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4955852" id="mwCME">4955852</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwCMI" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwCMM"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/27453897" id="mwCMQ">27453897</a>. <q id="mwCMU">Epigenetic modifications caused by addictive drugs play an important role in neuronal plasticity and in drug-induced behavioral responses. Although few studies have investigated the effects of AMPH on gene regulation (Table 1), current data suggest that AMPH acts at multiple levels to alter histone/DNA interaction and to recruit transcription factors which ultimately cause repression of some genes and activation of other genes. Importantly, some studies have also correlated the epigenetic regulation induced by AMPH with the behavioral outcomes caused by this drug, suggesting therefore that epigenetics remodeling underlies the behavioral changes induced by AMPH. If this proves to be true, the use of specific drugs that inhibit histone acetylation, methylation or DNA methylation might be an important therapeutic alternative to prevent and/or reverse AMPH addiction and mitigate the side effects generate by AMPH when used to treat ADHD.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J.+Addict.+Prev.&amp;rft.atitle=The+Epigenetic+Mechanisms+of+Amphetamine&amp;rft.volume=2015&amp;rft.issue=Suppl+1&amp;rft.date=2015-02&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4955852&amp;rft_id=info%3Apmid%2F27453897&amp;rft.aulast=McCowan&amp;rft.aufirst=TJ&amp;rft.au=Dhasarathy%2C+A&amp;rft.au=Carvelli%2C+L&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4955852&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt847" id="mwCMY"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt847" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwCMc"/></span></li><li about="#cite_note-HDACi_primaries-134" id="cite_note-HDACi_primaries-134"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-HDACi_primaries_134-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-HDACi_primaries_134-1"><span class="mw-linkback-text">2 </span></a></span> <span id="mw-reference-text-cite_note-HDACi_primaries-134" class="mw-reference-text">Primary references involving sodium butyrate:<br id="mwCMg"/><span typeof="mw:Transclusion mw:Entity" about="#mwt850" data-mw='{"parts":[{"template":{"target":{"wt":"bull","href":"./Template:Bull"},"params":{},"i":0}}]}' id="mwCMk"> </span><span typeof="mw:Entity" about="#mwt850" id="mwCMo">•</span><span typeof="mw:Entity" about="#mwt850" id="mwCMs"> </span><cite class="citation journal" about="#mwt851" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"vcite2 journal ","href":"./Template:Vcite2_journal"},"params":{"vauthors":{"wt":"Kennedy PJ, Feng J, Robison AJ, Maze I, Badimon A, Mouzon E, Chaudhury D, Damez-Werno DM, Haggarty SJ, Han MH, Bassel-Duby R, Olson EN, Nestler EJ"},"title":{"wt":"Class I HDAC inhibition blocks cocaine-induced plasticity by targeted changes in histone methylation"},"journal":{"wt":"Nat. Neurosci."},"volume":{"wt":"16"},"issue":{"wt":"4"},"pages":{"wt":"434–40"},"date":{"wt":"April 2013"},"pmid":{"wt":"23475113"},"pmc":{"wt":"3609040"},"doi":{"wt":"10.1038/nn.3354"},"quote":{"wt":"While acute HDAC inhibition enhances the behavioral effects of cocaine or amphetamine&lt;sup>1,3,4,13,14&lt;/sup>, studies suggest that more chronic regimens block psychostimulant-induced plasticity&lt;sup>3,5,11,12&lt;/sup>.&amp;nbsp;... The effects of pharmacological inhibition of HDACs on psychostimulant-induced plasticity appear to depend on the timecourse of HDAC inhibition. Studies employing co-administration procedures in which inhibitors are given acutely, just prior to psychostimulant administration, report heightened behavioral responses to the drug&lt;sup>1,3,4,13,14&lt;/sup>. In contrast, experimental paradigms like the one employed here, in which HDAC inhibitors are administered more chronically, for several days prior to psychostimulant exposure, show inhibited expression&lt;sup>3&lt;/sup> or decreased acquisition of behavioral adaptations to drug&lt;sup>5,11,12&lt;/sup>. The clustering of seemingly discrepant results based on experimental methodologies is interesting in light of our present findings. Both HDAC inhibitors and psychostimulants increase global levels of histone acetylation in NAc. Thus, when co-administered acutely, these drugs may have synergistic effects, leading to heightened transcriptional activation of psychostimulant-regulated target genes. In contrast, when a psychostimulant is given in the context of prolonged, HDAC inhibitor-induced hyperacetylation, homeostatic processes may direct AcH3 binding to the promoters of genes (e.g., G9a) responsible for inducing chromatin condensation and gene repression (e.g., via H3K9me2) in order to dampen already heightened transcriptional activation. Our present findings thus demonstrate clear cross talk among histone PTMs and suggest that decreased behavioral sensitivity to psychostimulants following prolonged HDAC inhibition might be mediated through decreased activity of HDAC1 at H3K9 KMT promoters and subsequent increases in H3K9me2 and gene repression."}},"i":0}}]}' id="mwCMw">Kennedy PJ, Feng J, Robison AJ, Maze I, Badimon A, Mouzon E,  et al. (April 2013). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3609040" id="mwCM0">"Class I HDAC inhibition blocks cocaine-induced plasticity by targeted changes in histone methylation"</a>. <i id="mwCM4">Nat. Neurosci</i>. <b id="mwCM8">16</b> (4): 434–40. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwCNA">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1038%2Fnn.3354" id="mwCNE">10.1038/nn.3354</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwCNI">PMC</a><span typeof="mw:Entity" id="mwCNM"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwCNQ"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3609040" id="mwCNU">3609040</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwCNY" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwCNc"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23475113" id="mwCNg">23475113</a>. <q id="mwCNk">While acute HDAC inhibition enhances the behavioral effects of cocaine or amphetamine<sup id="mwCNo">1,3,4,13,14</sup>, studies suggest that more chronic regimens block psychostimulant-induced plasticity<sup id="mwCNs">3,5,11,12</sup>.<span typeof="mw:Entity" id="mwCNw"> </span>... The effects of pharmacological inhibition of HDACs on psychostimulant-induced plasticity appear to depend on the timecourse of HDAC inhibition. Studies employing co-administration procedures in which inhibitors are given acutely, just prior to psychostimulant administration, report heightened behavioral responses to the drug<sup id="mwCN0">1,3,4,13,14</sup>. In contrast, experimental paradigms like the one employed here, in which HDAC inhibitors are administered more chronically, for several days prior to psychostimulant exposure, show inhibited expression<sup id="mwCN4">3</sup> or decreased acquisition of behavioral adaptations to drug<sup id="mwCN8">5,11,12</sup>. The clustering of seemingly discrepant results based on experimental methodologies is interesting in light of our present findings. Both HDAC inhibitors and psychostimulants increase global levels of histone acetylation in NAc. Thus, when co-administered acutely, these drugs may have synergistic effects, leading to heightened transcriptional activation of psychostimulant-regulated target genes. In contrast, when a psychostimulant is given in the context of prolonged, HDAC inhibitor-induced hyperacetylation, homeostatic processes may direct AcH3 binding to the promoters of genes (e.g., G9a) responsible for inducing chromatin condensation and gene repression (e.g., via H3K9me2) in order to dampen already heightened transcriptional activation. Our present findings thus demonstrate clear cross talk among histone PTMs and suggest that decreased behavioral sensitivity to psychostimulants following prolonged HDAC inhibition might be mediated through decreased activity of HDAC1 at H3K9 KMT promoters and subsequent increases in H3K9me2 and gene repression.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nat.+Neurosci.&amp;rft.atitle=Class+I+HDAC+inhibition+blocks+cocaine-induced+plasticity+by+targeted+changes+in+histone+methylation&amp;rft.volume=16&amp;rft.issue=4&amp;rft.pages=434-40&amp;rft.date=2013-04&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3609040&amp;rft_id=info%3Apmid%2F23475113&amp;rft_id=info%3Adoi%2F10.1038%2Fnn.3354&amp;rft.aulast=Kennedy&amp;rft.aufirst=PJ&amp;rft.au=Feng%2C+J&amp;rft.au=Robison%2C+AJ&amp;rft.au=Maze%2C+I&amp;rft.au=Badimon%2C+A&amp;rft.au=Mouzon%2C+E&amp;rft.au=Chaudhury%2C+D&amp;rft.au=Damez-Werno%2C+DM&amp;rft.au=Haggarty%2C+SJ&amp;rft.au=Han%2C+MH&amp;rft.au=Bassel-Duby%2C+R&amp;rft.au=Olson%2C+EN&amp;rft.au=Nestler%2C+EJ&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3609040&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt851" id="mwCOA"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt851" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwCOE"/><br id="mwCOI"/><span typeof="mw:Transclusion mw:Entity" about="#mwt852" data-mw='{"parts":[{"template":{"target":{"wt":"bull","href":"./Template:Bull"},"params":{},"i":0}}]}' id="mwCOM"> </span><span typeof="mw:Entity" about="#mwt852" id="mwCOQ">•</span><span typeof="mw:Entity" about="#mwt852" id="mwCOU"> </span><cite class="citation journal" about="#mwt853" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"vcite2 journal ","href":"./Template:Vcite2_journal"},"params":{"vauthors":{"wt":"Simon-O&apos;Brien E, Alaux-Cantin S, Warnault V, Buttolo R, Naassila M, Vilpoux C"},"title":{"wt":"The histone deacetylase inhibitor sodium butyrate decreases excessive ethanol intake in dependent animals"},"journal":{"wt":"Addict Biol"},"volume":{"wt":"20"},"issue":{"wt":"4"},"pages":{"wt":"676–89"},"date":{"wt":"July 2015"},"pmid":{"wt":"25041570"},"doi":{"wt":"10.1111/adb.12161"},"quote":{"wt":"Altogether, our results clearly demonstrated the efficacy of {{abbr|NaB|sodium butyrate}} in preventing excessive ethanol intake and relapse and support the hypothesis that {{abbr|HDACi|HDAC inhibitors}} may have a potential use in alcohol addiction treatment."}},"i":0}}]}' id="mwCOY">Simon-O'Brien E, Alaux-Cantin S, Warnault V, Buttolo R, Naassila M, Vilpoux C (July 2015). "The histone deacetylase inhibitor sodium butyrate decreases excessive ethanol intake in dependent animals". <i id="mwCOc">Addict Biol</i>. <b id="mwCOg">20</b> (4): 676–89. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwCOk">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1111%2Fadb.12161" id="mwCOo">10.1111/adb.12161</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwCOs" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwCOw"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/25041570" id="mwCO0">25041570</a>. <q id="mwCO4">Altogether, our results clearly demonstrated the efficacy of <abbr title="sodium butyrate" about="#mwt1775" typeof="mw:ExpandedAttrs" data-mw='{"attribs":[[{"txt":"title"},{"html":"&lt;span typeof=\"mw:Nowiki\" data-parsoid=\"{}\">sodium butyrate&lt;/span>"}]]}' id="mwCO8">NaB</abbr> in preventing excessive ethanol intake and relapse and support the hypothesis that <abbr title="HDAC inhibitors" about="#mwt1776" typeof="mw:ExpandedAttrs" data-mw='{"attribs":[[{"txt":"title"},{"html":"&lt;span typeof=\"mw:Nowiki\" data-parsoid=\"{}\">HDAC inhibitors&lt;/span>"}]]}' id="mwCPA">HDACi</abbr> may have a potential use in alcohol addiction treatment.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Addict+Biol&amp;rft.atitle=The+histone+deacetylase+inhibitor+sodium+butyrate+decreases+excessive+ethanol+intake+in+dependent+animals&amp;rft.volume=20&amp;rft.issue=4&amp;rft.pages=676-89&amp;rft.date=2015-07&amp;rft_id=info%3Adoi%2F10.1111%2Fadb.12161&amp;rft_id=info%3Apmid%2F25041570&amp;rft.aulast=Simon-O%27Brien&amp;rft.aufirst=E&amp;rft.au=Alaux-Cantin%2C+S&amp;rft.au=Warnault%2C+V&amp;rft.au=Buttolo%2C+R&amp;rft.au=Naassila%2C+M&amp;rft.au=Vilpoux%2C+C&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt853" id="mwCPE"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt853" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwCPI"/><br id="mwCPM"/><span typeof="mw:Transclusion mw:Entity" about="#mwt854" data-mw='{"parts":[{"template":{"target":{"wt":"bull","href":"./Template:Bull"},"params":{},"i":0}}]}' id="mwCPQ"> </span><span typeof="mw:Entity" about="#mwt854" id="mwCPU">•</span><span typeof="mw:Entity" about="#mwt854" id="mwCPY"> </span><cite class="citation journal" about="#mwt855" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"vcite2 journal ","href":"./Template:Vcite2_journal"},"params":{"vauthors":{"wt":"Castino MR, Cornish JL, Clemens KJ"},"title":{"wt":"Inhibition of histone deacetylases facilitates extinction and attenuates reinstatement of nicotine self-administration in rats"},"journal":{"wt":"PLoS ONE"},"volume":{"wt":"10"},"issue":{"wt":"4"},"pages":{"wt":"e0124796"},"date":{"wt":"April 2015"},"pmid":{"wt":"25880762"},"pmc":{"wt":"4399837"},"doi":{"wt":"10.1371/journal.pone.0124796"},"quote":{"wt":"treatment with NaB significantly attenuated nicotine and nicotine + cue reinstatement when administered immediately&amp;nbsp;... These results provide the first demonstration that HDAC inhibition facilitates the extinction of responding for an intravenously self-administered drug of abuse and further highlight the potential of HDAC inhibitors in the treatment of drug addiction."}},"i":0}}]}' id="mwCPc">Castino MR, Cornish JL, Clemens KJ (April 2015). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4399837" id="mwCPg">"Inhibition of histone deacetylases facilitates extinction and attenuates reinstatement of nicotine self-administration in rats"</a>. <i id="mwCPk">PLoS ONE</i>. <b id="mwCPo">10</b> (4): e0124796. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwCPs">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1371%2Fjournal.pone.0124796" id="mwCPw">10.1371/journal.pone.0124796</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwCP0">PMC</a><span typeof="mw:Entity" id="mwCP4"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwCP8"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4399837" id="mwCQA">4399837</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwCQE" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwCQI"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/25880762" id="mwCQM">25880762</a>. <q id="mwCQQ">treatment with NaB significantly attenuated nicotine and nicotine + cue reinstatement when administered immediately<span typeof="mw:Entity" id="mwCQU"> </span>... These results provide the first demonstration that HDAC inhibition facilitates the extinction of responding for an intravenously self-administered drug of abuse and further highlight the potential of HDAC inhibitors in the treatment of drug addiction.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=PLoS+ONE&amp;rft.atitle=Inhibition+of+histone+deacetylases+facilitates+extinction+and+attenuates+reinstatement+of+nicotine+self-administration+in+rats&amp;rft.volume=10&amp;rft.issue=4&amp;rft.pages=e0124796&amp;rft.date=2015-04&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4399837&amp;rft_id=info%3Apmid%2F25880762&amp;rft_id=info%3Adoi%2F10.1371%2Fjournal.pone.0124796&amp;rft.aulast=Castino&amp;rft.aufirst=MR&amp;rft.au=Cornish%2C+JL&amp;rft.au=Clemens%2C+KJ&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4399837&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt855" id="mwCQY"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt855" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwCQc"/></span></li><li about="#cite_note-HDAC_alcoholism_review-136" id="cite_note-HDAC_alcoholism_review-136"><a href="./Addiction#cite_ref-HDAC_alcoholism_review_136-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-HDAC_alcoholism_review-136" class="mw-reference-text"><cite class="citation journal" about="#mwt856" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Kyzar EJ, Pandey SC"},"title":{"wt":"Molecular mechanisms of synaptic remodeling in alcoholism"},"journal":{"wt":"Neurosci. Lett."},"volume":{"wt":"601"},"issue":{"wt":""},"pages":{"wt":"11–19"},"date":{"wt":"August 2015"},"pmid":{"wt":"25623036"},"pmc":{"wt":"4506731"},"doi":{"wt":"10.1016/j.neulet.2015.01.051"},"quote":{"wt":"Increased HDAC2 expression decreases the expression of genes important for the maintenance of dendritic spine density such as BDNF, Arc, and NPY, leading to increased anxiety and alcohol-seeking behavior. Decreasing HDAC2 reverses both the molecular and behavioral consequences of alcohol addiction, thus implicating this enzyme as a potential treatment target (Fig. 3). HDAC2 is also crucial for the induction and maintenance of structural synaptic plasticity in other neurological domains such as memory formation [115]. Taken together, these findings underscore the potential usefulness of HDAC inhibition in treating alcohol use disorders&amp;nbsp;... Given the ability of HDAC inhibitors to potently modulate the synaptic plasticity of learning and memory [118], these drugs hold potential as treatment for substance abuse-related disorders.&amp;nbsp;... Our lab and others have published extensively on the ability of HDAC inhibitors to reverse the gene expression deficits caused by multiple models of alcoholism and alcohol abuse, the results of which were discussed above [25,112,113]. This data supports further examination of histone modifying agents as potential therapeutic drugs in the treatment of alcohol addiction&amp;nbsp;... Future studies should continue to elucidate the specific epigenetic mechanisms underlying compulsive alcohol use and alcoholism, as this is likely to provide new molecular targets for clinical intervention."}},"i":0}}]}' id="mwCQg">Kyzar EJ, Pandey SC (August 2015). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4506731" id="mwCQk">"Molecular mechanisms of synaptic remodeling in alcoholism"</a>. <i id="mwCQo">Neurosci. Lett</i>. <b id="mwCQs">601</b>: 11–19. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwCQw">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1016%2Fj.neulet.2015.01.051" id="mwCQ0">10.1016/j.neulet.2015.01.051</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwCQ4">PMC</a><span typeof="mw:Entity" id="mwCQ8"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwCRA"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4506731" id="mwCRE">4506731</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwCRI" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwCRM"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/25623036" id="mwCRQ">25623036</a>. <q id="mwCRU">Increased HDAC2 expression decreases the expression of genes important for the maintenance of dendritic spine density such as BDNF, Arc, and NPY, leading to increased anxiety and alcohol-seeking behavior. Decreasing HDAC2 reverses both the molecular and behavioral consequences of alcohol addiction, thus implicating this enzyme as a potential treatment target (Fig. 3). HDAC2 is also crucial for the induction and maintenance of structural synaptic plasticity in other neurological domains such as memory formation [115]. Taken together, these findings underscore the potential usefulness of HDAC inhibition in treating alcohol use disorders<span typeof="mw:Entity" id="mwCRY"> </span>... Given the ability of HDAC inhibitors to potently modulate the synaptic plasticity of learning and memory [118], these drugs hold potential as treatment for substance abuse-related disorders.<span typeof="mw:Entity" id="mwCRc"> </span>... Our lab and others have published extensively on the ability of HDAC inhibitors to reverse the gene expression deficits caused by multiple models of alcoholism and alcohol abuse, the results of which were discussed above [25,112,113]. This data supports further examination of histone modifying agents as potential therapeutic drugs in the treatment of alcohol addiction<span typeof="mw:Entity" id="mwCRg"> </span>... Future studies should continue to elucidate the specific epigenetic mechanisms underlying compulsive alcohol use and alcoholism, as this is likely to provide new molecular targets for clinical intervention.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Neurosci.+Lett.&amp;rft.atitle=Molecular+mechanisms+of+synaptic+remodeling+in+alcoholism&amp;rft.volume=601&amp;rft.pages=11-19&amp;rft.date=2015-08&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4506731&amp;rft_id=info%3Apmid%2F25623036&amp;rft_id=info%3Adoi%2F10.1016%2Fj.neulet.2015.01.051&amp;rft.aulast=Kyzar&amp;rft.aufirst=EJ&amp;rft.au=Pandey%2C+SC&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4506731&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt856" id="mwCRk"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt856" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwCRo"/></span></li><li about="#cite_note-Valproate_for_methamphetamine_addiction_primary_source-137" id="cite_note-Valproate_for_methamphetamine_addiction_primary_source-137"><a href="./Addiction#cite_ref-Valproate_for_methamphetamine_addiction_primary_source_137-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-Valproate_for_methamphetamine_addiction_primary_source-137" class="mw-reference-text"><cite class="citation journal" id="mwCRs">Kheirabadi GR, Ghavami M, Maracy MR, Salehi M, Sharbafchi MR (2016). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC5025910" id="mwCRw">"Effect of add-on valproate on craving in methamphetamine depended patients: A randomized trial"</a>. <i id="mwCR0">Advanced Biomedical Research</i>. <b id="mwCR4">5</b>: 149. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwCR8">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.4103%2F2277-9175.187404" id="mwCSA">10.4103/2277-9175.187404</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwCSE">PMC</a><span typeof="mw:Entity" id="mwCSI"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwCSM"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC5025910" id="mwCSQ">5025910</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwCSU" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwCSY"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/27656618" id="mwCSc">27656618</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Advanced+Biomedical+Research&amp;rft.atitle=Effect+of+add-on+valproate+on+craving+in+methamphetamine+depended+patients%3A+A+randomized+trial&amp;rft.volume=5&amp;rft.pages=149&amp;rft.date=2016&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5025910&amp;rft_id=info%3Apmid%2F27656618&amp;rft_id=info%3Adoi%2F10.4103%2F2277-9175.187404&amp;rft.aulast=Kheirabadi&amp;rft.aufirst=GR&amp;rft.au=Ghavami%2C+M&amp;rft.au=Maracy%2C+MR&amp;rft.au=Salehi%2C+M&amp;rft.au=Sharbafchi%2C+MR&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5025910&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" id="mwCSg"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt1862" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwCSk"/></span></li><li about="#cite_note-139" id="cite_note-139"><a href="./Addiction#cite_ref-139" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-139" class="mw-reference-text"><cite class="citation web" about="#mwt869" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite web","href":"./Template:Cite_web"},"params":{"url":{"wt":"https://www.sciencedaily.com/releases/2008/04/080416081628.htm"},"title":{"wt":"Gene Therapy For Addiction: Flooding Brain With &apos;Pleasure Chemical&apos; Receptors Works On Cocaine, As On Alcohol"},"publisher":{"wt":""}},"i":0}}]}' id="mwCSo"><a rel="mw:ExtLink" class="external text" href="https://www.sciencedaily.com/releases/2008/04/080416081628.htm" id="mwCSs">"Gene Therapy For Addiction: Flooding Brain With 'Pleasure Chemical' Receptors Works On Cocaine, As On Alcohol"</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Gene+Therapy+For+Addiction%3A+Flooding+Brain+With+%27Pleasure+Chemical%27+Receptors+Works+On+Cocaine%2C+As+On+Alcohol&amp;rft_id=https%3A%2F%2Fwww.sciencedaily.com%2Freleases%2F2008%2F04%2F080416081628.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt869" id="mwCSw"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt869" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwCS0"/></span></li><li about="#cite_note-140" id="cite_note-140"><a href="./Addiction#cite_ref-140" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-140" class="mw-reference-text"><cite class="citation web" about="#mwt870" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite web","href":"./Template:Cite_web"},"params":{"url":{"wt":"https://www.drugabuse.gov/news-events/nida-notes/2016/01/gene-transfer-therapy-cocaine-addiction-passes-tests-in-animals"},"title":{"wt":"Gene Transfer Therapy for Cocaine Addiction Passes Tests in Animals"},"first":{"wt":"National Institute on Drug"},"last":{"wt":"Abuse"},"date":{"wt":"14 January 2016"},"publisher":{"wt":""}},"i":0}}]}' id="mwCS4">Abuse, National Institute on Drug (14 January 2016). <a rel="mw:ExtLink" class="external text" href="https://www.drugabuse.gov/news-events/nida-notes/2016/01/gene-transfer-therapy-cocaine-addiction-passes-tests-in-animals" id="mwCS8">"Gene Transfer Therapy for Cocaine Addiction Passes Tests in Animals"</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Gene+Transfer+Therapy+for+Cocaine+Addiction+Passes+Tests+in+Animals&amp;rft.date=2016-01-14&amp;rft.aulast=Abuse&amp;rft.aufirst=National+Institute+on+Drug&amp;rft_id=https%3A%2F%2Fwww.drugabuse.gov%2Fnews-events%2Fnida-notes%2F2016%2F01%2Fgene-transfer-therapy-cocaine-addiction-passes-tests-in-animals&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt870" id="mwCTA"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt870" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwCTE"/></span></li><li about="#cite_note-141" id="cite_note-141"><a href="./Addiction#cite_ref-141" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-141" class="mw-reference-text"><cite class="citation journal" about="#mwt871" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal","href":"./Template:Cite_journal"},"params":{"pmc":{"wt":"4077905"},"pmid":{"wt":"24892251"},"doi":{"wt":"10.1016/j.vaccine.2014.05.067"},"volume":{"wt":"32"},"issue":{"wt":"33"},"title":{"wt":"Physiologic and metabolic safety of butyrylcholinesterase gene therapy in mice"},"year":{"wt":"2014"},"vauthors":{"wt":"Murthy V, Gao Y, Geng L, LeBrasseur NK, White TA, Parks RJ, Brimijoin S"},"journal":{"wt":"Vaccine"},"pages":{"wt":"4155–62"}},"i":0}}]}' id="mwCTI">Murthy V, Gao Y, Geng L, LeBrasseur NK, White TA, Parks RJ, Brimijoin S (2014). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4077905" id="mwCTM">"Physiologic and metabolic safety of butyrylcholinesterase gene therapy in mice"</a>. <i id="mwCTQ">Vaccine</i>. <b id="mwCTU">32</b> (33): 4155–62. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwCTY">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1016%2Fj.vaccine.2014.05.067" id="mwCTc">10.1016/j.vaccine.2014.05.067</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwCTg">PMC</a><span typeof="mw:Entity" id="mwCTk"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwCTo"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4077905" id="mwCTs">4077905</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwCTw" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwCT0"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/24892251" id="mwCT4">24892251</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Vaccine&amp;rft.atitle=Physiologic+and+metabolic+safety+of+butyrylcholinesterase+gene+therapy+in+mice&amp;rft.volume=32&amp;rft.issue=33&amp;rft.pages=4155-62&amp;rft.date=2014&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4077905&amp;rft_id=info%3Apmid%2F24892251&amp;rft_id=info%3Adoi%2F10.1016%2Fj.vaccine.2014.05.067&amp;rft.aulast=Murthy&amp;rft.aufirst=V&amp;rft.au=Gao%2C+Y&amp;rft.au=Geng%2C+L&amp;rft.au=LeBrasseur%2C+NK&amp;rft.au=White%2C+TA&amp;rft.au=Parks%2C+RJ&amp;rft.au=Brimijoin%2C+S&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4077905&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt871" id="mwCT8"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt871" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwCUA"/></span></li><li about="#cite_note-142" id="cite_note-142"><a href="./Addiction#cite_ref-142" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-142" class="mw-reference-text"><cite class="citation web" about="#mwt872" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite web","href":"./Template:Cite_web"},"params":{"url":{"wt":"http://abstracts.aaps.org/Verify/AAPS2014/PosterSubmissions/T3009.pdf"},"title":{"wt":"Using Adeno-Associated Virus (AAV) Mediated Sustained Expression of an Anti-methamphetamine Antibody Fragment to Alter Methamphetamine Disposition in Mice"},"publisher":{"wt":""}},"i":0}}]}' id="mwCUE"><a rel="mw:ExtLink" class="external text" href="http://abstracts.aaps.org/Verify/AAPS2014/PosterSubmissions/T3009.pdf" id="mwCUI">"Using Adeno-Associated Virus (AAV) Mediated Sustained Expression of an Anti-methamphetamine Antibody Fragment to Alter Methamphetamine Disposition in Mice"</a> <span class="cs1-format" id="mwCUM">(PDF)</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Using+Adeno-Associated+Virus+%28AAV%29+Mediated+Sustained+Expression+of+an+Anti-methamphetamine+Antibody+Fragment+to+Alter+Methamphetamine+Disposition+in+Mice&amp;rft_id=http%3A%2F%2Fabstracts.aaps.org%2FVerify%2FAAPS2014%2FPosterSubmissions%2FT3009.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt872" id="mwCUQ"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt872" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwCUU"/></span></li><li about="#cite_note-143" id="cite_note-143"><a href="./Addiction#cite_ref-143" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-143" class="mw-reference-text"><cite class="citation web" about="#mwt873" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite web","href":"./Template:Cite_web"},"params":{"url":{"wt":"http://www.attcnetwork.org/explore/priorityareas/science/tools/asmeDetails.asp?ID=69"},"title":{"wt":"ATTC – Addiction Science Made Easy"},"website":{"wt":"www.attcnetwork.org"}},"i":0}}]}' id="mwCUY"><a rel="mw:ExtLink" class="external text" href="http://www.attcnetwork.org/explore/priorityareas/science/tools/asmeDetails.asp?ID=69" id="mwCUc">"ATTC – Addiction Science Made Easy"</a>. <i id="mwCUg">www.attcnetwork.org</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.attcnetwork.org&amp;rft.atitle=ATTC+%E2%80%93+Addiction+Science+Made+Easy&amp;rft_id=http%3A%2F%2Fwww.attcnetwork.org%2Fexplore%2Fpriorityareas%2Fscience%2Ftools%2FasmeDetails.asp%3FID%3D69&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt873" id="mwCUk"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt873" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwCUo"/></span></li><li about="#cite_note-144" id="cite_note-144"><a href="./Addiction#cite_ref-144" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-144" class="mw-reference-text"><cite class="citation web" about="#mwt879" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"Cite web ","href":"./Template:Cite_web"},"params":{"vauthors":{"wt":"Slade T, Johnston A, Teesson M, whiteford H, Burgess P, Pirkis J, Saw S"},"authorlink3":{"wt":"Maree Teesson"},"title":{"wt":"The Mental Health of Australians 2: Substance Use Disorders in Australia"},"publisher":{"wt":"Department of Health and Ageing, Canberra"},"date":{"wt":"May 2009"},"url":{"wt":"https://www.health.gov.au/internet/main/publishing.nsf/Content/A24556C814804A99CA257BF0001CAC45/$File/mha26.pdf"}},"i":0}}]}' id="mwCUs">Slade T, Johnston A, <a rel="mw:WikiLink" href="./Maree_Teesson" title="Maree Teesson" id="mwCUw">Teesson M</a>, whiteford H, Burgess P, Pirkis J, Saw S (May 2009). <a rel="mw:ExtLink" class="external text" href="https://www.health.gov.au/internet/main/publishing.nsf/Content/A24556C814804A99CA257BF0001CAC45/$File/mha26.pdf" id="mwCU0">"The Mental Health of Australians 2: Substance Use Disorders in Australia"</a> <span class="cs1-format" id="mwCU4">(PDF)</span>. Department of Health and Ageing, Canberra.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=The+Mental+Health+of+Australians+2%3A+Substance+Use+Disorders+in+Australia&amp;rft.pub=Department+of+Health+and+Ageing%2C+Canberra&amp;rft.date=2009-05&amp;rft.aulast=Slade&amp;rft.aufirst=T&amp;rft.au=Johnston%2C+A&amp;rft.au=Teesson%2C+M&amp;rft.au=whiteford%2C+H&amp;rft.au=Burgess%2C+P&amp;rft.au=Pirkis%2C+J&amp;rft.au=Saw%2C+S&amp;rft_id=https%3A%2F%2Fwww.health.gov.au%2Finternet%2Fmain%2Fpublishing.nsf%2FContent%2FA24556C814804A99CA257BF0001CAC45%2F%24File%2Fmha26.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt879" id="mwCU8"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt879" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwCVA"/></span></li><li about="#cite_note-146" id="cite_note-146"><a href="./Addiction#cite_ref-146" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-146" class="mw-reference-text"><cite class="citation journal" about="#mwt885" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Manubay JM, Muchow C, Sullivan MA"},"title":{"wt":"Prescription drug abuse: epidemiology, regulatory issues, chronic pain management with narcotic analgesics"},"journal":{"wt":"Primary Care"},"volume":{"wt":"38"},"issue":{"wt":"1"},"pages":{"wt":"71–90"},"date":{"wt":"March 2011"},"pmid":{"wt":"21356422"},"pmc":{"wt":"3328297"},"doi":{"wt":"10.1016/j.pop.2010.11.006"}},"i":0}}]}' id="mwCVE">Manubay JM, Muchow C, Sullivan MA (March 2011). <a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3328297" id="mwCVI">"Prescription drug abuse: epidemiology, regulatory issues, chronic pain management with narcotic analgesics"</a>. <i id="mwCVM">Primary Care</i>. <b id="mwCVQ">38</b> (1): 71–90. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwCVU">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1016%2Fj.pop.2010.11.006" id="mwCVY">10.1016/j.pop.2010.11.006</a>. <a rel="mw:WikiLink" href="./PubMed_Central" title="PubMed Central" id="mwCVc">PMC</a><span typeof="mw:Entity" id="mwCVg"> </span><span class="cs1-lock-free" title="Freely accessible" id="mwCVk"><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3328297" id="mwCVo">3328297</a></span>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwCVs" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwCVw"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21356422" id="mwCV0">21356422</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Primary+Care&amp;rft.atitle=Prescription+drug+abuse%3A+epidemiology%2C+regulatory+issues%2C+chronic+pain+management+with+narcotic+analgesics&amp;rft.volume=38&amp;rft.issue=1&amp;rft.pages=71-90&amp;rft.date=2011-03&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3328297&amp;rft_id=info%3Apmid%2F21356422&amp;rft_id=info%3Adoi%2F10.1016%2Fj.pop.2010.11.006&amp;rft.aulast=Manubay&amp;rft.aufirst=JM&amp;rft.au=Muchow%2C+C&amp;rft.au=Sullivan%2C+MA&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3328297&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt885" id="mwCV4"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt885" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwCV8"/></span></li><li about="#cite_note-NIDA_Addiction_Medicine-147" id="cite_note-NIDA_Addiction_Medicine-147"><span rel="mw:referencedBy"><a href="./Addiction#cite_ref-NIDA_Addiction_Medicine_147-0"><span class="mw-linkback-text">1 </span></a><a href="./Addiction#cite_ref-NIDA_Addiction_Medicine_147-1"><span class="mw-linkback-text">2 </span></a><a href="./Addiction#cite_ref-NIDA_Addiction_Medicine_147-2"><span class="mw-linkback-text">3 </span></a><a href="./Addiction#cite_ref-NIDA_Addiction_Medicine_147-3"><span class="mw-linkback-text">4 </span></a></span> <span id="mw-reference-text-cite_note-NIDA_Addiction_Medicine-147" class="mw-reference-text"><cite class="citation web" about="#mwt900" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite web","href":"./Template:Cite_web"},"params":{"author":{"wt":"Nora Volkow"},"title":{"wt":"A Major Step Forward for Addiction Medicine"},"url":{"wt":"https://www.drugabuse.gov/about-nida/noras-blog/2016/03/major-step-forward-addiction-medicine"},"website":{"wt":"National Institute on Drug Abuse"},"publisher":{"wt":"National Institutes of Health"},"accessdate":{"wt":"3 April 2016"},"date":{"wt":"31 March 2016"},"quote":{"wt":"Only about 10 percent of the 21 million Americans who meet the need for care for an alcohol or drug use disorder receive any form of treatment, and much of the treatment available does not meet standards for evidence-based care. There are many attitudinal and systemic reasons for this treatment gap, including stigma against treating people with addictions and institutional barriers to providing or funding addiction treatment.&amp;nbsp;... A major milestone was reached on March 14, 2016, when the American Board of Medical Specialties (ABMS) formally announced recognition of the field of Addiction Medicine as a medical subspecialty.&amp;nbsp;... In a statement issued to mark this milestone, ABAM President Robert J. Sokol summed up its significance: &apos;This landmark event, more than any other, recognizes addiction as a preventable and treatable disease, helping to shed the stigma that has long plagued it. It sends a strong message to the public that American medicine is committed to providing expert care for this disease and services designed to prevent the risky substance use that precedes it.&apos;"}},"i":0}}]}' id="mwCWA">Nora Volkow (31 March 2016). <a rel="mw:ExtLink" class="external text" href="https://www.drugabuse.gov/about-nida/noras-blog/2016/03/major-step-forward-addiction-medicine" id="mwCWE">"A Major Step Forward for Addiction Medicine"</a>. <i id="mwCWI">National Institute on Drug Abuse</i>. National Institutes of Health<span class="reference-accessdate" id="mwCWM">. Retrieved <span class="nowrap" id="mwCWQ">3 April</span> 2016</span>. <q id="mwCWU">Only about 10 percent of the 21 million Americans who meet the need for care for an alcohol or drug use disorder receive any form of treatment, and much of the treatment available does not meet standards for evidence-based care. There are many attitudinal and systemic reasons for this treatment gap, including stigma against treating people with addictions and institutional barriers to providing or funding addiction treatment.<span typeof="mw:Entity" id="mwCWY"> </span>... A major milestone was reached on March 14, 2016, when the American Board of Medical Specialties (ABMS) formally announced recognition of the field of Addiction Medicine as a medical subspecialty.<span typeof="mw:Entity" id="mwCWc"> </span>... In a statement issued to mark this milestone, ABAM President Robert J. Sokol summed up its significance: 'This landmark event, more than any other, recognizes addiction as a preventable and treatable disease, helping to shed the stigma that has long plagued it. It sends a strong message to the public that American medicine is committed to providing expert care for this disease and services designed to prevent the risky substance use that precedes it.'</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=National+Institute+on+Drug+Abuse&amp;rft.atitle=A+Major+Step+Forward+for+Addiction+Medicine&amp;rft.date=2016-03-31&amp;rft.au=Nora+Volkow&amp;rft_id=https%3A%2F%2Fwww.drugabuse.gov%2Fabout-nida%2Fnoras-blog%2F2016%2F03%2Fmajor-step-forward-addiction-medicine&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt900" id="mwCWg"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt900" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwCWk"/></span></li><li about="#cite_note-148" id="cite_note-148"><a href="./Addiction#cite_ref-148" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-148" class="mw-reference-text"><cite class="citation web" about="#mwt956" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite web","href":"./Template:Cite_web"},"params":{"title":{"wt":"Nearly half of Americans have a family member or close friend who&apos;s been addicted to drugs"},"url":{"wt":"http://www.pewresearch.org/fact-tank/2017/10/26/nearly-half-of-americans-have-a-family-member-or-close-friend-whos-been-addicted-to-drugs/"},"publisher":{"wt":"Pew Research Center"},"author":{"wt":"Gramlich J"},"date":{"wt":"26 October 2017"},"accessdate":{"wt":"14 January 2018"}},"i":0}}]}' id="mwCWo">Gramlich J (26 October 2017). <a rel="mw:ExtLink" class="external text" href="http://www.pewresearch.org/fact-tank/2017/10/26/nearly-half-of-americans-have-a-family-member-or-close-friend-whos-been-addicted-to-drugs/" id="mwCWs">"Nearly half of Americans have a family member or close friend who's been addicted to drugs"</a>. Pew Research Center<span class="reference-accessdate" id="mwCWw">. Retrieved <span class="nowrap" id="mwCW0">14 January</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Nearly+half+of+Americans+have+a+family+member+or+close+friend+who%27s+been+addicted+to+drugs&amp;rft.pub=Pew+Research+Center&amp;rft.date=2017-10-26&amp;rft.au=Gramlich+J&amp;rft_id=http%3A%2F%2Fwww.pewresearch.org%2Ffact-tank%2F2017%2F10%2F26%2Fnearly-half-of-americans-have-a-family-member-or-close-friend-whos-been-addicted-to-drugs%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt956" id="mwCW4"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt956" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwCW8"/></span></li><li about="#cite_note-Cheetham_2010-149" id="cite_note-Cheetham_2010-149"><a href="./Addiction#cite_ref-Cheetham_2010_149-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-Cheetham_2010-149" class="mw-reference-text"><cite class="citation journal" about="#mwt1004" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Cheetham A, Allen NB, Yücel M, Lubman DI"},"title":{"wt":"The role of affective dysregulation in drug addiction"},"journal":{"wt":"Clin Psychol Rev"},"volume":{"wt":"30"},"issue":{"wt":"6"},"pages":{"wt":"621–34"},"date":{"wt":"August 2010"},"pmid":{"wt":"20546986"},"doi":{"wt":"10.1016/j.cpr.2010.04.005"},"url":{"wt":""}},"i":0}}]}' id="mwCXA">Cheetham A, Allen NB, Yücel M, Lubman DI (August 2010). "The role of affective dysregulation in drug addiction". <i id="mwCXE">Clin Psychol Rev</i>. <b id="mwCXI">30</b> (6): 621–34. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwCXM">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1016%2Fj.cpr.2010.04.005" id="mwCXQ">10.1016/j.cpr.2010.04.005</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwCXU" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwCXY"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/20546986" id="mwCXc">20546986</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clin+Psychol+Rev&amp;rft.atitle=The+role+of+affective+dysregulation+in+drug+addiction&amp;rft.volume=30&amp;rft.issue=6&amp;rft.pages=621-34&amp;rft.date=2010-08&amp;rft_id=info%3Adoi%2F10.1016%2Fj.cpr.2010.04.005&amp;rft_id=info%3Apmid%2F20546986&amp;rft.aulast=Cheetham&amp;rft.aufirst=A&amp;rft.au=Allen%2C+NB&amp;rft.au=Y%C3%BCcel%2C+M&amp;rft.au=Lubman%2C+DI&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt1004" id="mwCXg"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt1004" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwCXk"/></span></li><li about="#cite_note-Franken_2006-150" id="cite_note-Franken_2006-150"><a href="./Addiction#cite_ref-Franken_2006_150-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-Franken_2006-150" class="mw-reference-text"><cite class="citation journal" about="#mwt1005" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Franken IH, Muris P"},"title":{"wt":"BIS/BAS personality characteristics and college students&apos; substance use"},"journal":{"wt":"Personality and Individual Differences"},"year":{"wt":"2006"},"volume":{"wt":"40"},"issue":{"wt":"7"},"pages":{"wt":"1497–503"},"doi":{"wt":"10.1016/j.paid.2005.12.005"}},"i":0}}]}' id="mwCXo">Franken IH, Muris P (2006). "BIS/BAS personality characteristics and college students' substance use". <i id="mwCXs">Personality and Individual Differences</i>. <b id="mwCXw">40</b> (7): 1497–503. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwCX0">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1016%2Fj.paid.2005.12.005" id="mwCX4">10.1016/j.paid.2005.12.005</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Personality+and+Individual+Differences&amp;rft.atitle=BIS%2FBAS+personality+characteristics+and+college+students%27+substance+use&amp;rft.volume=40&amp;rft.issue=7&amp;rft.pages=1497-503&amp;rft.date=2006&amp;rft_id=info%3Adoi%2F10.1016%2Fj.paid.2005.12.005&amp;rft.aulast=Franken&amp;rft.aufirst=IH&amp;rft.au=Muris%2C+P&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt1005" id="mwCX8"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt1005" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwCYA"/></span></li><li about="#cite_note-pmid18232522-151" id="cite_note-pmid18232522-151"><a href="./Addiction#cite_ref-pmid18232522_151-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-pmid18232522-151" class="mw-reference-text"><cite class="citation journal" about="#mwt1006" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Genovese JE, Wallace D"},"title":{"wt":"Reward sensitivity and substance abuse in middle school and high school students"},"journal":{"wt":"J Genet Psychol"},"volume":{"wt":"168"},"issue":{"wt":"4"},"pages":{"wt":"465–69"},"date":{"wt":"December 2007"},"pmid":{"wt":"18232522"},"doi":{"wt":"10.3200/GNTP.168.4.465-469"}},"i":0}}]}' id="mwCYE">Genovese JE, Wallace D (December 2007). "Reward sensitivity and substance abuse in middle school and high school students". <i id="mwCYI">J Genet Psychol</i>. <b id="mwCYM">168</b> (4): 465–69. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwCYQ">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.3200%2FGNTP.168.4.465-469" id="mwCYU">10.3200/GNTP.168.4.465-469</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwCYY" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwCYc"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18232522" id="mwCYg">18232522</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J+Genet+Psychol&amp;rft.atitle=Reward+sensitivity+and+substance+abuse+in+middle+school+and+high+school+students&amp;rft.volume=168&amp;rft.issue=4&amp;rft.pages=465-69&amp;rft.date=2007-12&amp;rft_id=info%3Adoi%2F10.3200%2FGNTP.168.4.465-469&amp;rft_id=info%3Apmid%2F18232522&amp;rft.aulast=Genovese&amp;rft.aufirst=JE&amp;rft.au=Wallace%2C+D&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt1006" id="mwCYk"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt1006" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwCYo"/></span></li><li about="#cite_note-Kimbrel_2007-152" id="cite_note-Kimbrel_2007-152"><a href="./Addiction#cite_ref-Kimbrel_2007_152-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-Kimbrel_2007-152" class="mw-reference-text"><cite class="citation journal" about="#mwt1007" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Kimbrel NA, Nelson-Gray RO, Mitchell JT"},"title":{"wt":"Reinforcement sensitivity and maternal style as predictors of psychopathology"},"journal":{"wt":"Personality and Individual Differences"},"date":{"wt":"April 2007"},"volume":{"wt":"42"},"issue":{"wt":"6"},"pages":{"wt":"1139–49"},"doi":{"wt":"10.1016/j.paid.2006.06.028"}},"i":0}}]}' id="mwCYs">Kimbrel NA, Nelson-Gray RO, Mitchell JT (April 2007). "Reinforcement sensitivity and maternal style as predictors of psychopathology". <i id="mwCYw">Personality and Individual Differences</i>. <b id="mwCY0">42</b> (6): 1139–49. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwCY4">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1016%2Fj.paid.2006.06.028" id="mwCY8">10.1016/j.paid.2006.06.028</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Personality+and+Individual+Differences&amp;rft.atitle=Reinforcement+sensitivity+and+maternal+style+as+predictors+of+psychopathology&amp;rft.volume=42&amp;rft.issue=6&amp;rft.pages=1139-49&amp;rft.date=2007-04&amp;rft_id=info%3Adoi%2F10.1016%2Fj.paid.2006.06.028&amp;rft.aulast=Kimbrel&amp;rft.aufirst=NA&amp;rft.au=Nelson-Gray%2C+RO&amp;rft.au=Mitchell%2C+JT&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt1007" id="mwCZA"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt1007" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwCZE"/></span></li><li about="#cite_note-Dawe-153" id="cite_note-Dawe-153"><a href="./Addiction#cite_ref-Dawe_153-0" rel="mw:referencedBy"><span class="mw-linkback-text">↑ </span></a> <span id="mw-reference-text-cite_note-Dawe-153" class="mw-reference-text"><cite class="citation journal" about="#mwt1008" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite journal ","href":"./Template:Cite_journal"},"params":{"vauthors":{"wt":"Dawe S, Loxton NJ"},"title":{"wt":"The role of impulsivity in the development of substance use and eating disorders"},"journal":{"wt":"Neurosci Biobehav Rev"},"volume":{"wt":"28"},"issue":{"wt":"3"},"pages":{"wt":"343–51"},"date":{"wt":"May 2004"},"pmid":{"wt":"15225976"},"doi":{"wt":"10.1016/j.neubiorev.2004.03.007"}},"i":0}}]}' id="mwCZI">Dawe S, Loxton NJ (May 2004). "The role of impulsivity in the development of substance use and eating disorders". <i id="mwCZM">Neurosci Biobehav Rev</i>. <b id="mwCZQ">28</b> (3): 343–51. <a rel="mw:WikiLink" href="./Digital_object_identifier" title="Digital object identifier" id="mwCZU">doi</a>:<a rel="mw:ExtLink" class="external text" href="//doi.org/10.1016%2Fj.neubiorev.2004.03.007" id="mwCZY">10.1016/j.neubiorev.2004.03.007</a>. <a rel="mw:WikiLink" href="./PubMed_Identifier" title="PubMed Identifier" id="mwCZc" class="mw-redirect">PMID</a><span typeof="mw:Entity" id="mwCZg"> </span><a rel="mw:ExtLink" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15225976" id="mwCZk">15225976</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Neurosci+Biobehav+Rev&amp;rft.atitle=The+role+of+impulsivity+in+the+development+of+substance+use+and+eating+disorders&amp;rft.volume=28&amp;rft.issue=3&amp;rft.pages=343-51&amp;rft.date=2004-05&amp;rft_id=info%3Adoi%2F10.1016%2Fj.neubiorev.2004.03.007&amp;rft_id=info%3Apmid%2F15225976&amp;rft.aulast=Dawe&amp;rft.aufirst=S&amp;rft.au=Loxton%2C+NJ&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt1008" id="mwCZo"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt1008" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}' id="mwCZs"/></span></li></ol></div></div>

</section><section data-mw-section-id="39" id="mwCZw"><h2 id="External_links">External links</h2>
<table class="infobox" style="width:22em;width:100%; margin:0 0 0.5em 0;" about="#mwt1013" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"Medical resources\n","href":"./Template:Medical_resources"},"params":{"ICD10":{"wt":"{{ICD10|F10-F19}} subdivision .2"}},"i":0}}]}' id="mwCZ0"><tbody><tr><th scope="row">Classification</th><td style="text-align:left;"><div style="position:relative; float:right; font-size:0.8em;"><a rel="mw:WikiLink/Interwiki" href="https://www.wikidata.org/wiki/Q12029%20" title="d:Q12029 ">D</a></div><div class="hlist hlist-separated" style="text-align:left;"><ul><li><b><a rel="mw:WikiLink" href="./International_Statistical_Classification_of_Diseases_and_Related_Health_Problems" title="International Statistical Classification of Diseases and Related Health Problems">ICD</a>-<a rel="mw:WikiLink" href="./ICD-10" title="ICD-10">10</a></b>: <a rel="mw:ExtLink" class="external text" href="http://apps.who.int/classifications/icd10/browse/2016/en#/F10-F19">F10-F19</a> subdivision .2</li></ul></div></td></tr></tbody></table>
<table role="presentation" class="mbox-small plainlinks sistersitebox" style="background-color:#f9f9f9;border:1px solid #aaa;color:#000" about="#mwt1014" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"Commonscat","href":"./Template:Commonscat"},"params":{},"i":0}}]}' id="mwCZ4">
<tbody><tr>
<td class="mbox-image"><figure-inline class="noviewer" typeof="mw:Image"><span><img alt="" resource="./File:Commons-logo.svg" src="//upload.wikimedia.org/wikipedia/en/thumb/4/4a/Commons-logo.svg/30px-Commons-logo.svg.png" data-file-width="1024" data-file-height="1376" data-file-type="drawing" height="40" width="30" srcset="//upload.wikimedia.org/wikipedia/en/thumb/4/4a/Commons-logo.svg/59px-Commons-logo.svg.png 2x, //upload.wikimedia.org/wikipedia/en/thumb/4/4a/Commons-logo.svg/45px-Commons-logo.svg.png 1.5x"/></span></figure-inline></td>
<td class="mbox-text plainlist">Wikimedia Commons has media related to <i><b><a rel="mw:WikiLink/Interwiki" href="https://commons.wikimedia.org/wiki/Category:Addiction" title="commons:Category:Addiction">Addiction</a></b></i>.</td></tr></tbody></table><link rel="mw:PageProp/Category" href="./Category:Commons_category_link_from_Wikidata" about="#mwt1014" id="mwCZ8"/>
<ul id="mwCaA"><li id="mwCaE"><cite class="citation web" about="#mwt1015" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"cite web ","href":"./Template:Cite_web"},"params":{"url":{"wt":"http://learn.genetics.utah.edu/content/addiction/"},"title":{"wt":"The Science of Addiction: Genetics and the Brain"},"author":{"wt":"&lt;!--Staff writer(s); no by-line.-->"},"date":{"wt":""},"website":{"wt":"learn.genetics.utah.edu"},"publisher":{"wt":"Learn.Genetics – [[University of Utah]]"},"access-date":{"wt":""},"quote":{"wt":""}},"i":0}}]}' id="mwCaI"><a rel="mw:ExtLink" class="external text" href="http://learn.genetics.utah.edu/content/addiction/">"The Science of Addiction: Genetics and the Brain"</a>. <i>learn.genetics.utah.edu</i>. Learn.Genetics – <a rel="mw:WikiLink" href="./University_of_Utah" title="University of Utah">University of Utah</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=learn.genetics.utah.edu&amp;rft.atitle=The+Science+of+Addiction%3A+Genetics+and+the+Brain&amp;rft_id=http%3A%2F%2Flearn.genetics.utah.edu%2Fcontent%2Faddiction%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAddiction" class="Z3988" about="#mwt1015"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008" about="#mwt1015" typeof="mw:Extension/templatestyles" data-mw='{"name":"templatestyles","attrs":{"src":"Module:Citation/CS1/styles.css"},"body":{"extsrc":""}}'/></li>
<li id="mwCaM"><a rel="mw:ExtLink" class="external text" href="http://www.tedmed.com/talks/show?id=309096" id="mwCaQ">Why do our brains get addicted?</a><span typeof="mw:Entity" id="mwCaU"> </span>– a <a rel="mw:WikiLink" href="./TEDMED" title="TEDMED" id="mwCaY">TEDMED</a> 2014 talk by <a rel="mw:WikiLink" href="./Nora_Volkow" title="Nora Volkow" id="mwCac">Nora Volkow</a>, the director of the <a rel="mw:WikiLink" href="./National_Institute_on_Drug_Abuse" title="National Institute on Drug Abuse" id="mwCag">National Institute on Drug Abuse</a> at <a rel="mw:WikiLink" href="./National_Institutes_of_Health" title="National Institutes of Health" id="mwCak">NIH</a>.</li>
<li id="mwCao"><a rel="mw:ExtLink" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4811731/" id="mwCas">Laterality of Brain Activation for Risk Factors of Addiction</a></li></ul>
<p id="mwCaw"><a rel="mw:WikiLink" href="./Kyoto_Encyclopedia_of_Genes_and_Genomes" title="Kyoto Encyclopedia of Genes and Genomes" id="mwCa0" class="mw-redirect">Kyoto Encyclopedia of Genes and Genomes</a> (KEGG) signal transduction pathways:</p>
<ul id="mwCa4"><li id="mwCa8"><a rel="mw:ExtLink" class="external text" href="http://www.genome.jp/kegg-bin/show_pathway?hsa05034+2354" id="mwCbA">KEGG – human alcohol addiction</a></li>
<li id="mwCbE"><a rel="mw:ExtLink" class="external text" href="http://www.genome.jp/kegg-bin/show_pathway?hsa05031+2354" id="mwCbI">KEGG – human amphetamine addiction</a></li>
<li id="mwCbM"><a rel="mw:ExtLink" class="external text" href="http://www.genome.jp/kegg-bin/show_pathway?hsa05030+2354" id="mwCbQ">KEGG – human cocaine addiction</a></li></ul>

<div role="navigation" class="navbox" aria-labelledby="Reinforcement_disorders:_Addiction_and_Dependence" style="padding:3px" about="#mwt1016" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"Addiction","href":"./Template:Addiction"},"params":{"state":{"wt":"expanded"}},"i":0}}]}' id="mwCbU"><table class="nowraplinks collapsible expanded navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div class="plainlinks hlist navbar mini"><ul><li class="nv-view"><a rel="mw:WikiLink" href="./Template:Addiction" title="Template:Addiction"><abbr title="View this template" style=";;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;">v</abbr></a></li><li class="nv-talk"><a rel="mw:WikiLink" href="./Template_talk:Addiction" title="Template talk:Addiction"><abbr title="Discuss this template" style=";;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;">t</abbr></a></li><li class="nv-edit"><a rel="mw:ExtLink" class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Addiction&amp;action=edit"><abbr title="Edit this template" style=";;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;">e</abbr></a></li></ul></div><div id="Reinforcement_disorders:_Addiction_and_Dependence" style="font-size:114%;margin:0 4em"><a rel="mw:WikiLink" href="./Reinforcement" title="Reinforcement">Reinforcement</a> disorders: <a rel="mw:WikiLink" href="./Addiction" title="Addiction">Addiction</a> and <a rel="mw:WikiLink" href="./Substance_dependence" title="Substance dependence">Dependence</a></div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a rel="mw:WikiLink" href="./Addiction" title="Addiction">Addiction</a></th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:8em;text-align:center;">Drug</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a rel="mw:WikiLink" href="./Alcoholism" title="Alcoholism">Alcoholism</a></li>
<li><a rel="mw:WikiLink" href="./Amphetamine#Addiction" title="Amphetamine">Amphetamine</a></li>
<li><a rel="mw:WikiLink" href="./Cocaine_addiction" title="Cocaine addiction" class="mw-redirect">Cocaine</a></li>
<li><a rel="mw:WikiLink" href="./Methamphetamine#Addiction" title="Methamphetamine">Methamphetamine</a></li>
<li><a rel="mw:WikiLink" href="./Methylphenidate#Addiction_and_dependence" title="Methylphenidate">Methylphenidate</a></li>
<li><a rel="mw:WikiLink" href="./Nicotine_addiction" title="Nicotine addiction" class="mw-redirect">Nicotine</a></li>
<li><a rel="mw:WikiLink" href="./Opioid_use_disorder" title="Opioid use disorder">Opioid</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:8em;text-align:center;"><a rel="mw:WikiLink" href="./Behavioral_addiction" title="Behavioral addiction">Behavioral</a></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Financial
<ul><li><a rel="mw:WikiLink" href="./Problem_gambling" title="Problem gambling">Gambling</a></li>
<li><a rel="mw:WikiLink" href="./Compulsive_buying_disorder" title="Compulsive buying disorder">Shopping</a></li></ul></li>
<li>Media
<ul><li><a rel="mw:WikiLink" href="./Computer_addiction" title="Computer addiction">Computer</a></li>
<li><a rel="mw:WikiLink" href="./Internet_addiction_disorder" title="Internet addiction disorder">Internet</a></li>
<li><a rel="mw:WikiLink" href="./Video_game_addiction" title="Video game addiction">Video game</a></li></ul></li>
<li><a rel="mw:WikiLink" href="./Food_addiction" title="Food addiction">Palatable food</a></li>
<li>Sex-related
<ul><li><a rel="mw:WikiLink" href="./Internet_sex_addiction" title="Internet sex addiction">Cybersex</a></li>
<li><a rel="mw:WikiLink" href="./Sexual_addiction" title="Sexual addiction">Intercourse</a></li>
<li><a rel="mw:WikiLink" href="./Pornography_addiction" title="Pornography addiction">Pornography</a></li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:8em;text-align:center;">Cellular<br/>mechanisms</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a rel="mw:WikiLink" href="./Transcription_factor" title="Transcription factor">Transcriptional</a>
<ul><li><b><a rel="mw:WikiLink" href="./FOSB#ΔFosB" title="FOSB">ΔFosB</a></b></li>
<li><a rel="mw:WikiLink" href="./C-Fos" title="C-Fos">c-Fos</a></li>
<li><a rel="mw:WikiLink" href="./Cdk5" title="Cdk5" class="mw-redirect">Cdk5</a></li>
<li><a rel="mw:WikiLink" href="./CREB" title="CREB">CREB</a></li>
<li><a rel="mw:WikiLink" href="./GluR2" title="GluR2" class="mw-redirect">GluR2</a></li>
<li><a rel="mw:WikiLink" href="./NF-κB" title="NF-κB">NF-κB</a></li></ul></li></ul>

<ul><li><a rel="mw:WikiLink" href="./Histone-modifying_enzymes" title="Histone-modifying enzymes">Epigenetic</a>
<ul><li><b><a rel="mw:WikiLink" href="./G9a" title="G9a" class="mw-redirect">G9a</a></b></li>
<li><a rel="mw:WikiLink" href="./G9a-like_protein" title="G9a-like protein" class="mw-redirect">G9a-like protein</a></li>
<li><b><a rel="mw:WikiLink" href="./HDAC1" title="HDAC1">HDAC1</a></b></li>
<li><b><a rel="mw:WikiLink" href="./HDAC2" title="HDAC2" class="mw-redirect">HDAC2</a></b></li>
<li><b><a rel="mw:WikiLink" href="./HDAC3" title="HDAC3">HDAC3</a></b></li>
<li><a rel="mw:WikiLink" href="./HDAC4" title="HDAC4">HDAC4</a></li>
<li><a rel="mw:WikiLink" href="./HDAC5" title="HDAC5" class="mw-redirect">HDAC5</a></li>
<li><a rel="mw:WikiLink" href="./HDAC9" title="HDAC9">HDAC9</a></li>
<li><a rel="mw:WikiLink" href="./HDAC10" title="HDAC10">HDAC10</a></li>
<li><a rel="mw:WikiLink" href="./SIRT1" title="SIRT1" class="mw-redirect">SIRT1</a></li>
<li><a rel="mw:WikiLink" href="./SIRT2" title="SIRT2" class="mw-redirect">SIRT2</a></li>
<li>...</li></ul></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a rel="mw:WikiLink" href="./Substance_dependence" title="Substance dependence">Dependence</a></th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:8em;text-align:center;">Concepts</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a rel="mw:WikiLink" href="./Physical_dependence" title="Physical dependence">Physical dependence</a></li>
<li><a rel="mw:WikiLink" href="./Psychological_dependence" title="Psychological dependence">Psychological dependence</a></li>
<li><a rel="mw:WikiLink" href="./Drug_withdrawal" title="Drug withdrawal">Withdrawal</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:8em;text-align:center;">Disorders</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Drugs
<ul><li><a rel="mw:WikiLink" href="./Alcoholism" title="Alcoholism">Alcoholism</a></li>
<li><a rel="mw:WikiLink" href="./Amphetamine_dependence" title="Amphetamine dependence">Amphetamine</a></li>
<li><a rel="mw:WikiLink" href="./Barbiturate_dependence" title="Barbiturate dependence">Barbiturate</a></li>
<li><a rel="mw:WikiLink" href="./Benzodiazepine_dependence" title="Benzodiazepine dependence">Benzodiazepine</a></li>
<li><a rel="mw:WikiLink" href="./Caffeine_dependence" title="Caffeine dependence">Caffeine</a></li>
<li><a rel="mw:WikiLink" href="./Cannabis_dependence" title="Cannabis dependence" class="mw-redirect">Cannabis</a></li>
<li><a rel="mw:WikiLink" href="./Cocaine_dependence" title="Cocaine dependence">Cocaine</a></li>
<li><a rel="mw:WikiLink" href="./Nicotine_dependence" title="Nicotine dependence">Nicotine</a></li>
<li><a rel="mw:WikiLink" href="./Opioid_use_disorder" title="Opioid use disorder">Opioid</a></li></ul></li>
<li>Non-drug stimuli
<ul><li><a rel="mw:WikiLink" href="./Tanning_dependence" title="Tanning dependence">Tanning dependence</a></li></ul></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a rel="mw:WikiLink" href="./Addiction#Treatment" title="Addiction">Treatment and management</a></th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><td colspan="2" class="navbox-list navbox-even" style="width:100%;padding:0px;text-align: left;"><div style="padding:0em 0.25em">
<ul><li><b>Behavioral therapies</b>: <a rel="mw:WikiLink" href="./Cognitive_behavioral_therapy" title="Cognitive behavioral therapy">Cognitive behavioral therapy</a>
<ul><li><a rel="mw:WikiLink" href="./Relapse_prevention" title="Relapse prevention">Relapse prevention</a></li>
<li><a rel="mw:WikiLink" href="./Contingency_management" title="Contingency management">Contingency management</a></li></ul></li>
<li><a rel="mw:WikiLink" href="./Community_reinforcement_approach_and_family_training" title="Community reinforcement approach and family training">Community reinforcement approach and family training</a></li>
<li><a rel="mw:WikiLink" href="./Motivational_interviewing" title="Motivational interviewing">Motivational interviewing</a></li>
<li><a rel="mw:WikiLink" href="./Neurobiological_effects_of_physical_exercise#Addiction" title="Neurobiological effects of physical exercise">Physical exercise</a></li></ul>
</div></td></tr><tr><td colspan="2" class="navbox-list navbox-odd" style="width:100%;padding:0px;text-align: left;"><div style="padding:0em 0.25em">
<ul><li><b>Types of treatment programs</b>: <a rel="mw:WikiLink" href="./Drug_rehab" title="Drug rehab" class="mw-redirect">Drug rehab</a>
<ul><li><a rel="mw:WikiLink" href="./Residential_treatment_center" title="Residential treatment center">Residential treatment center</a></li></ul></li>
<li><a rel="mw:WikiLink" href="./Low-threshold_treatment_programs" title="Low-threshold treatment programs">Low-threshold treatment programs</a></li>
<li><a rel="mw:WikiLink" href="./Needle_exchange_program" title="Needle exchange program" class="mw-redirect">Needle exchange program</a></li>
<li><a rel="mw:WikiLink" href="./Twelve-step_program" title="Twelve-step program">Twelve-step program</a></li></ul>
</div></td></tr><tr><td colspan="2" class="navbox-list navbox-even" style="width:100%;padding:0px;text-align: left;"><div style="padding:0em 0.25em">
<ul><li><b>Support groups</b>: <a rel="mw:WikiLink" href="./Addiction_recovery_groups" title="Addiction recovery groups">Addiction recovery groups</a></li>
<li><a rel="mw:WikiLink" href="./List_of_twelve-step_groups" title="List of twelve-step groups">List of twelve-step groups</a></li>
<li><a rel="mw:WikiLink" href="./NoFap" title="NoFap">NoFap</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">See also</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a rel="mw:WikiLink" href="./Category:Addiction" title="Category:Addiction">Category:Addiction</a></li>
<li><a rel="mw:WikiLink" href="./Discrimination_against_drug_addicts" title="Discrimination against drug addicts">Discrimination against drug addicts</a></li>
<li><a rel="mw:WikiLink" href="./Dopamine_dysregulation_syndrome" title="Dopamine dysregulation syndrome">Dopamine dysregulation syndrome</a></li>
<li><a rel="mw:WikiLink" href="./Cognitive_control" title="Cognitive control" class="mw-redirect">Cognitive control</a>
<ul><li><a rel="mw:WikiLink" href="./Inhibitory_control" title="Inhibitory control">Inhibitory control</a></li></ul></li>
<li><a rel="mw:WikiLink" href="./Harm_reduction" title="Harm reduction">Harm reduction</a></li>
<li><a rel="mw:WikiLink" href="./Motivational_salience" title="Motivational salience">Motivational salience</a>
<ul><li><a rel="mw:WikiLink" href="./Motivational_salience#Incentive_salience" title="Motivational salience">Incentive salience</a></li></ul></li></ul>
</div></td></tr><tr><td class="navbox-abovebelow hlist" colspan="2"><div>
<ul><li><figure-inline typeof="mw:Image" data-mw='{"caption":"Category"}'><span><img resource="./File:Folder_Hexagonal_Icon.svg" src="//upload.wikimedia.org/wikipedia/en/thumb/4/48/Folder_Hexagonal_Icon.svg/16px-Folder_Hexagonal_Icon.svg.png" data-file-width="36" data-file-height="31" data-file-type="drawing" height="14" width="16" srcset="//upload.wikimedia.org/wikipedia/en/thumb/4/48/Folder_Hexagonal_Icon.svg/32px-Folder_Hexagonal_Icon.svg.png 2x, //upload.wikimedia.org/wikipedia/en/thumb/4/48/Folder_Hexagonal_Icon.svg/24px-Folder_Hexagonal_Icon.svg.png 1.5x"/></span></figure-inline> <a rel="mw:WikiLink" href="./Category:Addiction" title="Category:Addiction">Category</a></li>
<li><figure-inline typeof="mw:Image" data-mw='{"caption":"Portal"}'><span><img resource="./File:Portal-puzzle.svg" src="//upload.wikimedia.org/wikipedia/en/thumb/f/fd/Portal-puzzle.svg/16px-Portal-puzzle.svg.png" data-file-width="32" data-file-height="28" data-file-type="drawing" height="14" width="16" srcset="//upload.wikimedia.org/wikipedia/en/thumb/f/fd/Portal-puzzle.svg/32px-Portal-puzzle.svg.png 2x, //upload.wikimedia.org/wikipedia/en/thumb/f/fd/Portal-puzzle.svg/24px-Portal-puzzle.svg.png 1.5x"/></span></figure-inline> <a rel="mw:WikiLink" href="./Portal:Addiction" title="Portal:Addiction">Portal</a></li></ul>
</div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Neuroscience" style="padding:3px" about="#mwt1017" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"Neuroscience","href":"./Template:Neuroscience"},"params":{},"i":0}}]}' id="mwCbY"><table class="nowraplinks collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="3"><div class="plainlinks hlist navbar mini"><ul><li class="nv-view"><a rel="mw:WikiLink" href="./Template:Neuroscience" title="Template:Neuroscience"><abbr title="View this template" style=";;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;">v</abbr></a></li><li class="nv-talk"><a rel="mw:WikiLink" href="./Template_talk:Neuroscience" title="Template talk:Neuroscience"><abbr title="Discuss this template" style=";;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;">t</abbr></a></li><li class="nv-edit"><a rel="mw:ExtLink" class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Neuroscience&amp;action=edit"><abbr title="Edit this template" style=";;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;">e</abbr></a></li></ul></div><div id="Neuroscience" style="font-size:114%;margin:0 4em"><a rel="mw:WikiLink" href="./Neuroscience" title="Neuroscience">Neuroscience</a></div></th></tr><tr><td class="navbox-abovebelow" colspan="3"><div id="Outline_of_neuroscience"><a rel="mw:WikiLink" href="./Outline_of_neuroscience" title="Outline of neuroscience">Outline of neuroscience</a></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a rel="mw:WikiLink" href="./Basic_research" title="Basic research">Basic<br/>science</a></th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a rel="mw:WikiLink" href="./Behavioral_epigenetics" title="Behavioral epigenetics">Behavioral epigenetics</a></li>
<li><a rel="mw:WikiLink" href="./Behavioural_genetics" title="Behavioural genetics">Behavioral genetics</a></li>
<li><a rel="mw:WikiLink" href="./Cellular_neuroscience" title="Cellular neuroscience">Cellular neuroscience</a></li>
<li><a rel="mw:WikiLink" href="./Computational_neuroscience" title="Computational neuroscience">Computational neuroscience</a></li>
<li><a rel="mw:WikiLink" href="./Connectomics" title="Connectomics">Connectomics</a></li>
<li><a rel="mw:WikiLink" href="./Imaging_genetics" title="Imaging genetics">Imaging genetics</a></li>
<li><a rel="mw:WikiLink" href="./Integrative_neuroscience" title="Integrative neuroscience">Integrative neuroscience</a></li>
<li><a rel="mw:WikiLink" href="./Molecular_neuroscience" title="Molecular neuroscience">Molecular neuroscience</a></li>
<li><a rel="mw:WikiLink" href="./Neural_engineering" title="Neural engineering">Neural engineering</a></li>
<li><a rel="mw:WikiLink" href="./Neuroanatomy" title="Neuroanatomy">Neuroanatomy</a></li>
<li><a rel="mw:WikiLink" href="./Neurochemistry" title="Neurochemistry">Neurochemistry</a></li>
<li><a rel="mw:WikiLink" href="./Neuroendocrinology" title="Neuroendocrinology">Neuroendocrinology</a></li>
<li><a rel="mw:WikiLink" href="./Neurogenetics" title="Neurogenetics">Neurogenetics</a></li>
<li><a rel="mw:WikiLink" href="./Neuroinformatics" title="Neuroinformatics">Neuroinformatics</a></li>
<li><a rel="mw:WikiLink" href="./Neurometrics" title="Neurometrics">Neurometrics</a></li>
<li><a rel="mw:WikiLink" href="./Neuromorphology" title="Neuromorphology">Neuromorphology</a></li>
<li><a rel="mw:WikiLink" href="./Neurophysics" title="Neurophysics">Neurophysics</a></li>
<li><a rel="mw:WikiLink" href="./Neurophysiology" title="Neurophysiology">Neurophysiology</a></li>
<li><a rel="mw:WikiLink" href="./Systems_neuroscience" title="Systems neuroscience">Systems neuroscience</a></li></ul>
</div></td><td class="navbox-image" rowspan="5" style="width:1px;padding:0px 0px 0px 2px"><div><figure-inline typeof="mw:Image"><a href="./File:Gray739.png"><img resource="./File:Gray739.png" src="//upload.wikimedia.org/wikipedia/commons/thumb/9/96/Gray739.png/130px-Gray739.png" data-file-width="500" data-file-height="379" data-file-type="bitmap" height="99" width="130" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/9/96/Gray739.png/260px-Gray739.png 2x, //upload.wikimedia.org/wikipedia/commons/thumb/9/96/Gray739.png/195px-Gray739.png 1.5x"/></a></figure-inline></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a rel="mw:WikiLink" href="./Clinical_neuroscience" title="Clinical neuroscience">Clinical<br/>neuroscience</a></th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a rel="mw:WikiLink" href="./Behavioral_neurology" title="Behavioral neurology">Behavioral neurology</a></li>
<li><a rel="mw:WikiLink" href="./Clinical_neurophysiology" title="Clinical neurophysiology">Clinical neurophysiology</a></li>
<li><a rel="mw:WikiLink" href="./Neurocardiology" title="Neurocardiology">Neurocardiology</a></li>
<li><a rel="mw:WikiLink" href="./Neuroepidemiology" title="Neuroepidemiology">Neuroepidemiology</a></li>
<li><a rel="mw:WikiLink" href="./Neurogastroenterology" title="Neurogastroenterology">Neurogastroenterology</a></li>
<li><a rel="mw:WikiLink" href="./Neuroimmunology" title="Neuroimmunology">Neuroimmunology</a></li>
<li><a rel="mw:WikiLink" href="./Neurointensive_care" title="Neurointensive care">Neurointensive care</a></li>
<li><a rel="mw:WikiLink" href="./Neurology" title="Neurology">Neurology</a></li>
<li><a rel="mw:WikiLink" href="./Neurooncology" title="Neurooncology" class="mw-redirect">Neurooncology</a></li>
<li><a rel="mw:WikiLink" href="./Neuro-ophthalmology" title="Neuro-ophthalmology">Neuro-ophthalmology</a></li>
<li><a rel="mw:WikiLink" href="./Neuropathology" title="Neuropathology">Neuropathology</a></li>
<li><a rel="mw:WikiLink" href="./Neuropharmacology" title="Neuropharmacology">Neuropharmacology</a></li>
<li><a rel="mw:WikiLink" href="./Neuroprosthetics" title="Neuroprosthetics">Neuroprosthetics</a></li>
<li><a rel="mw:WikiLink" href="./Neuropsychiatry" title="Neuropsychiatry">Neuropsychiatry</a></li>
<li><a rel="mw:WikiLink" href="./Neuroradiology" title="Neuroradiology">Neuroradiology</a></li>
<li><a rel="mw:WikiLink" href="./Neurorehabilitation" title="Neurorehabilitation">Neurorehabilitation</a></li>
<li><a rel="mw:WikiLink" href="./Neurosurgery" title="Neurosurgery">Neurosurgery</a></li>
<li><a rel="mw:WikiLink" href="./Neurotology" title="Neurotology">Neurotology</a></li>
<li><a rel="mw:WikiLink" href="./Neurovirology" title="Neurovirology">Neurovirology</a></li>
<li><a rel="mw:WikiLink" href="./Nutritional_neuroscience" title="Nutritional neuroscience">Nutritional neuroscience</a></li>
<li><a rel="mw:WikiLink" href="./Psychiatry" title="Psychiatry">Psychiatry</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a rel="mw:WikiLink" href="./Cognitive_neuroscience" title="Cognitive neuroscience">Cognitive<br/>neuroscience</a></th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a rel="mw:WikiLink" href="./Affective_neuroscience" title="Affective neuroscience">Affective neuroscience</a></li>
<li><a rel="mw:WikiLink" href="./Behavioral_neuroscience" title="Behavioral neuroscience">Behavioral neuroscience</a></li>
<li><a rel="mw:WikiLink" href="./Chronobiology" title="Chronobiology">Chronobiology</a></li>
<li><a rel="mw:WikiLink" href="./Molecular_cellular_cognition" title="Molecular cellular cognition">Molecular cellular cognition</a></li>
<li><a rel="mw:WikiLink" href="./Motor_control" title="Motor control">Motor control</a></li>
<li><a rel="mw:WikiLink" href="./Neurolinguistics" title="Neurolinguistics">Neurolinguistics</a></li>
<li><a rel="mw:WikiLink" href="./Neuropsychology" title="Neuropsychology">Neuropsychology</a></li>
<li><a rel="mw:WikiLink" href="./Sensory_neuroscience" title="Sensory neuroscience">Sensory neuroscience</a></li>
<li><a rel="mw:WikiLink" href="./Social_cognitive_neuroscience" title="Social cognitive neuroscience">Social cognitive neuroscience</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Interdisciplinary<br/>fields</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a rel="mw:WikiLink" href="./Consumer_neuroscience" title="Consumer neuroscience">Consumer neuroscience</a></li>
<li><a rel="mw:WikiLink" href="./Cultural_neuroscience" title="Cultural neuroscience">Cultural neuroscience</a></li>
<li><a rel="mw:WikiLink" href="./Educational_neuroscience" title="Educational neuroscience">Educational neuroscience</a></li>
<li><a rel="mw:WikiLink" href="./Evolutionary_neuroscience" title="Evolutionary neuroscience">Evolutionary neuroscience</a></li>
<li><a rel="mw:WikiLink" href="./Neuroanthropology" title="Neuroanthropology">Neuroanthropology</a></li>
<li><a rel="mw:WikiLink" href="./Neurobioengineering" title="Neurobioengineering">Neurobioengineering</a></li>
<li><a rel="mw:WikiLink" href="./Neurobiotics" title="Neurobiotics">Neurobiotics</a></li>
<li><a rel="mw:WikiLink" href="./Neurocriminology" title="Neurocriminology">Neurocriminology</a></li>
<li><a rel="mw:WikiLink" href="./Neuroeconomics" title="Neuroeconomics">Neuroeconomics</a></li>
<li><a rel="mw:WikiLink" href="./Neuroepistemology" title="Neuroepistemology">Neuroepistemology</a></li>
<li><a rel="mw:WikiLink" href="./Neuroesthetics" title="Neuroesthetics">Neuroesthetics</a></li>
<li><a rel="mw:WikiLink" href="./Neuroethics" title="Neuroethics">Neuroethics</a></li>
<li><a rel="mw:WikiLink" href="./Neuroethology" title="Neuroethology">Neuroethology</a></li>
<li><a rel="mw:WikiLink" href="./Neurohistory" title="Neurohistory">Neurohistory</a></li>
<li><a rel="mw:WikiLink" href="./Neurolaw" title="Neurolaw">Neurolaw</a></li>
<li><a rel="mw:WikiLink" href="./Neuromarketing" title="Neuromarketing">Neuromarketing</a></li>
<li><a rel="mw:WikiLink" href="./Neurophenomenology" title="Neurophenomenology">Neurophenomenology</a></li>
<li><a rel="mw:WikiLink" href="./Neurophilosophy" title="Neurophilosophy">Neurophilosophy</a></li>
<li><a rel="mw:WikiLink" href="./Neuropolitics" title="Neuropolitics">Neuropolitics</a></li>
<li><a rel="mw:WikiLink" href="./Neurorobotics" title="Neurorobotics">Neurorobotics</a></li>
<li><a rel="mw:WikiLink" href="./Neurotheology" title="Neurotheology" class="mw-redirect">Neurotheology</a></li>
<li><a rel="mw:WikiLink" href="./Paleoneurobiology" title="Paleoneurobiology">Paleoneurobiology</a></li>
<li><a rel="mw:WikiLink" href="./Social_neuroscience" title="Social neuroscience">Social neuroscience</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Concepts</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a rel="mw:WikiLink" href="./Brain–computer_interface" title="Brain–computer interface">Brain–computer interface</a></li>
<li><a rel="mw:WikiLink" href="./Neural_development" title="Neural development" class="mw-redirect">Neural development</a></li>
<li><a rel="mw:WikiLink" href="./Artificial_neural_network" title="Artificial neural network">Neural network (artificial)</a></li>
<li><a rel="mw:WikiLink" href="./Biological_neural_network" title="Biological neural network" class="mw-redirect">Neural network (biological)</a></li>
<li><a rel="mw:WikiLink" href="./Detection_theory" title="Detection theory">Detection theory</a></li>
<li><a rel="mw:WikiLink" href="./Intraoperative_neurophysiological_monitoring" title="Intraoperative neurophysiological monitoring">Intraoperative neurophysiological monitoring</a></li>
<li><a rel="mw:WikiLink" href="./Neurochip" title="Neurochip">Neurochip</a></li>
<li><a rel="mw:WikiLink" href="./Neurodegeneration" title="Neurodegeneration">Neurodegeneration</a></li>
<li><a rel="mw:WikiLink" href="./Neurodevelopmental_disorder" title="Neurodevelopmental disorder">Neurodevelopmental disorder</a></li>
<li><a rel="mw:WikiLink" href="./Neurodiversity" title="Neurodiversity">Neurodiversity</a></li>
<li><a rel="mw:WikiLink" href="./Neurogenesis" title="Neurogenesis">Neurogenesis</a></li>
<li><a rel="mw:WikiLink" href="./Neuroimaging" title="Neuroimaging">Neuroimaging</a></li>
<li><a rel="mw:WikiLink" href="./Neuroimmune_system" title="Neuroimmune system">Neuroimmune system</a></li>
<li><a rel="mw:WikiLink" href="./Neuromanagement" title="Neuromanagement">Neuromanagement</a></li>
<li><a rel="mw:WikiLink" href="./Neuromodulation" title="Neuromodulation">Neuromodulation</a></li>
<li><a rel="mw:WikiLink" href="./Neuroplasticity" title="Neuroplasticity">Neuroplasticity</a></li>
<li><a rel="mw:WikiLink" href="./Neurotechnology" title="Neurotechnology">Neurotechnology</a></li>
<li><a rel="mw:WikiLink" href="./Neurotoxin" title="Neurotoxin">Neurotoxin</a></li></ul>
</div></td></tr><tr><td class="navbox-abovebelow hlist" colspan="3" style="font-weight: bold"><div>
<ul><li><figure-inline typeof="mw:Image" data-mw='{"caption":"Wikipedia book"}'><span><img resource="./File:Symbol_book_class2.svg" src="//upload.wikimedia.org/wikipedia/commons/thumb/8/89/Symbol_book_class2.svg/16px-Symbol_book_class2.svg.png" data-file-width="180" data-file-height="185" data-file-type="drawing" height="16" width="16" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/8/89/Symbol_book_class2.svg/31px-Symbol_book_class2.svg.png 2x, //upload.wikimedia.org/wikipedia/commons/thumb/8/89/Symbol_book_class2.svg/23px-Symbol_book_class2.svg.png 1.5x"/></span></figure-inline> <b><a rel="mw:WikiLink" href="./Book:Neuroscience" title="Book:Neuroscience">Book</a></b></li>
<li><figure-inline typeof="mw:Image" data-mw='{"caption":"Category"}'><span><img resource="./File:Folder_Hexagonal_Icon.svg" src="//upload.wikimedia.org/wikipedia/en/thumb/4/48/Folder_Hexagonal_Icon.svg/16px-Folder_Hexagonal_Icon.svg.png" data-file-width="36" data-file-height="31" data-file-type="drawing" height="14" width="16" srcset="//upload.wikimedia.org/wikipedia/en/thumb/4/48/Folder_Hexagonal_Icon.svg/32px-Folder_Hexagonal_Icon.svg.png 2x, //upload.wikimedia.org/wikipedia/en/thumb/4/48/Folder_Hexagonal_Icon.svg/24px-Folder_Hexagonal_Icon.svg.png 1.5x"/></span></figure-inline> <b><a rel="mw:WikiLink" href="./Category:Neuroscience" title="Category:Neuroscience">Category</a></b></li>
<li><figure-inline typeof="mw:Image" data-mw='{"caption":"Portal"}'><span><img resource="./File:Portal-puzzle.svg" src="//upload.wikimedia.org/wikipedia/en/thumb/f/fd/Portal-puzzle.svg/16px-Portal-puzzle.svg.png" data-file-width="32" data-file-height="28" data-file-type="drawing" height="14" width="16" srcset="//upload.wikimedia.org/wikipedia/en/thumb/f/fd/Portal-puzzle.svg/32px-Portal-puzzle.svg.png 2x, //upload.wikimedia.org/wikipedia/en/thumb/f/fd/Portal-puzzle.svg/24px-Portal-puzzle.svg.png 1.5x"/></span></figure-inline> <b><a rel="mw:WikiLink" href="./Portal:Neuroscience" title="Portal:Neuroscience">Portal</a></b></li></ul>
</div></td></tr></tbody></table></div>
<div class="noprint metadata navbox" role="navigation" aria-label="Portals" style="font-weight:bold;padding:0.4em 2em" about="#mwt1018" typeof="mw:Transclusion" data-mw='{"parts":[{"template":{"target":{"wt":"Portal bar","href":"./Template:Portal_bar"},"params":{"1":{"wt":"Addiction"},"2":{"wt":"Neuroscience"},"3":{"wt":"Psychology"},"4":{"wt":"Medicine"},"5":{"wt":"Pharmacology"},"6":{"wt":"Molecular and cell biology"}},"i":0}}]}' id="mwCbc"><ul style="margin:0.1em 0 0"><li style="display:inline"><span style="display:inline-block;white-space:nowrap"><span style="margin:0 0.5em"><figure-inline typeof="mw:Image"><a href="./File:Portal-puzzle.svg"><img resource="./File:Portal-puzzle.svg" src="//upload.wikimedia.org/wikipedia/en/thumb/f/fd/Portal-puzzle.svg/24px-Portal-puzzle.svg.png" data-file-width="32" data-file-height="28" data-file-type="drawing" height="21" width="24" srcset="//upload.wikimedia.org/wikipedia/en/thumb/f/fd/Portal-puzzle.svg/48px-Portal-puzzle.svg.png 2x, //upload.wikimedia.org/wikipedia/en/thumb/f/fd/Portal-puzzle.svg/36px-Portal-puzzle.svg.png 1.5x"/></a></figure-inline></span><a rel="mw:WikiLink" href="./Portal:Addiction" title="Portal:Addiction">Addiction portal</a></span></li><li style="display:inline"><span style="display:inline-block;white-space:nowrap"><span style="margin:0 0.5em"><figure-inline typeof="mw:Image"><a href="./File:Neuro_logo.png"><img resource="./File:Neuro_logo.png" src="//upload.wikimedia.org/wikipedia/commons/thumb/f/f8/Neuro_logo.png/24px-Neuro_logo.png" data-file-width="75" data-file-height="62" data-file-type="bitmap" height="20" width="24" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/f/f8/Neuro_logo.png/48px-Neuro_logo.png 2x, //upload.wikimedia.org/wikipedia/commons/thumb/f/f8/Neuro_logo.png/36px-Neuro_logo.png 1.5x"/></a></figure-inline></span><a rel="mw:WikiLink" href="./Portal:Neuroscience" title="Portal:Neuroscience">Neuroscience portal</a></span></li><li style="display:inline"><span style="display:inline-block;white-space:nowrap"><span style="margin:0 0.5em"><figure-inline typeof="mw:Image"><a href="./File:Psi2.svg"><img resource="./File:Psi2.svg" src="//upload.wikimedia.org/wikipedia/commons/thumb/6/6c/Psi2.svg/21px-Psi2.svg.png" data-file-width="100" data-file-height="100" data-file-type="drawing" height="21" width="21" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/6/6c/Psi2.svg/42px-Psi2.svg.png 2x, //upload.wikimedia.org/wikipedia/commons/thumb/6/6c/Psi2.svg/32px-Psi2.svg.png 1.5x"/></a></figure-inline></span><a rel="mw:WikiLink" href="./Portal:Psychology" title="Portal:Psychology">Psychology portal</a></span></li><li style="display:inline"><span style="display:inline-block;white-space:nowrap"><span style="margin:0 0.5em"><figure-inline typeof="mw:Image"><a href="./File:WHO_Rod.svg"><img resource="./File:WHO_Rod.svg" src="//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/WHO_Rod.svg/9px-WHO_Rod.svg.png" data-file-width="107" data-file-height="250" data-file-type="drawing" height="21" width="9" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/WHO_Rod.svg/18px-WHO_Rod.svg.png 2x, //upload.wikimedia.org/wikipedia/commons/thumb/d/d6/WHO_Rod.svg/13px-WHO_Rod.svg.png 1.5x"/></a></figure-inline></span><a rel="mw:WikiLink" href="./Portal:Medicine" title="Portal:Medicine">Medicine portal</a></span></li><li style="display:inline"><span style="display:inline-block;white-space:nowrap"><span style="margin:0 0.5em"><figure-inline typeof="mw:Image"><a href="./File:Portal-puzzle.svg"><img resource="./File:Portal-puzzle.svg" src="//upload.wikimedia.org/wikipedia/en/thumb/f/fd/Portal-puzzle.svg/24px-Portal-puzzle.svg.png" data-file-width="32" data-file-height="28" data-file-type="drawing" height="21" width="24" srcset="//upload.wikimedia.org/wikipedia/en/thumb/f/fd/Portal-puzzle.svg/48px-Portal-puzzle.svg.png 2x, //upload.wikimedia.org/wikipedia/en/thumb/f/fd/Portal-puzzle.svg/36px-Portal-puzzle.svg.png 1.5x"/></a></figure-inline></span><a rel="mw:WikiLink" href="./Portal:Pharmacology" title="Portal:Pharmacology" class="mw-redirect">Pharmacology portal</a></span></li><li style="display:inline"><span style="display:inline-block;white-space:nowrap"><span style="margin:0 0.5em"><figure-inline typeof="mw:Image"><a href="./File:TPI1_structure.png"><img resource="./File:TPI1_structure.png" src="//upload.wikimedia.org/wikipedia/commons/thumb/1/1c/TPI1_structure.png/24px-TPI1_structure.png" data-file-width="1452" data-file-height="914" data-file-type="bitmap" height="15" width="24" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/1/1c/TPI1_structure.png/48px-TPI1_structure.png 2x, //upload.wikimedia.org/wikipedia/commons/thumb/1/1c/TPI1_structure.png/36px-TPI1_structure.png 1.5x"/></a></figure-inline></span><a rel="mw:WikiLink" href="./Portal:Molecular_and_cell_biology" title="Portal:Molecular and cell biology" class="mw-redirect">Molecular and cell biology portal</a></span></li></ul></div>

<link rel="mw:PageProp/Category" href="./Category:Addiction#%20" id="mwCbg"/>
<link rel="mw:PageProp/Category" href="./Category:Behavioral_addiction#*" id="mwCbk"/>
<!-- -->
<link rel="mw:PageProp/Category" href="./Category:Abnormal_psychology" id="mwCbo"/>
<link rel="mw:PageProp/Category" href="./Category:Brain_disorders" id="mwCbs"/>
<link rel="mw:PageProp/Category" href="./Category:Mental_and_behavioural_disorders" id="mwCbw"/></section></body></html>